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ABSTRACT 
This dissertation focuses on two fundamental yet unanswered questions in human health 
and disease concerning both diagnostics and therapeutics.  The first half addresses the lack of 
optimized near-infrared fluorophores for image-guided surgery.  Fluorescence imaging cameras 
and intraoperative imaging systems lack appropriately engineered contrast agents that allow the 
detection of sensitive normal tissue (i.e. endocrine and exocrine glands) for surgical avoidance.  
After systematically probing various fluorophore classes, we discovered promise in cyanine-based 
contrast agents.  By altering functional groups of cyanine fluorophores, we, for the first time, report 
the selective targeting of many endocrine glands, exocrine glands, cartilage and bone using NIR 
fluorescence to visualize the targeted tissue. Secondly, this dissertation elaborates a new pathway 
for developing functional and fluorescent chemotherapeutics based on the targeting, stabilization 
and imaging of G-quadruplex DNA – a folding pattern commonly associated with cancer cell 
proliferation through telomerase over-expression and oncogene promoter regions.  Chromophores 
modified to assume quadruplex binding characteristics – planar cationic structures – have been 
developed that stabilize the quadruplex as evaluated through several complementary methods 
toward developing novel theranostic agents in the NIR visualization and treatment of human 
cancers. 
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1 INTRODUCTION TO NIR-FLUORESCENCE IMAGE-GUIDED SURGERY 
Note: This chapter has been adapted from the following publication in WIREs Nanomedicine 
and Nanobiotechnology. My contributions as first author were the design and 
figure/manuscript preparation.  
Owens, E. A., Lee, S., Choi J, Henary, M, Choi, H.S. NIR Fluorescent Small Molecules for 
Intraoperative Imaging. 2015 WIREs Nanomedicine and Nanobiotechnology, Invited Focus 
Article In Press-Early View. 
1.1 Abstract 
Recent advances in bioimaging and nanomedicine have permitted the exploitation of 
molecular optical imaging in image-guided surgery; however, the parameters mediating 
optimum performance of contrast agents are not yet precisely determined. To develop ideal 
contrast agents for image-guided surgery, we need to consider the following criteria: 1) 
excitation and emission wavelengths in the NIR window, 2) optimized optical characteristics 
for high in vivo performance, 3) overcoming or harnessing biodistribution and clearance, and 
4) reducing nonspecific uptake. The design considerations should be focused on optimizing the 
optical and physicochemical property criteria. Biodistribution and clearance should first be 
considered because they mediate the fate of a contrast agent in the body such as how long after 
intravenous injection a contrast agent reaches the peak signal-to-background ratio (SBR) and 
how long the signal lasts (retention). 
1.2 Introduction 
 Despite advancements in oral medications, surgery remains the primary treatment 
option for controlling the progression of many diseases from dysplasia to carcinoma.1-3  
Surgeons currently perform complex long-duration surgical resections without the aid of real-
time image guidance.  The common colloquialism we use for “extremely precise” is surgical 
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precision, which is currently limited to anatomical structures and palpation with surgeons 
experience to perform complex surgeries.4 There are times, especially in the resection of 
cancerous tissues, when eyesight alone is not enough to complete a complicated surgical 
resection successfully—we define successful as the complete removal of disease tissue and the 
avoidance of nerves, blood vessels, and other vital tissues.5   
 Surgeons currently utilize many pre-surgical imaging modalities including computed 
tomography (CT), magnetic Resonance Image (MRI), single-photon emission computed 
tomography (SPECT), or positron emission tomography (PET)6-9 for deciphering the surgical 
field and for locating specific tissues, but subtle nuances after pre-surgical imaging can have 
severe consequences which could lead to additional surgical procedures, incomplete resection, 
poor patient outcomes or even death. It is undeniable that the development of biomedical 
imaging modalities has contributed significantly to the outcome of surgical procedures by 
locating the disease tissue prior to surgery.  Unfortunately, the surgical field remains an ever-
changing space where real-time imagery is required while the patient is undergoing an 
operation to minimize morbidity and mortality.  To avoid this, we require the development of 
a real-time approach to the imaging of surgical field but there remain significant obstacles in 
developing successful optical contrast agents, including the high background associated with 
current molecular imaging technology.   
1.3 High Background in Molecular Imaging 
Molecular imaging exploits the radioactive property of various elements or compounds for 
visualization.  Depending on the exact atomic or molecular characteristics, clinicians are able 
to observe the signal using positron or photon detecting equipment with appropriately 
radiolabeled contrast agents.  In order for surgeons to clearly visualize their target, the 
molecular imaging contrast agent must offer high signal to background for optimum 
delineation of meaningful signal from surrounding tissue which offers a more precise image of 
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the surgical field leading to increased surgical efficacy. Most clinically utilized contrast agents 
including 18F-FDG (PET) or 99mTc (SPECT) to target diseased tissue with properly detectable 
signal, however, the percent injected dose (%ID) taken up by non-target (normal) tissue and 
organ remaining in the body after several hours of circulation and clearance is still high, i.e., 
nonspecific background. As shown in Figure 1,5  elevated non-specific uptake of the contrast 
agent makes deducing meaningful signal more difficult. The major organs including liver, 
kidneys, spleen and lung display equal or higher signals compared to the targeted tumor.  
Reducing the background associated with any contrast agent remains a paramount and very 
difficult research endeavor.   The perfect contrast agent would exhibit high signal to 
background in the desired tissue with the remaining amount being cleared through renal 
filtration or hepatobiliary clearance with minimal off-target absorption.  
 
Figure 1-1.  (a) PET imaging. 100 µCi of scVEGF/Cu (top row) or inVEGF/Cu (bottom 
row) were injected into 4T1luc tumor-bearing mice in the left axillary fat pads. 
Radioactivity for each resected organ was obtained 2 h post-injection. (b) SPECT 
a 
b 
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imaging. 100 µCi of scVEGF/Tc (left) or inVEGF/Tc (right) were injected into 4T1luc 
tumor-bearing mice 1 h prior to imaging and resection. Arrows mark left mammary fat 
pad tumor; arrowheads and dotted boxes indicate nonspecific uptake.  H, heart; L, liver; 
scale bar, 1 cm [Adapted from Backer et al.5 Copyright permission from Nature 
Publishing Group]. 
 
1.4 Why Optical Imaging via Fluorescence? 
Conventional PET scan, as shown in Figure 1, provides whole body imaging to find disease 
target, commonly using radiolabeled 18F-FDG or other radioactive contrast agents such as 15O, 
11C and 64Cu.10, 11  The proton-rich radionuclides spontaneously convert a proton to a neutron, 
resulting in the emission of a positron.   This modality, similar to SPECT (usually exploits 
gamma rays emitted from 99mTc, 123I, 111In, 201Tl, 67Ga or 133Xe) poses significant safety 
concerns and must be utilized sparsely to avoid unhealthy radiation exposure to the patient.  
MRI utilizes high magnetic fields to noninvasively image diseased and healthy tissues.   
Unfortunately, these various imaging techniques fail to offer the desirable spatial resolution 
required for operative guidance and translating the currently employed imaging technology 
into a real-time setting exposes the patient and surgical team to harmful levels of radiation 
during long-term procedures.  Research endeavors are underway to develop a harmless and 
effective strategy for surgical imaging—one of the most promising methods is optical-based 
imaging using NIR fluorescence and herein we discuss the design concepts that must be 
considered for the development of these fluorescent compounds.   
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1.5 NIR Window of Optical Clarity 
Molecular imaging encompasses a highly broad category of techniques that; however, a more 
specific type of molecular imaging, optical imaging, relies on the photophysical properties of 
a contrast agent to report, usually through fluorescence, on the location of the targeted tissue.  
Optical imaging allows for a very detailed image with high spatial resolution to be obtained in 
real-time if the correct imaging agents are utilized.  Furthermore, optical imaging has been 
shown to be useful for image-guided surgery and allows target specific tissues inside the body 
using laser light excitation combined with corresponding fluorophores with excitation and 
emission in the NIR region of optical clarity. The NIR window is the optical range of the 
electromagnetic spectrum which is characterized by wavelengths between 650 nm and 900 nm 
and is depicted in Figure 2.  Absorption and scattering properties of tissue greatly affects the 
photon penetration into living tissue; however, the NIR region of the electromagnetic spectrum 
overcomes this obstacle and can significantly improve in vivo imaging. Understanding the NIR 
window and the optimized excitation and emission wavelengths along with the molecular 
characteristics required for NIR wavelengths are key in developing ideal contrast agents for 
image-guided surgery. 
 
There are several advantages of working in the NIR region of the spectrum. First, the 
endogenous chromophores present in living tissues absorb and scatter visible light, limiting 
light penetration to only a few millimeters. However, NIR light has a much lower tissue 
absorption coefficient, which permits its deeper penetration to several centimeters. Since 
common biological systems do not feature the capacity to absorb this wavelength of light it is 
innocuous to human cells and tissue resulting in an inherently safer imaging modality.  
Additionally, the scattered light from the excitation source is greatly reduced in the NIR region 
since the scattering intensity is proportional to the inverse fourth power of the wavelength. Low 
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background noise and low scattering of NIR fluorescence result in a high SBR, thereby 
allowing highly sensitive detection. Further advantages of NIR imaging includes low 
interferences from Raman scattering and reduced possibility of sample degradation.  
 
Figure 1-2. In vivo optical properties of injected fluorophores along with wavelength. 
  
Many biological compounds fluoresce within the ultraviolet  (< 400 nm) and visible (400-650 
nm) regions which makes observing contrast agents in this range nearly impossible; however, 
NIR-fluorescent compounds avoid this issue by being spectrally distinct from the native 
biological fluorescence (autofluorescence) which offers outstanding SBR. It has been 
convincingly demonstrated that native tissue greatly interferes with the extraction of 
meaningful signal in the red-shifted visible region. Therefore, the lower limit (> 650 nm) of 
the NIR window is bound by biological autofluorescence. The upper end of the NIR region (< 
900 nm) of optical clarity is bound by absorption arising from vibrational characteristics of 
water (> 950 nm).  These advantages along with the availability and low cost of long-
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wavelength diode lasers and detectors for the NIR light, have led to increasing research interest 
in the design, development, spectroscopic characterization and application of novel NIR 
fluorophores.12 
1.6 Small Molecule Optical Contrast Agents 
 Engineering optical contrast agents that satisfy the physical, chemical and biological 
requirements is a difficult process but remains crucial in maximizing the surgical 
implementation of image-guided surgery.13 The performance of contrast agents depends 
strongly on their physicochemical properties (i.e. molecular weight, total polar surface area, 
hydrogen bond donors/acceptors, acidic/basic pKa, distribution/partition coefficient and 
stability), which heavily influence their in vivo fate with slight structural modifications posing 
significant biological perturbation.14-23  
 Efficient optical properties are the very basic requirements for developing new contrast 
agents and there are several crucial parameters such as high solubility, high extinction 
coefficient, large Stokes’ Shift, high quantum yield, and high photobleaching threshold that 
directly influence the potential obtainable signal during the imaging process.24, 25 
Correspondingly, the first essential task is to optimize these parameters in the process of 
developing novel contrast agents.  
 The aqueous optical profile and water solubility normally go hand-in-hand; therefore, 
the first design consideration is either to avoid a highly hydrophobic core or alternately 
incorporate a charged group onto the fluorophore.  Following these design parameters 
drastically increases the aqueous solubility and can increase the quantum yield (up to 10x).  
Judicious placement of charge is necessary as superfluous intrinsic charge can reduce the 
efficacy of biological targeting moieties due to steric hindrance, electrostatic repulsion or 
general bio-incompatibility. Therefore, fluorophores should be designed to have high aqueous 
solubility, while maintaining target recognition. 
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 Additionally large extinction coefficient and quantum yield values are paramount for 
optical contrast agents, especially at the tissue depths required for image-guided surgery. The 
extinction coefficient—measure of the absorption at a particular wavelength by a compound—
accurately represents the ability of a compound to absorb radiation and can be determined using 
the Beer-Lambert equation26. For optical imaging, typical satisfactory extinction coefficients 
in aqueous systems are between 100,000 and 200,000 M-1cm-1. This range of extinction 
coefficients results in reasonable photon absorption by the fluorophore.  
 Last but not least, high photobleaching threshold is a very important area of 
consideration. Conventional fluorophores are highly susceptible to photobleaching which 
places severe limitation on the fluence rate and consequently the sensitivity and length of 
detection. For example, the NIR fluorescent indocyanine green (ICG) rapidly photobleaches in 
warm serum when fluence rates exceed 50 mW/cm2 .27 However, hybrid nanoparticles 
(quantum dots, etc.) and multivalent polymeric nanomaterials commonly have higher 
resistance to photobleaching compared to small molecules with ability to withstand fluence 
rates one to two orders of magnitude higher.  Because fluence rates improve the signal-to-
background, contrast agents with higher resistance to photobleaching will yield improved 
fluorophores. 
1.7 Classes of NIR Fluorophores 
 Among the optical contrast agents explored to date, the NIR region has gained 
considerable numbers of ideal fluorophores with potential for translation in image-guided 
surgery. Fortunately, there are several classes of fluorophores that offer appealing 
characteristics for further modifications towards designing contrast agents within the NIR 
window. The general molecular structures seen in Figure 3 represent a selection of 
chromophores that fluoresce in the NIR region.  These fluorophores have general properties 
that either make them more appealing or limit their overall utility as bioimaging agents. 
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Figure 1-3. Chemical structures of various classes of small molecule fluorophores that 
have been explored for biophotonic imaging, their general hydrophobicity maps, 
highlighted characteristics concerning their potential for in vivo performance and the 
overall optical properties concerning the general core structure.    
  
 Nile red and nile blue are notoriously solvatochromic (change absorption spectrum 
when changing solvent or environment), highly hydrophobic fluorophores that can be modified 
in several positions to achieve water solubility;28 however, analogs synthesized and evaluated 
to date fluoresce in the NIR albeit with low quantum yield in aqueous systems or in the presence 
of proteins.  These limitations have precluded them from being extensively evaluated in vivo.29-
32 Another class of compounds centers on the cyclic oxobutanal ring and is referred to as 
squaraine or squaric acid fluorophores.33  The extreme electrophilicity of this cyclic butane 
ring is susceptible to nucleophilic attack, which irreversibly diminishes the optical properties 
of the compound, unless the core is protected by one of several methods including rotaxane 
encapsulation34 which reduces the overall applicability in small molecule bioimaging.  
Contrary to the squaraine class of fluorophores, the tricyclic fused structures of phenoxazine 
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and phenothiazine are highly structurally and optically stable even in the presence of 
nucleophilic species due to the aromatic core.  The synthetic difficulty associated with this 
class limits the versatility and overall applicability in image-guided surgery.  Furthermore, the 
emission wavelengths of the oxazine class is too low and cannot be used due to interfering 
native tissue absorption and autofluorescence.35, 36 The boron-dipyrromethane (BODIPY) class 
of fluorophores exhibits excellent characteristics from high stability and above-average 
quantum yield but suffers from having a highly hydrophobic core and broad 
absorption/emission spectra.  These fluorophores have been successful in vivo due to their NIR 
emission, high quantum yield and ability to be synthetically tailored to several applications.23, 
37-41 currently, however, high background during intravenous injection limits the scope for this 
molecular class.23   
 Cyanine fluorophores are broadly defined as two heterocyclic nitrogen atoms that are 
connected via an electron deficient polymethine bridge.  Monomethine cyanines display one 
methine unit, in this case defined as (=CH-), between the heterocyclic structures, this class of 
compounds displays absorbance within the ultraviolet and visible regions with low 
fluorescence quantum yield.  Elongating the central chromophore length by sets of 2 methylene 
groups yields tri-, penta-, and heptamethine cyanines.  The wavelengths of most trimethine 
cyanines are too low to be effective in NIR imaging in biological systems; however, penta- and 
heptamethine cyanines have near-infrared absorbance and fluorescence characteristics that are 
a function of their exact heterocyclic structure and moieties within the polymethine chain which 
can be tuned to offer high quantum yield and molecular brightness with a high degree of 
structural amenability toward manipulating the pharmacophore in the generation of successful 
NIR fluorescent contrast agents.   
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1.8 State-of-the-art in Image-Guided Surgery 
 Figure 4 shows two of the most highly used optical contrast agents, methylene blue 
(MB), a fused phenothiazine compound, and ICG, a heptamethine cyanine dye.   Surgeons have 
found ways to utilize the FDA approved ICG;42-47 however, the high background signal in vivo, 
structural and optical instability and the lack of ability for a targeting functionality has opened 
several avenues for the manipulation of the chemical structure.  MB, perhaps the second most 
widely researched compound in image-guided surgery not because of its NIR fluorescence but 
its color staining properties48, 49 unfortunately suffers from non-dependable optical 
properties.50-57  The absorption and fluorescence characteristics are at appropriate wavelengths 
during in vitro experimentation; however, the redox state of the compound allows for the 
reduction of the central imine to the corresponding amine which destroys the NIR fluorescence 
of the compound.  These non-optimum properties along with low extinction coefficient and 
non-amenability to the addition of a targeting ligand limit the overall utility of this particular 
contrast agent.  In order to develop robust NIR fluorescent contrast agents for image guided 
surgery, the general structure of ICG was modified to include a central cyclic ring for increased 
optical and chemical stability along with a zwitterionic character to minimize cellular 
accumulation and prevent off-target localization. 14, 15  Additionally, a reactive carboxylate 
moiety was added for structural manipulation toward targeted imaging.16  The engineered 
molecule is depicted in Figure 4 and is known as ZW800-1 and is among the carbocyanine 
class of NIR contrast agents for targeted imaging once conjugated to a biological targeting 
ligand.16  
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Figure 1-4. Current state-of-the-art NIR fluorophores used in image-guided surgery.  The 
chemical structures of three NIR fluorescent contrast agents and the corresponding 
optical properties.  The negatively charged moieties are highlighted in red and the 
positively charged regions are designated in blue.    
1.9 Background Retention 
 Optical contrast agents have been designed to satisfy the optical property criteria and 
their capacity to luminesce using fluorescence light through skin and tissue has been 
convincingly demonstrated, but only a few fluorophores exhibit the ultralow background 
required for clinical translation.14-16, 25, 58-64 Obtaining this high signal to background depends 
on the clearance pathway from the body and there are structural constraints that allow 
compounds to be cleared through renal filtration—the pathway for obtaining clear background.  
 
 Renal clearance, involving the kidney, is the ideal route as it minimizes retention and 
toxicity risks within the body.65 There are three steps that comprise the process of renal 
clearance: glomerular filtration, tubular secretion, and urinary excretion.66, 67  The molecular 
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shape, conformation, size and surface charges are important determinants of renal clearance, 
more specifically glomerular filtration.24 Intravascular agents with a hydrodynamic diameter 
(HD) smaller than 6 nm are usually successfully filtered when the surface charges are neutral 
or zwitterionic, while injected molecules with an HD > 8 nm are not filtered through kidneys 
at all.58, 68  Large molecules or highly charged molecules undergo some level of hepatobiliary 
excretion, which generally involves catabolism and biliary excretion, and contaminates the 
gastrointestinal (GI) tract and increase non-specific uptake.   Although the overall size is 
smaller than 6 nm, cationic charged molecules trap in the negatively charged filters and 
vasculature, and increase background signal significantly.   
 The comparison between ZW800-1 and ICG shows a prime example of the clearance 
pathway leading to elevated background signal.  ZW800-1 displays unique and exciting 
biological and physiological properties in vivo.14-16 The highly charged yet neutral character 
prevents cellular accumulation and minimizes protein interactions allowing for complete and 
rapid clearance through renal filtration as shown in comparison to ICG in Figure 5.  The 
biodistribution pattern associated with ICG is more common among alternate NIR fluorophores 
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with high non-specific uptake shown through the high signal in the liver and duodenum 
evidenced by the high fluorescence signal in Figure 5.     
 
Figure 1-5. Biodistribution and clearance of ICG and ZW800-1. ICG shows elevated 
nonspecific uptake in liver and duodenum, while ZW800-1 represents ultralow 
background and renal clearance. Animals were housed in an AAALAC-certified facility 
and were studied under the supervision of BIDMC IACUC in accordance with approved 
institutional protocols (#101-2011 for rodents and #046-2010 for pigs). NIR fluorophores 
were injected intravenously into ~20 g CD-1 mice (10 nmol), ~250 g SD rats (50 nmol), 
and ~35 kg Yorkshire pigs (1 µmol) 1 h prior to imaging. Shown are color and 800 nm 
NIR fluorescence images of surgically exposed organs taken by the FLARE 
intraoperative imaging system.14-16 NIR fluorescence images have identical exposure 
times and normalizations. Abbreviations used are: Bl: bladder; BD: bile duct; Du: 
duodenum; In: intestine; Ki: kidneys; Li: liver; Sk: skin; St: stomach; Ur: ureter. Scale 
bars = 1 cm. 
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1.10 Nonspecific Uptake and Persistent Background Retention (PBR) 
 The focal point of optical imaging combined with appropriate contrast agents is to 
produce a high SBR: increase the target signal while decreasing the background signal and 
noise. While the focus of optical imaging is typically on generating signal, it is the SBR, and 
more often background, which dictates the performance of an injected contrast agent. From the 
moment an exogenous contrast agent is injected intravenously, it is likely non-specifically 
contributing to background signal and degrading overall performance. The SBR is adequate 
for imaging only after specific binding to the desired target and clearance of this non-specific 
background from tissue.  
 Although virtually all published mathematical models of contrast agent biodistribution 
and clearance suggest that background is cleared in a relatively short period of time, especially 
for small molecule contrast agents, in reality there is a phenomenon of persistent background 
retention (PBR) that results in 10-30% of the injected dose remaining non-specifically in tissues 
throughout the body.69, 70While the mechanism for PBR is presently unknown, it appears to be 
a strong function of molecular size, shape, charges, and charge-to-mass ratio.24 Therefore, in 
order to improve the SBR of an injected molecule thus improve its intraoperative use, reducing 
PBR is desperately needed through structural manipulating of its size, charge, absorption and 
clearance as the rapid biodistribution and complete elimination.  
1.11 Conclusions 
 Although surgery is the main path in curing almost half of all cancer patients, none can 
perfectly image the desired target due to high levels of background signal that results in extreme 
difficulty during surgery. Designing the best possible contrast agent is essential in maximizing 
the use of optical imaging to detect, target, and diagnose specific cancer cells in vivo. Therefore 
a thorough understanding of the molecular and tissue properties helps in designing the ideal 
contrast agent.  Monitoring the surgical field though the visualization of near-infrared 
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fluorescence stands firm as a leading alternative and arguably most viable option for real-time-
guided surgery. 
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2 SITE SPECIFIC NIR IMAGING: A REVIEW 
This chapter focuses on the design parameters and literature associated with developing 
contrast agents that selectively image diseased and native tissues for optical imaging.  The 
chapter has been amended from the manuscript prepared for invited submission. My 
contributions from inception concerned the design, organization, deciding material for 
incorporation, making figures, writing manuscript from beginning to end.  
Owens, E.A., Henary, M., Choi, H.S., Site Specific NIR Imaging. Expected 2016. Invited 
Review 
2.1 Abstract 
Clearly defining the physical margins of diseased tissue remains of paramount importance 
in intraoperative biomedical imaging.  An equally noteworthy yet less researched goal is the 
ability to outline healthy tissues that should be carefully navigated without transection.  Both 
of these paths require optimizing a gauntlet of design considerations to obtain an effective nano 
or subnano imaging agent that has the requisite NIR-absorbance and fluorescence wavelengths 
but also high quantum yield, water solubility, highly specific tissue-targeting and 
biocompatible characteristics.  Recent advances offer promise toward fulfilling these stringent 
requirements for developing a successful catalog of successful imaging agents for illuminating 
both diseased and healthy tissue in the same surgical space by employing spectrally distinct 
fluorophores in a single injected dose in real-time. 
Keywords. Disease-targeted imaging, native tissue imaging, structure inherent 
targeting, nanoparticles, fluorophores 
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2.2 Introduction 
Long-term survival of surgical patients depends on the ability to fully resect diseased 
tissue and avoid sensitive tissues/nerves present on the surgical field.  Currently, surgeons are 
limited to their eyesight and physical analyses to determine intra-operative intricacies on the 
surgical field, even in the performance of highly complicated resections.  Toward offering 
surgeons a real-time method of visualization, the imaging community has pursued various 
avenues by translating spectral imaging modalities from extant pre-operative techniques that 
include single photon emission computed tomography (SPECT) or positron emission 
tomography (PET). [1-4]   
Both of these molecular imaging methods have been explored with some success; 
however, high non-specific targeting leads to elevated background retention in non-targeted 
tissues which makes deciphering the surgical field challenging thus obviating potential 
benefits.  Furthermore, ionizing radiation associated with these techniques limits the overall 
scope of their real-time translation. In response to this severe clinical need, alternate 
possibilities have been established, and they rely on the emission of light by molecules, usually 
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through fluorescence (i.e. the absorption and conversion of one wavelength of light to one of 
lower energy, Figure 1), for illuminating the surgical field.[5-16] In this review, we focus on 
detailing the requisite parameters required for the development of a site-specific chemical 
probe, the biological infrastructure that must be overcome or harnessed to achieve selective 
imaging. 
 
Figure 2-1. A simplified jablonski diagram showing fluorescence and competing pathways 
for molecular relaxation from an excited state.   
Fluorescence is only one of the pathways that may occur after an incident photon 
promotes a chemical species from ground state S0 to excited S1, S2 and beyond.  Energetic 
relaxation occurs through several pathways. Shown in red (Figure 1) is internal conversion that 
correspond to molecular movements (vibration, stretching, twisting, etc.).  Another competing 
pathway is the process of fluorescence, or the release of light of lower energy (higher 
wavelength) than that absorbed (energy difference is the origin of the Stokes shift).  Lastly, the 
spin inversion from an excited singlet state to an excited triplet state can relax back to the spin 
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paired ground state through a time-lapsed phosphorescence pathway.  In all systems these 
various pathways are in dynamic equilibrium with the chemical structure significantly 
influencing the efficiency of each pathway for energy release.  Building on these principles, 
the chemical structure may be modified such that fluorescence dominates the alternate 
pathways which affords a high quantum yield of photon emission. This has proven to be very 
promising and the search for engineered fluorophores with optimum characteristics has been 
underway.      
2.2.1 Near-Infrared Window 
Molecular fluorescence relies on the emission of a photon from a molecule relaxing 
from an excited singlet state and compete with alternate relaxation pathways (i.e. 
phosphorescence, vibrational relaxation, etc.); the photon emission must be tuned to specific 
wavelengths using structural modifications. Fortunately, there exists a region where tissue 
features minimum absorption and fluorescence characteristics thus allowing engineered 
contrast agents to operate effectively by avoiding the disruptive background signal present at 
lower wavelengths.  It has been well defined and established that near-infrared (NIR, 650-900 
nm) light exhibits optimum characteristics for imaging applications in vivo, owing to the low 
tissue attenuation resulting in high penetration depth and minimum background 
autofluorescence. [17-31]  These characteristics afford high signal to background (SBR) which 
is recognized as the paramount descriptor for successful site-specific contrast agents.  The 
opportunity for high SBR paired with cost effective lasers/detectors and the inherent innocuous 
nature of NIR light makes it a promising technology for development. [32-38]   
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Figure 2-2. NIR Region and Characteristics. (A) The electromagnetic spectrum with a 
magnification of the visible and near-infrared region. (B) Imaging modalities, examples and their 
general characteristics with beneficial characteristics shown in blue and negative characteristics 
shown in red. 
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The holy grail of NIR imaging exploits the large wavelength window and offers two 
distinct imaging channels (i.e. channel 1: 680-720 nm and channel 2: 780-820 nm, Figure 2) 
which would theoretically allow a single disease targeted fluorophore to be spectrally distinct 
from another contrast agent directed to sensitive tissues (i.e. nerves, etc.) - should the optimum 
contrast agents exist.  The clinical platform that harnesses NIR irradiation is depicted in Figure 
2.  A broad spectrum excitation light source is used for brightening the surgical field and 
excitation of the two spectrally distinct targeted NIR fluorophores that have been intravenously 
injected.  Optical filters facilitates the isolated detection of 700 nm, 800 nm and visible light 
which can be viewed independently or as an overlay to obtain a merged image (Figure 3).  
Highly specific targeting and knowing the wavelength for each targeted tissue (i.e. one channel 
for diseased tissues and the other for native tissue) affords a clear real-time visualization of the 
surgical field. However, in our quest toward obtaining the dual-channel pinnacle of real-time 
NIR imaging, we must design contrast agents within the requisite boundaries for developing 
any pharmaceutical or medicinally relevant agent. 
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Figure 2-3. The general schematic of dual channel image guided surgery and color video 
overlay for real-time imaging of the surgical field. 
2.2.2 Requisite Design Parameters 
Before NIR imaging successfully emerges in the clinic, contrast agents must be 
designed to satisfy a very particular set of parameters that are requisite to future successes. 
Many classes of known fluorescent structures have been used successfully and they encompass 
three unique classes.  One of the most studied is the small molecule fluorophore such as 
cyanines [39-48], porphyrin-based fluorophores [49-56], metal complexes [57, 58], xanthene 
dyes [59-65], squaraine rotaxanes[66-74], phenothiazine-based fluorophores [6, 7, 75-82]; 2) 
synthetic nanoparticles such as quantum dots (QDs) [83-90] and 3) biologics such as green 
fluorescent protein [91-103].   All of these representative contrast agents must be chemically 
tailored to assume particular characteristics in the body to be clinically relevant.  The chemical 
structure must be engineered for stability, specificity and safety for human use. 
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The stability of a contrast agent in vitro and in vivo can be defined by the retention of 
the original chemical, physical and optical properties.  If the molecular structure becomes 
compromised in the presence of proteins in vivo, the signal to background may be lessened or 
the entire molecular targeting capability may become impaired.  These characteristics cannot 
be overlooked because long-duration surgeries require that the contrast agent remain visible in 
the diseased tissue for an extended period of time, this effect is known as enhanced permeation 
and retention (EPR).  In order to fulfill this criterion, the molecule must be non-labile to 
nucleophilic thiol and amine species, resistant to photobleaching and changing redox 
conditions while simultaneously retaining biological activity. Once narrowing the design 
criteria to include robust chemical bonds, the specificity to the target-site must be considered.  
Specificity is defined as the ability to differentiate between the targeted tissues and the 
non-targeted tissues. Specific targeting improves the overall image of the target tissue because 
it improves the target signal by lowering the signals around the target. The injected contrast 
agents’ traveling path (biodistribution) needs to be traced to achieve accurate targeting and 
complete excretion. Once the contrast agents are introduced into the body, the molecules gather 
in specific targeting tissues and cells. There are two types of ways in which contrast agents 
amass in specific tissues: organ-specific targeting and subcellular-specific targeting (to be 
discussed in detail later).  
Safety implies that contrast agents should not impart negative side effects or interfere 
with biological function in any way, but also, any potentially biodegraded products of the 
contrast agents should pose no harm to the surgical patient (re stability).  Minimizing undesired 
negative consequences due to potentially toxic characteristics of the contrast agents can be 
partially controlled by manipulating their size, charge, absorption and elimination. Since 
cyanine-based contrast agents, for example, are inherently non-toxic, based on the clinical 
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evaluation of ICG, exploring this class as nontoxic and biocompatible contrast agents could 
have outstanding clinical significance. 
 
These medicinal properties are highly important for future clinical translation and must 
be maintained throughout the developmental process of a contrast agent. The sensitivity, 
specificity, delivery, pharmacokinetics and toxicity depend highly on the targeting method used 
and the overall chemical composition of the contrast agent where the stability in also a 
determining factor to in vivo success, the chemical bonds and moieties present only limit the 
choices available for modification which does not directly influence the site-specific imaging 
characteristics.   
In the pursuit of efficacious NIR contrast agents, the specificity (i.e. targetability and 
clearance) remains the dominating factor that determines the future outlook of an engineered 
fluorophore and there are several molecular blueprints that have been used to overcome this 
obstacle. 
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2.3 Methods for Obtaining Site-Specific Imaging.  
Site-specificity is determined by the signal-to-background ratio (SBR).  As a simple 
comparison of the signal in the targeted tissue to the signal in the surrounding area, this ratio 
(SBR) plays a fundamental yet crucial role in the imaging of small and otherwise undetectable 
tissues. For example, when contrast agents fail to display high tissue specificity resulting in 
low SBR, small tumors or occult metastases would remain invisible, and the imaging procedure 
would not afford meaningful guidance to perform a complete resection thus leading to multiple 
unwarranted surgeries or poor patient survival.  Overcoming this obstacle has proved 
challenging and has been the focus of a recent thrust recent research. Throughout the years of 
developing targeted optical probes, various research labs have engineered contrast agents that 
exploit biological systems in various ways to achieve optimal signal-to-background ratio in 
desired tissues.   
These different methods of harnessing/manipulating our biological systems to achieve 
site-specific imaging can be grouped into three categories (shown in Figure 4) which all have 
inherent positive and negative characteristics.  These three methods are, 1) passive targeting 
via the enhanced permeability and retention (EPR) effect, 2) active targeting via biodistribution 
of known molecules and 3) activatable targeting through an internal stimulus.  
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Figure 2-4. The three main strategies for the imaging of a particular region of diseased or 
cancerous tissue. 
 
Passive targeting through EPR effect relies on the overall biodistribution of a NIR 
fluorescent contrast agent to achieve site selective imaging. For example, the leaky vasculature 
of tumors frequently allow larger molecules to enter compared to the more selective healthy 
tissue. In normal cells, the vasculature remains non-permeable allowing only those molecules 
of a particular size or bearing molecular recognition moiety through active transport.  This 
preferential accumulation in the tumor offers a pathway for obtaining site specific imaging 
through the EPR effect. A contrast agent of the appropriate size, charge and pKa bearing certain 
hydrogen bond donors/acceptor characteristics and other physicochemical properties must be 
engineered to passively localize within tumor tissues with unbound contrast agent being cleared 
rapidly from the body.  Unless careful design considerations are employed, this proves to be a 
relatively slow method that commonly results in nonspecific fluorophore distribution and high 
background signal resulting in reduced signal-to-background and loss in imaging clarity.   
The perhaps most straightforward strategy for disease-specific targeting is through the 
active approach, which involves an engineered NIR fluorophore being synthetically tethered 
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to a targeting moiety which selectively binds the diseased tissue [104-127] .  Surface 
biomarkers, specifically in cancer cells, have been effectively exploited for homing contrast 
agents directly to diseased tissues. This is a very rapid process with potential for high signal-
to-background ratio and complete excretion associated with reduced non-specific binding.  
However, problems occur when the tumor does not express large quantities of the surface 
integrin which significantly lowers the overall signal-to-background ratio. Other factors also 
must be considered when designing compounds for active-targeting of diseased tissue, 
including the size molecular weight/size of the contrast domain and the excretion pathway.   
The last method is when a contrast agent is activatable through a particular internal 
stimulus. Normally, when using this method the contrast agent’s fluorescence is quenched 
using any number of methods (i.e. synthetically attached and biologically labile dinitro 
compounds, reduction of azides, pH-sensitive moieties, etc).  Once injected, the molecules 
exhibiting diminished fluorescence intensity travel throughout the body and become activated 
at the target by a known stimulus commonly associated with the tissue or microenvironment 
(i.e. pH[128], concentration of metabolite, redox potential in hypoxic cells, etc.) and exhibits 
fluorescence. This is a very slow process with a nonspecific distribution of the molecules. This 
strategy displays very low background signal that results in an overall high signal-to-
background ratio.  
By developing distinct site-specific fluorophores with complete clearance of unbound 
contrast agent will afford surgeons a powerful real-time approach to complex surgeries and 
increased quality of care for surgical patients.  
2.4 Nanoparticles for In Vivo Imaging.  
The nanoparticle-based contrast agents for optical image-guided surgery are currently 
being developed and their total performance depends strongly on their molecular design, 
physiochemical and optical properties. [129-137]  The molecular design must feature four 
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major components that are depicted in Figure 5.  This modular schematic shows the effector 
domain, in this case a nanoparticle-based contrast agent, being attached to a targeting ligand 
through an isolating linker.[138-141]  It is important that this isolating linker does not influence 
the biological recognition of the targeting ligand which could be a small molecule or peptide.   
This is achieved by the addition of a balancing domain that helps the effector domain achieve 
a particular size, shape or hydrophobicity to improve the pharmacokinetic properties and 
overall biodistribution/clearance of the effector domain.  Ideally, the imaging agent without the 
targeting ligand would be cleared rapidly through renal filtration without non-specifically 
binding to tissues.  Adding the homing device (targeting ligand) to this nano-imaging agent 
would afford high signal-to-background imaging when a successful ligand is employed in the 
presence of the targeted tissue.  
 
Figure 2-5. General overview for the modular approach to the design of targeting contrast 
agents/therapeutics.    
Recent advancements in nanoparticle-based imaging suggest high promise in the future; 
currently, however, the intrinsic character of nanoparticles does not readily lend itself to 
biological compatibility.[142]  Owing to this principle, rapid clinical translation is not common 
in the nanoparticle space.  Though nanoparticles are slowly becoming accepted by regulation 
agencies, in the meantime, small molecule, (defined herein as subnano) imaging agents, offer 
a unique and appealing alternative with respect to the ability to synthesize a single chemical 
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entity with high reproducibility and purity.  These characteristics lend themselves to FDA-
approved clinical translation and predictably reproducible in vivo success. With the FDA 
approved indocyanine green, it is likely these subnano agents that will be the first clinically 
relevant contrast agents in site-specific imaging; therefore, the remainder of this review will 
focus on exciting and robust research in this area.  
2.5 Subnano Imaging Agents.  
Compared to the nanoparticle blueprint, a more simplistic modular design for disease 
or tissue specific imaging agents is shown in Figure 6A.  Similar to the first schematic, there is 
a targeting ligand that serves as the homing beacon that delivers the imaging agent to the tissue 
of interest; however, the effector domain must remain either comparatively small (against the 
targeting ligand) or biologically silent through the synthetic incorporation of a balancing 
domain within the structure of the fluorophore.  These two design approaches are not equal as 
reducing the effector domain size effectively limits the aromatic system resulting in blue-
shifted absorbance/fluorescence wavelengths (i.e. non-NIR region); therefore, we are left with 
perfecting the balancing domain to achieve a biologically inert effector domain portion of the 
overall contrast agent. Above this, however, the Holy Grail of NIR imaging (dual channel 
imaging capability of the surgical field) requires the targeting of healthy tissue which requires 
the engineering of additional fluorophores that exhibit native tissue site-selectivity.  Cellular 
surface receptors and subcellular targeting domains for native healthy tissue remain scarcely 
known within the literature; therefore, a tethered approach would not be an obvious choice for 
obtaining site-specific contrast agents for these tissues.  The greatest success thus far in healthy 
tissue targeting has been obtained through structure inherent targeting which features a 
simplified molecular design. 
Reducing the complexity in modular design even further, the isolating linker may be 
removed, leaving a single fluorophore with all three of the requisite characteristics expressed 
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on the one fluorophore domain—as shown in Figure 6B, known as structure inherent targeting  
Both molecular blueprints have been exploited to assume excellent properties in vivo, and the 
design and structural requirements vary greatly depending on the targeted tissue (i.e. 
disease/tumor for resection or sensitive tissue for avoidance).  
 
Figure 2-6.  (A) Compact modular design for preparing tissue-targeting imaging agents 
and (B) structure inherent imaging through the incorporation of targeting elements into the small 
molecule structure. 
2.6 Targeted Approach.  
Numerous peptidyl-fluorophore tethering approaches have been recently explored with 
a varying degree of success.  The three factors that are individually requisite in the in vivo 
performance of tethered fluorophores are shown in Figure 6A: the targeting ligand, the isolating 
linker and the dual-purposed fluorophore with an effector and balancing domain.  Successful 
implementation of this approach requires several specific engineering hurdles.   
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2.6.1 Targeting Ligand.  
Perhaps the most crucial aspect for the success of a targeted site-specific probe is the 
choice and overall efficacy of the targeting ligand—the homing beacon to the tissue of choice.  
Through direct covalent conjugation to the effector domain, this ligand may target and bind 
surface molecules or overexpressed receptors on the cell surface.  Figure 7 depicts a non-
exhaustive list of successful ligands that have shown promise in the targeting of various cell 
types.   
 
Figure 2-7. Small molecules and macromolecules used for tethering to direct NIR 
fluorescent domains to particular targets for developing site-specific contrast agents. 
2.6.2 Isolating Linker.  
Upon first glance, the isolating linker’s importance is immediately understated; 
however, the importance of optimizing the physicochemical, structural and dynamic properties 
cannot be underestimated. The isolating linker component of the entire contrast agent should 
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be sufficiently flexible to allow the targeting ligand and fluorophore to act independently but 
also satisfactorily rigid to keep these two domains physically separate in three dimensional 
conformational space.  Furthermore, the isolating linker should be chemically inert to avoid 
unfavorable interactions with either domains but should be robust throughout the procedure.  
Most importantly, the isolating linker must impart either a positive or negligible effect on the 
physicochemical properties (i.e. overall pKa, net charge, logD, etc) which highly influence in 
vivo biodistribution.  This concept is important in order to allow the targeting domain to remain 
the sole guiding force in the body. In balance with these design criteria, the isolating linker can 
also have a functional purpose as we will discuss later, wherein the linker may be enzymatically 
cleaved in tumor cells which can result in site-specific contrast through activatable 
fluorescence imaging, should the correct criteria be met.  
2.6.3 Effector and Balancing Domain.   
Satisfactory molecular brightness in vivo and clearance properties (pre-ligand 
attachment) are the major obstacles to perfecting characteristics for future implementation in 
the clinic (reviewed in [9]). 
The optical profile, specifically regarding Stokes shift, extinction coefficient and 
quantum yield, is high dependent on the rigidity of the core fluorophore structure, specific 
modifications to the conjugated system and solvent-fluorophore effects (reviewed in [9]).  
Indeed these are design considerations that must be overcome in the pursuit of an efficient 
effector domain; however, when navigating this area, it is also necessary to structurally 
engineer a balancing domain that reduces the biological interactions that result in off target 
imaging.  
Their physicochemical properties (i.e. molecular weight, total polar surface area, 
hydrogen bond donors/acceptors, acidic/basic pKa, distribution/partition coefficient and 
stability) heavily influence their in vivo fate with slight structural modifications posing 
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significant biological perturbation. If correctly selected, these physicochemical descriptors 
may provide a shielding characteristic to the fluorophore allowing the targeting ligand to act 
independently of the optical contrast agent.  In the most simplistic structural design, the 
targeting moieties and balancing domain must be well integrated into the overall molecular 
structure such that both properties are retained without jeopardizing site-selective targeting. 
2.6.4 Recent Literature on Targeted Imaging.  
Many of the fluorophores described to date have one or more detrimental fallbacks 
ranging from limited chemical/optical stability, insufficient fluorescence quantum yield in 
serum, or high background signal in vivo arising from non-specific binding to extracellular 
proteins.  These chemical structures have been extensively modified for decades with only 
minor improvements to tissue affinity and background reduction. Choi et al.[143, 144] 
explored the importance of judiciously incorporating charge in the engineering of fluorophores 
for maximizing targeting efficacy by carefully incorporating zwitterionic character into a 
heptamethine cyanine chromophore which yielded the final fluorophore, ZW800-1, resulting 
in minimal fluorophore-serum protein interactions.  This engineered characteristic imparts 
ZW800-1 with the unique ability to allow any functional biological ligand to act independently 
thus effectively targeting the corresponding receptor.  Building on this principle, Njiojob et 
al.[145] and Hyun et al.[146] developed analogous fluorophores bearing either a meso-
thioether bond or central carbon-carbon bond respectively, with either an available carboxylate 
or primary amine for conjugation; these modifications have increased functionality and 
improved stability for long-term surgical measurements while exhibiting the unparalleled 
clearance properties arising from the zwitterionic surface charge.  An immediate downfall of 
the commercial gold standard, indocyanine green (ICG), is the lack of a reactive handle for 
covalent modification with a targeting ligand, but ICG also demonstrates poor biodistribution 
and clearance properties with high background signal throughout the gastrointenstinal tract.  In 
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comparison, the ZW800 analogs are rapidly cleared through renal filtration as shown in Figure 
8.  The benefits of rapid excretion cannot be understated.  These data indicate that the 
zwitterionic balancing domain on the fluorophore is highly effective at preventing interactions 
with biological tissues and proteins.  In theory, once this fluorophore is conjugated with a 
targeting ligand, the biodistribution would rely solely on the targeting ligand as the fluorophore 
has be engineered to exhibit minimal in vivo binding.  In fact, when the commercial alternative, 
Cy5.5, and the ZW800-1 analog are modified with cRGD, Choi et al. observed unparalleled 
tumor targeting with low non-specific background as seen in Figure 8B. [143] 
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Figure 2-8.  (A) The in vivo performance of ICG, and 3 ZW800 analogs with attributes 
tabulated showing the net charge, availability for covalent targeting modification, LogD (pH = 
7.4),  clearance route, clearance % after 4h., overall biodistribution (Li, Liver; Du, duodenum; 
GB, gallbladder; Bl, bladder; Ki, kidney), and optical stability in FBS after 24h. (B) The 
performance of ZW800-analog compared to Cy5.5 both modified with cRGD in vivo. Adapted 
with the permission of The Royal Society of Chemistry, the American Chemical Society and 
Nature Publishing Group. 
 
These ZW800 analogs have laid fundamental groundwork for the translation of NIR 
image guided surgery into the clinic.  Building on these compounds, the Choi and Henary labs 
developed complementary analogs (i.e. ZW700 compounds, Figure 9) for identical imaging at 
the lower wavelength channel. [147] The ZW700-1 contrast agent was conjugated to bovine 
serum albumin which afforded effective imaging of the tumor angiography to identify major 
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blood vessels that should be avoided during cancer resection surgery.  When this bioconjugate 
is paired with the ZW800-cRGD, surgeons are armed with a powerful and effective dual-
channel imaging of both native and disease tissue in real-time without changing the look of the 
surgical field. 
 
Figure 2-9.  (A) The ZW700-1 structure that was prepared for the 700 nm channel of NIR 
imaging guided surgery alongside the biodistribution in mice showing rapid elimination after 4 
hr. into the bladder (Bl), (B) The ZW700-1 conjugation to bovine serum albumin which allowed 
for angiographic imaging using 700 nm channel which was used alongside cRGD-ZW800-1 to 
target cancerous tumor in 800 nm channel and the merged imaging provides real time image 
guidance with all three cameras overlaid. 
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Similarly, the bioconjugated imaging agent relies heavily on the targeting moiety for 
site specificity and developing new targeting ligands is a critical barrier toward imaging native 
tissues in the body.  Whitney et al. discovered new peptides that allow for the detection of 
nerves, NP41 (NTQTLAKAPEHT), that was conjugated to the pentamethine cyanine 
fluorophore Cy5. [148]  The nerve imaging of this Cy5-NP41 targeted contrast agent is shown 
in Figure 10.  In addition, the mice were genetically engineered to express yellow fluorescent 
protein in the axons of their nerves which is shown by the yellow fluorescence signal in Figure 
10B. When a cross section of the nerves are examined, there is clear delineation of the axon 
and nerve shown in the composite image in Figure 10 panels E-G. 
 
Figure 2-10. Cy5-NP41 imaging of the sciatic nerve in transgenic mice engineered to 
express yellow fluorescent protein with insets showing zoomed images in panels A-C. (A) Normal 
color camera view of the sciatic nerve. (B) Same nerve visualized byYFP fluorescence 
(pseudocolored yellow) superimposed on the visible video image (C) Cy5 fluorescence 
(pseudocolored cyan) superimposed on the brightfield image, showing nerve labeling with Cy5-
NP41. The arrows in panels B and C indicate improved Cy5 imaging of thin and obstructed nerve 
branches. (D-G) Cross sectional areas corresponding to the nerve shown in panels A-C. (D) Cross-
section of the sciatic nerve revealing myelin using differential interference contrast (DIC), 
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pseudocolored blue. (E) D Axoplasmic yellow fluorescent protein (YFP) pseudocolored green 
(arrows). (F) Cy5-NP41 labeling (pseudocolored red) of epineurium (arrows) and endoneurium 
(arrowheads). (G) Composite image of d, e and f showing that Cy5-NP41 labeling does not 
colocalize with either myelin or axoplasm. Figure was adapted with permission from Nature 
Publishing Group. 
 
When fluorescent compounds are tethered to large biomolecules or even small 
molecules through an isolating linker it generates a large molecular complex that is retained in 
non-specific locations which reduces the clarity of imaging.  While active targeting is an 
attractive and heavily researched field, there are also improvements that would come from 
reducing the size of the overall complex – this concept is embodied by structure inherent 
targeting. 
2.7 Structure-inherent Targeting.  
As previously discussed in Figure 4, the enhanced permeation and retention effect 
describes a contrast agents’ ability to localize within one particular tissue versus another, 
usually based on the general biodistribution phenomenon.  Recently, it has been postulated that 
the parent structures of various classes of fluorescent small molecules that have innate 
biodistribution pathways may be manipulated through the addition or removal of certain 
isolated functional groups to achieve site-selective imaging. [149-153]  Taking advantage of 
the modification potential of several fluorophore classes, several reports now suggest that 
specific modifications may improve site-specificity.  These modifiable chemical structures 
have been exploited to optimize the chemical structure and direct localization/imaging to 
diseased tissue or native organs.  A structure inherent approach would help overcome the 
obstacles of targeting ligand-based contrast agent to native tissues and sensitive glands which 
remains a longstanding clinical problem in contrast agent development.  Hyun et al.[152] and 
48 
 
Owens et al.[150] were two of the first suggestions in the literature that the molecular character 
may be modified and finely tuned to achieve selective uptake with high SBR in particular 
tissues using a structure-inherent approach which exploits chemical recognition to biological 
tissue for targeting and biodistribution.  Selective modifications can direct the pharmacophore 
to distinct regions utilizing the structure-inherent chemical recognition to the targeted tissue.  
We observed that tuning the hydrophobicity of NIR fluorescent compounds allows for high 
uptake in the endocrine system.[150]  Figure 11 shows ESNF-10 that localizes in the thyroid 
gland, adrenal gland and ovaries in female mice with the same compound exhibiting high 
localization in identical tissues in swine—thyroid gland shown as an example in Figure 11. 
 
Figure 2-11. The targeting ability of a pentamethine cyanine fluorophore showing site 
specific uptake through passive targeting.  The biodistribution offers high SBR with excellent 
imaging of the thyroid gland (TG) in CD-1 mice and swine and the adrenal gland (AG) and ovaries 
(Ov) in CD-1 mice. 
 
Similar results have been achieved through tuning the physicochemical properties and 
rationally incorporating recognition elements into the compounds. Cartilage and bone imaging 
plays a crucial role toward more fully understanding the disease progression within these 
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particular tissues.  Hyun et al. rationalized that the negatively charged sulfonato and 
carboxylate groups present in cartilage would be an effective characteristic to exploit for 
cartilage-selective imaging (Figure 12A).  Selecting quaternary ammonium moieties for 
chondrocyte targeting in cartilage afforded a core pharmacophore that highlighted all types of 
cartilage very nicely without discriminating between the specific types of cartilage.[154] 
Figure 12B shows the 700 nm channel which highlights the cartilage imaging contrast agent 
seen in red in the merged image. Similarly, phosphonate groups in the non-resonant side chain 
of the contrast agent serves as the structure-inherent homing beacon to bone.[151, 153] The 
phosphonate structures interacts favorably with the hydroxyapatite in bone tissue – likely 
through calcium binding – and very clear imaging can be obtained for long durations as the 
contrast agent becomes incorporated within the bone matrix.  There two contrast agents 
epitomize the desired success in dual-channel NIR imaging, and these two site-specific 
fluorophores have great potential in the monitoring of cartilage tissue engineering and 
therapeutics and also in the study of osteoblast formation and maturation in bone.   
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Figure 2-12. Physiological targets, molecular character, representative molecule and 
corresponding in vivo NIR images of subnano imaging agents that are tailored for imaging of 
cartilage and bone in pigs 4h post injection. Figure adapted with permission from Wiley 
Publishing. 
 
Other native structures must be imaged during surgical resection, especially in the 
removal of pancreatic tumors where healthy tissue should not be jeopardized. Also, pancreas-
related surgeries including peripancreatic lymph node resection, adrenalectomy, and 
nephrectomy currently show an intolerable level of risk. Towards alleviating this risk and 
affording surgeons real time imagery of the pancreas and surrounding tissue, Owens et al. and 
Wada et al. reported pentamethine fluorophores that target the pancreatic tissue with high SBR.  
Small and compact fluorophores with low hydrophobic character were found to be most 
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effective in the target-ability of pancreatic tissue.  Figure 13 shows the chemical structure of 
700 nm pancreatic targeting contrast agent used in two pancreatic surgeries, one surgery where 
the adrenal gland is targeted in the 800 nm channel using the hydrophobic heptamethine 
fluorophore and the other surgery imaging angiography using ZW800-1. 
 
Figure 2-13. Chemical structure of pancreas targeting and imaging of nearby structures 
with corresponding in vivo NIR images of subnano imaging agents that are tailored for imaging 
of specific tissues. Figure reproduced and adapted with permission from Theranostics and 
Ivyspring Publishing. 
 
Similarly, NIR fluorophores were developed that target the thyroid and parathyroid 
gland in identical surgical space using two fluorinated cyanine chromophores.  It was found 
that the pentamethine compound (700 nm fluorescence) localized effectively in the thyroid 
gland and the heptamethine cyanine (800 nm fluorescence) became flushed from the thyroid to 
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the parathyroid gland (Figure 14).  Dual channel imaging of these glands afforded a very clear 
delineation of these two glands for biopsy or surgical excision.   
 
 
Figure 2-14. Molecular structure of NIR fluorescent imaging agents and corresponding 
in vivo NIR images for the subnano imaging agents that are tailored for imaging of thyroid and 
parathyroid in the same surgical space. Figure reproduced and adapted with permission from 
Nature Publishing Group. 
 
Despite all of the small molecule derivatives that have been synthesized and tested 
throughout the literature, there are only scarce reports of nerve targeted contrast agents.  A 
screening of phenoxazine based fluorophores has been reported by Park et al. that shows 
exciting nerve targeting properties for identification and avoidance.  Shown in Figure 15, this 
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fluorophore successfully labels the brachial and sciatic nerve in mice with even small 
peripheral nerve endings being well visualized toward improving post operation patient 
prognosis.  Amazingly, only minor perturbations in the chemical structure removed the nerve 
targeting ability of the fluorophore.   
 
Figure 2-15. Oxazine 4 as an exemplary nerve targeting agent with corresponding in vivo 
NIR images for both the brachial and sciatic nerves.  Below the immunohistochemistry confirms 
the nerve targeting of Oxazine 4.  Figure reproduced and adapted from Theranostics and 
Ivyspring Publishers. 
2.8 Activatable NIR Imaging Agents.  
The development of successful paradigm shifting activatable NIR imaging probes has 
been slow compared to alternate approaches.  This owes strongly to the complexity in design 
and increased requirements required for engineering these highly intelligent molecules.  In this 
high-risk, high-reward situation, a successful imaging agent could dominate the optical 
imaging space; however, the site specificity of healthy tissues remains an unsolved 
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shortcoming of this approach though tumor targeting is well established.  These well-
established methods for targeting tumors exploit unique attributes of cancer cells, for example, 
the Urano and Kobayashi labs described pH activatable NIR fluorophores that are covalently 
linked to monoclonal antibody trastuzumab which binds to human epidermal grown factor 
receptor type 2 (HER2).  After binding, the probe-antibody complex is internalized within 
cancer cells through a lysosomal degradation pathway (Figure 16A).  This acidic environment 
causes protonation of the tertiary amine installed on the fluorophore core resulting in increased 
fluorescence compared to the non-protonated counterpart.  Figure 16B shows the fluorescence 
images of pH activatable contrast agent and the always on version as a function of pH.  Using 
these probes, we can see cellular turn-on of fluorescence in panel C in Figure 16 when the 
diethylamine is present; however, the always on probe retains fluorescence signal over time.  
The in vivo images (Figure 16D) show excellent tumor targeting but the always on probe shows 
high background in the tissue surrounding the tumors, but the activatable probe lowers the 
background signal which allows high SBR and a clear depiction of diseased tissue for surgical 
removal.  
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Figure 2-16. pH activatable BODIPY NIR imaging probes. (A) General strategy for 
targeting pH probes to tumor cells and activating fluorescence with a pH response, (B) two (of 
four, not shown) analogs of pH activatable and always on (control) compounds and their pH-
fluorescence profile, (C) cellular imaging at time 0 h and time 24 h showing always on fluorescence 
and cell endocytosis mediated fluorescence activation (see A), and (D) in vivo imaging showing 
effective targeting of tumors in both always on and activatable contrast agents—SBR is much 
higher when using the activatable probe. Figure reproduced and adapted with permission of 
Nature Publishing Group. 
 
The use of pH activation is a well described concept with this report embodying an 
excellent implementation of this approach. Despite this success, we require an arsenal of 
contrast agents for universal implementation of NIR imaging technology. Toward this goal, 
alternate designs have been explored that activate when reaching tumor sites. Increasing 
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evidence shows that folate receptors are overexpressed on the surface of many cancer cells and 
targeting these receptors through covalently tethering a folic acid moiety to a effector domain 
has been a longstanding concept.[155-172]  Using this folic acid dually as a quenching moiety 
and homing beacon, Lee et al. [173] explored the targeting of ovarian cancer using an 
activatable probe that remains quenched through intramolecular charge transfer between the 
effector domain, dye ATTO655, and folic acid (shown in Figure 17A [173]).  The isolating 
linker in this case is uniquely constructed to cleave in the presence of cathepsin B.  After the 
folic acid domain recognizes the cellular target and the probe enters the cell, the linker is 
recognized and cleaved by lysosomal cathepsin B resulting in enhanced fluorescence.  Cellular 
data that shows fluorescence “turn-on” in the presence of tumor cells and no fluorescence when 
a folate receptor inhibitor is added confirms the suspected mechanism of action. This enhanced 
fluorescence results in high signal to background imaging of tumors with small signal in the 
liver.  The peptide and folic acid incorporation is critical in the targeting ability of this contrast 
agent as the dye along is excreted rapidly from the body and does not preferentially accumulate 
in any particular organ or tissue based on the NIR images.    
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Figure 2-17. Folate receptor-specific activatable (FSA) probe. (A) The design and 
structure of the final probes using in (B) cellular experiments in SKOV3 cells expressing the folic 
acid receptor without a folic acid receptor inhibitor present and with a folate acid receptor 
inhibitor present and (C) in vivo data showing rapid clearance of the free dye after 30 minutes 
and high SBR imaging of the tumor tissue when using the FSA probe. Figure reproduced and 
adapted with permission of the Royal Society of Chemistry.   
 
The peptide-cleavage activation of NIR imaging is indeed a long standing concept; 
however, an elegant approach was reported by Nguyen et al.[174] and Savariar et al. [175] 
which describes the use of (ACPPs) [174, 176-179] and ratiometric activatable cell penetrating 
peptides (RACPPs) [180], respectively. A general depiction of these strategies are shown in 
Figure 18 with the peptides in the developed contrast agent being ion paired to facilitate 
clearance and limit non-specific binding.  When the cleavable peptide (shown in green) is 
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cleaved in the tumor environment, the cationic portion is retained within the tumor cell.  The 
difference in these two – ACPPs and RACPPs – lies on the negatively charged peptide. The 
ACPP diagram contains no additional domain on the negatively charged peptide (red) and is 
activatable in that tumor cells activate the peptide-portion and the signal is retained in the tumor 
tissue. However, the RACPP goes another step further and incorporates another fluorophore of 
longer wavelength (Cy7) that allows highly specific imaging of tumor tissue. Specifically, 
energy transfer arising from the fluorescence of a lower wavelength fluorophore to a quenching 
moiety (molecule that absorbs the fluorescence energy) is a well-established method for 
designing an activatable probe that selectively images tissues that facilitate the spatial 
separation of these two molecules. The key concept is maintaining close proximity before 
cleavage to allow the energy transfer to occur.  The ion-paired peptides help facilitate the 
orientation of these two fluorophores in the same space which allows the energy transfer from 
Cy5 to Cy7 (Cy5 quenching) to be efficient.  If these two fluorophores were not close to each 
other, this phenomenon would not be observed making this a very unique and effective strategy 
for high signal to background imaging.  Once the scissile peptide breaks, the two fluoophores 
are then allowed to separate through systemic circulation resulting in increased Cy5 
fluorescence being retained in the tumor with diffusion of the Cy7-peptide segment resulting 
in diminishing Cy7 fluorescence. 
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Figure 2-18.  (left) Activatable cell penetrating peptides (ACPPs) that harness ion paired 
peptides and a cleavable segment for sites-specific imaging (right) further modification of ACPPs 
that incorporates a second fluorophore Cy7 for ratiometric activation (RACPP). 
 
Figure 19A shows the timeline of tumor targeting for ACPPs that have been injected in 
to an organism containing tumor tissue.  After 6 hours, the polycationic-Cy5 ligand is retained 
with high fluorescence while a large amount of uncleaved contrast agent is cleared by the body.  
This leads to good contrast in the delineation of tumor tissue on the surgical field. After 24 
hours, however, the polycationic ligand begins to be excreted from the tumor cell resulting in 
equal signal in the tumor tissue and surroundings which reduces the SBR and makes imaging 
difficult.  Choosing the correct imaging timepoint is therefore highly significant.  Once all the 
procedures are optimized, it is possible to achieve proficient use of this technology resulting in 
the cancer surgery in Figure 19B where small remnants of tumor tissue was found using the 
ACPP NIR imaging method.  
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Figure 2-19. (A) Overall schematic for suitable imaging time points for ACPP contrast 
agent,  (B) the improved surgical resection with several small tumors being located by the ACPP 
contrast agent that would have been missed using current techniques (i.e. eyesight, feel, etc.). 
Figure reproduced and adapted with permission of Nature Publishing Group. 
Building on the activatable cell penetrating peptide scaffold, a second fluorophore was 
incorporated on the anionic peptide, creating a ratiometric activatable cell penetrating peptide. 
Figure 20A shows the fluorescence of the contrast agent before (black solid line) and after (red 
dashed line) peptide cleavage.  In essence, before cleavage energy transfer occurs from Cy5 to 
Cy7 resulting in the 780 nm fluorescence.  After peptide cleavage, the 670 nm fluorescence 
increases and the 780 nm fluorescence decreases due to an increase in distance.  This approach 
allows for high contrast imaging according to the mechanistic schematic in Figure 20B.  
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Immediately post-injection the contrast agent will be in equal concentration in tumor and 
normal tissues which offers no ability to distinguish the tumor margins.  After allowing more 
time for the peptide cleavage and clearance of unbound fluorophore, the Cy5-polycationic 
peptide fragment will be selectively retained in the cancer tissue.  This offers high signal to 
background imaging as seen in Figure 20C without dependence on the specific cancer cell type 
as both pancreatic and fibrosarcoma are imaged with clear identification, especially in 
comparison to a control contrast agent that features an uncleavable peptide in lieu of the 
cleavable peptide resulting in a fluorophore that only displays Cy7 fluorescence.  This ion-
paired control compound is effectively cleared from the body as indicated by the low signal 
indicated by the green color in Figure 20C.  The next logical technique would be to make 
cleavable peptides that respond to specific cancers.  Indeed, they prepared two contrast agents 
that respond to different enzymatic reactions that are dependent and unique to the tumor.  
Specifically, RACPP1 (MMP2,9-selective) or RACPP3 (elastase-sensitive) contrast agents 
were used to image PyMT 8119 GFP–positive metastases in mice liver.  After 2h, the livers 
were removed and the fluorescence values for GFP, Cy5, Cy7 and a ratio of Cy5/Cy7 were 
evaluated which indicated a higher and more accurate response for RACPP3 to identify tumor 
sites using high fluorescence ratios between Cy5 and Cy7. 
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Figure 2-20. The characteristics and imaging capabilities for RACPP. (A) the emission 
spectra of uncleaved and cleaved RACPP1 (630 nm excitation in mouse plasma) before (black 
solid curve) and after (red dashed curve) peptide cleavage with MMP-9. The starting spectrum 
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shows considerable quenching of the Cy5 peak at 670 nm which results in emission from Cy7 at 
780 nm, whereas the final spectrum is almost purely that of Cy5, (B) general schematic showing 
the imaging timeline for RACPP, (C) Cy5 intensity images (ex 620 nm, em 670 nm) 2 hours after 
intravenous injection of RACPP1 or an uncleavable control into mice bearing either HT-1080 
xenografts or subcutaneous LM-P syngeneic grafts after skin removal. Images are pseudocolored 
where pixels with only Cy5 emission are pseudocolored red (indicating cleavage of RACPP), 
whereas pixels with both Cy5 and Cy7 emission peaks are pseudocolored green indicating no 
cleavage, (D) RACPP1 (MMP2,9-selective) or RACPP3 (elastase-sensitive) contrast agents were 
administered via intravenous injection and the livers (PyMT 8119 GFP–positive metastases) were 
removed after 2 hours. The following images were obtained: GFP fluorescence images, Cy5 
fluorescence images obtained by exciting Cy5 at 620 nm, Cy7 emission images obtained by 
exciting Cy5 and Cy5/Cy7 emission ratio images.  Red indicates high Cy5/Cy7 fluorescence ratios 
and blue indicates low ratios. Arrows show regions that do not contain tumors which is indicated 
by low ratios of Cy5 to Cy7 fluorescence values. Figure reproduced and adapted with permission 
of Nature Publishing Group.   
2.9 Summary and Outlook.  
The technological advancements in this field of subnano near-infrared fluorophores in 
imaging has exploded resulting in tremendous potential to shift clinical paradigms.  With the 
sustained efficacious progress, as we have seen over the past five years, more in-human clinical 
trials will be seen and NIR imaging systems will become a more common technology in 
operating rooms. These advancements are, in turn, expected to solidify NIR fluorescence 
imaging technology and allow for the expanse into many surgical procedures. 
2.10 Future Directions.   
The influx of new site-specific NIR fluorescent contrast agents has great potential to 
revolutionize image guided surgery, but the NIR fluorescence imaging modality is limited to 
only intraoperative environments due to the signal loss through tissue. A single molecule that 
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allows for both whole-body imaging (i.e. PET/SPECT, MRI, etc.) paired with a disease-
specific fluorescent domain would allow one chemical entity to be used during an entire 
surgical operation from identification to resection.  Also, the ability to provide a structure-
inherent imaging approach for site-selectivity opens the doors to new possibilities of 
therapeutic imaging agents in the quest for new theranostic agents using a single chemical 
entity thus obviating the need for separate therapeutic and imaging domains.  
2.11 Conclusions.   
With these recent advancements, the imaging community is appreciating NIR 
fluorescence as a unique alternative to current imaging techniques.  Whole body pre-operative 
SPECT and PET imaging retains an important diagnostic utility, but they lack the efficacy of 
innocuous, targeted, subnano NIR fluorophores to simultaneously facilitate the real-time 
delineation of native and diseased tissue.  The library of site-specific fluorophores available in 
the literature offers clinicians an array of possibilities that will undoubtedly improve 
intraoperative success and long-term post-operation prognosis. 
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3 CORRELATING TISSUE LOCALIZATION OF HYDROPHOBIC CYANINES 
This chapter has been reprinted from the following publication in the Journal of 
Medicinal Chemistry.  My contributions as first author were the design, synthesis, optical 
property determination, molecular modeling and computational experiments, data 
interpretation and figure/manuscript preparation.  Owens, E. A., Hyun. H., Tawney, J. G., 
Choi, H. S., Henary, M. Correlating Molecular Character of NIR Imaging Agents with 
Endocrine-Specific Uptake 2015 Journal of Medicinal Chemistry 
 
3.1 Abstract 
 Near-infrared (NIR) fluorescent nanoprobes are emerging in optical imaging as 
sensitive, cost effective and non-harmful alternatives to current agents that emit harmful 
ionizing radiation.  Surgeons require these NIR-based nanoprobes to visualize sensitive vital 
tissues to selectively avoid them during surgical resection of diseased tissue; therefore, 
developing spectrally distinct fluorophores is of great significance to lower morbidity in the 
clinic.  In response to this clinical need, we report the synthetic variation of pentamethine 
cyanine fluorophores with systematic modifications of physicochemical properties towards 
prompting tissue-specific uptake into sensitive tissues (i.e., endocrine glands). Tissue-specific 
targeting and biodistribution studies revealed localization of intravenously injected nanoprobes 
in the adrenal glands, pituitary glands, pancreas and lymph nodes with strong dependence on 
the molecular characteristics. Heterocyclic modification involved the use of indolenine and 
benz[e]indoneline moieties to increase the logD of the compounds. Furthermore, incorporation 
of hydrophobic alkyl groups to the N-indolenyl site and halogens to the meso-carbon of the 
methine-bridge allowed a fine tuning capability to the hydrophobic character and overall dipole 
moment for observing perturbation in biological activity in response to minor structural 
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alterations. These NIR nanoprobes have potential for clinical translation for intraoperative 
imaging in the delineation of delicate glands.   
 
Figure 3-1. Graphical representation for this section which covers the development of 
structure-inherent NIR fluorophores.    
 
3.2 Introduction 
Molecular imaging agents that display selectivity toward various tissues are among 
paramount importance for use in image-guided surgery.1-7  For instance, visualizing native 
endocrine glands during head and neck surgery remains of high clinical significance as current 
imaging agents being explored utilize the emission of harmful ionizing radiation and place the 
patient and caregiver at undesirable levels of exposure.8, 9  Additional disadvantages of 
common molecular imaging modalities, such as positron emission tomography (PET) and 
single-photon emission computed tomography (SPECT), include their low spatial resolution of 
tissue and inability to conduct surgery in real-time with image capture.10 Optical imaging using 
near-infrared (NIR) light, however, is harmless as human tissues do not absorb these 
wavelengths of the electromagnetic spectrum.6  Developing fluorophores in the NIR window 
also helps to minimize the optical background that arises from fluorescence from native 
82 
 
biological tissue.11-17 This autofluorescence increases background signal which reduces the all-
important signal-to-background ratio (SBR) and makes delineating meaningful signal more 
difficult.   
Many groups have utilized a number of approaches for directing molecular imaging 
agents to particular organs using receptors attached to a reactive moiety residing on the 
fluorophore.18-21  These moieties normally include a carboxylic acid or amine for amide 
coupling or alkyne/azide for click chemistry which can be synthetically challenging. However, 
only a few methods have been explored for chemically tailoring a class of fluorophore for site-
specific uptake by glands and tissues using physicochemical predictors to systematically 
synthesize, evaluate and harness the inherent biodistribution of the fluorophores.22 To date, 
only one NIR fluorescent compound, indocyanine green (ICG), has been approved for clinical 
use by the U.S. Food and Drug Administration (FDA).23 Indeed the exact molecular structure 
does not offer appealing biodistribution properties or potential for additional chemical 
modifications, it serves to validate the cyanine class as an excellent choice for further 
optimization.24  Cyanine dyes are a unique class of compounds that are generally represented 
by two nitrogen-containing heterocycles linked via an electron-deficient conjugated 
polymethine bridge.25, 26   The absorption and fluorescence properties of these compounds can 
be tailored, and the two main subclasses of NIR-fluorescing cyanine compounds include 
pentamethine (~700 nm emission) and heptamethine backbones (~800 nm emission).  These 
compounds have appealing optical properties, including their red-shifted fluorescence, 
elevated quantum yields and high stability in serum.   
The FLARE (Fluorescence-Assisted Resection and Exploration) imaging system used 
for intraoperative NIR imaging utilizes two video channels (700 and 800 nm fluorescence) 
merged with a color video image.27, 28 We have previously reported a heptamethine cyanine 
dye (800 nm fluorescence) with unparalleled clearance properties that, after conjugation, 
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selectively images cancerous tissues.29, 30  For native endocrine-tissue imaging, therefore, we 
have reserved the lower 700 nm channel for dual imaging of the surgical field. Previously, we 
elucidated that cyanine chromophores have various binding strengths to serum albumin 
depending on their hydrophobicity31; therefore, we hypothesized that we could harness this 
interaction to manipulate the biodistribution of these compounds. Herein, we report the 
development of pentamethine cyanine imaging agents that display tissue-specific uptake into 
various endocrine glands resulted from the modification of the heterocyclic nitrogen and 
methine-bridge. 
3.3 Results and Discussion 
3.3.1 Synthesis of Pentamethine Fluorophores.   
 Using our optimized synthetic strategy for preparing pentamethine cyanines that exhibit 
varied hydrophobic character, we began by reacting either mucochloric 1 or mucobromic 2 
acid with aniline in warm ethanol and upon cooling and dilution with diethyl ether, the 
intermediate salts 4 and 5 precipitated as yellow solids with precursor 3 being commercially 
obtained.  In parallel, heterocyclic derivatives 8-15 were prepared from 2,3,3-
trimethylindolenine 6 and 1,1,2-trimethyl-1H-benzo[e]indole 7 using the corresponding alkyl 
halide in boiling acetonitrile.  Subsequently, the reaction of individual salts 8-15 with 
intermediate 3-5 formed the final pentamethine cyanines that were purified by open column 
chromatography or via our precipitation procedure from methanol using dilution with either 
diethyl ether or methyl tert-butyl ether until analytical purity was obtained for evaluating these 
compounds in bio-distribution experiments.   
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 Figure 3-2. The synthetic route to the final hydrophobic pentamethine fluorophores. 
 
Note: Cellular experiments were conducted regarding the following compounds and are 
previously referred to using ESNF nomenclature: 16 (ESNF-10), 22 (ESNF-11), 25 (ESNF-
12) and 31 (ESNF-14).32  Herein, we will discuss the animal studies concerning the entire 
systematic set of fluorophores and will be referred to by their numbers in the synthetic scheme.  
3.3.2 Optical and Physicochemical Properties.   
The optical properties, shown in Table 2.1, including max (ethanol and FBS), 
em(ethanol and FBS), extinction coefficient (ethanol, DMSO, PBS and FBS),  and 
fluorescence quantum yield (FBS) of the synthesized fluorophores were determined to ensure 
compatibility and visibility with the FLARE imaging.  All compounds showed excellent 
extinction coefficients in the near-infrared region in all four of the studied solvents with many 
compounds having very promising properties in serum.   
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Table 3-1 Optical properties of NIR fluorophores. All measurments were performed in 
several solvents, ethanol (EtOH), dimethyl sulfoxide (DMSO), phosphate-buffered saline 
(PBS), and fetal bovine serum (FBS), pH = 7.4 at 37 oC, and the fluorescence QY in FBS, 
pH = 7.4 at 37 °C. Abbreviations: λabs; maximum absorbance; λem; SS, Stokes shift; and 
QY, quantum yield. 
ID 

abs 
(nm) 
EtOH/FBS 

em 
(nm) 
EtOH/FBS 
SS (nm) 
EtOH/FBS 
Extinction Coefficient (M
-1
cm
-1
) QY (%) 
EtOH DMSO PBS FBS FBS 
16 645/649 660/662 15/13 212,500 248,200 218,800 184,500 31.0 
17 644/638 659/665 15/27 235,300 207,800 171,000 168,800 28.8 
18 641/634 657/660 16/26 257,330 253,200 204,400 211,700 43.6 
19 645/637 667/665 22/28 246,500 235,000 179,800 193,300 17.0 
20 646/649 662/659 16/10 262,200 237,000 213,600 204,000 25.5 
21 642/636 655/656 13/20 211,400 210,000 176,800 147,300 43.7 
22 644/640 666/668 22/28 210,200 182,800 177,600 140,200 16.0 
23 649/644 665/661 16/17 231,400 143,600 80,600 123,900 14.8 
24 646/640 661/660 15/20 218,300 134,600 73,600 135,200 15.7 
25 655/646 669/666 14/20 229,700 178,000 56,600 139,200 17.7 
26 652/653 664/665 12/12 254,500 228,200 62,000 113,000 22.1 
27 650/648 665/660 15/12 241,800 211,200 61,200 117,000 28.6 
28 680/688 701/711 21/23 177,500 167,600 60,000 168,400 17.5 
29 681/689 697/702 16/13 218,200 206,400 77,200 214,900 18.0 
30 676/682 699/699 23/17 164,800 173,400 54,600 161,100 17.9 
31 682/691 702/705 20/14 233,400 203,200 97,600 202,400 13.8 
32 684/690 700/705 16/15 215,200 172,800 86,000 207,400 21.9 
33 681/682 695/698 14/17 182,000 202,600 68,200 177,200 11.8 
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34 684/691 706/711 22/20 255,500 237,000 76,200 193,300 8.9 
35 685/691 703/702 18/11 233,800 201,200 56,600 157,100 12.0 
36 683/689 702/699 19/10 222,800 212,600 62,800 170,300 22.7 
37 685/698 711/710 26/12 194,200 95,800 39,400 166,700 14.5 
38 687/697 705/707 18/10 164,000 158,600 42,600 143,400 17.9 
39 685/695 704/709 19/14 285,200 220,200 56,400 133,900 12.9 
 
The more hydrophobic fluorophores displayed a second blue-shifted absorption 
maximum due to H-aggregation in the highly polar FBS (Figure 2.2).  Fortunately, we did not 
encounter loss in signal resulting from fluorescence quenching from microaggregation in vivo.    
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Figure 3-3 The absorption and emission spectra for each of the evaluated compounds (0.3 
M) in 100% FBS supplemented with 50 mM HEPES buffer at 37 oC.  
 
The quantum yield values are very high in serum suggesting great applicability in NIR-
fluorescence imaging.  In order to correlate in vivo biodistribution to the molecular 
characteristics of the synthesized fluorophores, the physicochemical properties (LogD, 
molecular weight and rotatable bonds) were predicted using ChemAxon (JChem plugin) with 
molecular dipole moment and volume being calculated using Spartan ‘10 (Wavefunction, Inc., 
Irvine, CA). The molecular weight values are independent of counter ion as the fluorophore 
and anion would become disassociated in vivo. The molecular weight values fall between 
383.55 and 770.86 and the distribution coefficient numbers fall between 3.56 and 10.85 with 
the halogenation at the central carbon, heterocyclic variation and alkyl length alteration 
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providing fine tuning characteristics to the hydrophobicity of the compounds for observing 
minor perturbation to the biological profile. Similarly, the molecular volume for the 
synthesized compounds fall between 445.39 and 806.74 and the compounds exhibit 0, 4 or 8 
rotatable bonds. 
3.3.3 Structure-Inherent Targeting Ability of Hydrophobic NIR Fluorophores.  
In order to assess the in vivo performance of the newly prepared pentamethine cyanines, 
we injected them into CD-1 mice and observed the passive localization and overall 
biodistribution. The synthesized compounds displayed very appealing structure-inherent 
endocrine targeting of biological tissues for intra-operative guidance using NIR light.  Surgeons 
require precise visualization of sensitive tissues to avoid accidental transection and we have 
focused our biodistribution study on the thyroid glands, adrenal glands, pancreas and lymph 
nodes.  
Table 3-2 The Physicochemical descriptors and targeting ability for each contrast agent. 
ID 
LogD           
(pH 7.4) 
Volume      
(Å3) 
Rotatable  
Bonds 
Dipole    
(debye) 
MW    
(g/mol) 
Targeted Tissues Biodistribution 
TG AG Pa LN Li Ki Lu Sp SG 
16 3.56 445.39 0 3.26 383.55         
17 3.79 458.97 0 1.88 417.99         
18 3.96 462.36 0 1.50 462.45         
19 4.27 482.09 4 2.10 411.60         
20 4.51 495.44 4 0.32 446.05         
21 4.67 499.85 4 1.35 490.5         
22 6.20 573.88 8 2.12 467.71         
23 6.44 587.27 8 3.47 502.15         
24 6.61 591.69 8 3.44 546.60         
25 8.47 686.97 8 3.42 591.85         
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26 8.71 700.36 8 5.05 626.29         
27 8.87 704.78 8 5.43 670.74         
28 5.54 546.41 0 4.45 483.67         
29 5.77 559.86 0 1.83 518.11         
30 5.94 564.29 0 0.67 562.56         
31 6.25 583.80 4 3.84 511.72         
32 6.49 597.23 4 1.36 546.16         
33 6.65 601.67 4 0.30 590.62         
34 8.18 657.21 8 0.71 567.83         
35 8.42 670.60 8 1.04 602.27         
36 8.59 675.02 8 1.04 646.72         
37 10.45 787.63 8 2.88 691.96         
38 10.69 800.94 8 4.42 726.41         
39 10.85 806.74 8 5.82 770.86         
In order to draw conclusions from these results and optimize a model for predicting the 
in vivo performance of NIR fluorophores, we attempted to correlate calculated 
physicochemical predictors with the biodistribution and localization within the targeted tissues.  
We have noticed a general trend for all of the tissues where the overall hydrophobicity (LogD, 
pH 7.4) greatly controls the in vivo fate of the molecules.  Specifically, thyroid gland (TG) 
targeting seems to be effective within a range of LogD values.  Observing the trend in Table 2, 
we see that the optimum hydrophobicity falls with 3.56 to 6.49.  Exemplifying this, we 
compared the butylated set of indolenine compounds 22-24 that spans the upper range we have 
set for TG targeting.  
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Figure 3-4. Thyroid gland (TG)-targeted NIR fluorophores. 10 nmol of each 
fluorophore was injected intravenoulsy into CD-1 mice 4 h prior to imaging and resection. 
Abbreviations used are: Du, duodenum; He, heart; In, intestine; Ki, kidney; Li, liver; Lu, 
lung; Mu, muscle; Pa, pancreas; SG, salvery gland, and Sp, spleen. Arrows indicate TGs. 
Scale bars = 1 cm. 
 
The compound with a meso-hydrogen atom 22 localizes effectively in the thyroid gland 
as seen in Figure 2.  The addition of meso-halogens to the butylated indolenine set of 
compounds 22-24 drastically lowers the thyroid targeting ability in deference to non-specific 
uptake in the lung resulting from an increase in hydrophobicity and higher enveloping by 
macrophages which carry the fluorophore to the liver for destruction and filtration.   
Similarly, we expected that since the TG and adrenal gland (AG) are both integrated 
into the endocrine system, they may be effectively targeted using similar molecular character.  
When comparing the adrenal gland uptake of compounds 34-36, all containing a 
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benzo[e]indoleine heterocyclic scaffold with a highly hydrophobic butyl group, we notice that 
the addition of meso halogens greatly reduces the successful targeting abilities.  Further 
examining the AG targeting set, we see that a wide range of LogD values spanning the entire 
set of compounds (3.56 to 10.85) are tolerated; however, meso-halogenation universally 
reduces the AG retention as seen in Table 2.   
 
Figure 3-5.  Adrenal gland (AG)-targeted NIR fluorophores. 10 nmol of each 
fluorophore was injected intravenoulsy into CD-1 mice 4 h prior to imaging and resection. 
Abbreviations used are: Du, duodenum; He, heart; In, intestine; Ki, kidney; Li, liver; LN, 
lymph nodes; Lu, lung; Mu, muscle; Pa, pancreas; and Sp, spleen. Arrows indicate AGs. 
Scale bars = 1 cm. 
 
The methylated dyes, 16-18, showed an interesting trend in pancreatic tissue (Pa) 
targeting (Figure 4).  The non-halogenated 16 (LogD = 3.56) displays increased signal in the 
pancreas compared to background signal with most of the fluorophore molecules being cleared 
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through renal filtration; correspondingly, the halogenated compounds, with slightly increased 
hydrophobicity (LogD = 3.79 and 3.96 respectively) and lower overall dipole moment shown 
in the electrostatic maps, shows slightly decreased SBR in the pancreas compared to 16.   
 
Figure 3-6. Pancreas (Pa)-targeted NIR fluorphores. 10 nmol of each fluorophore 
was injected intravenoulsy into CD-1 mice 4 h prior to imaging and resection. 
Abbreviations used are: Du, duodenum; He, heart; In, intestine; Ki, kidney; Li, liver; Lu, 
lung; Mu, muscle; Pa, pancreas; and Sp, spleen. Arrows indicate Pa. Scale bars = 1 cm. 
 
Observing the entire set of synthesized fluorophores, we observe that the lower LogD 
compounds with smaller molecular volume and smaller molar mass exhibit higher pancreatic 
uptake with compound 16 showing excellent localization.  
The last tissues that we aimed to target were the lymph nodes (LN), which are critical 
in locating during surgery to either remove, biopsy or avoid.  We see that as a general trend, 
the compounds exhibiting higher hydrophobicity localize within the LN with higher SBR 
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compared to more hydrophilic fluorophores; however, closely observing the correlation 
between LN targeting and LogD reveals that LN localization cannot be solely attributed to the 
hydrophobic character—though we have observed that the general hydrophobic nature of a 
compound greatly controls the in vivo fate in previous glands.  
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Figure 3-7. Lymph node (LN)-targeted fluorophores. A) Methylated 
benz[e]indolenine-based cyanines and B) ethylated benz[e]indolenine-based cyanines. 10 
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nmol of each fluorophore was injected intravenoulsy into CD-1 mice 4 h prior to imaging 
and resection. Abbreviations used are: Du, duodenum; He, heart; In, intestine; Ki, 
kidney; Li, liver; Lu, lung; Mu, muscle; Pa, pancreas; and Sp, spleen. Arrows indicate 
LNs. Scale bars = 1 cm. 
 
Building on this principle, we have noticed that the localization within the lymph node 
is dependent on hydrophobicity with overall dipole moment acting as a fine-tuning 
characteristic.  It has been previously reported that altering the dipole moment of steroid-based 
compounds drastically alters the overall biodistribution pattern33, and we have noticed a similar 
trend when comparing compounds 28-33.  Compounds bearing a meso-hydrogen atom 28 and 
31 display very high dipole moments ( >3.80 debye); however, the meso-halogenated 
compounds display comparatively low dipole moments ( < 1.85 debye) due to the inductive 
electron withdrawing characteristics acting adversely to the overall dipole.  Of all the 
physicochemical descriptors, only net dipole offers an effective explanation for the observation 
that only meso-halogen-bearing compounds localize effectively within the lymph node versus 
the hydrogen-containing parent compound within the effective LogD range.   
3.4 Experimental 
3.4.1 Chemicals, Reagents and Synthesis 
The chemical reagents used in the synthesis of these compounds were obtained from 
Acros Organics, Alfa Aesar and Matrix Scientific. The reactions were followed using silica gel 
60 F254 thin layer chromatography plates (Merck EMD Millipore, Darmstadt, Germany). Open 
column chromatography was utilized for the purification of all final compounds using 60-200u, 
60A classic column silica gel (Dynamic Adsorbents, Norcross, GA). The 1H NMR and 13C 
NMR spectra were obtained using high quality Kontes NMR tubes (Kimble Chase, Vineland, 
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NJ) rated to 500 MHz  and were recorded on a Bruker Avance (400 MHz) spectrometer using 
DMSO-d6 or MeOD-d4 containing tetramethylsilane (TMS) as an internal calibration standard 
set to 0.0 ppm. UV-Vis/NIR absorption spectra were recorded on a Varian Cary 50 
spectrophotometer. High-resolution accurate mass spectra (HRMS) were obtained either at the 
Georgia State University Mass Spectrometry Facility using a Waters Q-TOF micro (ESI-Q-
TOF) mass spectrometer or utilizing a Waters Micromass LCT TOF ES+ Premier Mass 
Spectrometer.  Liquid chromatography utilized a Waters 2487 single wavelength absorption 
detector with wavelengths set between 640 and 700 nm depending on the particular 
photophysical properties.  The column used in LC was a Waters Delta-Pak 5 uM 100A 3.9 x 
150 mm reversed phase C18 column. Evaporative light scattering detection analyzes trace 
impurities that cannot be observed by alternate methods; a SEDEX 75 ELSD was utilized in 
tandem with liquid chromatography to confirm purity.  
 
Synthesis of pentamethine cyanine precursors 4 and 5.  The synthesis of these two 
reagents has been previously reported by our laboratory, and they were obtained in 88% and 
75% yield, respectively.34 
 
General synthetic procedure for the formation of alkylated heterocycles.  The alkylation 
of the commercially obtained heterocyclic structures has been previously reported by our 
group.35  
 
Synthesis of pentamethine cyanines with varied hydrophobic character.  A mixture of 
individual salts (2 molar equivalents), either malonaldehyde bisphenylimine 
monohydrochloride 3, chlorinated analog 4 or brominated analog 5 (1 molar equivalent) and 
sodium acetate (3 equivalents) were heated to 40 oC for 2-6 hrs in acetic anhydride under 
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nitrogen atmosphere and then allowed to cool to room temperature. The reaction mixture was 
concentrated in vacuo and the resulting residue was dissolved in a minimum amount of 
methanol and precipitated after dilution with diethyl ether.  The final fluorophores were 
obtained in analytical purity after column chromatography with 2-5% methanol in DCM as the 
eluting solvent depending on the relative hydrophobicity of the compound.   
 
1,3,3-Trimethyl-2-((1E,3E,5E)-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-3H-indol-1-ium iodide (16): Yield 64%, MP >260 oC, 1H NMR (400 MHz, MeOD-d4) δ: 
1.71 (s, 12H), 3.63 (s, 6H), 6.28 (d, J = 16 Hz, 2H), 6.65 (t, J  = 12 Hz, 1H), 7.24 (t, J = 8 Hz, 
2H), 7.29 (d, J = 8 Hz, 2H), 7.39 (t, J = 8 Hz, 2H), 7.48 (d, J = 8 Hz, 2H), 8.25 (t, J = 12 Hz, 
2H);  13C NMR (100 MHz, MeOD-d4) δ 27.90, 31.71, 50.50, 104.44, 111.83, 123.31, 126.20, 
129.71, 142.56, 144.29, 155.52, 175.28.  Accurate mass TOF HRMS m/z [M]+ calculated for 
[C27H31N2]
+ 383.2487, found 383.2474. 
 
2-((1E,3Z,5E)-3-Chloro-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-
1,3,3-trimethyl-3H-indol-1-ium iodide (17): Yield 64%, MP 230-232 °C, 1H NMR (400 MHz, 
MeOD-d4) δ 1.76 (s, 12H), 3.71 (s, 6H), 6.435 (d, J = 12 Hz, 2H), 7.32 (t, J = 8 Hz, 2H), 7.39 
(d, J = 8 Hz, 2H), 7.45 (t, J = 8 Hz, 2H), 7.54 (d, J = 8 Hz, 2H), 8.345 (d, J = 12 Hz, 2H). 13C 
NMR (100 MHz, MeOD-d4) δ 25.03, 29.53, 48.55, 98.93, 110.02, 121.00, 121.86, 124.55, 
127.43, 140.42, 141.67, 146.72, 174.28. Accurate mass TOF HRMS m/z [M]+ calculated for 
[C27H30N2Cl]
+ 417.2098 found 417.2107. 
 
2-((1E,3Z,5E)-3-Bromo-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-
1,3,3-trimethyl-3H-indol-1-ium iodide (18): Yield 61%, MP 230-232 °C, 1H NMR (400 MHz, 
CDCl3-d1) δ 1.91 (s, 12H), 3.82 (s, 6H), 6.36 (d, 8 Hz, 2H), 7.16 (d, 8 Hz, 2H, 7.26-7.31 (m, 
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4H), 7.39-7.44 (m, 4H) 8.93 (d, 12 Hz, 2H).13C NMR (100 MHz, DMSO-d6) δ 27.04, 31.98, 
49.85, 102.61, 112.19, 115.98, 122.94, 125.97, 128.93, 141.78, 143.02, 149.64, 175.14. 
Accurate mass TOF HRMS m/z [M]+ calculated for [C27H30N2Br]
+ 461.1592 found 461.1585. 
 
1-Ethyl-2-((1E,3E,5E)-5-(1-ethyl-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-
3,3-dimethyl-3H-indol-1-ium iodide (19): Yield: 62%, MP > 260°C, 1H NMR (400 MHz, 
DMSO-d6) δ: 1.27 (t, J = 8 Hz, 6H), 1.68 (s, 12H), 4.14 (d, J = 8 Hz, 4H), 6.30 (d, J = 16 Hz), 
6.57 (t, J = 12 Hz, 1H), 7.26 (s, 2H), 7.39 (s, 4H), 7.62 (d, J = 8 Hz, 2H), 8.34 (t, J = 12 Hz, 
2H). 13C NMR (100 MHz, DMSO-d6) δ: 12.14, 27.05, 48.90, 102.74, 110.85, 122.47, 124.69, 
125.35, 128.44, 141.21, 141.55, 154.16, 172.20. Accurate mass TOF HRMS m/z [M]+ 
calculated for [C29H35N2]
+
 411.2880 found 411.2820. 
 
2-((1E,3Z,5E)-3-Chloro-5-(1-ethyl-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium iodide (20): Yield 71%, MP >260 oC 1H NMR (400 
MHz, DMSO-d6) δ 1.35 (d, J = 6.8 Hz, 6H), 1.74 (s, 12H), 4.23 (q, J = 6.8 Hz, 4H), 6.32 (d, J 
= 13.2 Hz, 2H), 7.32 (t, J = 7.2 Hz, 2H), 7.45 (t, J = 7.2 Hz, 2H), 7.50 (d, J = 7.2 Hz, 2H), 7.67 
(d, J = 7.2 Hz, 2H), 8.45 (d, J = 13.2 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 12.46, 27.20, 
39.65, 49.97, 99.93, 112.04, 122.71, 123.05, 126.02, 129.04, 141.82, 142.05, 148.05, 174.30.  
Accurate mass TOF HRMS m/z [M]+ calculated for [C29H34N2Cl]
+ 446.0462 found 446.0496. 
 
2-((1E,3Z,5E)-3-Bromo-5-(1-ethyl-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium iodide (21): Yield 59%, MP >250°C, 1H NMR (400 
MHz, DMSO-d6): δ 1.32 (s, 6H), 1.70 (s, 12H), 4.21 (s, 4H), 6.31(d, J = 12 Hz, 2H), 7.31 (s, 
2H), 7.43 (d, 2H), 7.50 (s, 2H), 7.69 (d, J = 8 Hz, 2H), 8.50 (d, J = 16 Hz, 2H); 13C NMR (100 
MHz, DMSO-d6): δ 11.52, 26.11, 48.99, 101.17, 111.08, 115.09, 122.17, 125.07, 128.07, 
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140.78, 140.98, 148.96, 173.28.  Accurate mass TOF HRMS m/z [M]+ calculated for 
[C29H34N2Br]
+ 489.1900 found 489.1879. 
 
1-Butyl-2-((1E,3E,5E)-5-(1-butyl-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-
3,3-dimethyl-3H-indol-1-ium iodide (22): Yield: 48%, MP > 260°C, 1H NMR (400 MHz, 
DMSO-d6) δ: 0.91 (t, J = 8 Hz, 6H), 1.37 (q, J = 8 Hz, 4H), 1.66 (s, 16H), 4.08 (s, 4H), 6.3 (d, 
J = 16 Hz, 2H), 6.59 (t, J = 12 Hz, 1H), 7.23 (s, 2H), 7.38 (s, 4H), 7.60 (d, J = 8 Hz, 2H), 8.33 
(t, J = 12 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ: 13.39, 19.11, 26.80, 28.73, 42.84, 48.52, 
102.81, 110.74, 122.09, 124.31, 125.25, 128.07, 140.75, 141.65, 153.65, 172.26.  Accurate 
mass TOF HRMS m/z [M]+ calculated for [C33H43N2]
+ 
 467.3426  found 467.3412    
 
1-Butyl-2-((1E,3Z,5E)-5-(1-butyl-3,3-dimethylindolin-2-ylidene)-3-chloropenta-1,3-
dien-1-yl)-3,3-dimethyl-3H-indol-1-ium iodide (23): Yield 60%, MP 206-208 oC, 1H NMR 
(400 MHz, MeOD-d4) δ  1.07 (t, 7.4 Hz, 6H), 1.48-1.58 (m, 4H), 1.78 (s, 12H), 1.83 (p, 7.6 
Hz, 4H), 4.22 (t, 8.0 Hz, 4H), 6.50 (d, 13.6 Hz, 2H), 7.35 (t, 8.0 Hz, 2H), 7.41 (d, 8.0 Hz, 2H), 
7.47 (t, 8.0 Hz, 2H), 7.57 (d, 7.2 Hz, 2H), 8.38 (d, 13.6 Hz, 2H).13C NMR (100 MHz, DMSO-
d6) δ 14.02, 19.96, 27.28, 29.43, 44.23, 49.94, 100.38, 112.26, 122.77, 123.01, 126.02, 129.02, 
141.92, 142.28, 147.83, 174.75. Accurate mass TOF HRMS m/z [M]+ calculated for 
[C33H42N2Cl]
+ 
 501.3037 found 501.3059.    
 
2-((1E,3Z,5E)-3-Bromo-5-(1-butyl-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-1-butyl-3,3-dimethyl-3H-indol-1-ium iodide (24): Yield 73%, MP 192-194 oC, 1H NMR 
(400 MHz, DMSO-d6): δ 0.95 (t, J = 8 Hz, 6H), 1.43-1.35 (m, 4H), 1.81-1.70 (m, 16 H), 4.18 
(t, J = 8 Hz, 4H), 6.355 (d, J = 12 Hz, 2H), 7.32 (t, J = 8 Hz, 2H), 7.45 (t, J = 8 Hz, 2H), 7.52 
(d, J = 8 Hz, 2H), 7.68 (d, J = 8 Hz, 2H), 8.505 (d, J = 12 Hz, 2H). 13C NMR (100 MHz, 
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DMSO-d6): δ 14.15, 20.03, 27.17, 29.40, 44.21, 49.96, 102.62, 112.30, 116.14, 123.09, 126.06, 
129.04, 141.87, 142.80, 174.80. Accurate mass TOF HRMS m/z [M]+ calculated for 
[C33H42N2Br]
+ 
 545.2531 found 545.2532. 
 
2-((1E,3E,5E)-5-(3,3-Dimethyl-1-(3-phenylpropyl)indolin-2-ylidene)penta-1,3-dien-1-
yl)-3,3-dimethyl-1-(3-phenylpropyl)-3H-indol-1-ium iodide (25): Yield 49%, MP 185-187°C, 
1H NMR (400 MHz, DMSO-d6) δ 1.68 (s, 12H), 2.01 (t, J = 8 Hz, 4H), 2.74 (t, J = 8 Hz, 4H), 
4.15 (t, J = 8 Hz, 4H), 6.075 (d, J = 12 Hz, 2H), 6.46 (t, J = 12 Hz, 1H0, 7.40-7.24 (m ,16H), 
7.62 (d, J = 8 Hz, 2H), 8.33 (t, J = 12 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 27.60, 29.16, 
32.58, 43.55, 49.40, 103.58, 111.47, 122.93, 125.19, 125.19, 125.97, 128.71, 128.91, 141.43, 
141.43, 142.46, 154.54, 173.11. Accurate mass TOF HRMS m/z [M]+ calculated for 
[C43H47N2]
+ 591.3739, found 591.3741. 
 
2-((1E,3Z,5E)-3-Chloro-5-(3,3-dimethyl-1-(3-phenylpropyl)indolin-2-ylidene)penta-
1,3-dien-1-yl)-3,3-dimethyl-1-(3-phenylpropyl)-3H-indol-1-ium iodide (26): Yield 53%, MP 
125-127 oC, 1H NMR (400 MHz, CDCl3-d1) δ 1.94 (s, 12H), 2.20 (t, J = 8.0 Hz, 4H), 2.84 (t, 
J = 8.0 Hz, 4H), 4.05 (t, J = 8.0 Hz, 4H), 6.24 (d, J = 16.0 Hz, 2H), 6.97 (d, J = 8.0 Hz, 2H), 
7.21-7.38 (m, 16H), 9.05 (d, J = 12.0 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 27.24, 28.68, 
32.66, 44.07, 49.93, 100.26, 112.14, 122.88, 123.00, 126.02, 126.58, 128.69, 128.95, 128.99, 
141.10, 141.93, 142.24, 147.96, 174.63 Accurate mass TOF HRMS m/z [M]+ calculated for 
[C43H46ClN2]
+ 
  625.3350 found 625.3369. 
 
2-((1E,3Z,5E)-3-Bromo-5-(3,3-dimethyl-1-(3-phenylpropyl)indolin-2-ylidene)penta-
1,3-dien-1-yl)-3,3-dimethyl-1-(3-phenylpropyl)-3H-indol-1-ium iodide (27): Yield 31%, MP 
189-191°C, 1H NMR (400 MHz, DMSO-d6) δ 1.69 (s, 12H), 2.05 (t, J = 8 Hz, 4H), 2.77 (t, J 
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= 8 Hz, 4H), 4.16 (t, J = 8 Hz, 4H), 6.155 (d, J = 12 Hz, 2H), 7.49-7.25 (m, 16H), 7.68 (d, J = 
8 Hz, 2H), 8.485 (t, J = 12 Hz, 2H).  13C NMR (100 MHz, DMSO-d6) δ 27.21, 28.70, 32.75, 
44.18, 49.96, 102.60, 112.17, 116.28, 123.02, 126.05, 126.59, 128.74, 128.98, 141.10, 141.92, 
142.23, 149.91, 174.80. Accurate mass TOF HRMS m/z [M]+ calculated for [C43H46BrN2]
+ 
669.2839, found 669.1030. 
 
1,1,3-Trimethyl-2-((1E,3E,5E)-5-(1,1,3-trimethyl-1H-benzo[e]indol-2(3H)-
ylidene)penta-1,3-dien-1-yl)-1H-benzo[e]indol-3-ium iodide (28): Yield 80%, MP >260 oC, 
1H NMR (400 MHz, DMSO-d6) δ 1.95 (s, 12H), 3.73 (s, 6H), 6.325 (d, J = 12 Hz, 2H), 6.59 
(t, J = 12.0 Hz, 1H), 7.52 (t, J = 8.0 Hz, 2H), 7.67 (t, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 
8.06 (t, J = 8.0 Hz, 4H), 8.24 (d, J = 8.0 Hz, 2H0, 8.465 (t, J = 12.0 Hz, 2H). 13C NMR (100 
MHz, DMSO-d6) δ 26.61, 31.47, 50.58, 102.98, 111.53, 122.09, 124.65, 125.26, 127.48, 
127.66, 129.87, 130.12, 131.23, 132.90, 140.39, 152.77, 174.114. Accurate mass TOF HRMS 
m/z [M]+ calculated for [C35H35N2]
+
  483.2800, found 483.2818. 
 
2-((1E,3Z,5E)-3-Chloro-5-(1,1,3-trimethyl-1H-benzo[e]indol-2(3H)-ylidene)penta-
1,3-dien-1-yl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium iodide (29): Yield 53%, MP 206-208 
oC, 1H NMR (400 MHz, DMSO-d6) δ 2.00 (s, 12H), 3.83 (s, 6H), 6.365 (d, 12.0 Hz, 2H), 7.56 
(t, 8.0 Hz, 2H), 7.72 (t, 8.0 Hz, 2H), 7.85 (d, 8.0 Hz, 2H), 8.08-8.15 (m, 4H), 8.29 (d, 8.0 Hz, 
2H), 8.60 (d, 16.0 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 26.73, 32.36, 51.50, 99.98, 
112.27, 122.58, 122.67, 125.59, 127.80, 128.34, 130.39, 130.77, 132.05, 134.10, 140.61, 
146.66, 175.96.  Accurate mass TOF HRMS m/z [M]+ calculated for [C35H34N2Cl]
+
  517.2411, 
found 517.2401. 
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2-((1E,3Z,5E)-3-Bromo-5-(1,1,3-trimethyl-1H-benzo[e]indol-2(3H)-ylidene)penta-
1,3-dien-1-yl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium iodide (30): Yield 90%, MP 229-230 
oC, 1H NMR (400 MHz, DMSO-d6) δ 1.97 (s, 12H), 3.80 (s, 6H), 6.345 (d, J = 12 Hz, 2H), 
7.53 (t, 8 Hz, 2H), 7.69 (t, J = 8 Hz, 2H), 7.83 (d, J = 8 Hz, 2H), 8.12-8.07 (m, 4H), 8.26 (d, J 
= 8 Hz, 2H), 8.635 (d, J = 12 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 25.91, 31.56, 50.78, 
101.49, 111.54, 115.27, 121.88, 124.78, 127.01, 127.51, 129.61, 129.95, 131.27, 133.26, 
139.85, 147.91, 175.31. Accurate mass TOF HRMS m/z [M]+ calculated for [C35H34N2Br]
+ 
561.1905 found 561.1914 
 
3-Ethyl-2-((1E,3E,5E)-5-(3-ethyl-1,1-dimethyl-1H-benzo[e]indol-2(3H)-
ylidene)penta-1,3-dien-1-yl)-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide (31): Yield 79%, 
MP 266-268°C, 1H NMR (400 MHz, DMSO-d6) δ 1.333 (t, J = 8 Hz, 6H), 1.962 (s, 12H), 
4.297 (t, J = 8 Hz, 4H), 6.37 (d, J = 12 Hz, 2H), 6.637 (t, J = 12 Hz, 1H), 7.51 (t, J = 8 Hz, 
2H), 6.68 (t, J = 8 Hz, 2H), 7.74 (d, J = 8 Hz, 2H), 8.08 (t, J = 8 Hz, 4H), 8.25 (d, J = 8 Hz, 
2H), 8.46 (t, J = 12 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 11.96, 26.17, 48.04, 50.19, 
102.05, 110.90, 121.58, 124.20, 125.07, 127.11, 127.19, 129.39, 129.83, 130.76, 132.72, 
138.77, 152.54, 172.71. Accurate mass TOF HRMS m/z [M]+ calculated for [C37H39N2]
+
  
511.3113, found 511.3098. 
 
2-((1E,3Z,5E)-3-Chloro-5-(3-ethyl-1,1-dimethyl-1H-benzo[e]indol-2(3H)-
ylidene)penta-1,3-dien-1-yl)-3-ethyl-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide (32): Yield 
68%, MP 231-233 oC, 1H NMR (400 MHz, DMSO-d6): δ 1.39 (s, 6H), 2.00 (s, 12H), 4.37 (s, 
4H), 6.38 (d, J = 16 Hz, 2H), 7.55 (t, 2H), 7.73 (t, 2H), 7.84 (d, J = 8 Hz, 2H), 8.12 (m, 4H), 
8.27 (d, J = 4 Hz, 2H) 8.65 (d, J = 16 Hz, 2H); 13C NMR (100 MHz, DMSO-d6): δ 11.81, 
25.80, 50.72, 98.52, 111.19, 121.60, 121.71, 124.67, 126.96, 127.37, 129.47, 130.01, 131.15, 
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133.41, 138.56, 146.10, 174.17.  Accurate mass TOF HRMS m/z [M]+ calculated for 
[C37H38N2Cl]
+
  545.2724, found 545.2717. 
 
2-((1E,3Z,5E)-3-Bromo-5-(3-ethyl-1,1-dimethyl-1H-benzo[e]indol-2(3H)-
ylidene)penta-1,3-dien-1-yl)-3-ethyl-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide (33): Yield 
50%. MP 226-229 oC, 1H NMR (400 MHz, MeOD-d4) δ 1.553 (t, 7.2 Hz, 6H), 2.091 (s, 12H), 
4.404 (q, 7.6 Hz, 4H), 6.588 (d, 13.6 Hz, 2H), 7.567 (t, 8 Hz, 2H), 7.736 (t, 8 Hz, 2H), 8.066(d, 
8.4 Hz, 2H), 8.104 (d, 8.8 Hz, 2H), 8.3115 (d, 8.4 Hz, 2H), 8.561 (d, 13.6 Hz, 2H).13C NMR 
(100 MHz, DMSO-d6) δ 12.65, 26.79, 51.72, 101.80, 112.07, 116.01, 122.65, 125.71, 127.94, 
128.05, 128.37, 130.44, 131.01, 132.14, 134.46, 139.46, 148.98, 175.39. Accurate mass TOF 
HRMS m/z [M]+ calculated for [C37H38N2Br]
+
  589.2218 found 589.2204. 
 
3-Butyl-2-((1E,3E,5E)-5-(3-butyl-1,1-dimethyl-1H-benzo[e]indol-2(3H)-
ylidene)penta-1,3-dien-1-yl)-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide (34): Yield 74%, 
MP 164-166 oC, 1H NMR (400 MHz, DMSO-d6) δ 0.940 (t, 6.8 Hz, 6H), 1.42-1.44 (m, 4H), 
1.725 (bs, 4H), 1.955 (s, 12H), 4.240 (bs, 4H),  6.380 (d, 13.6 Hz, 2H), 6.687 (t, 13.6 Hz, 1H), 
7.495 (t, 6.8 Hz, 2H), 7.650 (t, 6.8 Hz, 2H), 7.745 (d, 8.4 Hz, 2H), 8.056 (t, 8.8 Hz, 4H), 8.245 
(d, 8.4 Hz, 2H), 8.474 (t 12.8 Hz, 2H).  13C NMR (100 MHz, DMSO-d6) δ 14.28, 19.79, 27.28, 
29.87, 43.71, 51.17, 103.45, 103.48, 112.09, 122.61, 125.05, 125.22, 128.06, 128.13, 128.21, 
130.36, 130.76, 130.83, 131.72, 133.63, 140.16, 174.10.  Accurate mass TOF HRMS m/z [M]+ 
calculated for [C41H47N2] 567.3734 found 567.3718. 
 
3-Butyl-2-((1E,3Z,5E)-5-(3-butyl-1,1-dimethyl-1H-benzo[e]indol-2(3H)-ylidene)-3-
chloropenta-1,3-dien-1-yl)-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide (35): Yield 67%, MP 
160-163 oC, 1H NMR (400 MHz, DMSO-d6) δ 1.00 (t, 8 Hz, 6H), 1.42-1.49 (m, 4H), 1.81 (p, 
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8 Hz, 4H), 2.01 (s, 12H), 4.34 (t, 8 Hz, 4H),  6.42 (d, 16 Hz, 2H), 7.57 (t, 8 Hz, 2H), 7.73 (t, 8 
Hz, 2H), 8.12 (d, 12 Hz, 2H), 8.29 (8 Hz, 2H), 8.63 (d, 16 Hz, 2H).13C NMR (100 MHz, 
DMSO-d6) δ 14.11, 19.94, 26.91, 29.67, 44.29, 51.64, 99.97, 112.29, 122.68, 125.72, 127.88, 
128.39, 130.42, 130.95, 132.09, 134.34, 139.90, 146.80, 173.03, 175.67. Accurate mass TOF 
HRMS m/z [M]+ calculated for [C41H46N2Cl]
+
  601.3350 found 601.3350. 
 
2-((1E,3Z,5E)-3-Bromo-5-(3-butyl-1,1-dimethyl-1H-benzo[e]indol-2(3H)-
ylidene)penta-1,3-dien-1-yl)-3-butyl-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide (36): Yield 
74%, MP 153-156 oC, 1H NMR (400 MHz, DMSO-d6) δ 0.96 (t, J = 8 Hz, 6H), 1.46-1.40 (m, 
4H), 1.83-1.75 (m, 4H), 1.99 (s, 12H), 4.30 (s, 4H), 6.405 (d, J = 12 Hz, 2H), 7.55 (d, J = 8 Hz, 
2H), 7.70 (t, J = 8 Hz, 2H), 7.845 (d, J = 12 Hz, 2H), 7.10 (t, J = 12 Hz, 4H), 8.27 (J = 8 Hz, 
2H), 8.655 (d, J = 12 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 13.36, 19.19, 26.05, 28.82, 
50.89, 101.49, 111.55, 121.89, 124.89, 127.07, 127.55, 129.61, 130.12, 131.29, 133.46, 139.13, 
148.01, 174.93 Accurate mass TOF HRMS m/z [M]+ calculated for [C41H46N2Br]
+
  645.2844 
found 645.2866. 
 
2-((1E,3E,5E)-5-(1,1-Dimethyl-3-(3-phenylpropyl)-1H-benzo[e]indol-2(3H)-
ylidene)penta-1,3-dien-1-yl)-1,1-dimethyl-3-(3-phenylpropyl)-1H-benzo[e]indol-3-ium iodide 
(37): Yield 33%, MP 95-98 oC, 1H NMR (400 MHz, DMSO-d6) δ 1.95 (s, 12H), 2.05 (t, 8.4 
Hz, 4H), 2.78 (t, J = 8.0 Hz, 4H), 4.29 (t, J = 6.8 Hz, 4H), 6.27 (d, J = 13.6, 2H), 6.55 (t, J = 
12.4 Hz, 1H), 7.31-7.17 (m, 10H), 7.49 (t, J = 11.2 Hz, 2H), 7.72-7.64 (m, 4H), 8.07-8.03 (m, 
4H), 8.24 (d, J = 8.4, 2H), 8.49 (t, J = 13.2, 2H). 13C NMR (100 MHz, DMSO-d6) δ 27.24, 
29.53, 32.55, 43.74, 51.19, 103.40, 112.01, 119.44, 122.59, 125.21, 125.54, 128.05, 128.19, 
128. 73, 128.90, 130.38, 130.75, 131.74, 133.63, 140.13, 141.49, 153.41, 174.13. Accurate 
mass TOF HRMS m/z [M]+ calculated for [C51H51N2]
+ 691.4052 found 691.4028. 
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2-((1E,3Z,5E)-3-Chloro-5-(1,1-dimethyl-3-(3-phenylpropyl)-1H-benzo[e]indol-
2(3H)-ylidene)penta-1,3-dien-1-yl)-1,1-dimethyl-3-(3-phenylpropyl)-1H-benzo[e]indol-3-ium 
iodide  
(38): Yield 47%, MP 134-136 oC, 1H NMR (400 MHz, DMSO-d6) δ 1.98 (s, 12H), 2.04 (t, 4 
Hz, 4H), 2.82 (t, 4 Hz, 4H), 4.31 (t, 8 Hz, 4H), 6.235 (d, 16 Hz, 2H), 7.23-7.36 (m, 10H), 7.57 
(t, 8 Hz, 2H), 7.72 (t, 8 Hz, 2H), 7.82 (d, 8 Hz, 2H), 8.12 (t, 8 Hz, 4H), 8.28 (d, 8 Hz, 2H), 
8.585 (d, 12 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 27.65, 29.77, 33.39, 44.93, 52.44, 
100.59, 112.99, 123.47, 123.60, 126.49, 127.42, 128.68, 129.17, 129.55, 129.80, 131.22, 
131.73, 132.90, 135.16, 140.62, 141.89, 147.75, 176.31.  Accurate mass TOF HRMS m/z [M]+ 
calculated for [C51H50N2Cl]
+
 725.3663 found 725.3663. 
 
2-((1E,3Z,5E)-3-Bromo-5-(1,1-dimethyl-3-(3-phenylpropyl)-1H-benzo[e]indol-2(3H)-
ylidene)penta-1,3-dien-1-yl)-1,1-dimethyl-3-(3-phenylpropyl)-1H-benzo[e]indol-3-ium iodide 
(39): Yield 58%, MP 143-145 oC, 1H NMR (400 MHz, DMSO-d6) δ 1.98 (s, 12H), 2.13 (t, 8 
Hz, 4H), 2.83 (t, 8 Hz, 4H), 4.31 (t, 8 Hz, 4H), 6.24 (d, 12 Hz, 2H), 7.23-7.36 (m, 10H), 7.57 
(t, 8 Hz, 2H), 7.72 (t, 8 Hz, 2H), 7.83 (d, 8 Hz, 2H), 8.12 (t, 8 Hz, 4H), 8.28 (d, 8 Hz, 2H), 
8.615 (d, 12 Hz, 2H); 13C NMR (100 MHz, DMSO-d6) δ 26.96, 28.99, 32.76, 44.41, 51.72, 
102.30, 112.30, 112.21, 116.44, 122.68, 125.68, 126.60, 127.96, 128.35, 128.77, 128.99, 
130.42, 130.92, 132.21, 134.41, 139.89, 141.13, 148.91, 175.78. Accurate mass TOF HRMS 
m/z [M]+ calculated for [C51H50N2Br]
+
 769.3157, found 769.3138. 
3.4.2 Optical Property Measurements and Physicochemical Predictions.   
All optical measurements were performed in various solvents, including ethanol (200 
proof, Fischer Chemical), dimethyl sulfoxide (DMSO, 99.9% Acros Organics), phosphate 
buffered saline (PBS, pH 7.4, Fischer Scientific) and at 37oC in 100% fetal bovine serum (FBS, 
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Fischer Scientific) buffered with 50 mM HEPES, pH 7.4. Absorbance and fluorescence 
emission spectra of the series of NIR fluorophores were measured using Varian Cary 50 
absorbance spectrophotometer (190–1100 nm) and Shimadzu RF-5301PC spectrofluorometer 
(350–1000 nm). For fluorescence quantum yield (QY) measurements, rhodamine 800 in 
absolute ethanol (QY = 28%) was used as a calibration standard, under conditions of matched 
absorbance at 640 nm. In silico calculations of physicochemical distribution coefficient (logD 
at pH 7.4) was calculated using Marvin and JChem calculator plugins (ChemAxon, Budapest, 
Hungary).  Electrostatic maps were calculated using Spartan DFT calculations at the B3LYP 
level. 
3.4.3 LC-MS Spectroscopy.  
The purity of all compounds was measured using liquid chromatography-mass 
spectrometry (LC-MS) on a Waters system consisting of a 1525 binary HPLC pump with a 
manual 7725i Rheodyne injector, a 996 Photodiode Array (PDA) detector, and a 2475 
multiwavelength fluorescence detector. The column eluent was divided in 2 using a flow 
splitter (Upchurch Scientific). A portion of the eluent flowed into an ELSD (Richards 
Scientific) while the rest flowed into a Micromass LCT ESI-TOF spectrometer (Waters) 
equipped with a Symmetry (R) C18 (4.6 x 150 mm, 5 μm) reverse-phase HPLC column. For 
mass spectrometry mobile phase was solvent A = 0.1% formic acid (FA) in water and solvent 
B = CH3CN with 95% A for 5 min and a linear gradient from 5% to 40% CH3CN (from A to 
B for 30 min) at a flow rate of 1 mL/min, capillary voltage was -3317V, and sample cone 
voltage was -50V. 
3.4.4 Optical Imaging System and Fluorescence Microscopy.   
The real-time intraoperative FLARE imaging system has been described in detail 
previously.27, 28 In this study, 670 nm excitation was used at a fluence rate of 4 mW/cm2, with 
white light (400-650 nm) at 40,000 lx. Color and NIR fluorescence images were acquired 
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simultaneously with custom software at rates up to 15 Hz over a 15 cm diameter field of view. 
The imaging system was positioned at a distance of 18 inches from the surgical field. The 
wavelength used for excitation and emission filters was 650 ± 22 nm. 
3.5 Conclusions 
As the clinical need for intraoperative NIR contrast agents reaches a critical level, we 
have successfully generated a series of pentamethine cyanine fluorophores for the targeting of 
vital tissues that should be carefully avoided during surgery.  The targetability of these 
compounds represents the first successful correlation of tissue-specific contrast agents with 
their physicochemical properties reported to date that could help solve an unmet clinical need 
in image-guided surgery.  We are currently investigating the cellular targets that explain this 
interesting phenomenon which will be thoroughly explored in subsequent publications.  
Additionally, it should be noted that the physiological filtration and clearance pathways of 
these compounds are highly consistent with the Lipinski’s rules with the more hydrophobic 
compounds being observed in the liver and the less hydrophobic contrast agents being cleared 
through renal filtration.  
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4 ELECTRONIC FACTORS INFLUENCE BIODISTRIBUTION OF CYANINES 
This chapter focuses on altering the electron effects on pentamethine cyanines and 
observing the overall perturbation in biodistribution.  By observing these effects, it is possible 
to design additional contrast agents targeted using the inherent chemical structure. My 
contributions as first author were the design, synthesis, optical property determination, 
molecular modeling and computational experiments, data interpretation and figure/manuscript 
preparation. This manuscript is prepared and is awaiting submission to the Journal of Medicinal 
Chemistry. Owens, E.A, Hyun, H., Dost, T, Choi, H.S., Henary, M., NIR Illumination of 
Native Tissues for Image-Guided Surgery. Prepared for Submission to J. Med Chem. 2015 
4.1 Abstract 
Our initial efforts to prepare tissue-specific near-infrared (NIR) fluorescent compounds 
generated successful correlation between physicochemical properties and global uptake in 
major organs after systemic circulation and biodistribution. Herein, we focus on the effects on 
biodistribution based on modulating electronic influencing moieties from donating to 
withdrawing moieties at both the heterocyclic site and through meso-substitution of 
pentamethine cyanine fluorophores. These selected modifications harnessed innate 
biodistribution pathways through the structure-inherent targeting resulting in effective imaging 
of the adrenal glands, pituitary gland, lymph nodes, pancreas, thyroid and salivary glands. 
These native-tissue contrast agents will arm surgeons with a powerful and versatile arsenal for 
intraoperative NIR imaging in real time. 
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4.2 Introduction 
During endocrine surgeries and intricate surgical resections, surgeons mostly rely on 
their naked eye and experience during often-lengthy procedures to avoid sensitive glands and 
tissues.1-3 Neglecting to carefully navigate the surgical field can lead to poor patient prognosis 
even morbidity.4-11 Endocrine and exocrine tissues regulate the body’s hormone levels and any 
perturbation, especially transection, can jeopardize the patient’s ability to recover after surgery 
and maintain proper hormone levels.12-15 The important task of avoiding sensitive tissues is 
often difficult as these small and imperative glands are often obscured by blood and 
surrounding tissues. Surgeons require an imaging modality that can allow them to visualize 
these tissues during cancer resection surgeries to improve the surgical success rate, lower 
overall fatalities and advance patient prognoses.  
Near-infrared (NIR) fluorescence guided resection of cancerous tissues has 
demonstrated significant promise with increasing advancements being reported over the recent 
years.15-25 Unfortunately, the research efforts have been overwhelmingly concentrated on 
developing cancer-specific NIR-fluorophores with optimal optical, physicochemical and 
targeting properties. This only satisfies one-half of the main objective: the ability to 
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simultaneously image the surgical field with both a disease-targeted fluorophore and a native-
tissue targeted fluorophore of distinct wavelengths that can both be simultaneously and 
separately detected for direct dual-target imaging in real time.  
Significant advancements have been made to develop NIR-fluorescent compounds that 
target sensitive endogenous tissue and help surgeons avoid these hormonal glands in real time 
without changing the overall look of the surgical field. The class of NIR-fluorescent cyanine 
dyes has shown excellent promise in the area of NIR-fluorescence image guided surgery for in 
vivo tumor targeting. Cyanine chromophores are broadly defined by having two nitrogen-
containing heterocycles that are connected through an electron deficient polymethine bridge 
with a delocalized monocation conjugated between both nitrogen atoms. The wavelengths 
associated with these compounds are heavily dependent on the length of the polymethine-
bridge and the terminal heterocyclic moieties. Polymethine cyanines are chemically stable 
NIR-fluorescent compounds, and we have investigated the pentamethine class of compounds 
previously16, 20 and herein for laying the groundwork for endogenous tissue targeting. The 
heptamethine cyanine class (~800 nm fluorescence) has been more extensively explored for 
disease targeting through the development of cRGD-ZW800-1.10, 21, 22 The longer NIR 
wavelengths (i.e. 800 nm) are more easily detected against the background and usually reserved 
to detect occult cancerous metastasis due to the minimal autofluorescence. We plan to further 
exploit the 700 nm channel (pentamethine cyanines) for native tissue imaging for dual channel 
intraoperative imaging.  
Toward achieving this goal, we have continued to harness the structure-inherent tissue 
affinity to determine the innate biodistribution and targeting by modulating overall molecular 
characteristics such as hydrophobicity (determined through LogD calculations), total polar 
surface area, molecular size/weight and the electronic contributions (electron 
donating/withdrawing characteristics). The compounds synthesized and analyzed herein vary 
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by their heterocyclic moieties (electron donating or withdrawing) and various halogenation at 
the central carbon atom of the polymethine chain which alters the net dipole, volume, 
polarization and even overall shape of the compounds. We expect these selected modifications 
to offer biological perturbation toward understanding the molecular characteristics for targeting 
specific tissues. Correlating these molecular descriptors with in vivo biodistribution in expected 
to result in a clinically significant paradigm in the quest of translating NIR-targeted contrast 
agents into the clinic, and every analyzed compound offers another evidentiary piece to the 
puzzle.   
4.3 Results and Discussion 
4.3.1 Synthesis of Pentamethine Fluorophores.  
Since it has been previously reported that halogenated hydrocarbons localize in higher 
concentration within endocrine and exocrine glands compared to their non-halogenated 
counterparts,16 we decided to probe the effect of halogenation on pentamethine cyanines for 
endocrine and exocrine tissue targeting. For a direct comparison, we synthesized electron-
donating counterparts that could offer insight into how potential electronic factors present in 
the compounds may influence biodistribution.  
We have developed several optimized synthetic routes for maximizing the structural 
diversity in the pentamethine cyanine pharmacophore. The compounds with neutral effects and 
electron with drawing groups are synthesized starting with the corresponding phenyl hydrazine 
salts being refluxed in the presence of 3-methyl-2-butanone in acidic conditions. This reaction 
furnishes the indolenines 2-5 in excellent yield. We then alkylated the obtained oil using 
iodomethane in acetonitrile, which yields the cationic salt 6-10 bearing an acidic methylene 
proton. We also separately react aniline with a warm ethanolic solution of either mucochloric 
or mucobromic acid to obtain the pentamethine precursor 12 or 13 with 11 being commercially 
obtained. These two compounds are individually combined in the presence of acetic anhydride 
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and either triethylamine (fluorine-containing compounds) or sodium acetate and are heated to 
afford the brilliant blue pentamethine fluorophores. 
Scheme 1. The synthesis of 700 nm emitting pentamethine cyanines featuring neutral (X = H) 
and electron withdrawing (X = F, Cl, Br, CF3) moieties. 
 
 
Scheme 2. The synthesis of 700 nm emitting pentamethine cyanines featuring electron 
donating methoxy groups. 
 
Scheme 3. The synthesis of 700 nm emitting pentamethine cyanines featuring electron 
donating methylene dioxy substitution on the phenyl rings. 
The electron donating-containing methoxy-substituted compounds are prepared 
through an identical synthetic route; however, the final step requires a longer reaction time at 
a slightly elevated temperature, due to the methoxy group electron donating effects which 
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increases the pKa of the methylene proton resulting in reduced reactivity of the methylene 
carbon.  We also designed a complementary set of compounds bearing heterocyclic 
donating groups features the methylene dioxy ring shown in compounds 36-38.  These 
compounds are prepared using an alternate synthetic strategy beginning with the acidic 
bromination of 3-methyl-2-butanone followed by SN1 replacement of the tertiary bromine by 
the methylene dioxyaniline compound. Upon heating in the presence of acid catalyst, para-
toluenesulphonic acid, the compound forms the cyclic methylene dioxy 2,3,3-
trimethylindolenine ring through a largely unexplored Bischler-Möhlau method that can be 
alkylated using aforementioned conditions for the formation of compound 35.  The final 
methylene dioxy compounds 36-38 were synthesized using similar chemistry as the methoxy 
group. 
4.3.2 Optical and Physicochemical Properties.   
The optical properties, shown in Table 1, were performed in several solvents to 
determine the in vivo success for the fluorophores. We can see that the compounds with 
hydrogen, chlorine, bromide and methoxy groups (14-25, 31-33) exhibit sharp and NIR 
absorbance bands with very high molar absorptivity all being greater than 100,000 M
-1
cm
-
1
which suggests that these fluorophores will satisfactorily absorb NIR wavelengths in vivo and 
will be compatible with the intraoperative imaging system. As expected, the methylenedioxy 
compounds exhibited slightly lower molar absorptivity due to a broadening of the absorption 
profile which results from a more widely dispersed sub-energy levels.  Similarly, the 
trifluoromethyl substituted compounds are very poor at absorbing light at their wavelength of 
maximum absorbance as indicated by their low molar absorptivity values in Table 1. We 
attribute this to the high electron withdrawing characteristics of the trifluromethyl groups 
which lowers the overall probability of electron movement across the methine-bridge 
connecting the aza-heterocycles. The in vivo success of these compounds also depends of the 
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quantum yield, and more importantly the molecular brightness (determined as the product of 
extinction coefficient and quantum yield), of the compounds in serum; therefore, we examined 
the quantum yield of these fluorophores in FBS. Compounds 14-28, 31-33 exhibit high 
quantum yield values in serum which is very appealing. All of the synthesized compounds have 
sufficiently high molecular brightness values in serum with many compounds exhibiting 
molecular brightness values of >20,000. We observed an overall trend for the majority of 
compounds that as the size of the central halogen increases, the molecular brightness decreases. 
When analyzing the minimized three-dimensional structures, we see that the meso-
halogenation perturbs the trans-alkene angles and the elongated structure of the fluorophore 
which actually shortens the overall length and perturbs the conjugated bridge. This is an 
interesting finding since upon first glance, it seems that adding larger groups to the middle of 
the compound should result in an elongation of the compound simply because it would force 
the neighboring hydrogen atoms apart.  Another potential explanation for the decrease in 
molecular brightness is the heavy atom effect that can effectively stabilize the triplet state 
allowing for other competing decay processes (i.e. phosphorescence or energy transfer).   
 
Table 4-1. Optical properties of 700 nm emitting NIR fluorophores. All measurments were 
performed in dimethyl sulfoxide (DMSO), ethanol (EtOH), phosphate-buffered saline (PBS), and 
fetal bovine serum (FBS), pH = 7.4 at 37 oC. Abbreviations: λ
abs
, wavelength of maximum 
absorbance; λ
em
, wavelength of maximum emission; QY, quantum yield; and MB, molecular 
brightness. 
ID 
λ
abs 
(nm) Extinction Coefficient (, M
-1
cm
-1
) λem (nm) Stokes Shift QY (, %) MB  x ) 
DMSO EtOH PBS FBS DMSO EtOH PBS FBS EtOH FBS EtOH FBS EtOH FBS EtOH FBS 
14 647 645 640 649 212,500 248,200 218,800 184,500 660 662 15 13 32.7 31.0 81,161 57,195 
15 645 644 642 638 235,300 207,800 171,000 168,800 659 665 15 27 29.2 28.8 60,677 48,614 
16 645 641 638 634 257,330 253,200 204,400 211,700 657 660 16 26 30.1 43.6 76,213 92,301 
17 645 641 638 649 216,700 225,800 196,500 164,400 663 662 22 13 31.6 35.2 71,352 58,868 
18 646 643 638 638 210,900 233,700 193,400 193,400 658 660 15 22 16.5 15.3 38,561 29,590 
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19 642 641 635 644 173,200 210,500 170,900 145,800 658 658 17 14 16.3 11.9 34,312 17,350 
20 652 649 645 660 183,400 204,200 174,200 136,000 658 669 19 9 41.5 57.5 84,743 78,200 
21 653 652 647 658 192,800 207,800 140,200 136,000 664 666 14 8 18.3 28.5 38,027 38,760 
22 650 648 643 655 233,100 250,600 185,000 153,700 665 663 17 12 15.4 17.4 38,592 26,744 
23 653 650 653 662 181,200 174,500 144,800 141,100 670 671 20 9 42.4 57.0 73,988 80,427 
24 655 653 660 648 140,200 189,600 121,500 119,700 667 671 14 23 20.8 23.0 39,437 27,531 
25 643 641 635 644 169,000 169,600 166,900 159,600 657 663 16 21 15.5 11.8 26,288 18,833 
26 642 638 636 648 41,200 45,200 28,700 30,600 656 654 18 6 58.7 89.2 26,532 27,295 
27 644 640 638 649 72,000 114,900 56,300 19,500 656 655 16 6 20.5 47.4 23,555 9,243 
28 641 638 635 644 32,400 49,700 19,600 8,400 653 651 15 7 21.1 29.0 10,487 2,436 
31 671 668 658 674 152,300 205,000 133,600 135,000 696 696 28 22 9.6 11.9 19,680 16,070 
32 672 671 658 676 148,100 210,000 135,900 162,000 694 692 23 16 3.9 9.7 8,190 15,710 
33 669 669 655 676 94,200 154,000 82,100 109,000 689 688 20 12 5.1 9.7 7,218 10,570 
36 691 690 680 698 107,200 108,100 89,200 85,900 705 716 15 18 4.7 6.5 5,081 5,584 
37 689 690 678 693 147,200 156,600 127,100 117,800 716 712 26 19 3.0 4.2 4,698 4,948 
38 687 687 675 691 154,900 165,800 135,700 125,000 715 716 28 25 2.9 3.1 4,808 3,875 
 
Table 4-2. In silico physicochemical properties of 700 nm emitting NIR fluorophores 
(LogD, TPSA and H-bond acceptors) calculated using Marvin and JChem calculator plugins 
(ChemAxon, Budapest, Hungary). LogD = partition coefficient at pH 7.4, TPSA = total polar 
surface area while molecular parameters (length, volume dipole and polarizability) were 
calculated using Spartan Wavefunction (V10) DFT starting with the minimized structural 
conformation of the lowest energy. 
ID 
 Physicochemical Properties 
MW 
(g/mol) 
LogD 
(pH = 
7.4) 
TPSA 
H-bond 
acceptors 
Length 
(A) 
Volume 
(Å3) 
Dipole 
(debye) 
Polarizability  
14 383.548 3.56 6.25 1 18.665 445.51 1.95 76.14 
15 417.994 3.79 6.25 1 18.530 458.45 0.89 77.21 
16 462.445 3.96 6.25 1 18.453 462.96 0.79 77.55 
17 419.529 3.84 6.25 2 18.684 455.28 4.23 76.95 
18 453.974 4.08 6.25 3 18.536 468.22 3.32 78.02 
19 498.425 4.24 6.25 3 18.475 472.73 3.26 78.36 
20 452.439 4.77 6.25 2 18.674 472.01 3.55 78.30 
21 486.884 5.00 6.25 3 18.539 484.95 2.58 79.37 
22 531.335 5.17 6.25 3 18.464 489.45 2.52 79.71 
23 541.341 5.09 6.25 2 18.665 481.25 3.74 79.05 
24 575.786 5.33 6.25 3 18.517 494.19 2.79 80.12 
25 620.237 5.50 6.25 3 18.340 498.70 2.73 80.40 
26 519.544 5.31 6.25 6 20.188 511.26 8.04 81.47 
27 553.989 5.55 6.25 7 19.547 524.14 7.58 82.54 
28 598.440 5.70 6.25 7 19.406 528.65 7.62 82.88 
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31 443.600 3.24 24.71 2 20.631 500.23 4.10 80.61 
32 478.045 3.48 24.71 3 20.527 513.28 3.04 81.68 
33 522.496 3.64 24.71 3 20.142 517.72 2.89 82.02 
36 471.577 2.80 43.17 4 21.203 496.69 2.69 80.33 
37 506.019 3.04 43.17 5 20.847 509.64 1.77 81.39 
38 550.473 3.21 43.17 5 20.680 514.15 1.72 81.74 
 
4.3.3 Structure-Inherent Targeting Ability of NIR Fluorophores.  
As native tissue targeting remains predominantly understudied, we focused our 
attention to the salivary, thyroid, pituitary, adrenal glands, lymph nodes and pancreas. As these 
tissues facilitate the regulation of human hormone levels they are important for long-term 
health and should be carefully avoided during surgical resection in surrounding areas.  
After in vivo studies, we found compounds that exhibited high SBR in targeted tissues 
(high is designated as a ratio of target signal to surrounding tissue being >2.0). Without surface 
or subcellular receptors readily available for the particular native tissues, it has been difficult 
to infer mechanistic insight of how these fluorophores localize within their respective tissues. 
However, we have found several key structural components that help facilitate structure-
inherent biodistribution and localization in important tissues, including the salivary, thyroid, 
pituitary, adrenal glands, lymph nodes and pancreas. 
Table 4-3. Targeting properties and biodistribution of 700 nm emitting NIR fluorophores 
for specific organs/tissues at 4 h post-injection. 
 Targeted Tissues Biodistribution 
ID AG Pa PG SG TG LN Li Ki He Lu Sp Bo 
14            
15            
16            
17            
18            
19            
20            
21            
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22            
23            
24            
25            
26            
27            
28            
31            
32            
33            
36            
37            
38            
Abbreviations used are: AG, adrenal gland; Pa, pancreas; PG, pituitary gland; TG, thyroid gland; SG, 
salivary gland; Li, liver; Ki, kidneys; He, heart; Lu, lungs; Sp, spleen; Bo, bone; LN, lymph node. The 
SBR of each organ/tissue relative to the abdominal wall was quantified and labeled as –, 1 to 2; +, 2 to 
3; ++, 3 to 5; and +++, > 5. 
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In surgical resections such as thyroidectomies, it is crucial to remove the entire thyroid 
gland while maintaining complete integrity of the parathyroid gland. Selective thyroid gland 
imaging is paramount in the ability to avoid partial thyroid resection or accidental parathyroid 
transection which can cause several abnormal human conditions such as hypocalcemia. 
The common clinical indications of salivary gland imaging are pain and swelling. 
Imaging is useful in identifying the masses of salivary glands and also in differentiating them 
from the masses/pathologies of adjacent cervical spaces. In proven case of salivary gland 
tumors, imaging helps in delineating the extent of the lesion and invasion of adjacent cervical 
spaces. Cancerous tissues in this area can grow quickly and surgical resection of the diseased 
tissue is needed while sparing excision of the exocrine salivary glands themselves.  
Toward finding the thyroid and salivary glands targeting by using NIR fluorophores, 
we evaluated the imaging capability of these compounds in thyroid and salivary glands. Table 
3 shows the thyroid and salivary glands targeting for the entire set of compounds. The targeting 
of these two tissues seemed to parallel each other suggesting a biological connection between 
these two tissues, though despite an extensive literature review, an explanation for this remains 
unclear. Among the entire set of prepared compounds we found that central halogenation 
reduced the targeting efficacy into these glands. Surprisingly, the parent set of compounds (14-
16) all targeted the salivary gland with superior SBR. From our data, we can see overall that 
the salivary glands are sensitive to the central halogenation but remain tolerant to the 
heterocyclic halogen incorporation. Compounds 20-25 exhibit the halogen trend we observed. 
With the heterocyclic halogen substitution the salivary gland targeting remains high; however, 
when the central halogen is incorporated within the same compounds we have a severely 
diminished targeted ability (i.e. from compound 20 with SBR of >5 to compounds 21 and 22 
with SBR of 1-2). Specifically compounds 17-25 shown in Figures 1 and 2 exemplify this 
trend. Compounds 17, 20, 23 do not feature halogens at the central carbon of the polymethine 
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chain and exhibit the most effective thyroid and salivary glands localization. As the halogen 
incorporation increases, the thyroid and salivary glands localization is forfeited in deference to 
non-specific accumulation and high liver uptake due to hepatobiliary clearance arising from 
the increase in hydrophobicity.   
 
Figure 4-1. Compounds 20-22, targeting to salivary glands and thyroid glands, and 
biodistribution of resected organs in CD-1 mice. 10 nmol of each fluorophore was injected 
intravenously into 25 g CD-1 mice 4 h prior to imaging and resection. Abbreviations used 
are: Du, duodenum; He, heart; In, intestine; Ki, kidneys; Li, liver; Lu, lungs; Mu, muscle; 
Pa, pancreas; SG, salivary gland, Sp, spleen. Arrows indicate the targeted gland. 
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Figure 4-2. Compounds 23-25, targeting to salivary glands and thyroid glands, and 
biodistribution of resected organs in CD-1 mice. 10 nmol of each fluorophore was injected 
intravenously into 25 g CD-1 mice 4 h prior to imaging and resection. Abbreviations used 
are: Du, duodenum; He, heart; In, intestine; Ki, kidneys; Li, liver; Lu, lungs; Mu, muscle; 
Pa, pancreas; SG, salivary gland, Sp, spleen. Arrowheads indicate the targeted gland. 
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As one of the important endocrine glands, the pituitary gland (dubbed the master gland) 
is responsible for controlling the hormonal release of signaling chemicals throughout the body.  
Transecting this precious gland during surgery causes lasting side effects from hormone 
dysregulation with imbalances perpetuating during the lifetime of the patent. Tumors 
associated with the pituitary gland can interfere with signaling the release of many hormones 
such as thyroid-stimulating hormone which directly influences metabolic activity, energy 
levels, growth hormones and the nervous system. Efforts to remove pituitary gland tumors must 
critically and clearly image the native tissue to prevent accidental damage. We found excellent 
pituitary gland targeting with the triufluromethyl compounds 26-28 (Figure 3). The 
trifluoromethyl substitutions increase the dipole of the compound considerably (Table 2) which 
we anticipated to elicit a drastic biological response compared to the alternate halogenated 
counterparts.  Indeed, the vast change in electronic dipole from 1-4 debye (other compounds) 
to >7.5 debye in the trifluoromethyl substituted compounds lowered the target recognition to 
some endocrine tissues; however, the thyroid gland targeting remained elevated when the 
central position was halogen-free.   
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Figure 4-3. Compounds 26-28, targeting to thyroid glands and pituitary gland, and 
biodistribution of resected organs in CD-1 mice. 10 nmol of each fluorophore was injected 
intravenously into 25 g CD-1 mice 4 h prior to imaging and resection. Abbreviations used 
are: Du, duodenum; He, heart; In, intestine; Ki, kidneys; Li, liver; LN, lymph node; Lu, 
lungs; Mu, muscle; Pa, pancreas; SG, salivary gland, Sp, spleen. Arrows indicate the 
targeted gland. For pituitary glands, arrowheads indicate the anterior portion, and 
arrows for posterior pituitary. 
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Lymph nodes are widely distributed and are responsible for immune system function 
and can indicate an abnormal physiological condition. For example, an increase in size may 
indicate leukemia due to increased trafficking of lymphocytes from the blood into the lymph 
nodes. Additionally, thorough examination of the lymph nodes is crucial for the staging of 
cancer as tumor metastases normally first localize in sentinel lymph nodes. For surgical 
avoidance and the frequent necessity to biopsy, a NIR imaging technique to visualize this tissue 
is highly important. In the developed set of compounds, we noticed effective targeting of the 
lymph node by the methoxy derivatives 31-33 which is surprising in the context of the 
methylene dioxy compounds 36-38 exhibiting low lymph node targeting. Interestingly we see 
an inverse effect of the previous set of compounds where the meso halogenation increases the 
imaging signal as compared to the surrounding tissue in the lymph node with 32 and 33 having 
a SBR of >5 as indicated by the +++ in Table 3. Figure 4 shows two successful examples of 
nodal imaging in the inguinal and lumbar nodes with compound 33 exhibiting excellent 
targeting characteristics. 
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Figure 4-4. Compounds 31-33, targeting to inguinal and lumbar lymph nodes, and 
biodistribution of resected organs in CD-1 mice. 10 nmol of each fluorophore was injected 
intravenously into 25 g CD-1 mice 4 h prior to imaging and resection. Abbreviations used 
are: Bl, bladder; Du, duodenum; He, heart; In, intestine; Ki, kidneys; Li, liver; LN, lymph 
node; Lu, lungs; Mu, muscle; Pa, pancreas; Sp, spleen. Arrows indicate the targeted 
gland. 
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The adrenal glands, located above the kidney, produce essential and nonessential 
hormones that primarily control the body’s metabolism, blood pressure and stress response. In 
Figure 5, we observed that the methylene dioxy compounds 36-38 exhibited adrenal gland 
targeting characteristics (++, SBR 3-5) that also seemed to be tolerant to the addition of meso-
halogens. It seems that the logD values predominantly govern the localization of these 
compounds as the 5 compounds (31, 32, 36-38) with the lowest logD were the most effective 
at targeting this tissue with the methylene dioxy compounds 36-38 prevailing as the best 
contrast agents for the adrenal gland across the series. This finding is also true in their pancreas 
targeting ability as all three compounds within this set exhibit excellent SBR in pancreatic 
tissue. Interestingly, the small change from methoxy 31-33 to the locked ring structure of 36-
38 alters the targeting ability of the compound (i.e. comparing 33 and 38). This finding also 
corroborates our previous results that pancreatic targeting requires low comparative logD 
values. Indeed the highest pancreas targeting characteristics are from compounds exhibiting 
comparatively low logD values (i.e. compounds 36-38, logD 2.80-3.21). Additionally, the 
central halogenation seems to lower pancreas-targeting substantially except for the methylene 
dioxy set of compounds. It is very interesting that independent halogenation (either central or 
terminal heterocycles) does not seem to greatly perturb the pancreatic tissue uptake, except for 
when the trifluoromethyl group is incorporated. Halogenating both positions, however, has a 
detrimental effect on the compound-pancreas localization. For example, compounds 15, 16, 
17, 20, 23 are all effective at pancreas targeting and only have halogens at either the 
heterocycles or bridge. Compounds 18, 19, 21, 22, 24, 25 with all sites halogenated exhibit 
reduced pancreas uptake. We attribute this effect to an increase in overall hydrophobicity 
imparted by too many halogens on the core structure. Additionally, structures with higher 
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molecular weight in addition to greater hydrophobic character seem to be poor at pancreatic 
localization. 
 
Figure 4-5. Compounds 36-38, targeting to adrenal glands and pituitary gland, 
and biodistribution of resected organs in CD-1 mice. 10 nmol of each fluorophore was 
injected intravenously into 25 g CD-1 mice 4 h prior to imaging and resection. 
Abbreviations used are: Du, duodenum; He, heart; In, intestine; Ki, kidneys; Li, liver; 
Lu, lungs; Mu, muscle; Pa, pancreas; SG, salivary gland, Sp, spleen. Arrows indicate the 
targeted gland. Arrows indicate the targeted gland. For pituitary glands, arrowheads 
indicate the anterior portion, and arrows for posterior pituitary. 
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4.4 Experimental  
4.4.1 Synthesis of pentamethine cyanine analogs.  
The chemical reagents used in the synthesis of these compounds were obtained from 
Acros Organics, Alfa Aesar and Matrix Scientific. The reactions were followed using silica gel 
60 F254 thin layer chromatography plates (Merck EMD Millipore, Darmstadt, Germany). Open 
column chromatography was utilized for the purification of all final compounds using 60-200 
μm, 60A, classic column silica gel (Dynamic Adsorbents, Norcross, GA). The 1H NMR and 
13C NMR spectra were obtained using high quality Kontes NMR tubes (Kimble Chase, 
Vineland, NJ) rated to 500 MHz and were recorded on a Bruker Avance (400 MHz) 
spectrometer using DMSO-d6 or MeOD-d4 containing tetramethylsilane (TMS) as an internal 
calibration standard set to 0.0 ppm. UV-Vis/NIR absorption spectra were recorded on a Varian 
Cary 50 spectrophotometer. High-resolution accurate mass spectra (HRMS) were obtained 
either at the Georgia State University Mass Spectrometry Facility using a Waters Q-TOF micro 
(ESI-Q-TOF) mass spectrometer or utilizing a Waters Micromass LCT TOF ES+ Premier Mass 
Spectrometer.  Liquid chromatography utilized a Waters 2487 single wavelength absorption 
detector with wavelengths set between 640 and 700 nm depending on the particular 
photophysical properties.  The column used in LC was a Waters Delta-Pak 5 μM 100A 3.9 x 
150 mm reversed phase C18 column. Evaporative light scattering detection analyzes trace 
impurities that cannot be observed by alternate methods; a SEDEX 75 ELSD was utilized in 
tandem with liquid chromatography to confirm purity.  
4.4.2 General Synthetic Procedure for the formation of heterocyclic derivatives 1-5. 
Appropriate 4-substituted phenylhydrazine hydrochloride derivative (20 g) was slowly 
added to a 250-mL round bottom flask containing 150-mL of vigorously stirring warm glacial 
acetic acid.  After a heterogenous mixture was observed, 3-methyl-2-butanone (3 mol. equiv.) 
was added.  The light brown solution was allowed to heat at reflux for 48-72 h.  The reddish 
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brown mixture was concentrated on a rotary evaporator to form a viscous oil after removal of 
acetic acid.  The oil was dissolved in dichloromethane (35 mL) and washed with water (3 x 25 
mL) and saturated sodium bicarbonate (3 x 50 mL).  The organic layer was extracted, dried 
over sodium sulfate and obtained, after solvent removal, as a deep-reddish brown oil (Note: 
fluorine-containing indolenine analog 2 was obtained as a red solid).  Compound 1 was a 
commercially obtained starting material and was not synthesized.  
 
 
5-fluoro-2,3,3-trimethyl-3H-indole (2): Yield 84%, MP 146-149 oC ; 1H NMR (400 
MHz, DMSO-d6) δ: 1.24 (s, 6H), 2.19 (s, 3H), 7.09-7.04 (m, 1H), 7.33 (d, J  = 8.0 Hz, 1H), 
7.41 (br s, 1H). 
 
5-chloro-2,3,3-trimethyl-3H-indole (3) and 5-bromo-2,3,3-trimethyl-3H-indole (4) 
have been previously reported by our group.1 
 
2,3,3-trimethyl-5-(trifluoromethyl)-3H-indole (5): Yield 43%, 1H NMR (400 MHz, 
DMSO-d6) δ: 1.32 (s, 6H), 2.60 (s, 3H), 7.89 (br s, 1H), 8.01 (br s, 1H), 8.24 (br s, 1H). 
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4.4.3 Synthesis of heterocyclic salts 6-10. 
The methylated heterocyclic salts were synthesized using a general method by 
dissolving the viscous indolenine oil in anhydrous acetonitrile (25 mL) and heated to reflux in 
the presence of iodomethane (3 mol eq) for 12-18 h.  The reaction mixture was allowed to cool 
to room temperature and the acetonitrile was removed under reduced pressure to afford a red 
residue.  The crude was dissolved in methanol and diethyl ether was added to the solution to 
afford a light brown solid which was suction filtered and dried to obtain the final product. 
 
1,2,3,3-tetramethyl-3H-indol-1-ium iodide (6) was commercially obtained and used in 
the dye syntheses without purification. 
 
5-fluoro-1,2,3,3-tetramethyl-3H-indol-1-ium iodide (7): Yield 81%,  1H NMR (400 
MHz, DMSO-d6) δ: 1.29 (s, 6H), 2.31 (s, 3H), 4.11 (s, 3H), 7.21-7.16 (m, 1H), 7.80 (d, J  = 
8.0 Hz, 1H), 7.99 (br s, 1H). 
 
5-chloro-1,2,3,3-tetramethyl-3H-indol-1-ium iodide (8) and 5-bromo-1,2,3,3-
tetramethyl-3H-indol-1-ium iodide (9) were synthesized as previously described.  
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1,2,3,3-tetramethyl-5-(trifluoromethyl)-3H-indol-1-ium iodide (10): Yield 33%, 1H 
NMR (400 MHz, DMSO-d6) δ: 1.59 (s, 6H), 2.84 (s, 3H), 4.02 (s, 3H), 8.07 (br s, 1H), 8.15 
(br s, 1H), 8.37 (br s, 1H). 
 
4.4.4 Synthesis of Methine Precursor 11-13. 
Precursor 11 was obtained commercials from Acros Organics and was used as obtained 
without modification.  Compounds 12 and 13 have been previously described by our laboratory 
and the compounds were synthesized as described. 
 
4.4.5 Synthesis of Methylated Pentamethine Cyanines 14-28, 31-33. 
A mixture of indolium salt 6-10 (1 mmol), bis-iminium salt 11-13 (0.5 mmol), sodium 
acetate (0.23 mmol) and acetic anhydride (1 mL) was added to an oven dried round bottom 
flask with magnetic stirring bar.  The reaction mixture was heated using a standard oil bath for 
a particular reaction time and was followed using TLC and UV-Vis-NIR absorption in ethanol. 
After starting materials were consumed, the reaction was allowed to cool to room temperature.  
Diethyl ether was added to the round bottom flask resulting in an oily metallic blue residue.  
The diethyl ether was decanted and the oil was dissolved in a minimal amount of methanol 
followed by the addition of diethyl ether (50 mL) resulting in the formation of light blue 
crystals, which were filtered.  The crystals were dissolved in dichloromethane leaving 
unreacted sodium acetate on the funnel.  The dichloromethane was removed in vacuo. Silica-
gel column chromatography eluting with 2-5% methanol in dichloromethane afforded the 
various pentamethine cyanines in their respective yield. 
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1,3,3-Trimethyl-2-((1E,3E,5E)-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-3H-indol-1-ium iodide (14): Yield 64%, MP >260 oC ; 1H NMR (400 MHz, MeOD-d4) δ: 
1.71 (s, 12H), 3.63 (s, 6H), 6.28 (d, J = 16.0 Hz, 2H), 6.65 (t, J  = 12.0 Hz, 1H), 7.24 (t, J = 8.0 
Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 7.39 (t, J = 8.0 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 8.25 (t, J 
= 12.0 Hz, 2H);  13C NMR (100 MHz, MeOD-d4) δ 27.90, 31.71, 50.50, 104.44, 111.83, 
123.31, 126.20, 129.71, 142.56, 144.29, 155.52, 175.28.  TOF HRMS m/z [M]+ calculated for 
[C27H31N2]
+ 383.2487, found 383.2474. 
 
 
 
 
2-((1E,3Z,5E)-3-chloro-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-
1,3,3-trimethyl-3H-indol-1-ium iodide (15): Yield 64%, M.P. 230-232 °C, 1H NMR (400 MHz, 
MeOD-d4) δ 1.76 (s, 12H), 3.71 (s, 6H), 6.435 (d, J = 12 Hz, 2H), 7.32 (t, J = 8 Hz, 2H), 7.39 
(d, J = 8 Hz, 2H), 7.45 (t, J = 8 Hz, 2H), 7.54 (d, J = 8 Hz, 2H), 8.345 (d, J = 12 Hz, 2H). 13C 
NMR (100 MHz, MeOD-d4) δ 25.03, 29.53, 48.55, 98.93, 110.02, 121.00, 121.86, 124.55, 
127.43, 140.42, 141.67, 146.72, 174.28. TOF HRMS m/z [M]+ calculated for [C27H30N2Cl]
+ 
417.2098 found 417.2107. 
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2-((1E,3Z,5E)-3-Bromo-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-
1,3,3-trimethyl-3H-indol-1-ium iodide (16): Yield 61%, M.P. 230-232 oC ; 1H NMR (400 
MHz, CDCl3-d1) δ 1.91 (s, 12H), 3.82 (s, 6H), 6.36 (d, J = 8 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H, 
7.26-7.31 (m, 4H), 7.39-7.44 (m, 4H) 8.93 (d, J = 12 Hz, 2H). 13C NMR (100 MHz, DMSO-
d6) δ 27.04, 31.98, 49.85, 102.61, 112.19, 115.98, 122.94, 125.97, 128.93, 141.78, 143.02, 
149.64, 175.14. TOF HRMS m/z [M]+ calculated for [C27H30N2Br]
+
  461.1592 found 461.1585. 
 
 
 
5-Fluoro-2-((1E,3E,5E)-5-(5-fluoro-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-
1-yl)-1,3,3-trimethyl-3H-indol-1-ium iodide (17): Yield 78%, MP >260 oC,  1H-NMR(400 
MHz, DMSO-d6) δ 1.68 (s, 12H), 3.59 (s, 6H), 6.23 (d, J = 12.0 Hz, 2H), 6.52 (s, 1H), 7.24 (s, 
2H), 7.39 (s, 2H), 7.62 (s, 2H), 8.29 (s, 2H). 13C-NMR (100 MHz, DMSO-d6) δ: 27.27, 31.85, 
49.54, 103.64, 103.76, 110.82, 111.07, 112.43, 112.49, 112.59, 112.66, 115.15, 125.54, 139.55, 
143.60, 143.69, 154.27, 154.29, 159.32, 161.72, 173.64. TOF HR-MS ESI m/z [M]+ calculated 
for [C27H29F2N2]
+ 419.2299, found 419.2296. 
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2-((1E,3Z,5E)-3-chloro-5-(5-fluoro-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-
1-yl)-5-fluoro-1,3,3-trimethyl-3H-indol-1-ium (18): Yield 37%, MP >260 oC, 1H-NMR(400 
MHz, DMSO-d6) δ: 1.72 (s, 12H), 3.67 (s, 6H), 6.26 (d, J = 14 Hz, 2H), 7.29,7.31 (t, J = 6.8 
Hz, 8.8 Hz, 2H), 7.52-7.54 (m, 2H), 7.70 (d, J = 6 Hz, 2H), 8.41 (d, J = 14 Hz, 2H). 19F NMR 
(375 MHz, DMSO- d6) δ: -116.67 (s, 2F). TOF HR-MS ESI m/z [M]
+ calculated for 
[C27H29F2ClN2]
+  453.1909 found 453.1914. 
 
 
2-((1E,3Z,5E)-3-Bromo-5-(5-fluoro-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-
1-yl)-5-fluoro-1,3,3-trimethyl-3H-indol-1-ium (19) Yield 52%, 1H-NMR(400 MHz, DMSO-
d6) δ: 1.72 (s, 12H), 3.67 (s, 6H), 6.26 (d, J = 13.2 Hz, 2H), 7.32 (t, J = 8.8 Hz, 2H) , 7.55-7.52 
(m, 2H), 7.70 (d, J = 7.6, 2H), 8.46 (d, J = 13.6, 2H). 19F NMR (375 MHz, DMSO- d6) δ: -
116.67 (s, 2F). TOF HR-MS ESI m/z [M]+ calculated [C27H29F2N2Br]
+ was 497.1404 found 
497.1394. 
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5-Chloro-2-((1E,3E,5E)-5-(5-chloro-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-
1-yl)-1,3,3-trimethyl-3H-indol-1-ium iodide (20): Yield 59%, MP >260 oC, 1H-NMR(400 
MHz, DMSO-d6) δ: 1.69 (s, 12H), 3.59 (s, 6H), 6.27 (d, J = 14 Hz, 2H), 6.551 (t, J = 12.4, 12.0 
Hz, 1H), 7.39 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 7.80 (s, 2H), 8.32 (t, J = 13.2 Hz, 
2H). 13C-NMR (100 MHz, DMSO-d6) δ: 27.30, 31.84, 49.51, 104.09, 112.87, 123.29, 126.16, 
128.67, 129.50, 142.23, 143.54, 154.72, 173.65. TOF HR-MS ESI m/z [M]+ calculated for 
[C27H29Cl2N2]
+  451.1708, found 451.1722. 
 
5-chloro-2-((1E,3Z,5E)-3-chloro-5-(5-chloro-1,3,3-trimethylindolin-2-ylidene)penta-
1,3-dien-1-yl)-1,3,3-trimethyl-3H-indol-1-ium (21): Yield 53%, MP >260 oC, 1H-NMR(400 
MHz, DMSO-d6) δ: 1.72 (s, 12H), 3.67 (s, 6H), 6.26 (d, J = 14 Hz, 2H), 7.52 (m, 4H), 7.89 (s, 
2H), 8.43 (d, J = 13.6, 2H). 13C-NMR (100 MHz, DMSO-d6) δ: 26.81, 32.15, 49.98, 100.72, 
113.62, 123.06, 123.49, 128.80, 130.31, 142.02, 143.83, 147.96, 174.97. TOF HR-MS ESI m/z 
[M]+ calculated for [C27H29Cl3N2]
+  485.1318 found 485.1317. 
 
 
 
2-((1E,3Z,5E)-3-Bromo-5-(5-chloro-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-
1-yl)-5-chloro-1,3,3-trimethyl-3H-indol-1-ium iodide (22) Yield 69%, MP 252-254 oC 1H-
140 
 
NMR(400 MHz, DMSO-d6) δ: 1.73 (s, 12H), 3.67 (s, 6H), 6.28 (d, J = 13.2 Hz, 2H), 7.52 (m, 
4H), 7.89 (s, 2H), 8.47 (d, J = 13.2 Hz, 2H). 13C-NMR (100 MHz, DMSO-d6) δ: 26.79, 32.16, 
50.03, 102.96, 113.65, 116.40, 123.51, 128.82, 130.35, 141.99, 143.83, 149.98, 175.15. TOF 
HR-MS ESI m/z [M]+ calculated [C27H28BrN2Cl2]
+  was 529.0813 found 529.0810. 
 
5-Bromo-2-((1E,3E,5E)-5-(5-bromo-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-
1-yl)-1,3,3-trimethyl-3H-indol-1-ium iodide (23): Yield 62%, MP >260 oC, 1H-NMR(400 
MHz, DMSO-d6) δ: 1.69 (s, 12H), 3.58 (s, 6H), 6.27 (d, J = 14 Hz, 2H), 6.56 (t, J = 12.4, 12 
Hz, 1H), 7.35 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 8.4, 2H), 7.93 (s, 2H), 8.33 (t, J = 13.2 Hz, 
2H).  13C-NMR (100 MHz, DMSO-d6) δ 27.25, 31.71, 49.48, 104.07, 113.33, 117.45, 126.09, 
131.51, 142.63, 143.85, 154.86, 173.45.  TOF HR-MS ESI m/z [M]+ calculated for 
[C27H29Br2N2]
+ 539.0697, found 539.0695. 
 
5-Bromo-2-((1E,3Z,5E)-5-(5-bromo-1,3,3-trimethylindolin-2-ylidene)-3-chloropenta-
1,3-dien-1-yl)-1,3,3-trimethyl-3H-indol-1-ium (24): Yield 72%, MP >260 oC, 1H-NMR(400 
MHz, DMSO-d6) δ: 1.72 (s, 12H), 3.67 (s, 6H), 6.28 (d, J = 12.0 Hz, 2H), 7.47 (d, J = 8.0 Hz, 
2H), 7.63 (d, J = 8.0 Hz, 2H), 8.01 (s, 2H), 8.43 (d, J = 12.0 Hz, 2H). 13C-NMR (100 MHz, 
DMSO-d6) δ: 26.81, 32.17, 49.96, 100.69, 114.05, 118.37, 123.13, 126.26, 131.63, 142.40, 
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144.11, 147.96, 174.78. TOF HR-MS ESI m/z [M]+ calculated for [C27H28Br2N2Cl]
+  573.0308, 
found 573.0316. 
 
5-Bromo-2-((1E,3Z,5E)-3-bromo-5-(5-bromo-1,3,3-trimethylindolin-2-ylidene)penta-
1,3-dien-1-yl)-1,3,3-trimethyl-3H-indol-1-ium iodide (25): Yield 46%, MP 231-232 oC, 1H-
NMR(400 MHz, DMSO-d6) δ: 1.72 (s, 12H), 3.66 (s, 6H), 6.28 (d, J = 13.2 Hz, 2H), 7.47 (d, 
J = 8.0 Hz, 2H), 6.64 (d, J = 8.4 Hz, 2H), 8.01 (s, 2H), 8.48 (d, J = 13.6 Hz, 2H). 13C-NMR 
(100 MHz, DMSO-d6) δ: 26.79, 32.11, 50.03, 102.97, 114.07, 116.47, 118.42, 126.27, 131.65, 
142.40, 144.13, 150.03, 175.01. TOF HR-MS ESI m/z [M]+ calculated [C27H28Br3N2]
+  was 
616.9803, found 616.9814 
 
1,3,3-trimethyl-5-(trifluoromethyl)-2-((1E,3E)-5-((E)-1,3,3-trimethyl-5-
(trifluoromethyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3H-indol-1-ium iodide (26): Yield 
55%, MP 218-221°C, 1H NMR (400 MHz, CDCl3): δ 1.81 (s, 12H), 3.79 (s, 6H), 6.53 (d, J = 
13.6 Hz, 2H), 7.11 (t, J = 13.6 Hz, 1H), 7.21(d, J = 8.4 Hz, 2H), 7.60 (s, 2H), 7.70 (d, J = 7.6 
Hz, 2H), 8.02 (t, J = 13.6, 2H). 19FNMR: (375 MHz, DMSO-d6): δ 62.00. TOF HRMS m/z 
[M]+ calculated for [C29H29N2F6]
+ 519.2297, found 519.2393 
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2-((1E,3Z)-3-chloro-5-((E)-1,3,3-trimethyl-5-(trifluoromethyl)indolin-2-
ylidene)penta-1,3-dien-1-yl)-1,3,3-trimethyl-5-(trifluoromethyl)-3H-indol-1-ium iodide (27): 
Yield 71%, MP 226-228 °C, 1H NMR (400 MHz, CDCl3): δ 1.91 (s, 12H), 3.87 (s, 6H), 6.47 
(d, J = 13.6 Hz, 2 H), 7.30 (s, 2H), 7.65 (m, 4H), 8.90 (d, J = 10.4 Hz, 2H).  19F NMR (375 
MHz, DMSO-d6): δ 62.05. TOF HRMS m/z [M]
+ calculated for [C29H28N2F6Cl]
+ 553.1840, 
found 553.1996. 
 
 
2-((1E,3Z)-3-bromo-5-((E)-1,3,3-trimethyl-5-(trifluoromethyl)indolin-2-
ylidene)penta-1,3-dien-1-yl)-1,3,3-trimethyl-5-(trifluoromethyl)-3H-indol-1-ium iodide (28): 
Yield 71%, MP 226-228 °C, 1H NMR (400 MHz, CDCl3): δ 1.91 (s, 12H), 3.87 (s, 6H), 6.46 
(bs, 2H), 7.30 (s, 2H), 7.69 (m, 4H), 8.91 (d, J =, 7.2 Hz, 2H). 19F NMR (375 MHz, DMSO-
d6), δ: 62.01. TOF HRMS m/z [M]
+ calculated for [C29H28N2F6Br]
+ 597.1335, found 597.1597. 
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5-methoxy-2,3,3-trimethyl-3H-indole (29): Yield 78%, reddish brown oil; 1H NMR 
(400MHz, DMSO-d6) δ 1.17 (s, 6H), 2.16 (s, 3H), 3.68 (s, 3H), 6.74 (m, 2H), 7.38 (s,1H). 
 
5-methoxy-1,2,3,3-tetramethyl-3H-indol-1-ium iodide (30): 1H NMR (400 MHz, 
DMSO-d6) δ 1.51 (s, 6H), 2.71 (s, 3H), 3.86 (s, 3H), 3.94 (s, 3H), 7.14 (d, J = 8.0 Hz, 1H), 7.47 
(s, 1H), 7.81 (d, J = 8.0 Hz, 1H). 
 
5-Methoxy-2-((1E,3E,5E)-5-(5-methoxy-1,3,3-trimethylindolin-2-ylidene)penta-1,3-
dien-1-yl)-1,3,3-trimethyl-3H-indol-1-ium iodide (31): Yield 75%, MP 228-230 °C, 1H NMR 
(400 MHz, DMSO-d6): δ 1.66 (s, 12H), 3.56 (s, 3H), 3.81 (s, 6H), 6.17 (d, J = 12 Hz, 2H), 6.46 
(t, J = 12 Hz, 1H), 6.95 (d, J = 8 Hz, 2H), 7.30-7.28 (m, 4H), 8.23 (t, J = 12 Hz, 2H).  13C NMR 
(100 MHz, DMSO-d6): δ 26.48, 30.62, 48.45, 55.29, 102.06, 108.43, 111.02, 112.84, 123.73, 
135.80, 142.15, 151.94, 156.98, 171.55. TOF HRMS m/z [M]+ calculated for [C29H35N2O2]
+ 
443.2699, found 443.2692. 
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2-((1E,3Z,5E)-3-Chloro-5-(5-methoxy-1,3,3-trimethylindolin-2-ylidene)penta-1,3-
dien-1-yl)-5-methoxy-1,3,3-trimethyl-3H-indol-1-ium iodide (32): Yield 80%, MP 235-237 
oC, 1H NMR (400 MHz, MeOD-d4) δ 1.73 (s, 12H), 3.67 (s, 6H), 3.85 (s, 6H), 6.34 (d, J = 12 
Hz, 2H), 6.99 (d, J = 8.0 Hz, 2H), 7.14 (s, 2H), 7.29 (d, J = 8.0 Hz, 2H), 8.23 (d, J = 12 Hz, 
2H). 13C NMR (100 MHz, DMSO-d6) δ 27.05, 31.96, 49.88, 56.33, 99.74, 109.36, 112.76, 
114.07, 121.81, 136.50, 143.49, 146.18, 158.51, 173.76. TOF HRMS m/z [M]+ calculated for 
[C29H34N2O2Cl]
+ 477.2309; found 477.2327. 
 
 
2-((1E,3Z,5E)-3-Bromo-5-(5-methoxy-1,3,3-trimethylindolin-2-ylidene)penta-1,3-
dien-1-yl)-5-methoxy-1,3,3-trimethyl-3H-indol-1-ium iodide (33): Yield 55%, MP 214-216 oC, 
1H NMR (400 MHz, DMSO-d6): δ 1.69 (s , 12H), 3.63 (s, 6H), 3.81 (s, 6H), 6.18 (d, J = 12 
Hz, 2H), 6.97 (d, J = 8.0 Hz, 2H), 7.35 (s, 2H), 7.40 (d, J = 8 Hz, 2H), 8.38 (d, J = 12 Hz, 2H). 
13C NMR (100 MHz, DMSO-d6): δ 26.20, 31.16, 49.13, 55.53, 101.20, 108.56, 112.00, 113.28, 
114.41, 135.67, 142.68, 147.32, 157.72, 173.09. TOF HRMS m/z [M]+ calculated for 
[C29H34N2O2Br]
+ 521.1804 found 521.1801.  
 
3-bromo-3-methyl-2-butanone (34):  A mixture of 3-methylbutan-2-one (25.00 mL, 
233.65 mmol) and acetic acid (38.00 mL) was added to a three-neck oven-dried round bottom 
flask and maintained at a temperature of 5 oC.  Next, both molecular bromine (12.03 mL, 
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233.65 mmol) and acetic acid (13.00 mL) was combined in an addition funnel and added 
dropwise to the round bottom flask.  When all of the bromine was added the reaction mixture 
was allowed to stir overnight at room temperature.  To the resulting mixture, water (100 mL) 
was added, then transferred to a separatory funnel where another 100 mL of water was added 
and the organic layer was extracted with diethyl ether (3 x 150 mL).  The compound was then 
washed with cold, saturated sodium bicarbonate (4 x 100 mL), dried over anhydrous sodium 
sulfate, and the reaction mixture was concentrated in vacuo to afford a yellow oil.  The crude 
product was further purified via vacuum distillation (52 oC , ~ 25 mmHg) to yield a colorless 
oil. Yield 34%.  1H NMR (400 MHz, CDCl3) δ: 1.824 (s, 6H), 2.401 (s, 3H).     
 
6,7,7-trimethyl-7H-[1,3]dioxolo[4,5-f]indole: A solution of DMF, (8 mL), aniline (1.56 
g, 11.38 mmol), and potassium carbonate (1.05 g, 6.8 mmol) was brought to 45 oC in a two-
neck round bottom flask with small magnetic stir-bar. 3-Bromo-3-methylbutan-2-one (34, 1.86 
g, 1 mL) was added to the solution overnight with a syringe pump (Kd Scientific, Model 100). 
After addition was completed, solution was stirred for 24 h at 45 oC and monitored by TLC. 
After TLC showed that the starting material was consumed, dimethylformamide was 
evaporated in vacuo, and concentrate was extracted with toluene (5 x 20 mL) and was washed 
with deionized water. Toluene was concentrated to an amount of 10-20 mL, and p-
methyltoluenesulfonic acid (0.110 g, 0.1 mol equiv.) was added to solution. Solution was 
allowed to reflux for 24h, until TLC showed an absence of starting material. Toluene was 
evaporated in vacuo, and dichloromethane (20 mL) was added to the reaction mixture. Solution 
was washed with a saturated solution of sodium carbonate (5 x 50 mL) until the organic layer 
was a red/brown color. DCM was removed under reduced pressure and the resulting red/brown 
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oil was recovered and the crude cyclic intermediate (obtained in 57% yield) was used without 
purification. 5,6,7,7-Tetramethyl-7H-[1,3]dioxolo[4,5-f]indol-5-ium iodide (35): This crude 
product was added to a round bottom flask with acetonitrile (50 mL) and iodomethane (3 mol. 
eq.).  The mixture was heated to 60 oC for 4h. until the starting material was consumed.  The 
reaction mixture was allowed to cool to rt and diethyl ether (80 mL) was added to the solution 
resulting in a dark brown oil.  Several precipitations from methanol by diluting with diethyl 
ether afforded a light grey pure solid. Yield 60%, 1H NMR (400 MHz, DMSO-d6) δ: 1.48 (s, 
6H) 2.70 (br. s., 3H) 3.90 (s, 3H) 6.19 (s, 2H) 7.48 (s, 1H) 7.64 (s, 1H), 13C NMR (100 MHz, 
DMSO-d6) δ: 15.43, 21.48, 23.05, 53.61, 55.34, 101.44, 103.34, 125.76, 128.64, 129.34, 
139.90, 145.50, 146.91, 147.91, 187.11. 
 
A mixture of indolium salt 35 (1 mmol), bis-iminium salt 11-13 (0.5 mmol), sodium 
acetate (0.23 mmol) and acetic anhydride (1 mL) was added to an oven dried round bottom 
flask with magnetic stirring bar.  The reaction mixture was heated using a standard oil bath for 
a particular reaction time and was followed using TLC and UV-Vis-NIR absorption in ethanol. 
After starting materials were consumed, the reaction was allowed to cool to room temperature.  
Diethyl ether was added to the round bottom flask resulting in an oily metallic blue residue.  
The diethyl ether was decanted and the oil was dissolved in a minimal amount of methanol 
followed by the addition of diethyl ether (50 mL) resulting in the formation of light blue 
crystals, which were filtered.  The crystals were dissolved in dichloromethane leaving 
unreacted sodium acetate on the funnel.  The dichloromethane was removed in vacuo. Silica-
gel column chromatography eluting with 2-5% methanol in dichloromethane afforded the 
various pentamethine cyanines 36-38 in their respective yield. 
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5,7,7-Trimethyl-6-((1E,3E,5Z)-5-(5,7,7-trimethyl-5H-[1,3]dioxolo[4,5-f]indol-6(7H)-
ylidene)penta-1,3-dien-1-yl)-7H-[1,3]dioxolo[4,5-f]indol-5-ium iodide (36): Yield 38%, 1H 
NMR (400 MHz, DMSO-d6) δ: 1.63 (s, 12H), 3.54 (s, 6H), 6.06 (s, 4H), 6.18 (d, J = 16.0 Hz, 
2H), 6.46 (t, J = 16.0 Hz, 1H), 7.13 (s, 2H), 7.28 (s, 2H), 8.16 (t, J = 15 Hz, 2H). 13C NMR 
(100 MHz, DMSO-d6) δ: 27.59, 31.89, 49.29, 94.35, 102.18, 103.40, 104.03, 125.11, 134.93, 
137.52, 145.55, 148.02, 152.68, 173.32. TOF HRMS m/z [M]+ calculated for [C29H31O4N2]
+ 
471.2278 found 471.2268.  
 
6-((1E,3Z,5E)-3-chloro-5-(5,7,7-trimethyl-5,7-dihydro-6H-[1,3]dioxolo[4,5-f]indol-
6-ylidene)penta-1,3-dien-1-yl)-5,7,7-trimethyl-7H-[1,3]dioxolo[4,5-f]indol-5-ium (37): Yield 
39%, 1H NMR (400 MHz, DMSO-d6) δ: 1.66 (s, 12H), 3.63 (s, 6H), 6.10 (s, 4H), 6.21 (d, J = 
13.6 Hz, 2H), 7.29 (s, 2H), 7.38 (s, 2H), 8.30 (d, J = 13.6 Hz, 2H). 13C NMR (100 MHz, 
DMSO-d6) δ: 27.10, 32.20, 49.70, 94.92, 100.10, 102.34, 104.12, 135.49, 137.25, 146.04, 
146.12, 148.10, 174.41. TOF HRMS m/z [M]+ calculated for [C29H30N2O4Cl]
+ 505.1894 found 
505.1871. 
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6-((1E,3Z,5E)-3-bromo-5-(5,7,7-trimethyl-5,7-dihydro-6H-[1,3]dioxolo[4,5-f]indol-
6-ylidene)penta-1,3-dien-1-yl)-5,7,7-trimethyl-7H-[1,3]dioxolo[4,5-f]indol-5-ium (38): Yield 
27%, 1H NMR (400 MHz, DMSO-d6) δ: 1.66 (s, 12H), 3.62 (s, 6H), 6.10 (s, 4H), 6.21 (d, J = 
13.6 Hz, 2H), 7.29 (s, 2H), 7.39 (s, 2H), 8.36 (d, J = 13.6 Hz, 2H). 13C NMR (100 MHz, 
DMSO-d6) δ: 27.08, 32.20, 49.76, 94.94, 102.34, 104.14, 113.95, 135.50, 137.22, 146.16, 
146.16, 148.02, 174.59. TOF HRMS m/z [M]+ calculated for [C29H30N2O4Br]
+ 549.1389 found 
549.1368. 
4.4.6 Optical and physicochemical property analyses.  
All optical measurements were performed in various solvents, including ethanol, 
dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS, pH 7.4) and at 37oC in 100% 
fetal bovine serum (FBS) buffered with 50 mM HEPES, pH 7.4. Absorbance and fluorescence 
emission spectra of the series of NIR fluorophores were measured using Varian Cary 50 
absorbance spectrophotometer (190–1100 nm) and Shimadzu RF-5301PC spectrofluorometer 
(350–1000 nm). For fluorescence quantum yield (QY) measurements, rhodamine 800 in 
absolute ethanol (QY = 28%) was used as a calibration standard, under conditions of matched 
absorbance at 640 nm. In silico calculations of physicochemical distribution coefficient (logD 
at pH 7.4) was calculated using Marvin and JChem calculator plugins (ChemAxon, Budapest, 
Hungary).  Electrostatic maps were calculated using Spartan DFT calculations at the B3LYP 
level. 
 
4.4.7 LC-MS analysis.  
The purity of all compounds was measured using liquid chromatography-mass 
spectrometry (LC-MS) on a Waters system consisting of a 1525 binary HPLC pump with a 
manual 7725i Rheodyne injector, a 996 Photodiode Array (PDA) detector, and a 2475 
multiwavelength fluorescence detector. The column eluent was divided in 2 using a flow 
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splitter (Upchurch Scientific). A portion of the eluent flowed into an ELSD (Richards 
Scientific) while the rest flowed into a Micromass LCT ESI-TOF spectrometer (Waters) 
equipped with a Symmetry (R) C18 (4.6 x 150 mm, 5 μm) reverse-phase HPLC column. For 
mass spectrometry mobile phase was solvent A = 0.1% formic acid (FA) in water and solvent 
B = CH3CN with 95% A for 5 min and a linear gradient from 5% to 40% CH3CN (from A to 
B for 30 min) at a flow rate of 1 mL/min, capillary voltage was -3317V, and sample cone 
voltage was -50V. 
 
4.4.8 Animal models and biodistribution.  
Animals were housed in an AAALAC-certified facility and were studied under the 
supervision of BIDMC’s IACUC in accordance with the approved institutional protocol #057-
2014. Male CD-1 mice (20–30 g, 6-8 weeks, Charles River Laboratories, Wilmington, MA) 
were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine intraperitoneally (Webster 
Veterinary, Fort Devens, MA). For intraoperative imaging and biodistribution, the imaging 
system equipped with a custom filter set (Chroma Technology Corporation, Brattleboro, VT) 
composed of a 650 ± 22 nm excitation filter, a 680 nm dichroic mirror, and an 710 ± 25 nm 
emission filter was used at a fluence rate of 4 mW/cm2, with white light (400-650 nm) at 40,000 
lx. Color and NIR fluorescence images were acquired simultaneously with custom software at 
rates up to 15 Hz over a 15 cm diameter field of view. The imaging system was positioned at 
a distance of 18 inches from the surgical field. For each experiment, camera exposure time and 
image normalization was held constant. 
4.4.9 Quantitative analysis.  
At each time point, the fluorescence and background intensity of a region of interest 
(ROI) over each tissue was quantified using custom imaging software and ImageJ software 
(NIH, Bethesda, MD) version 1.45q. The signal-to-background ratio (SBR) was calculated as 
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SBR = fluorescence/background, where background is the signal intensity of neighboring 
tissues such as muscle or skin obtained over the period of imaging time. All NIR fluorescence 
images for a particular fluorophore were normalized identically for all conditions of an 
experiment. At least three animals were analyzed at each time point. Statistical analysis was 
carried out using the unpaired Student’s t-test or one-way analysis of variance (ANOVA). 
Results were presented as mean ± s.d. and curve fitting was performed using Prism version 
4.0a software (GraphPad, San Diego, CA). 
4.5 Conclusions 
Toward satisfying the clinical need for native tissue targeted contrast agents in real-
time NIR image-guided surgery, we present compounds that are effective at imaging the 
salivary, thyroid, pituitary, adrenal glands, lymph nodes and pancreas. We are confident that 
this work will lay the foundation for development of native tissue contrast agents for clinical 
use.   
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5 MICROWAVE ASSISTED SYNTHESIS OF NITROGEN CONTAINING 
HETEROCYCLES 
This chapter serves to introduce microwave assisted organic synthetic methods for the 
application toward various nitrogenous heterocycles.  Using these advancements, we have 
developed a green route using microwave irradiation to synthesize a series of pentamethine 
cyanines in the following chapter.  This is an excerpt from a review article that has been 
prepared about many different microwave reactions and we are planning to publish the article 
in Med Chem Comm. My contributions as first author were the structural design, data 
interpretation and figure/manuscript preparation as well as guiding the other authors in looking 
up articles and preparing their individual portions of the manuscript. 
Owens, E.A., Kananda, C., Holder, C, Ma, X., Bruschi, N., Henary, M. Microwave 
Synthesis of Drug-like Nitrogen Containing Heterocycles. Prepared for submission to 
MedChemComm. 2015. 
5.1 Abstract 
Heterocyclic compounds are of immense research interest because they are found 
frequently in natural compounds and exhibit a wide range of interesting biological activities.  
The prominence of such compounds makes it vital to develop methods to increase the 
efficiency of their synthesis and probe effects of their modifications on biological efficacy.  It 
is often these occur in a combinatorial manner, and many medicinal chemists have employed 
microwave-assisted organic synthesis (MAOS) in their laboratories as a way of efficiently and 
time-effectively synthesizing various heterocycles. Microwave assisted synthesis is of growing 
popularity amongst medicinal chemists and has proved more efficient in terms of reaction 
yield, time, purity and environmental friendliness for many reactions when compared to 
conventional thermal methods—especially in forming carbon-nitrogen heterocyclic ring 
systems. The importance of nitrogen-containing ring systems in medicine cannot be 
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understated as such ring systems have shown to have applicability ranging from vitamins and 
herbicides to anti-fungal, anti-bacterial and anti-cancer agents, among other things. The 
significance of these applications has created an unprecedented need for more efficient 
synthetic methods. This review presents the most recent and pressing advancements made in 
the field of microwave-assisted synthesis for the formation of small and medium nitrogen-
containing heterocycles, including pyrrole, indole, pyridine, pyrrolidine, imidazole and 
pyrazoline structures and their corresponding biological profile. 
5.2 Introduction.  
Heterocyclic ring systems have attracted a great deal of attention from medicinal 
chemists due to their prominent use in several significant biologically active small molecules. 
A brief survey of the most active pharmacological heterocyclic atoms shows that nitrogen-
based heterocycles are the most prevalent in biologically relevant small molecules. 
Heterocyclic compounds containing these atoms are of current research interest because they 
are building scaffolds for compounds that exhibit interesting biological activities and are used 
for many different pharmacological applications. Such ring systems have shown to have 
various applications ranging from vitamins and herbicides to anti-fungal, anti-bacterial and 
anti-cancer agents, among other things, and it is because of their wide range of applications 
that a more proficient method of synthesis should be developed.  The development of efficient 
methods for their synthesis has been an ongoing quest.  In the past few years, synthetic chemists 
have developed various methods for the preparation of heterocyclic compounds with many 
utilizing expensive palladium, gold or other equally expensive and environmentally polluting 
reagents. In this context, the need for improving reaction conditions has shown that microwave 
irradiation is particularly beneficial in generating heterocyclic compounds in elevated yield 
with a reduction or elimination of caustic reagents.  
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Microwave assisted organic synthesis (MAOS) use a different type of heating distinct 
to the external heating source used in conventional methods. This “superman heat vision” effect 
is based on temperature increase by dielectric heating which happens through two means: 
dipolar polarization and ionic conduction. Microwave dielectric heating drives chemical 
reactions by taking advantage of the ability of the medium to transform electromagnetic 
radiation into heat. It happens when the dipoles or ions present in the reaction mixture align in 
an applied electric field as a result to microwave irradiation. As the electric field oscillates, the 
dipoles or ion field tend to realign itself with the oscillating electric field, in the process, losing 
energy in the form of heat, due to molecular friction and dielectric losses. The microwave 
energy passes through the walls of the reaction vessel, heating the reactants and solvents by 
coupling directly with the molecules of the entire reaction mixture, consequently, the tendency 
for the initiation of boiling is reduced, and superheating above the boiling point of the solvent 
is possible. A properly designed cavity allows the temperature increase to be uniform 
throughout the sample, leading to reduction of reaction time, typically from days or hours to 
minutes or even seconds, and this method usually results in a direct increase in product yields, 
purity and atom efficiency—if the correct conditions are optimized.  Additionally, these 
benefits lend themselves directly toward developing green methods for the production of 
medicinal compounds in an environmentally friendly approach. In order to maximize the 
effective use of microwave chemistry, one must judiciously select reagents (i.e. reactants, 
solvents, etc.) as well as understand the benefits yet also design around the inherent limitations 
of microwave assisted methods.  One important concept is the dipole effect which is 
responsible for the dielectric heating afforded by microwave irradiation.  
a 
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Figure 5-1. General schematic for microwave energy. 
 
Microwave synthesis generally allows for one pot sequences for many reaction 
processes in the formation of such compounds. It can also be incorporated as a step in the 
overall scheme of pre-existing reactions. This review article presents the most recent and 
pressing advancements made in the field of microwave-assisted synthesis for the formation of 
small and medium nitrogen-containing heterocycles, including pyrrole, indole, pyridine, 
pyrrolidine, imidazole and pyrazoline structures among others. We are confident that medicinal 
chemists will be able to utilize these reactions toward the synthesis of new and promising 
therapeutic compounds. 
5.3 Pyrrole-Containing Heterocyclic Compounds 
The pyrrole ring has extreme notoriety in all aspects of the chemical industry; it is 
among the most frequently observed heterocyclic system in the structure of natural products 
and synthetic materials. Both the blood respiratory pigment heme and the photosynthesis 
pigment chlorophyll are biosynthesized from the pyrrole porphobilinogen; furthermore, 
Atorvastatin known commercially as Lipitor, a drug used to treat high cholesterol, is also a 
very well-known pyrrole-containing derivative(Figure 2) 1. There are many classic protocols 
for the synthesis of pyrroles including the Knorr, Pall- Knorr, Hantzsch condensation and 
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Clauson-Kaas synthesis.  The yields and conditions for performing this chemistry has been 
improved through microwave assistance. 
 
 
Figure 5-2. The chemical structures of porphobilinogen and atorvastatin.  
 
Miles et al. [10] adopted the Clauson-Kaas synthesis by reacting 2,5-
dialkoxytetrahydrofurans 1 with a variety of nitrogen derivatives 2 using microwave irradiation 
at 170 °C for 10 minutes in either acetic acid or water as both solvent and promoter to produce 
N-substituted pyrroles 3 in good yields (Equation 1). In this reaction, higher yields (70-96%) 
were obtained when acetic acid was used as a solvent compared to water (12-74%). For the 
water solvated reactions, the yield and purity were found higher when the amine reacted were 
anilines or sulfonamides.  
 
Equation 1. 
 
Pyrrole derivatives bearing higher order substitution compared to 3 have been reported 
by Bremner et al. [11]. They described a novel method for the synthesis of pyrrole derivatives 
consisting of the reaction of various secondary propargylamines 4 with aldehydes 5 in DMF 
using microwave irradiation at 200 °C for 30 minutes to yield pyrrole compounds 6 (Equation 
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2). The following methodology exploits a tandem condensation/aza-Claisen 
rearrangement/cyclization sequence. It is highly tolerable to bulky aliphatic groups substituted 
on the R3 position, as well as pharmaceutically relevant functionality such as nitrogen and 
sulfur heterocycles at the acetylenic position.  
 
 
Equation 2.  
 
Hatamjafari et al2 described a short and efficient 3-component reaction of ninhydrins 
7, alkyl propiolates 8, and simple primary amines 9 under solvent free MW irradiation for 5 
minutes for the synthesis of a series of tetrahydro-dihydroxy-oxoindeno[1,2-b]pyrroles 10 with 
good yield 60-87% (Equation 3). These polyhydroxylated pyrroles are very interesting pyrrole 
derivatives as they structurally resemble the sugar moiety of monosaccharide carbohydrates 
and can be used as potent inhibitors for enzymes that are involved in a wide range of important 
biological processes. 
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Equation 3. 
5.4 Indole 
In the hierarchy of biologically privileged structures the indole ring system is one of 
the most prevalent3. Indole nuclei are prevalent in many bioactive natural products and 
medicinally important synthetics. The search for an efficient construction of indole skeletons 
of chemical and biomedical importance has remained a prevailing theme in organic synthesis4. 
One of the most robust and proven methods is Fisher indole synthesis—the reaction of a ketone 
with phenyl hydrazine in acidic media.  Toward optimizing this effective route, microwave 
synthesis methods have been employed for maximizing the atom efficiency, yield, purity and 
scope toward the synthesis of natural products and medicines.  
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Figure 5-3. Drugs bearing the indole (or similar) moiety. 
 
Creencia et al. described the synthesis of substituted indole 13 by a one-pot-one-step, 
solvent-free, microwave-assisted Fischer indole reaction using various readily available 
substituted phenylhydrazines 11 and enolizable ketones 12 (Equation 4). This synthesis method 
does not require the preparation and isolation of unstable arylhydrazones because commercially 
available precursors are used as starting reagents. Good product yields were obtained at shorter 
reaction times compared to the non-microwave assisted methods that generally offer complex 
mixtures in extended reaction timescales. 
 
Equation 4. 
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The robust and diverse Fischer indole reaction was again utilized by Porcheddu and his 
co-workers5 starting from readily available alcohols. This reaction was carried out under W 
irradiation, combining the classical Fischer indole synthesis with the innovative hydrogen auto 
transfer technology to catalytically oxidize primary or secondary alcohols 15 in the presence 
of phenylhydrazine 14 and a protic or Lewis acid, using Ru and ZnCl2 as a metal catalyst at 
130 °C to give the corresponding indoles 16 (Equation 5). This method allows the formation 
of substituted indole rings using less toxic, and cheaper starting material.  
Equation 5. 
 
Ranasinghe et al.6 applied microwave, flow chemistry, and a combination of both 
methodologies through the Hemetsberger– Knittel (HK) indole synthesis to produce a number 
of substituted indoles. A series of azidoesters 18 were converted to the corresponding indole-
2-carboxylates 19 under a variety of conditions. The use of microwave gave good yields at the 
optimal temperature of 200 °C for 10 min using toluene as solvent. A tandem HK-
decarboxylation sequence was also performed by converting substrate 18 to the corresponding 
indole 22. The process involved the conversion of the azidoester to azidoacid 20, which was 
the substituted indole presumably though intermediate 21, which could only be isolated using 
the Rh based catalyst (Scheme 1). An extension of the HK decarboxylation sequence reaction 
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involved the synthesis of analogs of agent PLX-4032 (Figure 3), an azaindoles recently 
approved as an anti-melanoma agent, and also used in peptide tagging.  
 
Scheme 1. 
 
Nguyen et al.7 described the versatility of tetrakis triphenylphosphine palladium(0) 
(Pd(PPh3)4) for the intermolecular Heck cyclization of N-aryl β-nitroenamines 23 as a route to 
the synthesis of functionalized 3-nitroindoles 24 using microwave irradiation at 140 °C 
(Scheme 2). This methodology utilized catalytic amount of the ubiquitous Pd(PPh3)4 and 
enamines readily available in one synthetic step from commercially available 21 o-
bromoanilines and aryl and alkyl ketones. This method also allows for the synthesis of indoles 
bearing alternate and diverse electron-withdrawing groups (EWG) at 3-C. 
Scheme 2. 
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5.5 Pyridines 
Pyridine-based chemical compounds rank among the most highly represented in the 
pharmaceutical industry with many having several key biological characteristics—such as 
antibacterial, anti-inflammatory and analgesics8. Figure 4 shows three important compounds 
that utilize the pyridine structure in the pharmaceutical mendicant, among them are some of 
the most successful drugs in the market—particularly esomeprazole (Nexium™) ranks as 2nd 
in leading the U.S. pharmaceutical market in sales. Consequently, the development of methods 
for the preparation of substituted pyridine derivatives is of importance to synthetic and 
medicinal chemistry. 
 
 
  
Figure 5-4. Drugs that exhibit a pyridine structure. 
 
In response to the need for developing methods for the microwave synthesis of pyridine 
compounds, Shi et al.9 reported the optimization of the chemo selective synthesis of novel 
thiazolo[3,2-a]pyridines derivatives 28 and 29 via microwave-assisted three-component 
reactions of malononitrile 25, aromatic aldehydes 26 and 2-mercaptoacetic acid 27 in water 
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(Scheme 3). These pyridine derivatives were examined for their antioxidant and cytotoxic 
activities. The novel class of thiazolo[3,2-a]pyridine derivatives, possess electron acceptors 
and donors that exhibited potent antioxidant activity and selective tumor cytotoxicity. 
 
Scheme 3. 
 
Jiang et al.10 developed a new improved reaction that offered a simple and efficient 
route for diversity-oriented synthesis, DOS, of highly functionalized 2 pyridine collections 
(Kro ̈hnke pyridines). The goal of diversity-oriented synthesis is the facile preparation of 
collections of structurally complex and diverse compounds from simple starting materials11. 
This methodology involved the variation of aromatic aldehydes 30, 3-oxo-3-
phenylpropanenitrile 33 and 2-acetylpyridine substrates 31 in the presence of ammonium 
acetate using microwave heating at optimized reaction conditions to form highly functionalized 
pyridine derivatives (2, 2′-bipyridines, unsymmetrical 2,4,6-triarylpyridines) 34 and penta-aryl 
pyridines 35 (Scheme 4). The DOS methodology under microwave heating provides rapid 
access to pyridines with predictable control to selectively introduce various substituents. 
166 
 
 
Scheme 4. 
5.6 Conclusion.  
The need for the improvement of reaction condition in the synthesis of organic 
heterocyclic compounds is certainly a very current topic that has promoted the quest for 
methodologies that will alleviate the many hurdles encountered. The microwave assisted 
organic synthesis seems to clear some obstacles by enabling for the formation of many 
compounds in shorter reaction times, with higher yields and purity that either do not occur 
under conventional heating or occur at much higher temperatures. This article highlights some 
key applications of microwave assisted organic synthesis in the ring formation of organic 
heterocyclic for the development of N, O, and S based systems in the past 4 years. The many 
benefits of microwave-assisted organic synthesis are pushing it to become a key component in 
many step for the formation of many heterocyclic systems. The examples cited above are 
impressive and provide a good insight of the use of microwave-assisted organic synthesis in 
the field of heterocyclic chemistry.  
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6 ENVIRONMENTALLY BENIGN SYNTHETIC APPROACHES—APPLIED TO 
FLUORESCENT DYES AND THEIR PRECURSORS 
The chapter has been adapted from the publication in Dyes and Pigments concerning 
the application microwave and green methods to the synthesis of carbocyanine compounds and 
many calculations to begin predicting microwave energetics in reactions as well as HOMO 
LUMO associations with bathochromically shifted fluorophores. My contributions as first 
author were the design, synthesis, optical property determination, molecular modeling and 
computational experiments, data interpretation and figure/manuscript preparation. 
Owens, E.A., Bruschi, N., Tawney, J. G., Henary, M. M. A Microwave-Assisted and 
Environmentally Benign Approach to the Synthesis of Near-Infrared Fluorescent Pentamethine 
Cyanine Dyes 2015 Dyes and Pigments 113, 27-37. 
 
6.1 Abstract 
A time-efficient and eco-conscious microwave methodology was developed and 
applied to synthesize a systematic library of pentamethine cyanine dyes and their 
corresponding precursors. The synthesis outlined herein drastically reduced the reaction 
pathway for pentamethine carbocyanine dye syntheses from days to min, as well as producing 
increased yields (89-98%) to the conventional heating method (18-64%). Twelve examples of 
pentamethine cyanine dyes were synthesized by means of microwave-assisted organic 
synthesis which provided excellent yield in expedited reaction time and were obtained using 
facile isolation methods. Furthermore, three cyanines were prepared with a novel methylene 
dioxy heterocyclic structure which imparted an approximately 40 nm bathochromic shift 
compared to unsubstituted counterparts; these results were shown to be in agreement with DFT 
calculations and HOMO-LUMO energy differences. 
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Figure 6-1. Graphical representation for the microwave assisted green method for the 
preparation of pentamethine cyanines. 
6.2 Introduction 
Mother Nature provides our atmosphere to breathe, food required to eat and beautiful 
scenery to enjoy.  Protecting and nurturing our environment should be a task shared by all in 
the research community.  There are many methods for helping to preserve our precious natural 
resources which include the following: (1) using green solvents, (2) reducing heating times to 
conserve energy, (3) increasing atom efficiency by using higher yielding reaction conditions 
and (4) eliminating wasteful purification steps by using optimized methods that reduce side-
products.  These principles have been applied to the synthesis of many classes of compounds 
that are interesting to a broad population of the scientific community.  Correspondingly, we 
have chosen to develop a completely benign synthetic route for the synthesis of near-infrared 
fluorescent compounds that have shown excellent promise in biological imaging, solar-cell 
technology, as chemodosimeters in sensing biologically relevant species and for non-covalent 
labeling of biomolecules.   
Near-infrared (NIR, 640-900 nm) fluorescent chromophores have garnered 
considerable research interest for biomolecular labeling because of their unique red-shifted 
optical properties. [1-4] The majority of fluorescent sensors have shown to emit light in the 
visible region (400-600 nm), which forces unwanted competition with background noise that 
arises from inherent biomolecular auto-fluorescence.  This competition disrupts the meaningful 
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signal and can lead to extreme difficulty in signal delineation often with undesirable results. 
[5] To avoid the problems associated with visible-light-emitting fluorophores, molecules which 
absorb and emit light in the near-infrared region have been of significant interest to the 
scientific community. [1-3, 5-7] 
Specifically among the NIR emitting dyes, immense interest has been placed in the 
particular class of chromophores known as cyanine dyes, and they have shown extensive 
applications in cancer imaging, nucleic acid detection, biomolecular labeling, photographic 
processes, information storage and dye lasers. [7-10] Possessing relatively high molar 
absorption coefficients and a broad range of tunable fluorescence wavelengths (650-900 nm) 
cyanine dyes have been synthesized to emit light in the NIR range while maintaining biological 
efficacy. [4, 5, 8-11] Chiefly among these fluorophores, pentamethine cyanine dyes have 
shown significant promise for image guided surgery using NIR light. [1] Specifically, we 
reported several pentamethine cyanine dyes that have been shown to specifically locate various 
tissues of clinical importance during image-guided surgery. [1] Expanding upon the synthesis 
of pentamethine cyanine dyes as biomolecular imaging agents has been a focus of many 
bioorganic research labs worldwide. [12, 13]  
The design and synthesis of various substituted pentamethine cyanines has been 
achieved in a combinatorial manner by changing the N-alkyl substituent or functionalizing 
different positions of the heterocyclic backbone. [2, 4] It has been observed that minor 
structural alterations elicits a drastic biological response which makes synthesis of highly 
varied chemical structures very important.[1] This provides a significant rationale for 
developing a fast, facile and effective method for generating a library of pentamethine cyanines 
with high purity levels. 
Synthesis of various pentamethine cyanine dyes with slightly altered connectivity has 
been shown to take hours to days by the conventional oil bath heating method with lengthy, 
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difficult column chromatography that generates environmentally polluting solvent waste. [2, 6, 
14] Cyanine dyes are sensitive to the acidic nature of silica gel, photodegrade during 
purification steps and cleave in the basic solutions required for their synthesis (Figure 4-2); 
therefore, expediting the reaction time and increasing purity levels is of highly important.   
 
 
Figure 6-2. The reaction intermediates and postulated degradation products that form 
during either the classical heating method of synthesis or purification of cyanine dyes that 
lead to difficulty in obtaining analytically pure compounds for biological testing. 
 
Recently, the implementations of microwave chemistry has helped speed reactions and 
decrease the environmentally harmful waste common in organic labs; it has received interest 
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throughout the scientific community and it is very desirable to conduct synthetic protocol under 
microwave irradiation.   
In order to implement this technology in cyanine synthesis, we have harnessed the 
ability of our reaction mixture to absorb microwave energy. Electromagnetic irradiation of 
molecules results in rapid, volumetric heating caused by the dielectric effect which yields the 
final compounds without the need for column purification that may jeopardize the chemical 
integrity of the compounds from photodegradation or decomposition on the silica matrix [9]. 
The pentamethine class of cyanine dyes has not been optimized using MAOS. Utilizing a green 
approach, an entire synthetic pathway has been designed to prepare pentamethine cyanines 
with diverse chemical structures. Specifically, in the final synthetic step, using the CEM 
Discover LabMate several different substituted pentamethine cyanine dyes have been 
synthesized within 20 min in analytical purity without column purification. In comparison to 
the conventional heating method, the syntheses described herein provide drastically decreased 
reaction times and comparable or increased yields (89-98% in the final step, 80-91% overall). 
6.3 Results and Discussion 
6.3.1 Eco-friendly Synthesis of Pentamethine Cyanine Fluorophores 
The common synthetic method for the preparation of pentamethine cyanines begins 
with the formation of the terminal heterocyclic moieties.  The four heterocycles used to afford 
the compounds were synthesized according to Figures 4-3 and 4-4.  We optimized each step 
for the synthesis beginning with heterocyclic formation and begins when substituted 
phenylhydrazines are refluxed in glacial acetic acid with 3-methyl-2-butanone to afford 1 and 
2.   
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Figure 6-3. The new, green microwave assisted method for preparation of alkylated salts 
3-11 based off of the indolenine heterocyclic structure. 
 
This reaction affords the desired indolenine compounds in good yield, but this method requires 
extended periods of reaction time exceeding 24 hours and excess acetic acid as solvent.  Our 
green microwave method employs water as an environmentally conscious solvent and a 
catalytic (0.1 mol. eq.) amount of sulfuric acid to achieve quantitative conversion in 10 min.  
The second synthetic step is the quaternization of the indolenine nitrogen atom.  A classical 
method for this synthesis is mixing the two reagents in acetonitrile and refluxing until the 
reaction goes to completion.  The volatile nature of short chain alkyl halides limits the reaction 
scope and many molar equivalents should be used to completely react with the heterocyclic 
starting materials.  This leads to low atom efficiency and the use of an unnecessarily high 
quantity of alkylating agent.  Our optimized alkylation is effective at a 1.2 molar equivalency 
of alkyl iodide (Me, iodomethane, Et, iodoethane, Pr, iodopropane) without the use of harmful 
solvents at a drastically reduced reaction time.  After 20 min, the corresponding quaternary 
salts precipitate in >98% yield as a fine power and can be utilized in the next reaction without 
purification procedures.     
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Achieving new heterocyclic building blocks for the synthesis of cyanine dyes has been 
limited by the number of commercially available hydrazine hydrochlorides.  The synthesis of 
hydrazines with a number of interesting substitutions has remained scarce throughout the 
literature; however, utilizing a modified Bischler-Möhlau approach, we can achieve the 
synthesis of an acidic methylene proton with the quaternized nitrogen through a facile 
microwave-assisted approach (accessing the scope of this reaction using additional 
heterocycles are explored in another paper, Owens et al. manuscript in preparation).  Our model 
compound was the dioxolane structure.   
 
Figure 6-4. The preparation the brominated ketone 12. 
 
The initial precursor to the dioxolane heterocyclic unit, 3-bromo-3-methylbutan-2-one 
(shown in Figure 5-4), was classically prepared beginning with bromination of 3-methyl-2-
butanone under acidic conditions at 0 oC.  The high volatility and dangerous nature of working 
with molecular bromine requires the use of an alternate and environmentally friendly route.  
Applying the the bromine “on water” method reported by the Iskra lab [15], we achieved 
selective and high yielding bromination of 3-methy-2-butanone to afford 12.  
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Figure 6-5. The preparation of the fused dioxolane heterocycle 13. 
 
The cyclic product 13 is formed through treatment of the commercially available 3,4-
(methylenedioxy)aniline with intermediate 12 in DMF with potassium carbonate followed by 
addition of para-toluenesulfonic acid in toluene at 125 oC (Equation 2).  
In order to develop a green-method for the formation of this dioxolane, we began by 
examining the mechanism of this reaction. From a mechanistic point-of-view, this reaction is 
very interesting.  In basic conditions, the anilino-amine is highly nucleophilic substituting the 
tertiary bromine alpha to the carbonyl of 12 through an SN1 pathway. Monoalkylation of the 
arylamine is successful due to high steric hindrance from the dimethyl groups. Treatment of 
this intermediate with para-toluenesulfonic acid in the presence of excess catalytic aniline 
yields the dehydrated arylimine intermediate that undergoes loss of aniline through 
electrophilic aromatic substitution and re-aromatization yields the heterocyclic precursor 13.   
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Figure 6-6. The proposed mechanism based off of an adaptation of the Bischler-Möhlau 
method for indole formation. 
 
We postulated that this may work satisfactorily using eco-friendly conditions through 
microwave irradiation and successfully replaced the organic solvents with the ionic liquid 
[BMIM][PF6] and we maintained the use of potassium carbonate as the base.  The first part of 
the reaction was completed using microwave irradiation (150W) at 150 oC followed by 
treatment with para-toluene sulphonic acid as the catalytic activation of the carbonyl and 
cyclization of the ring.  The alkylation of 13 was performed using the methodology previously 
employed in Figure 5-3 and the salts 14-16 were obtained in moderate yield with classical 
reflux methods and excellent yield using MAOS (Figure 4-5).   
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Equation 3: The preparation of the alkylated fused dioxolane heterocycles 14-16. 
 
6.3.2 The Final Synthetic Step—Optimization 
In the final synthetic step, shown in Scheme 3, two equivalents of individual 
monocationic salt were allowed to react with malonaldehyde bis(phenylimine) 
monohydrochloride in the presence of sodium acetate and acetic anhydride open vessel 
classical oil-heating causes a wide variety of decomposition and incomplete reaction products 
and results in a substantial net loss of product, yielding between 18% and 64%.  In order to 
optimize the microwave-assisted reaction temperature, we first anticipated that the optimum 
reaction temperatures would be most heavily dependent on the length of the N-indolenyl 
substituent. We performed the synthesis of a representative fluorophore with various alkyl 
lengths on the indolenyl nitrogen to obtain the correct temperature to employ for all of the 
pentamethine cyanines.   
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Figure 6-7. The microwave assisted preparation of a systematic set of pentamethine 
cyanines with variance in heterocyclic and N-alkyl groups. 
 
As the alkyl length increases, the insulation properties of the compound also increase.  
In order to determine the optimal temperature, the systematic set of dyes 17-19 were tested at 
a range of temperatures.  The isolated yield for each of the reactions are shown as a function 
of temperature in Figure 2 and shows a correlation as the alkyl group becomes longer, the most 
desirable reaction temperature also increases. 
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Figure 6-8. Isolated yield (%) versus reaction temperature (oC) versus the three 
pentamethine carbocyanine dyes with varied lengths of the N-alkyl groups 17 (methyl, 
blue), 18 (ethyl, red), and 19 (propyl, green).  Reactions were held at 20 min for the 
isolated yield. 
 
The medium length N-substituted ethyl dye 18 was chosen as a model for discussing 
optimal reaction temperatures. As shown in Table 1, multiple trials were conducted varying 
temperature by 10 oC increments starting with 90 oC while alternating reaction time for 10 and 
20 min.  
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.  
Table 6-1 Optimization Data for Pentamethine Carbocyanine Dye 18 with an ethyl group. 
 
Conducting the reaction at temperatures between 50 oC and 90 oC showed 
comparatively low yields.  The optimum temperature was observed as a maximum and heating 
above this temperature resulted in undesirable byproducts and decomposition of the product, 
which decreased yield shown in Figure 2 this method was applied to the synthesis of 
compounds 17 and 19.  Methyl substituted dye, 17 was shown to reach a maximum yield at 80 
oC, ethyl 18 at 130 oC and propyl 19 at 140 oC.  Continuing the reaction time past 20 min to 25 
min and 30 min also resulted in reduced percentage isolated yield. 
We suspected that the increasing N-alkyl chain length was corresponded to a decrease 
in overall dipole moment of the corresponding indolinium salt, causing a reduced microwave 
energy absorption which required an increase in thermal energy to attain a comparable reaction 
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yield [9].  We became intrigued with this observation and performed DFT calculations at the 
BLYP 6-31G* level beginning with the conformer of the lowest energy.   
 
Figure 6-9  DFT calculation results showing a decrease in the dipole moment as alkyl 
length increases. 
 
The electrostatic maps qualitatively show less polarization and the decrease in dipole 
moment corresponds directly to the decrease in microwave energy absorbed by the compound.  
In order for the molecule to react in the microwave, a higher amount of energy is required.  The 
salt containing a methyl group has a dipole moment of 3.39 debye which is more than double 
the dipole moment of the salt with a propyl substituent which was calculated to be only 1.69 
debye.  This is in agreement with the thermal energy required to form the final product with 
methyl and propyl; the methyl salt required only 80 oC to form the final compound in optimized 
yield whereas the propyl compound was optimized at 140 oC.           
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6.3.3 Microwave Assisted Organic Synthesis Application to a Systematic Library of 
Pentamethine Cyanines 
After optimizing the reaction conditions for each of the three sets of pentamethine 
cyanines (Me, Et and Pr), we subjected the other structures with heterocyclic variation to the 
same reaction conditions and isolated the compounds using precipitation and facile 
recrystallization techniques.  Notably, the reaction time, shown in Table 2, is drastically 
reduced in some cases more than 13-fold.  Additionally, the purified yield increased, especially 
for compound 23 which showed an increase from 32% to 98%; correspondingly, compound 
28, which was difficult to purify and obtain an 18% overall yield using classical methods, 
precipitated as a nearly analytically pure solid after initial workup in 89% yield.  
Table 6-2 Microwave Synthesis versus Conventional Synthesis 
 
The conventional synthetic method affords numerous byproducts which are not 
efficiently removed from the desired compound; however, the microwave methods developed 
herein have avoided the undesirable side reactions which have led to much reduced solvent 
waste with substantially less time and hazardous solvent waste spent on purification.        
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6.3.4 Heterocyclic Variation Alters the Optical Properties of the Cyanine Fluorophores 
The effect of changing the N-alkyl chain length of cyanine dyes has been shown by our 
laboratory to minimally alter optical properties [2]; therefore, we will not concentrate on re-
evaluating this phenomenon. However, while keeping the alkyl groups constant, differences in 
absorbance, emission, molar absorptivity (extinction coefficient) and relative quantum yield 
were observed for dyes containing heterocyclic variations, including chlorine, bromine and 
methylene dioxy groups (Table 3). 
 
Figure 6-10 Near infrared (NIR) absorbance of fluorohores in methanol at a 2.0 M 
concentration. 
 
 The effect of chlorine 20 and bromine 23 was almost negligible in methanol along with 
except for an increased Stoke’s Shift from 22 nm to 32/34 nm (Table 3). The addition of the 
methylene dioxy group 26 was shown to red shift the dye 35 nm, where the Stokes’ Shift was 
observed to increase to 43 nm. Extinction coefficients for all dyes were shown to be favorably 
large, (85,100 to 222,800 M-1cm-1) while quantum yields ranged from 30.5 to 9.5% (Table 3).  
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The quantum yield of the dioxy compound 26 is lower due to the possibility for non-radiative 
energy decay associated with the non-aromatic substituents on the heterocyclic ring.   
Table 6-3 The optical properties of propyl substituted dyes 17, 20, 23 and 26 with respect 
to different substituents on the heterocyclic backbone. The data presented was obtained 
in methanol from 1 mM stock solutions made in DMSO. 
 
In order to confirm the observed red-shift of the methylene-dioxy substituted 
compounds, and knowing the N-alkyl substitution does not significantly alter the optical 
properties of the chromophore, we performed density functional theory calculations on the 
synthesized compounds 17 and 26 to look at the HOMO and LUMO levels to determine 
energetic differences between the compounds.  The calculations were performed at the BLYP 
6-31G* level starting from the most energetically stable state.  
 
Figure 6-11 In silico DFT calculations depicting the HOMO and LUMO for each 
compound 17 and 26 with corresponding energy levels (eV) shown below the structures. 
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The DFT calculations reveal a larger energy gap for compound 17 (Egap (eV) = 1.41 
eV) predicting a blue-shifted absorption spectrum compared to the small energy barrier for 
compound 26 (Egap (eV) = 1.11 eV) which displays a 41 nm bathochromic shift.  These results 
corroborate the observed bathochromic shift of compound 26 and we can use similar 
computational methods for predicting a red or blue shift before synthesizing additional 
compounds (Figure 5).  
6.4 Conclusions 
The complete synthetic route for various substituted pentamethine carbocyanine dyes 
was completed using microwave-based green eco-conscious methods including the preparation 
of a novel methylene dioxy heterocyclic structure. Optimal reaction conditions were found at 
a constant reaction time of 20 min for all dyes with increasing alkyl lengths resulting in 
increased optimal reaction temperatures. The benefits associated with our methodology include 
decreased reaction time with significantly improved yield and outstanding purity (based on 1H 
NMR spectra) without the need for lengthy purification methods.  Additionally, the red-shifted 
compounds dioxymethylene compounds were shown, through DFT calculations, to have small 
HOMO-LUMO energy differences resulting in the red-shifted optical profile.  As NIR 
fluorophores continue to garner increasing interest in the scientific community, the optimized 
synthetic protocol will help to increase efficiency while simultaneously reducing the 
environmental impact.     
6.5 Experimental 
6.5.1 Synthesis  
The chemical reagents used in the synthesis of these compounds were obtained from 
Acros Organics (Geel, Belgium), Alfa Aesar and Matrix Scientific. Microwave irradiation was 
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completed using a Discover LabMate apparatus interfaced to a PC using the provided Synergy 
software to monitor reaction temperature, pressure, wattage and simultaneous cooling.  Scale-
up reactions of indolenine salts were performed using the open-vessel accessories and the same 
protocol as detailed in the experimental with similar yield. All classical method reactions were 
kept under a positive pressure of nitrogen during the entirety of the reaction. Microwave-
assisted reaction vessels were purged with nitrogen before the reaction was initially subjected 
to irradiation.  The reactions were followed using silica gel 60 F254 thin layer chromatography 
plates (Merck EMD Millipore, Darmstadt, Germany) with 5% methanol in DCM as the mobile 
phase. Open column chromatography was utilized for the purification of the final compounds 
needing additional purification using 60-200u, 60A classic column silica gel (Dynamic 
Adsorbents, Norcross, GA). The 1H NMR and 13C NMR spectra were obtained using high 
quality Kontes NMR tubes (Kimble Chase, Vineland, NJ) rated to 500 MHz  and were recorded 
on a 400 MHz Bruker Avance (at either 400 MHz or 100 MHz for 1H NMR and 13C NMR, 
respectively) spectrometer using DMSO-d6 or CDCl3 containing tetramethylsilane (TMS) as 
an internal calibration standard. High-resolution accurate mass spectra (HRMS) were obtained 
either at the Georgia State University Mass Spectrometry Facility using a Waters Q-TOF micro 
(ESI-Q-TOF) mass spectrometer or utilizing a Waters Micromass LCT TOF ES+ Premier Mass 
Spectrometer. Liquid chromatography utilized a Waters 2487 single wavelength absorption 
detector with wavelengths set between 640 and 700 nm depending on the dye’s photophysical 
properties. The column used in LC was a Waters Delta-Pak 5 μm 100Å 3.9 × 150 mm reversed 
phase C18 column. Evaporative light scattering detection analyzes trace impurities that cannot 
be observed by alternate methods; a SEDEX 75 ELSD (Olivet, France) was utilized in tandem 
with liquid chromatography to confirm purity.   
2,3,3-trimethylindolenine was commercially obtained and used in the alkylation 
reaction without purification. 
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6.5.2 Classical synthesis of indolenine compounds 1 and 2 
Substituted phenylhydrazine hydrochloride heterocyclic starting materials (1 g) were 
added to an oven dried and nitrogen flushed round bottom flask.  Acetic acid (15 mL) was 
added to the flask and the reaction mixture was heated using an oil bath to reflux.  Ketone, 3-
methyl-2-butanone (1.5 mol. eq.), was added to the reaction mixture.  The mixture was allowed 
to heat for 12-48h until TLC indicated a consumption of starting materials.  After the reaction 
was completed, the acetic acid and excess ketone was removed under high vacuum rotary 
evaporation at elevated temperature.  The resulting reddish oil was dissolved in 
dichloromethane and a saturated aqueous solution of sodium bicarbonate was added carefully 
to the organic layer.  The organic layer was washed with sodium bicarbonate (3 x 10 mL), the 
organic layer was extracted, dried over magnesium sulfate and concentrated to afford the final 
compounds in 76% and 81% yield, respectively.  
6.5.3 Microwave synthesis of indolenine compounds 1 and 2 
Heterocyclic phenylhydrazine hydrochloride (1 g) was added to a 10-mL microwave 
vessel equipped with a micro magnetic stir bar along with 3-methyl-2-butanone (1.2 mol. eq.).  
Deionized water (3 mL) and sulfuric acid (0.1 mol. eq.) was added to the reaction mixture. The 
reaction vessel was securely capped and then subjected to microwave irradiation for 10 min at 
100 oC allowing for the complete transformation of the starting material.  The water was 
decanted off and a saturated solution of sodium bicarbonate (3 mL) was added.  The flask was 
sonicated for 10 min to quench the reactive acid.  The liquid was poured off and the resulting 
oil was dissolved in minimum dichloromethane dried over sodium sulfate for 30 min, gravity 
filtered and concentrated to yield the corresponding products in quantitative yield.   
6.5.4 Classical synthesis of indolenine salts 3-11  
Individual indolenine derivative 1-3 was added to a 50 mL round bottom flask with a 
magnetic stir bar along with appropriate alkyl iodide (3 mol. eq) and acetonitrile (10 mL).  The 
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low boiling point of the alkyl iodide limits the reaction temperature; also, some of the alkylating 
agent will evaporate during the reactions, higher equivalents are needed in the classical 
methods.  The reaction mixtures were heated to reflux for 48-72h. After TLC indicated a 
consumption of the starting materials, the reaction was allowed to cool and the mixture was 
concentrated under reduced pressure.  Diethyl ether (25 mL) was added to the flask resulting 
in an oily residue.  Acetone (5 mL) was added to the residue and the reaction mixture was 
sonicated for 10 min resulting in a free flowing solid which was filtered, washed with diethyl 
ether and hexanes and dried under vacuum.  The compounds were obtained in 58-79% yield.     
6.5.5 Microwave synthesis of indolenine salts 3-11 
Individual indolenine derivative, 2,3,3-trimethlyindolenine, 1, or 2 was added to a 10-
mL microwave vessel equipped with a micro magnetic stir bar along with appropriate alkyl 
iodide (1.2 mol. eq.).  The reaction vessel was securely capped and then subjected to microwave 
irradiation for 20 min allowing for the complete transformation of the heterocyclic starting 
material to the corresponding salt.  The resulting residue was filtered, dried overnight on 
vacuum and the corresponding salts were obtained in 98%+ yield in excellent purity as 
determined by NMR (1H and 13C) spectroscopy.   
Salts 3, 4, 6, 7, 9 and 10 are previously published compounds and the data agrees with 
the literature values. 105 
 
2,3,3-Trimethyl-1-propyl-3H-indol-1-ium iodide (5): 1H NMR (400 MHz, DMSO-d6) 
δ: 1.00 (t, J = 7.20 Hz, 3H), 1.56 (s, 6H) 1.80 - 1.98 (m, 2H), 2.88 (s, 3H), 4.47 (t, J = 7.45 Hz, 
2H) 7.63 (d, J = 5.05, J = 3.28 Hz, 2H), 7.82 - 7.92 (m, 1H), 7.96 - 8.07 (m, 1H), 13C NMR 
(100 MHz, DMSO-d6) δ: 10.76, 14.22, 20.78, 22.06, 48.83, 54.14, 115.53, 123.51, 128.90, 
129.37, 141.06, 141.82, 196.54 
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5-Chloro-2,3,3-trimethyl-1-propyl-3H-indol-1-ium iodide (8): 1H NMR (400 MHz, 
CDCl3) δ: 1.05 (t, J = 8.00 Hz, 3H) 1.65 (s, 6H) 1.93 - 2.10 (m, 2H) 3.09 (s, 3H) 4.62 (t, J = 
8.0 Hz, 2H) 7.48 - 7.60 (m, 2H) 7.79 (d, J = 8.0 Hz, 1H). 13C NMR (100 MHz, DMSO-d6) δ:  
11.22, 14.77, 21.22, 22.35, 49.52, 54.92, 118.01, 123.29, 127.41, 132.32, 140.94, 144.64, 
197.61.  
 
5-Bromo-2,3,3-trimethyl-1-propyl-3H-indol-1-ium iodide (11): 1H NMR (400 MHz, 
DMSO-d6) δ:  0.99 (t, J = 7.20 Hz, 3H) 1.57 (s, 6H) 1.86 (d, J = 7.33 Hz, 2H) 2.81 - 2.91 (m, 
3H) 4.37 - 4.55 (m, 2H) 7.86 (s, 1H) 8.00 (d, J = 8.59 Hz, 1H) 8.21 (s, 1H), 13C NMR (100 
MHz, DMSO-d6) δ:  11.24, 14.86, 21.24, 22.17, 22.36, 49.56, 54.92, 118.03, 123.29, 127.41, 
132.32, 140.94, 144.64, 182.07, 188.62, 197.60. 
6.5.6 Classical bromination 
3-bromo-3-methyl-2-butanone (12):  A mixture of 3-methylbutan-2-one (25.00 mL, 
233.65 mmol) and acetic acid (38.00 mL) was added to a three-neck oven-dried round bottom 
flask and maintained at a temperature of 5 oC.  Next, both molecular bromine (1.2 mL, 23.4 
mmol) and acetic acid (5.0 mL) was combined in an addition funnel and added dropwise to the 
round bottom flask.  When all of the bromine was added the reaction mixture was allowed to 
stir overnight at room temperature.  To the resulting mixture, water (10 mL) was added, and 
then transferred to a separatory funnel where another 10 mL of water was added and the organic 
layer was extracted with diethyl ether (3 x 15 mL).  The compound was then washed with cold, 
saturated sodium bicarbonate (4 x 10 mL), dried over anhydrous sodium sulfate, and the 
reaction mixture was concentrated in vacuo to leave yellow oil.  The crude product was further 
purified via vacuum distillation (52 oC , ~ 25 mmHg) to yield a colorless oil, 3.14 g (81%).  1H 
NMR (400 MHz, CDCl3) δ: 1.824 (s, 6H), 2.401 (s, 3H).     
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6.5.7 Eco-friendly bromination 
3-bromo-3-methyl-2-butanone (12):  3-methylbutan-2-one (20.1 mmol) was added to 
water (10 mL) a round bottom flask at room temperature.  The round bottom flask was 
enveloped in aluminum foil to prevent light-induced interactions.  A 48% aqueous solution of 
HBr (30.2 mmol) was added to the stirring mixture.  After 10 min of stirring at room 
temperature, a solution of H2O2 (30% in water, 40.2 mmol) was added to the reaction mixture.  
The clear solution was allowed to stir for 18h.  After full consumption of the starting materials, 
the reaction was quenched by adding excess saturated sodium bicarbonate solution and the 
final brominated compound was extracted in diethyl ether. After concentration under reduced 
pressure, the resulting oil was vacuum distilled (52 oC , ~ 25 mmHg) to afford the final 
compound in 91% yield.   
6.5.8 Classical cyclization 
6,7,7-trimethyl-7H-[1,3]dioxolo[4,5-f]indole (13): A solution of DMF, (8 mL), aniline 
(1.56 g, 11.38 mmol), and potassium carbonate (1.05 g, 6.8 mmol) was brought to 45 oC in a 
two-neck round bottom flask with small magnetic stir-bar. 3-Bromo-3-methylbutan-2-one (12, 
1.86 g, 1 mL) was added to the solution overnight with a syringe pump (Kd Scientific, Model 
100). After addition was completed, solution was stirred for 24 h at 45 oC and monitored by 
TLC. After TLC showed that the starting material was consumed, dimethylformamide was 
evaporated in vacuo, and concentrate was extracted with toluene (5 x 20 mL) and was washed 
with deionized water. Toluene was concentrated to an amount of 10-20 mL, and p-
methyltoluenesulfonic acid (0.110 g, 0.1 mol equiv.) was added to solution. Solution was 
allowed to reflux for 24h, until TLC showed an absence of starting material. Toluene was 
evaporated in vacuo, and dichloromethane (20 mL) was added to the reaction mixture. Solution 
was washed with a saturated solution of sodium carbonate (5 x 50 mL) until the organic layer 
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was a red/brown color. DCM was removed under reduced pressure and the resulting red/brown 
oil was recovered and the crude 13 (obtained in 57% yield) was used without purification.  
6.5.9 Microwave assisted cyclization 
6,7,7-trimethyl-7H-[1,3]dioxolo[4,5-f]indole (13): A solution of [BMIM][PF6] (4 mL), 
potassium carbonate (1.2 mol. eq.) and aniline (1.2 mol. eq.) was added to a microwave vessel 
(10 mL).  3-Bromo-3-methylbutan-2-one (1.0 mol. eq.) was added to the microwave vessel.  
The contents were subjected to microwave irradiation at 150 W, 150 oC for 20 min. 
Approximately 90% of the reactive aniline (100% of the butanone was consumed) was allowed 
to go to completion leaving an additional amount to participate in the imine formation seen in 
the mechanism.  Para-toluene sulphonic acid was added to the vessel (0.2 mol. eq.) and the 
reaction was heated to 100 oC for 20 min.  The brown solution was dissolved in DCM (10 mL) 
and washed with saturated solution of sodium bicarbonate (3 x 15 mL).  The organic layer was 
dried over magnesium sulfate and was evaporated under reduced pressure to afford the final 
heterocyclic dioxolane.  The compound was obtained in 92% yield.  
6.5.10 Classical alkylation 
The classical alkylation of 6,7,7-trimethyl-7H-[1,3]dioxolo[4,5-f]indole was achieved 
using identical procedures found above and the respective yields are found below. 
6.5.11 Microwave assisted alkylation  
Dioxyindolenine was added to a 10-mL microwave vessel equipped with a micro 
magnetic stir bar along with appropriate alkyl iodide (1.2 mol. eq.).  The reaction vessel was 
securely capped and then subjected to microwave irradiation for 20 min allowing for the 
complete transformation of the heterocyclic starting material to the corresponding salt.  The 
resulting residue was filtered, dried overnight on vacuum and the corresponding salts were 
obtained in 98% yield in excellent purity as determined by NMR (1H and 13C) spectroscopy.   
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5,6,7,7-Tetramethyl-7H-[1,3]dioxolo[4,5-f]indol-5-ium iodide (14): Classical Yield 
60%, Microwave Yield 95%. 1H NMR (400 MHz, DMSO-d6) δ: 1.48 (s, 6H) 2.70 (br. s., 3H) 
3.90 (s, 3H) 6.19 (s, 2H) 7.48 (s, 1H) 7.64 (s, 1H), 13C NMR (100 MHz, DMSO-d6) δ: 15.43, 
21.48, 23.05, 53.61, 55.34, 101.44, 103.34, 125.76, 128.64, 129.34, 139.90, 145.50, 146.91, 
147.91, 187.11. 
5-Ethyl-6,7,7-trimethyl-7H-[1,3]dioxolo[4,5-f]indol-5-ium (15): Classical Yield 53%, 
Microwave Yield 94%. 1H NMR (400 MHz, DMSO-d6) δ: 1.48 (s, 6H) 2.70 (br. s., 3H) 3.90 
(s, 3H) 6.19 (s, 2H) 7.48 (s, 1H) 7.64 (s, 1H), 13C NMR (100 MHz, DMSO-d6) δ: 13.28, 14.33, 
22.37, 43.71, 54.33, 97.77, 103.21, 104.52, 134.88, 137.31, 148.54, 149.29, 194.54 
6,7,7-Trimethyl-5-propyl-7H-[1,3]dioxolo[4,5-f]indol-5-ium (16): Classical Yield 
45%, Microwave Yield 92%. 1H NMR (400 MHz, DMSO-d6) δ:  0.85 - 1.06 (m, 3H) 2.79 (s, 
6H) 4.38 (br. s., 1H) 6.20 (s, 4H) 7.51 (s, 1H) 7.75 (s, 1H), 13C NMR (100 MHz, DMSO-d6) δ: 
11.14, 14.50, 21.35, 22.55, 49.39, 54.36, 97.65, 103.23, 104.44, 135.27, 137.24, 148.55, 
149.34, 195.03. 
6.5.12 General classical synthesis for NIR dyes 17-25 and 26-28 
A mixture of indolium salt (40 mg, 0.154 mmol), bis-iminium salt (20 mg, 0.077 
mmol), NaOAc (17 mg, 0.23 mmol) and acetic anhydride (1 mL) was added to an oven dried 
round bottom flask with stirring bar.  The reaction mixture was heated using a standard oil bath 
for a particular reaction time (refer to Table 1).  After starting materials were consumed, the 
reaction was allowed to cool to room temperature.  Diethyl ether was added to the round bottom 
flask resulting in an oily metallic blue residue.  The diethyl ether was decanted and the oil was 
dissolved in a minimal amount of methanol followed by the addition of diethyl ether (50 mL) 
resulting in the formation of light blue crystals, which were filtered.  The crystals were 
dissolved in dichloromethane leaving unreacted sodium acetate on the funnel.  The 
dichloromethane was removed in vacuo.  Many compounds needed additional purification 
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methods.  Silica-gel column chromatography eluting with 2-5% methanol in dichloromethane 
afforded the various pentamethine cyanines in their respective yield.    
6.5.13 General microwave assisted synthesis for NIR dyes 
A mixture of indolium salt (40 mg, 0.154 mmol), bis-iminium salt (20 mg, 0.077 
mmol), NaOAc (17 mg, 0.23 mmol) and acetic anhydride (1 mL) was placed in sealed 
microwave vessel with stirring bar. Sealed vessel was placed in single-mode microwave (CEM 
Discover) on standard power setting, at indicated temperature, see Table 1 for 20 min resulting 
in increased pressure (40-100 psi). Reaction mixture was diluted with diethyl ether (10-20 mL) 
and filtered in vacuo. Solid was washed twice with diethyl ether (5 mL). A clean filter flask 
was attached to the funnel and the resulting solid was dissolved with dichloromethane (10-15 
mL) leaving unreacted sodium acetate crystals on the filter funnel. The filtrate was transferred 
to a clean round bottom flask and dichloromethane was removed with a rotary evaporator. 
Metallic blue/green crystals were formed after solvent removal resulting in the yield of 
individual compounds reported in Table 2. Compounds 17-21, 23 and 24 have been previously 
reported by conventional method. 105  
 
1,3,3-Trimethyl-2-((1E,3E,5E)-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-3H-indol-1-ium iodide (17): 1H NMR (400 MHz, DMSO-d6) δ 1.71 (s, 12H), 3.63 (s, 6H), 
6.28 (d, J = 16.0 Hz, 2H), 6.65 (t, J  = 12.0 Hz, 1H), 7.24 (t, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 
Hz, 2H), 7.39 (t, J = 8.0  Hz, 2H), 7.48 (d, J = 8.0  Hz, 2H), 8.25 (t, J = 12.0  Hz, 2H) 
 
1-Ethyl-3,3-trimethyl-2-((1E,3E,5E)-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-
dien-1-yl)-3H-indol-1-ium iodide (18): 1H NMR (400 MHz, DMSO-d6) δ 1.27 (t, J = 4.0, 6H), 
1.68 (s, 12H), 4.15 (d, J = 8.0, 4H), 6.57 (t, J = 12.0, 1H), 7.26 (t, J = 4.0, 2H), 7.39 (s, 4H), 
7.63 (d, J = 8.0, 2H), 8.34 (t, J = 12.0, 2H).  
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1-Propyl-3,3-dimethyl-2-((1E,3E,5E)-5-(1-propyl,3,3-dimethylindolin-2-
ylidene)penta-1,3-dien-1-yl)-3H-indol-1-ium iodide (19): 1H NMR (400 MHz, DMSO-d6) δ 
0.95 (t, J = 4.0 Hz, 6H), 1.69 (s, 12H), 4.08 (m, J = 4.0 Hz, 4H), 6.35 (d, J = 16.0 Hz, 2H), 6.60 
(t, J = 12.0 Hz, 1H), 7.25 (d, J = 8.0 Hz, 2H), 7.42 (s, 4H), 7.64 (d, J = 8.0 Hz, 2H), 8.34 (t, J 
= 12.0 Hz, 2H). HR-MS calculated for [C31H39N2]
+ 439.3108 found 439.3093.  
 
2-((1E,3Z,5E)-3-Chloro-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-
1,3,3-trimethyl-3H-indol-1-ium iodide  (20): 1H NMR (400 MHz, DMSO-d6) δ 1.69, (s, 12H), 
3.58 (s, 6H), 6.29 (d, J = 12.0 Hz, 2H), 6.55 (t, J = 12.0 Hz, 1H), 7.39 (d, J = 8.0 Hz, 2H), 7.46 
(d, J = 8.0 Hz, 2H), 7.81 (s, 2H), 8.33 (t, J = 12.0 Hz, 2H). 
 
2-((1E,3Z,5E)-3-Chloro-5-(1-ethyl-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium iodide  (21): 1H NMR (400 MHz, DMSO-d6) δ 1.25 
(s, 6H), 1.69 (s, 12H), 4.13 (s, 4H), 6.33 (d, J = 12.0 Hz, 2H), 6.58 (t, J = 12.0 Hz, 1H), 7.46 
(m, J = 12.0 Hz, 2H), 7.89 (s, 2H), 8.35 (t, J = 12.0 Hz, 2H). 
 
2-((1E,3Z,5E)-3-Chloro-5-(1-propyl-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-1-propyl-3,3-dimethyl-3H-indol-1-ium iodide  (22): 1H NMR (400 MHz, DMSO-d6) δ 0.94 
(t, J = 8.0 Hz, 6H), 1.70 (s, 16H), 4.07 (t, J = 8.0 Hz, 4H), 6.35 (d, J = 12.0 Hz , 2H), 6.65 (t, J 
= 12.0 Hz, 1H), 7.45 (s, 4H), 7.83 (s, 2H), 8.35 (t, J = 12.0 Hz, 2H). 13C NMR (100 MHz, 
DMSO-d6) δ: 0.57, 11.39, 20.80, 27.43, 45.33, 49.57, 104.08, 113.08, 123.50, 128.75, 129.48, 
141.53, 143.65, 154.93, 173.20. HR-MS calculated for [C31H37N2Cl2]
+ 507.2328 found 
507.2315. 
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2-((1E,3Z,5E)-3-Bromo-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-
1,3,3-trimethyl-3H-indol-1-ium iodide (23): 1H NMR (400 MHz, DMSO-d6) δ 1.91 (s, 12H), 
3.82 (s, 6H), 6.36 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H, 7.26-7.31 (m, 4H), 7.39-7.44 
(m, 4H), 8.93 (d, J = 12.0 Hz, 2H). 
 
2-((1E,3Z,5E)-3-Bromo-5-(1-ethyl-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium iodide  (24): 1H NMR (400 MHz, DMSO-d6) δ 1.25 
(m, J = 4.0 Hz, 6H), 1.69 (s, 12H), 4.12 (m, J = 8.0 Hz, 4H), 6.30 (d, J = 16.0 Hz, 2H), 6.58 (t, 
J = 8.0 Hz, 1H), 7.37 (t, J = 8.0 Hz, 2H), 7.59 (d, J = 8.0 Hz, 2H), 7.94 (s, 2H), 8.35 (d, J = 
12.0 Hz, 2H). 
 
2-((1E,3Z,5E)-3-Bromo-5-(1-propyl-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-
yl)-1-propyl-3,3-dimethyl-3H-indol-1-ium iodide  (25): 1H NMR (400 MHz, DMSO-d6) δ 0.94 
(t, J = 4.0 Hz, 6H), 1.70 (m, J = 12.0 Hz, 16H), 4.06 (t, J = 4.0 Hz, 4H), 6.35 (d, J = 12.0 Hz, 
2H), 6.65 (t, J = 12.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 8.0 Hz, 2H), 7.95 (s, 2H), 
8.35, (t, J = 12.0 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ: 11.39, 20.79, 27.43, 45.29, 
49.56, 104.09, 113.53, 117.49, 126.26, 126.60, 131.59, 141.95, 143.97, 154.97, 173.06.  HR-
MS calculated for [C31H37N2Br2]
+ 595.1318 found 595.1311. 
 
5,7,7-Trimethyl-6-((1E,3E,5Z)-5-(5,7,7-trimethyl-5H-[1,3]dioxolo[4,5-f]indol-6(7H)-
ylidene)penta-1,3-dien-1-yl)-7H-[1,3]dioxolo[4,5-f]indol-5-ium iodide (26): 1H NMR (400 
MHz, DMSO-d6) δ 1.63 (s, 12H), 3.54 (s, 6H), 6.06 (s, 4H), 6.18 (d, J = 16.0 Hz, 2H), 6.46 (t, 
J = 16.0 Hz, 1H), 7.13 (s, 2H), 7.28 (s, 2H), 8.16 (t, J = 15 Hz, 2H). HR-MS calculated for 
[C29H31O4N2]
+ 471.2278 found 471.2268. 
 
197 
 
5-Ethyl-7,7-dimethyl-6-((1E,3E,5Z)-5-(5-ethyl-7,7-dimethyl-5H-[1,3]dioxolo[4,5-
f]indol-6(7H)-ylidene)penta-1,3-dien-1-yl)-7H-[1,3]dioxolo[4,5-f]indol-5-ium iodide (27): 1H 
NMR (400 MHz, DMSO-d6) δ 1.24 (t, J = 4.0 Hz, 6H), 1.63 (s, 12H), 4.08 (m, J = 4.0 Hz, 4H), 
6.07 (s, 4H), 6.22 (d, J = 16.0 Hz, 2H), 6.48 (t, J = 12.0 Hz, 1H), 7.18 (s, 2H), 7.32 (s, 2H), 
8.20 (t, J = 12.0 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 12.68, 27.55, 49.34, 94.24, 102.17, 
102.95, 104.30, 135.15, 136.19, 145.50, 148.05, 152.99, 172.22.  HR-MS calculated for 
[C31H35O4N2]
+ 499.2591 found 499.2577. 
 
5-Propyl-7,7-dimethyl-6-((1E,3E,5Z)-5-(5-propyl-7,7-dimethyl-5H-[1,3]dioxolo[4,5-
f]indol-6(7H)-ylidene)penta-1,3-dien-1-yl)-7H-[1,3]dioxolo[4,5-f]indol-5-ium iodide (28):1H 
NMR (400 MHz, DMSO-d6) δ  0.93 (t, J = 8.0 Hz, 6H), 1.63 (m, 16H), 4.01 (s, 4H), 6.07 (s, 
4H), 6.24 (d, J = 16.0 Hz, 2H), 6.50 (t, J = 12.0 Hz, 1H), 7.21 (s, 2H), 7.32 (s, 2H), 8.20 (t, J = 
16.0 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ: 11.35, 20.89, 27.69, 49.06, 49.32, 94.49, 
102.19, 103.42, 104.20, 135.01, 136.77, 145.50, 148.04, 152.81, 172.78. HR-MS calculated 
for [C33H39O4N2]
+ 527.2904 found 527.2883. 
6.5.14 Computational Experimental 
Spartan Computational Modeling Software was utilized to draw the chemical structures 
and calculations were performed using Density Functional Theory at the B3LYP level.  
Chemical structures were minimized to the conformer of the lowest energy and calculations 
were performed using appropriately applied charges in a vacuum.   
6.5.15 Analytical Instrumentation 
Absorbance spectra were measured using a Varian Cary 50 UV-Visible 
Spectrophotometer interfaced to a PC, with a spectral bandwidth of 2 nm. Fluorescence spectra 
for the pentamethine cyanine dyes were obtained using a Shimadzu RF-1501 
Spectrofluorophotometer (Shimadzu Scientific Instruments, Colombia, MD) interfaced to a 
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PC, with spectral bandwidths for both excitation and emission set to 10 nm and the sensitivity 
set to “high”. Disposable absorbance and fluorescence cuvettes were used with a pathlength of 
1.00 cm. All calculations were performed on Microsoft Excel 2010, (Microsoft Corporation, 
Redmond, WA). 
6.5.16 Stock Solutions 
Stock solutions of the dyes in 1 mM concentration were prepared by weighing the dye 
on a 5-digit analytical balance directly into a brown glass vial and adding DMSO, (98.5% 
Spectroscopy grade, Sigma Aldrich) with an auto pipette (100-1000 uL, Eppendorf). The stock 
solutions were vortexed for 30 sec, and subsequently sonicated for 20 min to ensure complete 
dissolution. 
6.5.17 Method of Determining Molar Absorptivity 
Stock solutions were used to prepare six to seven samples in methanol with various 
concentrations such that absorbance values remained less than 1. Samples were prepared in 
5.00 mL of DMSO having used 5-50 uL, 10-100uL, and 100-1000 uL Micropipettes, 
(Eppendorf). Samples were prepared in disposable glass test tubes, (10 mL, Fischer Scientific) 
and vortexed for 20 seconds to ensure dissolution.  Appropriate measurements were chosen to 
ensure the absorbance values were less than 1.0 but greater than 0.1.  Five measurements were 
taken and the recorded absorbance values versus concentration were plotted and the linear 
regression was determined to obtain the molar absorptivity according to Beer’s law.   
6.5.18 Method of Determining Quantum Yield 
Rhodamine 800, (99.9 % Fluorescence grade, Sigma Aldrich) was used as a standard 
within the given range of absorbance maxima, (648-682 nm). Samples of the dyes and their 
respective standards were prepared from stock solutions such that their absorbance maxima 
were less than 0.1. The absorbance and fluorescence spectra of each sample were obtained 
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concurrently to minimize experimental error from photobleaching. Each dye was diluted 
accordingly, to ensure fluorescence was below 1000 units.   
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7 CARTILAGE AND BONE TARGETING FLUOROPHORES 
This chapter was adapted from the following publication in which I was designated co-
first author for my contributions in the design, synthesis, optical determinations and manuscript 
preparation. 
Hyun, H.*, Owens, E.A.*, Wada, H., Levitz, A., Park, G., Park, M., H., Frangioni, J. V., 
Henary, M., Choi, H. S., Cartilage-Specific Near-Infrared Fluorophores for Biomedical 
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Imaging 2015 Accepted by Angewandte Chemie—Hot Article—Top 10% of Publications. 
*Co-First Authors. 
7.1 Abstract 
Almost every human tissue develops abnormalities that inflict pain as physically 
debilitating conditions that are detrimental in an emotional, familial, societal and even 
economic sense.  Over 27 million United States citizens are inflicted by osteoarthritis and other 
conditions that relate primarily to cartilage and bone.  Unfortunately, these diseases and 
proposed treatment regimens are either poorly understood or currently unavailable.  This lack 
of knowledge concerning disease progression and treatment impact stems from an inability to 
image the degradation or repair of bone and cartilage tissue (i.e. osteoblast activity and 
chondrocyte maturation).  Since near-infrared fluorescence imaging has been recognized as an 
established real-time tracking protocol for imaging in live tissue, we sought to develop NIR 
fluorescent contrast agents for cartilage and bone imaging that allows simultaneous delineation 
of both tissues in the same surgical space in real-time.  
7.2 Introduction 
To achieve direct in vivo imaging of cartilage tissues, positively charged contrast agents 
using magnetic resonance (MR) and computed tomography (CT) imaging systems have 
recently been designed. Presently, however, it is still a challenge to design near-infrared (NIR) 
emitting optical probes that bind to cartilage tissue after an intravenous injection and highlight 
its location and quantity. The NIR fluorescent light can penetrate millimeters to centimeters 
inside living tissue in real-time, then researchers and clinicians could, for the first time, detect 
and measure cartilage noninvasively during surgery. In this study, we report a new class of 
cationic NIR fluorescent agents that could highlight various cartilage tissues in small and large 
animals based on structure-inherent targeting. The results from in vivo and histological 
assessments demonstrate the high affinity of quaternary ammonium cations to cartilage tissues 
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with little to no nonspecific uptake. This new strategy for cartilage-specific imaging has the 
potential to revolutionize tissue engineering, joint surgery, and cartilage-specific drug 
development. 
Intrarvital near-infrared (NIR) fluorescence imaging technique is a promising method 
that allows us to investigate complex vital physiological and biological phenomena in vivo.1, 2 
In particular, discovery and development of targeted contrast agents in conjunction with 
appropriate equipment such as FLARE imaging system enable visualization of the behavior 
and function of specific tissues/organs inside the living body.3 Currently, NIR fluorophores are 
developed to target various vital tissues such as pan and sentinel lymph nodes,4 peripheral 
nerves,5 bone, 6 pancreas,7 thyroid and parathyroid glands8 as well as many tumorous tissues.9. 
Furthermore, design of novel tissue-specific NIR fluorophores is continuously required for 
image-guided surgery. 
Most recently, we have developed NIR fluorophores specific to bone components such 
as hydroxylapatite and calcium phosphate, which are able to incorporated into the bone matrix 
without interfering with normal bone deposition.6 Armed with this data, we aimed to develop 
a therapeutic solution for osteoarthritis, which is a degenerative joint disease caused by 
destruction of cartilage on the articular surfaces of joints accompanying severe pain and 
debilitation.10 The clinical challenge is a lack of cartilage-targeted contrast agents. Cartilage is 
an essential component of the human body, being found on the articular surfaces of joints, in 
the rib cage, in the intervertebral spaces, protecting the trachea, and giving structure to the ears 
and nose. Because cartilage cannot regenerate like bone, replacement therapy using tissue 
engineering, and pharmacologic treatment using drugs that prevent destruction, are being 
intensely explored. However, without the ability to monitor and quantify cartilage in living 
animals, these treatment approaches have yet to reach their full potential. In addition, during 
traumatic injury to joints, cartilage fragments can lead to chronic joint pain, which requires 
203 
 
arthroscopic removal of rough surfaces. Once, again, direct imaging of cartilage could have a 
major impact on the time required for the procedure and its efficacy. 
Despite its extreme importance, cartilage is difficult to image. So far, most efforts to 
image and quantify cartilage have focused on magnetic resonance imaging (MRI),11 however, 
the water-deficient composition of cartilage makes it a poor target for MRI.12  Low x-ray 
absorption also makes cartilage a relatively poor target for clinical computed tomography (CT), 
and when using conventional microCT it is essentially invisible.13 There is one single-photon 
emission computed tomography (SPECT) radiotracer for cartilage described in the literature in 
2001,14 99mTc-labeled N-(triethylammonium)-3-propyl-[15]ane-N5, but no clinical studies 
have been followed and recently published preclinical studies show poor image quality.15 
7.3 Results and Discussion 
To date, there isn’t a single optical contrast agent for cartilage, and certainly not one in 
the NIR wavelength range of 650 nm to 900 nm. NIR light has certain key advantages for 
biomedical imaging including relatively low tissue absorption, reduced scatter, and minimal 
autofluorescence.1-3 Thus, unlike visible light, which only penetrates a few hundred microns 
below a tissue surface, NIR light can penetrate millimeters to centimeters into living tissue. 
Therefore, the use of NIR fluorophores, i.e., molecules that convert one NIR wavelength into 
another, permits a high signal-to-background ratio (SBR) to be produced.3 
For cartilage-specific targeting, it is known that the surface chemical group of imaging 
molecules should be positively charged to prevent the coulombic repulsion between the 
contrast agents and anionic glycosaminoglycans (GAGs) and induce the electrostatic 
interactions.16-18 GAG, a key component of the extracellular matrix in the articular cartilage, 
bears a high density of fixed negative charges owing to a number of sulfates and carboxylates, 
and hence strong hydrophilicity to retain a large amount of water in the tissue. 16 Based on the 
theory, we therefore hypothesized that cationic groups substituted on a NIR fluorophore could 
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interact with the anionic cartilage tissues. Herein, we explored this hypothesis by using the 
quaternary ammonium cations (quats) as the primary modification and also studied the ability 
of other substituents, such as sulfonates, phenyl rings, and methoxy groups, to enhance the 
performance of the final molecules. 
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Figure 7-1. Synthetic scheme (a) and physicochemical and optical properties (b) 
of C700 and C800 NIR fluorophores. In silico calculations of physicochemical properties 
were calculated using Marvin and JChem calculator plugins (ChemAxon, Budapest, 
Hungary). All optical measurements were performed at 37°C in 100% fetal bovine serum 
(FBS) buffered with 50 mM HEPES, pH 7.4.  
As shown in Figure 1a, a series of cationic NIR fluorophores were synthesized from a 
pentamethine core for 700 nm fluorescence and a heptamethine core for 800 nm fluorescence, 
with the addition of three different substituents as indicated. The synthetic pathways for C700 
and C800 were detailed in Experimental. The physicochemical and optical properties of all 
NIR fluorophores are summarized in Figure 1b. By modulating the side chains of the 
polymethine core, final NIR fluorophores could be systematically altered in terms of 
hydrophobicity, polarity, and electron-resonance properties without affecting the emission 
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wavelength in the range of 650 to 800 nm, which together could potentially minimize tissue 
autofluorescence and maximize fluorescence signal.19 
 
Figure 7-2. In vivo cartilage targeting using C700 (a) and C800 (b) NIR 
fluorophores in mice. Each fluorophore was injected intravenously into 25 g CD-1 mice 
(10 nmol; 0.3 mg kg-1) 4 h prior to imaging. SBR was calculated by the fluorescence 
intensity of costal cartilage tissues versus the signal intensity of neighboring muscle 
obtained over the imaging period (n = 3, mean ± s.d.). *P < 0.05, ***P < 0.001. All NIR 
fluorescence images have identical exposure and normalizations. Scale bars = 1 cm.  
As a preliminary in vivo test for cartilage targeting, C700 and C800 NIR fluorophores 
were intravenously injected into CD-1 mice (10 nmol; 0.3 mg kg-1) imaged after 4 h, and the 
fluorescent signals in costal cartilage tissues were respectively quantified (Figure 2). 
Interestingly, C700-OMe and C800-OMe showed the highest SBR (calculated by fluorescence 
intensities between costal cartilage and neighboring muscle) values compared to the other 
molecules, and both C700-H and C800-H showed significantly high signals in cartilage tissues. 
Although the synergy of methoxy groups on the cationic polymethine structure for efficient 
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cartilage binding is not well understood, methoxy groups improve hydrophilicity (LogD at pH 
7.4 < −4.0) and increase polar surface area properly (24.71 Å). In contrast, the addition of 
sulfonates and phenyl groups on the polymethine backbone diminished the cartilage-specific 
targeting of the final fluorophores. C700-Ph and C800-Ph showed high nonspecific background 
signals everywhere due to the increased hydrophobicity and imbalanced 3D conformation (data 
not shown), whereas the entire surface charges of C700-SO3 and C800-SO3 are geometrically 
balanced between sulfonates and quaternary ammonium groups resulting in no cartilage tissue 
uptake. In addition, the polarity values of sulfonated fluorophores are close to the 120 Å2, which 
tend to be poor at permeating cell membranes.20  
Because C700-OMe and C800-OMe showed the highest SBR for cartilage tissues 
among the different side chains, we selected these methoxy-substituted NIR fluorophores for 
further in vivo study. To confirm if their targeting ability exhibits in other types of cartilage 
including hyaline, elastic or fibrocartilage, we observed all the major cartilage tissues at 4 h 
post-injection of C700-OMe and C800-OMe in CD-1 mice (Figure 3). After a single 
intravenous injection of each agent, all cartilage tissues were visualized clearly including 
ears/nose, knee joints, sternum, and intervertebral discs. Since the compositions of each 
cartilage tissue are different, we further performed histological evaluations using Alcian Blue 
and Hematoxylin and Eosin (H&E) staining. As shown in Figure 3, the histology and NIR 
fluorescence images obtained from the same animals prove clearly where the fluorescence 
signals came from. Alcian Blue mainly stained acidic GAGs in cartilages as a dark blue color, 
where strong NIR fluorescence observed. The histology data also prove that those cationic NIR 
fluorophores have high affinities with not only hyaline cartilage but also elastic and 
fibrocartilage. Since the cartilage tissues are all produced by chondrocytes (or more precisely 
chondroblasts until entrapment within their own extracellular matrix) and differ mainly in the 
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relative amounts of collagen, proteoglycans, and elastin present, we believe the intravenously 
injected molecules mainly target chondrocytes in all types of cartilage tissues.  
Interestingly, as shown in Figure 3b, the growth (epiphyseal) plate (arrows) was also 
targeted in company with fibrocartilage of knee joint. Growth plate is also one of hyaline 
cartilage tissues located in the metaphysis at each end of a long bone. The plate is typically 
found in children and adolescents, that is, we could observe the unexpected fluorescence signal 
at the growth plate because of the use of relatively young mice (8 wk) in this study. This result 
indicates that cationic NIR fluorophores can specifically bind to all cartilage tissues present in 
the body, even at the development stage.  
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Figure 7-3. In vivo NIR imaging and histological analysis of cartilage tissues from 
ear (a), knee joint (b), and inside chest (c) in mice. C700-OMe and C800-OMe were 
intravenously injected into 25 g CD-1 mice (10 nmol; 0.4 mg/kg) 4 h prior to imaging. #1 
(arrows) and #2 (arrowheads) in (c) indicate hyaline and fibrocartilage, respectively. 
Alcian Blue, H&E, and NIR images of resected cartilage tissues were obtained from the 
same animal. All NIR fluorescence images for each condition have identical exposure 
times and normalizations. Scale bars = 1 cm (for in vivo image) and 100 µm (for histology 
image). Images are representative of n = 3 independent experiments. 
Finally, we exploited the dual-NIR channel capability of the FLARE imaging system 
to highlight cartilage and bone tissues simultaneously in real time. Since the bone-targeting 
NIR fluorophores (e.g., P800SO3) have been previously developed by our group,6 the 
combination of C700-OMe (emitting at 700 nm) and P800SO36 (emitting at 800 nm) were used 
by injecting both agents together into mice and pigs, respectively. As shown in Figure 4, 
cartilage tissues were identified by C700-OMe in 700 nm channel, whereas bone tissues were 
visualized by P800SO3 in 800 nm channel, independently, despite the co-injection. This 
approach is especially important in complex surgery when resection of the damaged tissues 
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(i.e., using one NIR channel) needs to be performed, while neighboring critical structures need 
to be preserved (i.e., using the second NIR channel).  
 
Figure 7-4. Dual-channel in vivo fluorescence imaging of cartilage and bone tissues 
by using C700-OMe and P800SO36  in the same animals. 10 nmol and 1 µmol of C700-
OMe and P800SO3 were intravenously injected into 25 g CD-1 mice (top; 0.4 mg kg-1) 
and 35 kg Yorkshire pigs (bottom; 0.02 mg kg-1), simultaneously, 4 h prior to imaging. 
All NIR fluorescence images for each condition have identical exposure times and 
normalizations. Scale bars = 1 cm. Images are representative of n = 3 independent 
experiments. Pseudo-colored red and green colors were used for 700 nm and 800 nm 
channel images, respectively, in the color-NIR merged image. 
 
In summary, by incorporating low affinity quats into the polymethine backbone, we 
could design a new class of high affinity cartilage-targeted NIR fluorescent agents. “Structure-
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inherent targeting” was initially reported in our previous paper8 for thyroid and parathyroid 
targeting, and now we expand this concept for cartilage specific targeting and imaging. The 
high affinity of cationic NIR fluorophores for cartilage provides high-quality tissue 
visualization, ultralow background signal, and low injected dose. Hence, this method 
complements other imaging modalities being explored for cartilage imaging, including MR 
imaging and CT. In addition, this technique may be useful for assessment in longitudinal 
animal models of cartilage degeneration without destructive methods often used for 
biochemical analysis. We anticipate that this finding of the cationic NIR fluorophores will form 
the basis of further development of optical contrast agents and give guidance to the early 
noninvasive diagnosis and treatment of cartilage diseases. 
7.4 Experimental Section 
7.4.1 Synthesis of C700 and C800 NIR fluorophores  
All chemicals and solvents were of American Chemical Society grade or HPLC purity 
and were used as received. HPLC grade acetonitrile (CH3CN) and water were purchased from 
VWR International (West Chester, PA) and American Bioanalytic (Natick, MA), respectively. 
All other chemicals were purchased from Fisher Scientific (Pittsburgh, PA, USA), Sigma-
Aldrich (Saint Louis, MO) and Acros Organics. The reactions were followed using silica gel 
60 F254 thin layer chromatography plates (Merck EMD Millipore, Darmstadt, Germany). Open 
column chromatography was utilized for the purification of all hydrophobic final compounds 
using 60-200u, 60A classic column silica gel (Dynamic Adsorbents, Norcross, GA). Highly 
charged final products were isolated using revered phase C18 column chromatography (Fluka). 
The 1H NMR and 13C NMR spectra were obtained using high quality Kontes NMR tubes 
(Kimble Chase, Vineland, NJ) rated to 500 MHz and were recorded on a Bruker Avance (400 
MHz) spectrometer using D2O, DMSO-d6 or MeOD-d4 containing tetramethylsilane (TMS) as 
an internal calibration standard set to 0.0 ppm. NMR abbreviations used throughout the 
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experimental section are as follows, s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, 
m = multiplet, dd = doublet doublets, and bs = broad singlet. UV-Vis/NIR absorption spectra 
were recorded on a Varian Cary 50 spectrophotometer. High-resolution accurate mass spectra 
(HRMS) were obtained either at the GSU Mass Spectrometry Facility using a Waters Q-TOF 
micro (ESI-Q-TOF) mass spectrometer or utilizing a Waters Micromass LCT TOF ES+ 
Premier Mass Spectrometer. The purity of each compound tested was determined by using 
LC/MS instrument possessing a Waters 2487 single wavelength absorption detector with 
wavelengths set between 640 and 700 nm depending on the particular photophysical properties. 
The column used in LC was a Waters Delta-Pak 5 uM 100A 3.9 x 150 mm reversed phase C18 
column, with a flow rate of 1mL/min employing a 5-100% acetonitrile/water/0.1 formic acid 
gradient; a SEDEX 75 Evaporative light scattering detection (ELSD) was also utilized in 
tandem with liquid chromatography to confirm purity. All compounds tested were > 95% pure. 
Synthesis of heterocyclic salts 6 and 7.  
Compounds 5 and 8 have been previously described by our laboratory.  Heterocyclic 
starting material 2 or 3 (1 mol. eq.) was added to an oven dried and nitrogen purged 250-mL 
round bottom flask. Toluene (100 mL) was added to the round bottom flask under a positive 
pressure of nitrogen. (3-Bromopropyl)trimethylammonium bromide (1.2 mol. eq.) was quickly 
added to the reaction vessel to avoid absorption of water from the atmosphere. The reaction 
was heated to reflux for 72 h. under heavy stirring. After 72 h., the reaction vessel was allowed 
to cool to rt. The toluene was evaporated in vacuo and the residue was dissolved in methanol 
and subsequently diluted with diethyl ether to afford the corresponding salt which was suction 
filtered and washed with diethyl ether, ethyl acetate and acetone to obtain the pure compounds. 
The powdered solids were dried under high vacuum for >24h. 
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1,1,2-Trimethyl-3-(3-(trimethylammonio)propyl)-1H-benzo[e]indolium bromide (6). 
Yield 52%; 1HNMR (400 MHz, DMSO-d6), : 1.79 (s, 6H), 2.42-2.37 (m, 2H), 3.03 (s, 3H), 
3.41 (s, 9H), 3.65 (t, J = 8.0 Hz, 2H), 4.64 (t, J = 8.0 Hz, 2H), 7.82-7.75 (m, 2H), 8.26 (t, J = 
8.8 Hz, 2H), 8.33 (d, J = 8.8 Hz, 1H), 8.39 (d, J = 8.8 Hz, 1H). 
 
 
5-Methoxy-2,3,3-trimethyl-1-(3-(trimethylammonio)propyl)-3H-indolium bromide (7). 
Yield 88%; 1HNMR (400 MHz, DMSO-d6)  1.55 (s, 6H), 2.33 (m, 2H), 2.87 (s, 3H), 3.12 (s, 
9H), 3.63 (t, J = 8.4 Hz, 2H), 3.87 (s, 3H), 4.48 (t, J = 8.4 Hz, 2H), 7.16 (d, J = 8.8 Hz, 1H), 
7.58 (s, 1H), 8.03 (d, J = 8.8 Hz, 1H). 
 
Synthesis of Cartilage Targeting C700 (11-14) and C800 (15-18) Fluorophores. 
Individual heterocyclic salt 5-8 (2 mol. eq.) were added to a clean, dry and nitrogen 
cooled round bottom flask (25-mL) along with a magnetic stir bar followed by acetic anhydride 
(5 mL) and sodium acetate (4 mol. eq.). The resulting mixture was heated to 40 oC under 
vigorous stirring with a maintained positive pressure of nitrogen. Individual malonaldehyde 
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bis(phenylimine) monohydrochloride 9 or N-[5-(phenylamino)-2,4-pentadienylidene]aniline 
monohydrochloride 10 (1 mol. eq.) was added to the reaction mixture. The reaction was then 
heated to 60 oC and kept for 2-6 hr. depending on the dye structure. The reactions were 
monitored by Vis/NIR spectrophotometry by analyzing the change in absorption spectrum, i.e. 
increase in characteristic absorbance >600 nm (product) and corresponding decrease <500 nm 
(starting materials). After the absorbance signature indicated the completion of the reaction, 
the reaction mixture was allowed to cool to room temperature. Diethyl ether was added to the 
reaction mixture under heavy stirring resulting in a fine powder which was suction filtered, 
washed with acetone, ethyl acetate and diethyl ether and placed on heavy vacuum for 24 h. The 
compounds were purified on either reversed phase C18 silica gel with 5% acetonitrile:water as 
the eluting solvent or via multiple precipitation by dissolving the compounds in methanol and 
diluting with ether. The purification steps afforded the final C700 and C800 compounds in 
excellent purity. 
 
 
2-((1E,3E)-5-((E)-3,3-dimethyl-5-sulfonato-1-(3-(trimethylammonio)propyl)indolin-2-
lidene)penta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium-5-
sulfonate bromide (C700-SO3, 11) . Yield 90%; MP >260 °C; 1H NMR (400 MHz, D2O)  
1.579 (s, 12H), 2.232 (bs, 4H), 3.046 (bs, 4H), 3.427 (s, 18H), 3.728 (bs, 4H), 4.103 (bs, 4H), 
6.271 (d, J = 14.0 Hz, 2H), 6.606 (t, J = 11.2 Hz, 1H), 7.235 (d, J = 6.8 Hz, 2H), 7.765-7.703 
(m, 4H), 8.058 (t, J = 12.0 Hz, 2H). 13C NMR (100 MHz, D2O)  21.29, 27.37, 41.01, 49.66, 
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53.59, 63.79, 104.67, 111.06, 120.41, 126.92, 127.09, 140.30, 142.18, 144.05, 155.90, 175.13. 
High-resolution electrospray ionization (ESI) accurate mass spectra calculated m/z for 
[C37H53N4O6S2]
3+ 713.9730 found 713.9751. 
 
 
2-((1E,3E,5E)-5-(1,1-dimethyl-3-(3-(trimethylammonio)propyl)-1H-benzo[e]indol-
2(3H)- ylidene)penta-1,3-dien-1-yl)-1,1-dimethyl-3-(3-(trimethylammonio)propyl)-
1Hbenzo[e]indolium bromide (C700-Ph, 12). Yield 60%; MP 250-252 °C; 1H NMR (400 
MHz, MeOD-d4)  2.04 (s, 12H), 2.39 (m, 4H), 3.23 (s, 18H), 3.80 (s, 4H), 4.38 (s, 4H), 6.65 
(t, J = 12.8 Hz, 2H), 7.17 (m, 1H), 7.49 (m, 2H), 7.62 (m, 2H), 7.73 (t, J = 9.2 Hz, 2H), 8.08-
7.97 (m, 4H), 8.26 (t, J = 9.2 Hz, 2H), 8.41 (m, 2H). 13CNMR (100 MHz, MeOD-d4)  21.30, 
26.32, 40.7, 51.02, 52.62, 63.10, 103.28, 110.79, 121.97, 124.68, 126.55, 127.35, 128.06, 
129.63, 130.46, 132.02, 132.02, 133.70, 139.16, 153.57, 174.48. High-resolution ESI accurate 
mass spectra calculated m/z for [C45H59N4]
3+ 218.4908 found 218.4383; calculated m/z for 
[C45H59N4]
2+ 327.7365, found 327.1663. 
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5-Methoxy-2-((1E,3E,5E)-5-(5-methoxy-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indolium bromide (C700-OMe, 13). Yield 81%; MP 235-
237°C; 1HNMR (400 MHz, DMSO-d6)  1.70 (s, 12H), 2.10 (s, 4H), 3.12 (s, 18H), 3.65 (t, J 
= 8.0 Hz, 4H), 3.80 (s, 6H), 4.15 (t, J = 8.0 Hz, 4H), 6.37 (d, J = 13.6 Hz, 2H), 6.65 (t, J = 12.0 
Hz, 1H), 6.94 (d, J = 8.8 Hz, 2H), 7.33 (s, 2H), 7.45 (d, J = 8.8 Hz, 2H), 8.30 (t, J = 13.6 Hz, 
2H). 13CNMR (100 MHz, DMSO-d6)  21.30, 27.63, 41.17, 49.63, 52.95, 56.39, 62.82, 103.31, 
109.64, 112.21, 114.00, 125.69, 135.73, 143.32, 153.80, 158.13, 172.34. High-resolution ESI 
accurate mass spectra calculated m/z for [C39H59N4O2]
3+ 205.1541 found 205.1466; calculated 
m/z for [C39H59N4O2]
2+ 307.2314, found 307.2271. 
 
 
2-((1E,3E,5E)-5-(3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-
ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indolium 
bromide (C700-H, 14). Yield 71%; MP 218-221 °C; 1H NMR (400 MHz, MeOD-d4)  1.78 (s, 
12H), 2.35-2.38 (m, 4H), 3.24 (s, 18H), 3.75 (t, J = 8.4 Hz, 4H), 4.25 (t, J = 7.6 Hz, 4H), 6.62 
(d, J = 13.6 Hz, 2H), 7.14 (t, J = 12.4 Hz, 1H), 7.28-7.32 (m, 2H), 7.43-7.48 (m, 4H), 7.54 (d, 
J = 7.6 Hz, 2H), 8.34 (t, J = 13.2 Hz, 2H). 13CNMR (100 MHz, MeOD-d4)  20.93, 26.56, 
40.26, 49.22, 52.49, 63.08, 103.72, 110.41, 122.20, 125.07, 127.11, 128.50, 141.23, 141.76, 
154.80, 173.47. High-resolution ESI accurate mass spectra calculated m/z for [C37H55N4]
3+ 
185.1470 found 185.1070; calculated m/z for [C37H55N4]
2+ 277.7208, found 277.1687. 
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2-((1E,3E,5E,7E)-7-(3,3-dimethyl-5-sulfonato-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium-5-sulfonate bromide (C800-SO3, 15) Yield 53%; 
MP >260 oC; 1H NMR (400 MHz, DMSO-d6)  1.68 (s, 12 H), 2.16 (m, 4 H), 3.10 (s, 18 H), 
3.51 (t, J = 7.6 Hz, 4 H), 4.14 (t, J = 7.6 Hz, 4 H), 6.44 (d, J = 13.6 Hz, 2 H), 6.58 (t, J = 13.2 
Hz, 2 H), 7.36 (d, J = 8.0 Hz, 2 H), 7.68 (d, J = 8.4 Hz, 2 H), 7.79 (s, 2 H), 8.91 (m, 3 H). 13C 
NMR (100 MHz, DMSO-d6)  21.30, 27.63, 41.24, 49.25, 52.98, 62.95, 110.45, 120.39, 
126.59, 140.77, 142.31, 145.93. High-resolution ESI accurate mass spectra calculated m/z for 
[C39H55N4O6S2]
3+ 739.3558 found 739.3571. 
 
 
2-((1E,3E,5E,7E)-7-(1,1-dimethyl-3-(3-(trimethylammonio)propyl)-1H-
benzo[e]indol-2(3H)-ylidene)hepta-1,3,5-trien-1-yl)-1,1-dimethyl-3-(3-
(trimethylammonio)propyl)-1H-benzo[e]indol-3-ium bromide (C800-Ph, 16). Yield 62%; MP 
219-221 oC; 1H NMR (400 MHz, DMSO-d6)  1.92 (s, 12 H), 2.20 (m, 4 H), 3.16 (s, 18 H), 
3.76 (t, J =  Hz, 4 H), 4.13 (t, J =  Hz, 4 H), 6.74 (m, 4 H), 7.50 (t, J = 7.2 Hz, 2 H), 7.65 (t, J 
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= 7.2 Hz, 2 H), 7.87 (m, 3 H), 8.07 (m, 6 H), 8.26 (d, J = 8.4, 2 H). 13C NMR (100 MHz, 
DMSO-d6)  21.61, 27.27, 50.89, 53.02, 62.81, 104.43, 112.03, 122.67, 122.67, 125.22, 
126.66, 128.06, 128.17, 130.35, 130.77, 131.74, 133.52, 140.05, 172.74. High-resolution ESI 
accurate mass spectra calculated m/z for [C47H61N4]
3+ 227.1627, found 227.1599. 
 
 
5-methoxy-2-((1E,3E,5E,7E)-7-(5-methoxy-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide (C800-OMe, 17). Yield 15%; MP 183-
185 oC; 1H NMR (400 MHz, MeOD-d4)  1.65 (s, 12 H), 2.30 (m, 4 H), 3.25 (s, 18 H), 3.78 (s, 
6 H), 3.84 (t, J = 8.4 Hz, 4 H), 4.32 (t, J = 8.4 Hz, 4 H), 6.66 (t, J = 12 Hz, 2 H), 6.93, (d, J = 
8.4 Hz, 2 H), 7.08 (s, 2 H), 7.43 (m, 3 H), 7.77 (d, J = 10.8 Hz, 2 H). 13C NMR (100 MHz, 
MeOD-d4)  20.95, 26.66, 40.53, 49.02, 52.51, 54.99, 63.16, 108.77, 111.25, 113.27, 125.90, 
135.44, 142.77, 150.61, 158.28, 170.65. High-resolution ESI accurate mass spectra calculated 
m/z for [C41H61N4O2]
3+ 213.8260 found 213.7877. 
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2-((1E,3E,5E,7E)-7-(3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-
ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium 
bromide (C800-H, 18). Yield 46%; MP 191-193 oC; 1H NMR (400 MHz, MeOD-d4)  1.69 (s, 
12 H), 2.32 (m, 4 H), 3.25 (s, 18 H), 3.85 (t, J = 8.0 Hz, 4 H), 4.32 (t, J = 7.6 Hz, 4 H), 6.62 (d, 
J = 13.2 Hz, 2 H), 6.77 (t, J = 12 Hz, 2 H), 7.23 (t, J = 7.2 Hz, 2 H), 7.40 (t, J = 7.6 Hz, 2 H), 
7.49 (t, J = 8.0 Hz, 4 H) 7.61 (t, J =12 Hz, 1 H), 7.91 (t, J = 11.6 Hz, 2 H). 13C NMR (100 
MHz, MeOD-d4)  20.93, 26.70, 40.39, 48.93, 52.48, 52.52, 52.56, 63.11, 110.58, 122.08, 
124.75, 126.63, 128.46, 141.02, 141.93, 152.22, 171.63. High-resolution ESI accurate mass 
spectra calculated m/z for [C39H57N4]
3+ 193.8189 found 193.7919.  
7.4.2 Optical and physicochemical property analyses 
All optical measurements were performed at 37°C in 100% fetal bovine serum (FBS) 
buffered with 50 mM HEPES, pH 7.4. Absorbance and fluorescence emission spectra NIR 
fluorophores were measured using fiber optic HR2000 absorbance (200–1100 nm) and 
USB2000FL fluorescence (350–1000 nm) spectrometers (Ocean Optics, Dunedin, FL). NIR 
excitations were provided by 5 mW of 655 nm red laser pointer (Opcom Inc., Xiamen, China) 
and 8 mW of 765 nm NIR laser diode light source (Electro Optical Components, Santa Rosa, 
CA) coupled through a 300 µm core diameter, NA 0.22 fiber (Fiberguide Industries, Stirling, 
NJ). For fluorescence quantum yield (QY) measurements, oxazine 725 in ethylene glycol (QY 
= 19%) and ICG in DMSO (QY = 13%) were used as calibration standards, under conditions 
of matched absorbance at 655 and 765 nm, respectively. In silico calculations for surface 
molecular charge, the partition coefficient (logD at pH 7.4) and total polar surface area (TPSA) 
were calculated using Marvin and JChem calculator plugins (ChemAxon, Budapest, Hungary). 
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7.4.3 NIR fluorescence imaging system 
The dual-NIR channel FLARE imaging system has been described in detail 
previously.21, 22 In this study, 4 mW/cm2 of 670 nm excitation light and 11 mW/cm2 of 760 nm 
excitation light were used with white light (400–650 nm) at 40,000 lx. Color and NIR 
fluorescence images were acquired simultaneously with custom software at rates up to 15 Hz 
over a 15 cm diameter field of view. The imaging system was positioned at a distance of 18 
inches from the surgical field. For each experiment, camera exposure time and image 
normalization was held constant. 
7.4.4 Animal models  
Animals were housed in an AAALAC-certified facility and were studied under the 
supervision of BIDMC IACUC in accordance with approved institutional protocols (#101-
2011 for rodents and #034-2013 for pigs). Male CD-1 mice (25–30 g, 8 weeks, Charles River 
Laboratories, Wilmington, MA) were anesthetized with 100 mg/kg ketamine and 10 mg/kg 
xylazine intraperitoneally (Webster Veterinary, Fort Devens, MA). Female Yorkshire pigs 
(E.M. Parsons and Sons, Hadley, MA) averaging 35 kg were induced with 4.4 mg/kg 
intramuscular Telazol (Fort Dodge Labs, Fort Dodge, IA), intubated, and maintained with 2% 
isoflurane (Baxter Healthcare Corp., Deerfield, IL). Following anesthesia, electrocardiogram, 
heart rate, pulse oximetry, and body temperature were monitored throughout surgery. 
7.4.5 Quantitative analysis 
At each time point, the fluorescence and background intensity of a region of interest 
(ROI) over each tissue was quantified using custom FLARE software. The signal-to-
background ratio (SBR) was calculated as SBR = fluorescence/background, where background 
is the signal intensity of neighboring tissues, such as muscle or skin, obtained over the imaging 
period. All NIR fluorescence images for a particular fluorophore were normalized identically 
for all conditions of an experiment. At least 3 animals were analyzed at each time point. 
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Statistical analysis was carried out using the unpaired Student’s t-test or one-way analysis of 
variance (ANOVA). Results were presented as mean ± s.d. and curve fitting was performed 
using Prism version 4.0a software (GraphPad, San Diego, CA). 
7.4.6 Histology and NIR fluorescence microscopy  
Cartilage tissues were placed in 2% paraformaldehyde in PBS for 30 min before 
mounting in Tissue-Tek OCT compound (Fisher Scientific, Pittsburgh, PA) and flash-freezing 
in liquid nitrogen. Frozen samples were cryosectioned (10 µm per slice), observed by NIR 
fluorescence microscopy, and also stained with alcian blue or hematoxylin and eosin (H&E), 
respectively. NIR fluorescence microscopy was performed on a 4-filter Nikon Eclipse TE300 
microscope system as previously described.23, 24 The microscope was equipped with a 100 W 
mercury light source (Chiu Technical Corporation, Kings Park, NY), NIR-compatible optics, 
and a NIR-compatible 10X Plan Fluor objective lens and a 100X Plan Apo oil immersion 
objective lens (Nikon, Melville, NY). Images were acquired on an Orca-AG (Hamamatsu, 
Bridgewater, NJ). Image acquisition and analysis was performed using iVision software 
(BioVision Technologies, Exton, PA). Two custom filter sets (Chroma Technology 
Corporation, Brattleboro, VT) composed of 650 ± 22 nm and 750 ± 25 nm excitation filters, 
675 nm and 785 nm dichroic mirrors, and 710 ± 25 nm and 810 ± 20 nm emission filters were 
respectively used to detect C700-OMe and C800-OMe signals in the frozen tissue samples. 
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8 BROWN ADIPOSE TISSUE TARGETED NIR FLUOROPHORES 
8.1 Abstract 
The prevalence of brown adipose tissue in human health and disease is being unraveled; 
however, detection methods remain critically scarce for the longitudinal monitoring of this 
important tissue.  As near-infrared fluorescence imaging has emerged as a leading alternative to 
other harmful and non-spatially resolved imaging techniques, we have explored small molecule 
fluorophores that report on the location of brown adipose tissue for longitudinal monitoring. 
8.2 Introduction 
Similar to, yet more effective than, its skeletal muscle relative, brown adipose tissue (BAT) 
helps newborns and hibernating animals avoid hypothermic conditions when they are unable to 
effectively regulate their internal temperature.1-3  BAT uniquely combats hypothermia through two 
structural characteristics, 1) a large population of mitochondria which is responsible for increased 
temperature through thermogenesis and 2) a disproportionally high concentration of UCP1 
(uncoupled protein 1, also referred to as thermogenin) located within the mitochondrial inner 
membrane.4, 5  UCP1 affords the efficient heat-generating mechanism of BAT by dissipating the 
proton electrochemical gradient within the inner mitochondrial membrane causing reduction in the 
rate of ATP synthesis.  It had been long assumed that BAT lacked a prevailing presence in adults 
in large part because of developed thermoneutrality or the ability for adults to maintain their body 
temperatures in alternate ways (i.e. clothes, air conditioning/heat, fire, etc.).6-8  Importantly, it was 
recently discovered that BAT persists into adulthood and is responsible for maintaining 
metabolism and plays a vital role in the propensity to gain weight and develop obesity.   
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Figure 8-1. General physiological and cellular diagrams of brown and white fat. (left) 
Presence and location of brown and white fat at different stages of development and health, (right) 
cellular differences between brown adipose tissues which are high in mitochondria with small fat 
deposits and white adipose tissues which contains mostly fat.  Nucleus is represented by purple and 
fat is represented by white circles. 
 
The highly ubiquitous nature of BAT, the extremely important interplay with the global 
obesity epidemic and the unknown mechanism for production/dissipation of BAT demands a 
technique for effective real-time monitoring of this important tissue. This task has been difficult 
as the three dimensional structures for targetable molecular receptors remain critically unknown; 
therefore, engineering contrast agents that specifically target BAT remains a significant unmet 
clinical need and a challenging research endeavor.  Clinicians have relied on position emission 
tomography (PET) and magnetic resonance imaging (MRI) for studying the location and lifetime-
dynamics of brown adipose tissue.  PET experiments should be limited for patients due to their 
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characteristically harmful irradiation; similarly, the spatial resolution of these techniques cannot 
provide accurate, real-time longitudinal studies for analysis of brown adipose tissue.9-12  Our lab 
focuses on an emerging imaging technique using optical fluorescence of targeted small molecules 
(fluorophores).  Correctly engineered fluorophores are required for in vivo use.  They must be 
synthetically modified to assume near-infrared (NIR) absorbance and fluorescence properties.  The 
NIR region is unique in that it features a minimum of human tissue absorbance and fluorescence 
characteristics—this offers an appealing potential for imaging with low background, reduced 
tissue attenuation and high signal given the contrast agent exists for a particular tissue.  Utilizing 
a NIR-fluorescent BAT-targeted contrast agent would allow long-term and real-time analysis of 
brown adipose tissue in vivo.   Recently, Azhdarinia et al.13  probed potential BAT-targeted 
peptides systematically in a combinatorial manner.  These peptides were covalently conjugated to 
a cyanine dye (Cy5) and shows whole-body imaging of BAT.  This longstanding approach of 
fluorophore-dye conjugation has been substantially researched; however, owing to low success in 
clinical translation, a new approach has been actively researched—structure-inherent targeting.  
Toward this goal, we realized that mitochondria-targeted small molecules are commonly lipophilic 
cations and since BAT cells are enriched with high levels of mitochondria we started with 
fluorophore structures featuring lipophilic cations.  
8.3 Results and Discussion 
After a systematic screening of >300 small molecules that feature a hydrophobic core with 
a central cation, we were able to define a generic pharmacophore that showed appealing BAT 
localization.   
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Figure 8-2. The numbering of 2-methylbenzothiazole and synthetic methods to final 
methylated cyanine chromophores for BAT targeting. 
We then directed our focus to modifying this lead compound by systematically installing 
selected heterocyclic and alkyl modifications that directly influence the all-important lipophilic 
character for BAT targeting.  After screening and analyzing a structure activity relationship for a 
large series of fluorophores (>300 chemical structures), we identified an overall pharmacophore 
of pentamethine cyanines bearing the benzothiazole heterocycle.  After this general 
pharmacophore was found, we began systematically modifying the heterocyclic units from 
hydrophilic (-OH and –OMe) to hydrophobic (methyl, fluorine) to observe potential perturbation 
in BAT accumulation.  The preparation of these fluorophores in shown in Figure 2.  We initially 
began with the commercially available benzothiazoles that were subjected to a facile alkylation 
with iodomethane in a sealed tube.  This quaternization proceeded in near quantitative yield to 
afford the salts 2-10. The fluorine heterocycle was prepared from the starting 4-fluoro-2-
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iodoaniline which was acetylated and the cyclization reaction was performed in the presence of 
catalytic copper iodide.   
 
 
Figure 8-3. The chemical structures, color video and 70 nm NIR fluorescence for final BAT 
targeting compounds.   
 
Since we observed that both the unsubstituted parent and the 5-methyl substituted 
compound offered an appealing increase in BAT targeting and began modifying the heterocyclic 
nitrogen alkyl chains while maintaining the active heterocyclic units.  As mitochondria is the major 
component of brown adipose tissues, and mitochondrial targeting small molecules are lipophilic 
cations with heavy dependence on the molecular character of the lipophilic cation and related 
physicochemical descriptors (i.e. LogD, etc.) for their efficacy. Elongating the alkyl chains and 
increasing the hydrophobic character was thought to direct the compound to areas on increased 
lipophilic environments while maintaining the BAT targeting character of the heterocyclic unit.  
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We have found in our previous work on developing structure inherent targeting small molecule 
fluorophores that minor structural alterations can cause significant and often beneficially 
serendipitous biological results.  Elongating the alkyl chain focused on moving from methyl to 
ethyl, butyl and phenylpropyl for fully examining a broad range of lipophilic groups.   
 
 
Figure 8-4. The chemical structures, color video and 700 nm NIR fluorescence for final BAT 
targeting compounds.   
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When the BAT localization is examined, the butyl side-chains seems to be most effective 
at selective and high signal brown adipose tissue targeting with the 5-methyl benzothiazole 
exhibiting higher signal compared to the non-modified heterocyclic analog.  
8.4 Conclusions.  
For the first time, structure inherent targeting has been successfully applied to the 
fluorescence imaging of brown adipose tissue.  By fine tuning the hydrophobicity in conjunction 
with heterocyclic manipulation, we achieved highly specific imaging with low surrounding 
background.  These optimized contrast agents can be readily employed for longitudinal monitoring 
and research toward fully elucidating the intricate nature and therapeutic potential of brown 
adipose tissue. 
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8.6 Experimental.  
Chemicals and Reagents.  The chemical reagents used in the synthesis of these compounds 
were obtained from Acros Organics, Alfa Aesar and Matrix Scientific. The reactions were 
followed using silica gel 60 F254 thin layer chromatography plates (Merck EMD Millipore, 
Darmstadt, Germany). Open column chromatography was utilized for the purification of all final 
compounds using 60-200u, 60A, classic column silica gel (Dynamic Adsorbents, Norcross, GA). 
The 1H NMR and 13C NMR spectra were obtained using high quality Kontes NMR tubes (Kimble 
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Chase, Vineland, NJ) rated to 500 MHz  and were recorded on a Bruker Avance (400 MHz) 
spectrometer using DMSO-d6 or MeOD-d4 containing tetramethylsilane (TMS) as an internal 
calibration standard set to 0.0 ppm. UV-Vis/NIR absorption spectra were recorded on a Varian 
Cary 50 spectrophotometer. High-resolution accurate mass spectra (HRMS) were obtained either 
at the Georgia State University Mass Spectrometry Facility using a Waters Q-TOF micro (ESI-Q-
TOF) mass spectrometer or utilizing a Waters Micromass LCT TOF ES+ Premier Mass 
Spectrometer.  Liquid chromatography utilized a Waters 2487 single wavelength absorption 
detector with wavelengths set between 640 and 700 nm depending on the particular photophysical 
properties.  The column used in LC was a Waters Delta-Pak 5 uM 100A 3.9 x 150 mm reversed 
phase C18 column. Evaporative light scattering detection analyzes trace impurities that cannot be 
observed by alternate methods; a SEDEX 75 ELSD was utilized in tandem with liquid 
chromatography to confirm purity (>95% as determined by LC-ELSD-MS).  
8.6.1 Synthetic Procedures and Structural Characterizations. 
General Procedure for preparation of salts 
These compounds were synthesized with slight modification of the previously published 
procedure.14, 15 A mixture of 2-methylbenzothiazole (1 eq.) and alkyl halide (3 eq.) was heated at 
800C for 6 to 18 hours. The mixture was cooled to room temperature and resulting crude solid was 
subjected for purification by precipitation from methanol and diethyl ether (10 mL, 1:4). The 
precipitated solid was then filtered and dried in vacuo.  
 
2,3-dimethylbenzo[d]thiazol-3-ium iodide: Yield 81%; 1H NMR (DMSO-d6 , 400 MHz): δ 8.49 
(d, J = 8 Hz, 1H), 8.31 (d, J = 8.4 Hz, 1H), 7.89 (q, J1 = 7.2 Hz, J2 = 0.8Hz, 1H), 7.80 (t, J1 = 8.4 
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Hz, J2 = 7.2 Hz, 1H), 4.24 (s, 3H), 3.22 (s, 3H). 
13C NMR (DMSO-d6, 100 MHz): δ 177.04, 141.47, 
129.15, 128.58, 127.93, 124.47, 116.70, 36.44, 17.48. 
 
2, 3, 5-trimethylbenzo[d]thiazol-3-ium iodide: Yield 76%; 1H NMR (DMSO-d6, 400 
MHz): δ 8.31 (d, J = 8.4 Hz, 1H), 8.15 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 4.18 (s, 3H), 3.17 (s, 3H), 
2.56 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): δ 176.73, 141.79, 139.75, 129.45, 125.75, 124.00, 
123.90, 116.51, 116.37, 36.29, 21.14, 17.32. 
General procedure for synthesis of BAT targeted compounds  
A mixture of benzothiazole quaternary salt (2 eq.) and malonaldehyde bis(phenylimine) 
monohydrochloride (1 eq.) were heated to 45 0C in presence of triethylamine (2 eq.) in acetonitrile 
for 2 hours. The solution was cooled down to room temperature and resulting solid was filtered. 
The resulting crude solid was purified by precipitation from DMF–diethyl ether (20 mL, 1:4). 
3-methyl-2-((1E,3E,5Z)-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)penta-1,3-dien-1-
yl)benzo[d]thiazol-3-ium iodide: Yield 68% (0.21 g); m.p. >260 0C; 1H NMR (DMSO-d6, 400 
MHz): δ 7.98 (d, J = 8 Hz, 2H), 7.75~7.67 (m, 4H), 7.55 (t, J = 7.2 Hz, 2H), 7.38 (t, J = 7.6 Hz, 
2H), 6.53~6.50 (m, 3H), 3.80 (s, 6H). 13C NMR (DMSO-d6, 100 MHz): δ 164.01, 150.28, 142.02, 
127.95, 125.14, 124.94, 122.93, 113.35, 100.62, 33.48. ESI-HRMS m/z: calc. for (C21H19N2S2)
+ 
363.0990, found 363.1004.  λabs = 650 nm λfluo = 670 nm 
2-((1E,3E,5Z)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)penta-1,3-dien-1-yl)-
3,5-dimethylbenzo[d]thiazol-3-ium iodide: Yield 63% (0.15 g); m.p. >260 0C; 1H NMR 
(DMSO-d6, 400 MHz): δ 7.83 (d, J = 8 Hz, 2H), 7.70 (t, J = 12 Hz, 2H), 7.52 (s, 2H), 7.21 (d, J = 
8 Hz, 2H), 6.50~6.42 (m, 3H), 3.77 (s, 6H), 2.43 (s, 6H). 13C NMR (DMSO-d6, 100 MHz): δ 
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164.05, 149.90, 142.14, 138.03, 125.94, 122.47, 122.02, 113.53, 100.54, 33.36, 21.11. ESI-HRMS 
m/z: calc. for (C23H23N2S2)
+ 391.1297, found 391.1308. λabs = 654 nm λfluo = 678 nm 
6-hydroxy-2-((1E,3E,5Z)-5-(6-hydroxy-3-methylbenzo[d]thiazol-2(3H)-
ylidene)penta-1,3-dien-1-yl)-3-methylbenzo[d]thiazol-3-ium 4-methylbenzenesulfonate: 
Yield 61% (0.16 g); m.p. >260 0C; 1H NMR (DMSO-d6 , 400 MHz) : δ 10.06 (s, 2H), 7.61~7.46 
(m, 5H), 7.35 (s, 2H), 7.10 (d, J = 7.6 Hz, 1H), 6.96 (d, J = 6.96 Hz, 2H), 6.40~6.34 (m, 3H), 3.73 
(m, 6H), 2.28 (s, 1H). 13C NMR (DMSO-d6, 100 MHz): δ 162.04, 155.25, 148.70, 134.80, 127.90, 
126.32, 125.37, 115.69, 113.86, 108.63, 99.62, 33.28, 20.73. ESI-HRMS m/z: calc. for 
(C21H19N2O2S2)
+ 395.0888, found 395.0893. λabs = 665 nm λfluo = 688 nm 
 
Repeat of salt synthesis procedure from above: 
3-ethyl-2-methylbenzo[d]thiazol-3-ium iodide: Yield 72%; 1H NMR (DMSO-d6 , 400 
MHz): δ 8.47 (d, J = 8 Hz, 1H), 8.35 (d, J = 8.4 Hz, 1H), 7.92 ~ 7.79 (m, 2H), 4.78 (q, J = 7.2 Hz, 
2H), 3.23 (s, 3H), 1.46 (t, J = 7.2 Hz, 3H). 13C NMR (DMSO-d6, 100 MHz): δ 176.87, 140.46, 
129.37, 129.14, 128.05, 124.69, 116.68, 44.74, 16.79, 13.22. 
3-butyl-2-methylbenzo[d]thiazol-3-ium iodide: Yield 50%; 1H NMR (DMSO-d6 , 400 
MHz): δ 8.47 (d, J = 8 Hz, 1H), 8.35 (d, J = 8.8 Hz, 1H), 7.88~7.78 (m, 2H), 4.72 (t, J = 7.6 Hz, 
2H), 3.23 (s, 3H), 1.89~1.78 (m, 2H), 1.50 ~ 1.41 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H). 13C NMR 
(DMSO-d6, 100 MHz): δ 176.98, 140.81, 129.33, 129.05, 128.05, 124.64, 116.88, 49.06, 29.77, 
19.27, 16.99, 13.52. 
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3-ethyl-2,5-dimethylbenzo[d]thiazol-3-ium iodide: Yield 65%; 1H NMR (DMSO-d6, 
400 MHz): δ 8.32 (d, J = 8.4 Hz, 1H), 8.20 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 4.73 (q, J = 7.2 Hz, 
2H) , 3.21 (s, 3H), 2.58 (s., 3H), 1.46 (t, J = 7.2 Hz, 3H). 13C NMR (DMSO-d6, 100 MHz): δ 
176.45, 140.76, 140.01, 129.52, 126.25, 124.15, 116.33, 44.60, 21.17, 16.73, 13.21. 
 
General Procedure for synthesis of alkylated BAT agents:  
A mixture of benzothiazole quaternary salts (2 eq.) and malonaldehyde bis(phenylimine) 
monohydrochloride (1 eq.) were heated to 45 0C in presence of triethylamine (2 eq.) in acetonitrile 
for 2 hours. The solution was cooled to room temperature and the resulting solid was filtered. It 
was then purified by precipitation from DMF–diethyl ether (20 mL, 1:4). 
3-ethyl-2-((1E,3E,5Z)-5-(3-ethylbenzo[d]thiazol-2(3H)-ylidene)penta-1,3-dien-1-
yl)benzo[d]thiazol-3-ium iodide: Yield 65% (0.19 g); m.p. >260 0C; 1H NMR (DMSO-d6, 400 
MHz): δ 7.98 (d, J = 7.6 Hz, 2H), 7.77~7.69 (m, 4H), 7.53 (t, J = 7.6 Hz, 2H), 7.37 (t, J = 7.6 Hz, 
2H), 6.55~6.46 (m, 3H), 4.38 (q, J = 6.8 Hz, 4H), 1.30 (t, J = 7.2 Hz, 3H). 13C NMR (DMSO-d6, 
100 MHz): δ 163.22, 150.57, 140.93, 128.00, 125.39, 124.91, 123.05, 120.74, 113.09, 100.06, 
41.28, 12.65. ESI-HRMS m/z: calc. for (C23H23N2S2)
+ 391.1297, found 391.1298. λabs = 650 nm 
λfluo = 673 nm 
3-butyl-2-((1E,3E,5Z)-5-(3-butylbenzo[d]thiazol-2(3H)-ylidene)penta-1,3-dien-1-
yl)benzo[d]thiazol-3-ium iodide: Yield 62% (0.14 g); m.p. 240 - 242 0C; 1H NMR (DMSO-d6, 
400 MHz): δ 7.99 (d, J = 8 Hz, 2H), 7.79~7.71 (m, 4H), 7.55 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.6 
Hz, 2H), 6.55~6.48 (m, 3H), 4.34 (brt,  J = 7.2 Hz, 4H), 1.71 (m, 4H),  1.41 (m, 4H), 0.94 (t, J = 
7.2 Hz, 6H). 13C NMR (DMSO-d6, 100 MHz): δ 163.34, 150.26, 141.23, 127.89, 125.21, 124.82, 
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122.95, 120.91, 113.26, 100.36, 45.82, 29.38, 19.29, 13.63. ESI-HRMS m/z: calc. for 
(C27H31N2S2)
+ 447.1923, found 447.1933. λabs = 655 nm λfluo = 673 nm 
3-(3-phenylpropyl)-2-((1E,3E,5Z)-5-(3-(3-phenylpropyl)benzo[d]thiazol-2(3H)-
ylidene)penta-1,3-dien-1-yl)benzo[d]thiazol-3-ium bromide: Yield 63% (0.17 g); m.p. 130 - 
132 0C; 1H NMR (DMSO-d6, 400 MHz): δ 7.97 (d, J = 8 Hz, 2H), 7.73 ~ 7.52 (m, 6H), 7.39 ~ 
7.21 (m, 10H), 6.42 ~ 6.39 (m, 3H), 4.35 (brt, J = 6.8 Hz, 4H), 2.76 (t, J = 7.6 Hz, 4H), 2.03 (m, 
4H). 13C NMR (DMSO-d6, 100 MHz): δ 163.56, 150.40, 141.31, 140.77, 128.40, 128.21, 127.94, 
126.09, 125.31, 124.93, 123.01, 120.77, 113.21, 100.26, 45.65, 31.81, 28.79. ESI-HRMS m/z: 
calc. for (C37H35N2S2)
+ 571.2236, found 571.2240. λabs = 655 nm λfluo = 674 nm 
3-ethyl-2-((1E,3E,5Z)-5-(3-ethyl-5-methylbenzo[d]thiazol-2(3H)-ylidene)penta-1,3-
dien-1-yl)-5-methylbenzo[d]thiazol-3-ium iodide: Yield 56% (0.16 g); m.p. >260 0C; 1H NMR 
(DMSO-d6, 400 MHz): δ  7.85 (d, J  =8 Hz, 2H), 7.73 (t, J = 12.4 Hz, 2H), 7.57 (s, 2H), 7.22 (d, 
J = 7.6 Hz, 2H), 6.54~6.42 (m, 3H), 4.36 (brd, J = 6.4 Hz, 4H), 2.44 (s, 6H), 1.31 (t, J = 6.8 Hz, 
6H). 13C NMR (DMSO-d6, 100 MHz): δ 163.36, 150.14, 141.05, 138.14, 125.94, 125.53, 122.20, 
113.22, 99.91, 41.10, 21.02, 12.56. ESI-HRMS m/z: calc. for (C25H27N2S2)
+ 419.1610, found 
419.1602. λabs = 660 nm λfluo = 679 nm 
Optical and Physicochemical Property Analyses.  All optical measurements were 
performed in various solvents, including ethanol (200 proof, Fischer Chemical), dimethyl 
sulfoxide (DMSO, 99.9% Acros Organics), phosphate buffered saline (PBS, pH 7.4, Fischer 
Scientific) and at 37oC in 100% fetal bovine serum (FBS, Fischer Scientific) buffered with 50 mM 
HEPES, pH 7.4. Absorbance and fluorescence emission spectra of the series of NIR fluorophores 
were measured using Varian Cary 50 absorbance spectrophotometer (190–1100 nm) and Shimadzu 
RF-5301PC spectrofluorometer (350–1000 nm). For fluorescence quantum yield (QY) 
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measurements, rhodamine 800 in absolute ethanol (QY = 28%) was used as a calibration standard, 
under conditions of matched absorbance at 640 nm. In silico calculations of physicochemical 
distribution coefficient (logD at pH 7.4) was calculated using Marvin and JChem calculator 
plugins (ChemAxon, Budapest, Hungary).  Electrostatic maps were calculated using Spartan DFT 
calculations at the B3LYP level. 
 
LC-MS Analysis. The purity of all compounds was measured using liquid chromatography-
mass spectrometry (LC-MS) on a Waters system consisting of a 1525 binary HPLC pump with a 
manual 7725i Rheodyne injector, a 996 Photodiode Array (PDA) detector, and a 2475 
multiwavelength fluorescence detector. The column eluent was divided in 2 using a flow splitter 
(Upchurch Scientific). A portion of the eluent flowed into an ELSD (Richards Scientific) while 
the rest flowed into a Micromass LCT ESI-TOF spectrometer (Waters) equipped with a Symmetry 
(R) C18 (4.6 x 150 mm, 5 μm) reverse-phase HPLC column. For mass spectrometry mobile phase 
was solvent A = 0.1% formic acid (FA) in water and solvent B = CH3CN with 95% A for 5 min 
and a linear gradient from 5% to 40% CH3CN (from A to B for 30 min) at a flow rate of 1 mL/min, 
capillary voltage was -3317V, and sample cone voltage was -50V. 
Optical Imaging System and Fluorescence Assisted Surgical Resection.  The real-time 
intraoperative FLARE imaging system has been described in detail previously.16, 17 In this study, 
670 nm excitation was used at a fluence rate of 4 mW/cm2, with white light (400-650 nm) at 40,000 
lx. Color and NIR fluorescence images were acquired simultaneously with custom software at 
rates up to 15 Hz over a 15 cm diameter field of view. The imaging system was positioned at a 
distance of 18 inches from the surgical field. The wavelength used for excitation and emission 
filters was 650 ± 22 nm. 
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Animal models. Animals were housed in an AAALAC-certified facility and were studied 
under the supervision of BIDMC’s IACUC in accordance with the approved institutional protocol 
#057-2014. Male CD-1 mice (20–30 g, 6-8 weeks, Charles River Laboratories, Wilmington, MA) 
were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine intraperitoneally (Webster 
Veterinary, Fort Devens, MA). For intraoperative imaging and biodistribution, the imaging system 
equipped with a custom filter set (Chroma Technology Corporation, Brattleboro, VT) composed 
of a 650 ± 22 nm excitation filter, a 680 nm dichroic mirror, and an 710 ± 25 nm emission filter 
was used at a fluence rate of 4 mW/cm2, with white light (400-650 nm) at 40,000 lx. Color and 
NIR fluorescence images were acquired simultaneously with custom software at rates up to 15 Hz 
over a 15 cm diameter field of view. The imaging system was positioned at a distance of 18 inches 
from the surgical field. For each experiment, camera exposure time and image normalization was 
held constant. 
Quantitative analysis. At each time point, the fluorescence and background intensity of a 
region of interest (ROI) over each tissue was quantified using custom imaging software and ImageJ 
software (NIH, Bethesda, MD) version 1.45q. The signal-to-background ratio (SBR) was 
calculated as SBR = fluorescence/background, where background is the signal intensity of 
neighboring tissues such as muscle or skin obtained over the period of imaging time. All NIR 
fluorescence images for a particular fluorophore were normalized identically for all conditions of 
an experiment. At least three animals were analyzed at each time point. Statistical analysis was 
carried out using the unpaired Student’s t-test or one-way analysis of variance (ANOVA). Results 
were presented as mean ± s.d. and curve fitting was performed using Prism version 4.0a software 
(GraphPad, San Diego, CA). 
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9 STRUCTURALLY STABLE AND ULTRA-BRIGHT SQUARAINE DYES: THE 
ROLE OF QUATERNARY AMMONIUM CATIONS IN OXOCYCLOBUTANAL 
STABILIZATION 
This chapter is a manuscript that has been prepared for publication for submission as a 
communication to Angewandte Chemie based on the stability and biological tagging applications 
of new ultrabright squaraine dyes.  My co-first author designation is for the design of the project, 
the molecular modeling, NMR studies to confirm the modeling (not currently shown), the 
manuscript/figure preparation and the synthesis of final asymmetric compounds for later biological 
applications.  
Yadav, Y. *, Owens, E. A.*, Henary, M., Near-infrared Fluorescent Squaric Acid Dyes with 
Unparalleled Brightness and Stability in Serum 2015 Submitted to Angewandte Chemie. *Co-First 
Authors 
9.1 Abstract 
Highly stable symmetric and asymmetric squaric acid fluorophores have been synthesized 
featuring an internal salt bridge between a quaternary ammonium cation and the central 
oxycyclobutenolate ring of the chromophore.  The newly synthesized symmetric and asymmetric 
compounds display increased molar absorptivity (DMSO: symmetric average 447,325 M-1cm-1 
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and asymmetric average 333,725 M-1cm-1; Fetal Bovine Serum: 398,050 M-1cm-1 and 375,100 M-
1 cm-1, respectively), quantum yield in serum (symmetric average  = 45%, asymmetric average   
= 79%) , and thermal/photochemical stability over previously reported squaric acid based dyes.  
Consequently, both classes show great promise in re-surfacing the normally environment-labile 
squaric acid dyes as novel imaging agents and scaffolds for fluorescence sensing. Furthermore, 
incorporating a covalent attachment point away from the conjugated system allows for biological 
tagging applications without disturbing the optimum optical characteristics of the newly designed 
fluorophore. 
9.2 Introduction 
Biological sensors and imaging agents that absorb and fluoresce within the near-infrared 
(NIR) region of the electromagnetic spectrum continue to garner sustained research interest due to 
their inherent optical clarity for in vivo and in vitro use.  The NIR region features a reduction in 
light scattering, low light absorption by biomolecules and the removal of fluorescence signal 
competition arising from biological sources.  Designing a NIR-absorbing and fluorescing 
compound must satisfy an array of diverse and crucial characteristics, including, (1) the compound 
must display absorbance and fluorescence above 630 nm which is red-shifted enough to be easily 
filtered from lower wavelength biomolecular autofluorescence, (2) a sufficient extinction 
coefficient and quantum yield in serum/water to be used in living/aqueous systems, (3) sustained 
water solubility to avoid micro-crystallization and reduction in optical performance and (4) high 
photo- and chemical stability to retain absorbance and fluorescence abilities in harsh conditions.  
Many fluorophore subclasses, including fluorescein1, 2, BODIPY3-5 and aminocoumarin6, 7 based 
fluorophores (Figure 1) satisfy some of these characteristics, and they have been explored with 
great interest.  These fluorophores display non-optimum optical properties, limited water 
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solubility, difficult synthetic protocols or tedious purification methods, which limit their 
widespread utility.  One particularly interesting class of NIR fluorescent compound centers on an 
oxocyclobutenolate ring and are called squaric acid dyes.8-10 These compounds are characterized 
by extremely high fluorescence quantum yield (20-40%) which is highly desirable for increasing 
meaningful signal; however, since their initial discovery, they have been reported by various 
researchers to be unstable due to their highly chemically and photolytically labile 
oxocyclobutenolate ring which quickly diminishes their widespread utility.11  The delocalized 
cation between the terminal heterocyclic rings helps to resolve this but adds only minor stability 
to the overall structure; however, various strategies such as dye polymerization12, rotaxane-
protection of the squaraine-core13, polymer-incorporation14 or dextran enveloping15 have been 
employed to harness the characteristically remarkable quantum yield of these compounds.  All of 
these methods have been shown to impart a subtle increase on the stability by protecting the 
electrophilic core of the chromophore, but these low-yielding (10%) and tedious manufacturing 
processes have not offered a substantial breakthrough in increasing squaraine dye stability or 
overall utility.  In addition, these fluorophores cannot be utilized for many specific labeling 
techniques that require a relatively small molecular size—such as imaging in vivo or in 
biomolecular labeling which renders squaric acid compounds useless in these highly demanding 
applications16-18.  Many efforts have been exhausted in the attempt to develop a system for 
increasing the stability of squaric acid fluorophores and herein, we report a facile scaffold for 
producing the most stable squaric acid compounds synthesized to date with unparalleled brightness 
in serum as determined by their measured extinction coefficients (), quantum yield () and optical 
brightness ().  Using our generic fluorophore platform, we are able to harness the optical prowess 
of squaric acid-based NIR fluorophores without sacrificing stability.  
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Figure 9-1. (top) General overview of covalently labeling a biomolecule with a NIR-dye 
(bottom) commonly used fluorophores with benefits, in green, and negatives, in red, 
associated with their in vivo use. 
 
9.3 Results and Discussion 
We initiated this finding by synthesizing water-soluble squaric acid fluorophores (Figure 
9-2) for image guided surgery.  To begin, we utilized Fischer indole synthesis, which proceeds 
well in acetic acid, to install various halogens on the ring for influencing physicochemical 
descriptors for in vivo studies.  Alkylating the heterocyclic nitrogen with a propyl based quaternary 
ammonium side chain is followed by the corresponding dicationic salt is allowed to react with 
squaric acid under dean-stark conditions. Having the final fluorophores in hand we initially 
confirmed that we successfully installed improved water solubility; however, we were skeptical 
that our squaric acid dyes would be able to survive intravenous injection and we investigated the 
optical profile.  To our serendipitous advantage, when observing the photo-stability, we found 
retained optical performance after continuous irradiation for 10 hours.   
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Figure 9-2. Preparation of squaric acid dyes 9-12. 
 
Similarly to the above synthesis, we prepared additional analogs containing only a single 
quaternary ammonium arm, shown in Figure 9-3. The synthetic route begins with methylation and 
subjecting the precursor 13 to a reaction with diisopropyl squarate.  Careful reaction monitoring 
and using triethyl amine affords the single heterocyclic adduct which is then reacted with an 
ethanolic sodium hydroxide solution which prepares the intermediate 15 for reaction with a second 
heterocyclic equivalent (5-8) under identical reaction conditions—this yields the final asymmetric 
dyes 16-19 in good to excellent yield.   
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Figure 9-3. Final asymmetric compound 16-19 preparation. 
 
Similar stability tests confirmed that the asymmetric compounds exhibited excellent 
stability compared to previously known squaric acid dyes and we began to realize that we could, 
in fact, use these in vivo and take full advantage of the elevated optical brightness.  Biological 
experiments often require a reactive handle for covalent attachment of a fluorophore and, at this 
point, our compounds lacked a reactive functionality; therefore, using the chemistry optimized in 
Scheme 2, we prepared the derivative 22 (Figure 9-3) bearing the reactive carboxylic acid 
functionality for further covalent modification.   Having confirmed that we could synthesize a 
biologically relevant squaric acid dye, we fully examined the optical profile in various solvents 
(ethanol, dimethylsulfoxide, phosphate buffered saline and fetal bovine serum) to confirm the 
near-infrared properties and ensure our scaffold still featured the positive properties of squaric acid 
dyes with improved stability. 
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Figure 9-4. Final carboxylate-modified zwitterionic squaric acid dye 22 preparation. 
 
All dyes dissolve immediately in aqueous systems without the need for a co-solvent and 
show near-infrared absorption and fluorescence characteristics with common Stokes’ Shift values 
(8-15 nm).  The sharpness of the absorption band in serum is highly remarkable as other 
fluorophores display signature aggregation which reduces their in vivo applicability. Common 
molar absorptivity of squaric acid dyes has been reported around 300,000-340,000 in organic 
solvents which decreases drastically in aqueous and protein-based media.  We found that our newly 
prepared fluorophores display the highest extinction coefficient values observed to date with some 
greater than 450,000 M-1cm-1 (Figure 9-5) probably due to the rigidity associated with the 
electrostatic interaction between the ammonium cation and the partially negative central oxygen 
atoms (Figures 9-5 and 9-6).  Common intermolecular salt bridge distances are less than 4A which 
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larger spatial separation being too large for ionic interactions to occur.  DFT calculations suggest 
that the quaternary ammonium arms fold back onto the central core of the electrophilic chain to 
within 4A. In Figure 9-6, we show these intermolecular distances and the electrostatic maps 
associated with both the symmetric and asymmetric fluorophores.  All distances for the 
compounds’ quaternary ammonium nitrogen and corresponding central oxygen are less than 3.7A 
with representative compounds 10 and 17 shown for example.  This adds the rigidity and stability 
by locking the conformational state of the squaric acid fluorophore.  We suspect that this 
ridgidization of the conjugated system of the compounds owes to the increase in quantum yield as 
well with some measured values approaching unity (compound 16  (FBS) = 93%).  We noted, 
however, that bromine incorporation reduced the overall quantum yield, especially in serum.  
Finally, the paramount issue associated with squaric acid dyes is their inherent labiality.  The 
stability tests to determine the stability of these fluorophores bearing an internal salt bridge 
included irradiation using a high energy light while the compound was dissolved in FBS and 
heating the compound in FBS to 37 oC to determine stability at physiological temperature in the 
presence of proteins.  The optical half-life recognized by absorbance reaching half of the original 
value for each of the compounds 9 and 16 was not reached after 72h; however, the industry 
standard, Cy5 (inherently more stable than previously known squaric acid dyes) was depleted of 
>75% of the absorption measurements after the same timeframe.  We noted an increase in stability 
of the symmetric version over the asymmetric compound however the difference was not 
substantial as even the asymmetric compound is vastly more stable compared to previously 
published squaric acid compounds. 
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Figure 9-5. (top, left) The absorption and fluorescence spectra for each compounds in 
Fetal Bovine Serum supplemented with HEPES buffer at pH = 7.4 and warmed to 
physiological temperature (37 oC). (top, right) The absorption-based stability in light and 
under heat in FBS buffer for compounds 9, 16 and industry standard Cy5 (bottom) Optical 
properties of the synthesized fluorophores in various solvents, dimethyl sulfoxide (DMSO), 
ethanol (EtOH, 200 proof), phosphate buffered saline (PBS, pH = 7.4) and fetal bovine serum 
(FBS, pH = 7.4, 37 oC) supplemented with HEPES buffer were utilized to show biological 
compatibility. 
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Figure 9-6. DFT calculations (Wavefunction, Spartan, ‘10, B3LYP 6-311++G**) 
confirm the presence of a salt-bridge between the quaternary ammonium cation and the 
delocalized negative charge across the central oxygens in both the symmetric and 
asymmetric compounds. 
 
9.4 Conclusions 
To conclude, we have synthesized and evaluated the ability of an intermolecular salt bridge 
to protect the central oxocyclobutenolate ring of squaric acid fluorophroes and increase the molar 
absorptivity and quantum yield owing to increased rigidity associated with the locked structure.  
The asymmetric compounds were shown to have unparalleled optical brightness in serum and were 
modified to include a carboxylic acid moiety was optimum for all biological labeling experiments 
which require high NIR extinction coefficients and quantum yield.  These findings offer a facile 
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solution to squaric acid stability while finally increasing the in vivo appeal of squaric acid 
fluorophores.         
9.5 Experimental 
General procedure for the synthesis of symmetric squaric acid fluorophores: A 
mixture of the corresponding indolenine salt (1.0 mol. eq.) and squaric acid (0.5 mol. eq.) and 
quinoline (5.0 mol. eq.) was refluxed in a mixture of n-butanol and benzene (40ml, 1:1) with 
azeotropic distillation using dean stark apparatus for 15 hr. Reaction mixture was monitoring by 
Vis/NIR spectrophotometry. The solvent was removed under reduced pressure. The residue was 
stirred in ethyl acetate (100 mL). The precipitated product was filtered, washed with ethyl acetate, 
acetone and dried under vacuum. The crude material was dissolved in methanol (10 mL), and 
poured into ethyl acetate (100 mL). The precipitated product was filtered and dried under vacuum. 
This precipitation procedure was repeated once more and the obtained pure product was dried 
under vacuum. 
Mono((Z)-4-((3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium-2-yl) 
methylene)-2-((E)-(3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-ylidene) methyl)-3-
oxocyclobut-1-enolate) tribromide (9) Yield 70%. MP >260oC 1H NMR (400 MHz, DMSO) δ 1.71 
(s, 6H, CH3), 2.15 (s, 2H, CH2), 3.12 (s, 9H, CH3), 3.57-3.61 (s, 2H, CH2), 4.16 (s, 2H, CH2), 5.86 
(s, 1H, CH), 7.20 (t, J = 7.2 Hz, 1H, ArH), 7.38 (t, J = 8.0 Hz, 1H, ArH), 7.46 (d, J = 8.0 Hz, 1H, 
ArH), 7.55 (d, J = 7.2 Hz, 1H, ArH)  13C NMR (100 MHz, DMSO) δ 21.0, 27.1, 49.3, 53.0, 63.2, 
86.8, 110.8, 122.7, 124.3, 128.4, 141.8, 142.4, 169.6, 180.4, 181.0. MS for C38H52N4O2
2+ 
calculated 298.2, found  298.3. 
Mono((Z)-4-((5-fluoro-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium-2-
yl)methylene)-2-((E)-(5-fluoro-3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-
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ylidene)methyl)-3-oxocyclobut-1-enolate) tribromide (10) Yield 64%. MP >260oC 1H NMR (400 
MHz, DMSO) δ 1.71 (s, 12H, CH3), 2.13 (s, 4H, CH2), 3.10 (s, 18H, CH3), 3.55 (s, 4H, CH2), 4.14 
(s, 4H, CH2), 5.83 (s, 2H, CH), 7.21-7.25 (s, 2H, Ar-H), 7.46 (brs, 2H, Ar-H), 7.53-7.54 (m, 2H, 
ArH) 13C NMR (100 MHz, DMSO) δ 20.7, 26.5, 40.8, 49.5, 53.3, 63.3, 86.4, 110.4, 110.6, 111.7, 
111.8, 115.0, 115.2, 138.1, 143.8, 143.9, 159.0, 161.4, 170.9, 175.8, 182.7 HRMS for 
C38H50F2N4O2
2+ calculated 316.1946, found 316.1965 
Mono((Z)-4-((5-chloro-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium-2-
yl)methylene)-2-((E)-(5-chloro-3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-
ylidene)methyl)-3-oxocyclobut-1-enolate) tribromide (11) Yield 75%. MP >260oC 1H NMR (400 
MHz, DMSO) δ 1.71 (s, 12H, CH3), 2.13 (s, 4H, CH2), 3.10 (s, 18H, CH3), 3.54 (s, 4H, CH2), 4.15 
(s, 4H, CH2), 5.86 (s, 2H, CH), 7.43-7.49 (s, 4H, Ar-H), 7.70 (s, 2H, Ar-H), 
13C NMR (100 MHz, 
DMSO) δ 21.0, 26.9, 49.0, 49.5, 53.1, 63.3, 87.3, 112.2, 123.1, 128.3, 128.8, 141.4, 143.9, 169.6, 
180.9, 181.2. 
Mono((Z)-4-((5-bromo-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium-2-
yl) methylene)-2-((E)-(5-bromo-3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-ylidene) 
methyl)-3-oxocyclobut-1-enolate) tribromide (12) Yield 62%. MP >260oC 1H NMR (400 MHz, 
DMSO) δ 1.70 (s, 12H, CH3), 2.12 (s, 4H, CH2), 3.09 (s, 18H, CH3), 3.54 (s, 4H, CH2), 4.14 (s, 
4H, CH2), 5.85 (s, 2H, CH), 7.43-7.55 (s, 4H, Ar-H), 7.80 (s, 2H, Ar-H), 
13C NMR (100 MHz, 
DMSO) δ 20.9, 26.9, 49.5, 53.0, 63.1, 87.3, 112.8, 116.5, 125.9, 131.2, 141.8, 144.2, 159.4, 162.3, 
169.3, 180.9 HRMS for C38H50Br2N4O2
2+ calculated 377.1135, found 378.1139. 
(Z)-2-hydroxy-3-oxo-4-((1,3,3-trimethyl-3H-indol-1-ium-2-yl)methylene)cyclobut-1-
enolate iodide (15) Mehylindolium salt (4.0 mol), 3,4-diisopropoxycyclobutane-1,2-dione 
(4.0mol) and triethylamine (1.0 ml) was heated in EtOH for 3 hr. After the reaction was completed, 
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the reaction was cooled and removes the solvent under reduced pressure. The crude product was 
purified by silicagel column chromatography (CH2Cl2/MeOH). Yield 65%; purified Compound 
(1.0 mol) was dissolved in ethanol (10 ml) and NaOH (40%, 0.5 ml) was added. The mixture was 
heated at 70oC for 30 min. After the reaction was completed, the mixture was cooled and 2N HCl 
(5 ml) was added. The product was purified by silicagel column chromatography (MeOH/DCM 
1:9). 
General procedure for the synthesis of asymmetric squaric acid fluorophores: A 
mixture of the corresponding indolenine salt (1.0 mol. eq.) and mono squaric acid modified 
compound 15 or 21 (1 mol. eq.) and quinoline (5.0 mol. eq.) was refluxed in a mixture of n-butanol 
and benzene (40 ml, 1:1) with azeotropic distillation using dean stark apparatus for 12 hr. Reaction 
mixture was monitoring by Vis/NIR spectrophotometry. The solvent was removed under reduced 
pressure. The residue was stirred in ethyl acetate (100 mL). The precipitated product was filtered, 
washed with ethyl acetate, acetone and dried under vacuum. The crude material was dissolved in 
methanol (10 mL), and poured into ethyl acetate (100 mL). The precipitated product was filtered 
and dried under vacuum. This precipitation procedure was repeated once more and the obtained 
pure product was dried under vacuum. 
Mono((Z)-2-((E)-(3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-ylidene) 
methyl)-3-oxo-4-((1,3,3-trimethyl-3H-indol-1-ium-2-yl)methylene)cyclobut-1-enolate mono 
bromide mono iodide (16) Yield 37%. MP >198-200oC 1H NMR (400 MHz, MeOD) δ 1.76-1.77 
(m, 12H, CH3), 2.34 (brs, 2H, CH2), 3.22 (s, 9H, CH3), 3.63-3.67 (m, 5H, CH3&CH2), 4.23 (brs, 
2H, CH2), 5.89 (s, 1H, CH), 5.99 (s, 1H, CH), 7.21-7.26 (m, 2H, Ar-H), 7.32-7.43 (m, 4H, Ar-H), 
7.46-7.50 (m, 2H, Ar-H), 13C NMR (100 MHz, MeOD) δ 20.6, 25.6, 26.1, 30.3, 40.0, 49.0, 49.4, 
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52.5, 52.8, 62.3, 63.3, 109.8, 110.3, 121.9, 122.0, 123.9, 124.6, 128.0, 129.2, 130.0, 135.2, 141.3, 
141.8, 142.6, 144.6, 147.5, 182.7. HRMS for C33H40N3O2
+ calculated 510.3115, found 510.8995 
Mono((Z)-2-((E)-(5-fluoro-3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-
ylidene)methyl)-3-oxo-4-((1,3,3-trimethyl-3H-indol-1-ium-2-yl)methylene)cyclobut-1-enolate) 
mono bromide monoiodide (17) Yield 43%. 1H NMR (400 MHz, MeOD) δ 1.76 (s, 12H, CH3), 
2.32 (s, 2H, CH2), 3.22 (s, 9H, CH3), 3.62-3.70 (m, 5H, CH3 & CH2), 4.20 (s, 2H, CH2), 5.85 (s, 
1H, CH), 5.99 (s, 1H, CH), 7.13 (t, J = 8.0 Hz, 1H, ArH), 7.25-7.29 (m, 2H, Ar-H), 7.32-7.36 (m, 
2H, Ar-H), 7.40-7.43 (m, 1H, Ar-H), 7.50 (t, J = 7.6 Hz, 1H, ArH), 13C NMR (100 MHz, MeOD) 
δ 20.5, 25.5, 26.1, 30.3, 40.1, 52.5, 63.5, 85.3, 86.2, 109.8, 110.1, 110.2, 110.3, 114.0, 114.3, 
121.8, 124.7, 127.9, 138.2, 141.9, 142.7, 169.0, 173.4, 173.9, 177.8, 183.0 HRMS for 
C33H39FN3O2
+ calculated 528.3021, found 528.2086  
Mono((Z)-2-((E)-(5-chloro-3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-
ylidene)methyl)-3-oxo-4-((1,3,3-trimethyl-3H-indol-1-ium-2-yl)methylene)cyclobut-1-enolate) 
mono bromide monoiodide (18) Yield 31%. 1H NMR (400 MHz, MeOD) δ 1.75 (s, 12H, CH3), 
2.30-2.31 (m, 2H, CH2), 3.23 (s, 9H, CH3), 3.63-3.65 (m, 2H, CH2), 3.71 (s, 3H, CH3), 4.17-4.21 
(m, 2H, CH2), 5.84 (s, 1H, CH), 6.01 (s, 1H, CH), 7.26-7.36 (m, 4H, ArH), 7.40-7.42 (m, 1H, Ar-
H), 7.44-7.46 (m, 1H, Ar-H), 7.49-7.51 (m, 1H, Ar-H), 13C NMR (100 MHz, MeOD) δ 20.4, 25.5, 
26.2, 30.4, 40.0, 49.7, 52.5, 63.5, 85.5, 86.6, 110.5, 121.9, 122.5, 124.9, 127.8, 128.0, 128.8, 141.0, 
142.0, 142.6, 143.1, 168.0, 173.9, 183.0 HRMS for C33H39ClN3O2
+ calculated 544.2725, found 
545.1194  
Mono((Z)-2-((E)-(5-bromo-3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-
ylidene)methyl)-3-oxo-4-((1,3,3-trimethyl-3H-indol-1-ium-2-yl)methylene)cyclobut-1-enolate) 
mono bromide monoiodide (19) Yield 36%. M.P. 204-206 oC 1H NMR (400 MHz, MeOD) δ 1.75-
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1.76 (m, 12H, CH3), 2.31 (s, 2H, CH2), 3.23 (s, 9H, CH3), 3.71-3.72 (m, 5H, CH3&CH2), 4.17 (s, 
2H, CH2), 5.84 (s, 1H, CH), 6.01 (s, 1H, CH), 7.28-7.32 (m, 2H, Ar-H), 7.35-7.37 (m, 1H, Ar-H), 
7.40-7.43 (m, 1H, Ar-H), 7.49-7.51 (m, 2H, Ar-H), 7.58-7.61 (m, 1H, Ar-H), 13C NMR (100 MHz, 
MeOD) δ 20.4, 25.5, 26.1, 30.4, 39.9, 49.6, 52.5, 63.3, 85.5, 86.6, 110.6, 111.1, 116.0, 121.9, 
124.9, 125.4, 128.0, 130.8, 141.4, 142.0, 142.5, 173.6, 178.2, 182.9 HRMS for C33H39BrN3O2
+ 
calculated 588.2220, found 589.6223  
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10 QUADRUPLEX-DNA: HISTORY, FUNCTION AND THERAPEUTIC POTENTIAL 
This chapter is an excerpt from a review article that I initiated for the gathering of ligands 
associated with binding the quadruplex with a high affinity and specificity.  My role has been 
universal since inception. 
Owens, E. A., Henary, M. G-Quadruplex DNA: History, Function and Potent Target for New 
Chemotherapeutics 2015 In Preparation. 
10.1 Abstract 
Nucleic acids have always been an attractive target for developing novel drugs targeting 
the information machinery to arrest translation into biologically active proteins; however, 
specificity and efficacy have limited the success of this field.  Recently, however, the discovery of 
G-quadruplex and development of small molecules that stabilize this structure has opened a novel 
avenue to target cancer cells as they are often located in oncogene promoter regions. The classes 
of compounds used to target this structure are diverse, but after a screening of the literature, 
elongated planar compounds with a high degree of cationic character were the most effective at 
binding the tetraplex structure.  Also, with a diverse array of folding patterns, there are many 
different binding modes that these compounds can assume depending on the particular ligand.  We 
present an analysis and a critical review of the synthetic development of compounds identified to 
be quadruplex binding agents, the degree and mode of quadruplex binding, the specificity to 
quadruplex DNA over other duplex-forming sequences and the biological efficacy concerning the 
medicinal chemistry properties of the evaluated compounds. 
Keywords: G-quadruplex, chemotherapeutics, DNA-targeted therapies. 
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10.2 Preface 
The medical community has long drawn on the foundations of scientific physical, chemical 
and biological research to provide powerful targets and therapeutics to fight against malignancies 
in human disease.  As the incidence rate of cancer is ever increasing, we continue to search for 
new routes with a high aptitute for killing tumors while sparing the formation and proliferation of 
native tissues toward increasing the quality of our patients' lives.  Decades have past searching for 
a miracle cure ubiquitous for all cancers, but this Holy Grail of modern medicine continues to 
elude researchers despite most valiant scientific efforts paired with an unthinkable amount of 
funding. The National Cancer Institute (NCI) issues approximately $5 billion per annum in the 
fight againt cancer with many insitutions focued on inhibiting proteins in distitnct cellular 
pathways, but ... could it be that targeting the proteins and molecular machinery that propel cancer 
cells isn’t the most attractive therapeutic target?  Maybe the answer lies within the realm of nucleic 
acids—killing cancer through the manipulation of the genetic code.  One recently recognized 
therapeutic target is the G-quadruplex folding region seen spontaneously forming in DNAs and 
RNAs with dependence on salt concentration.  Due to the emerging importance of the G-
quadruplex, researchers have synthesized and tested compounds with many performing with 
higher efficacy. The main concern centers around compound specificity to quadruplex-forming  
regions rather than binding linear and alternate folding patterns of DNA.  This review focuses on 
the discovery, hypothesized in vivo functions, anti-cancer drug targeting, clinical translation and 
the future directions of the G-quadruplex as a potent target for new chemotherapeutics. 
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10.3 Nucleic Acids as a Functional Therapeutic Target 
Ever since Watson, Crick, Wilkins and Franklin helped de-mystify the information storage 
vehicle known as DNA, we as a scientific community have considered it, since the 1953 
publication, an overwhelmingly appealing target for designing therapeutics.1  The thought of 
controlling disease on a genetic level remains a paramount research field; however, multiple 
experimental failures from lack of sequence specificity and in vivo shortcomings have led interest 
away from the utilization of DNA as an efficacious therapeutic target2, 3; however, in recent years, 
the resurgence of nucleic acid drug targets has been prompted by the overwhelming support that 
alternate folding patterns of DNA occur spontaneously in vivo.4-9  These findings allow an alternate 
avenue for the utilization of DNA as a potent drug target. 
 
10.4 The Double Edge Sword of Nucleic Acid Drug Targets 
DNAs fold in very peculiar ways and they have all been postulated and probed for various 
therapeutic efficacy.4, 10  These folding patterns are notoriously difficult for being unrelentingly 
selective and only rarely allow ligands to bind while maintaining discrimination against all other 
DNAs.  Knocking down genetic anomalies has numerous benefits but also numerous negative 
aspects that must be overcome in the pursuit of potent nucleic acid-targeted therapeutics.  To fully 
understand and begin analyzing the various aspects of this field, we must consirder the alternate 
folding patterns of DNA and how to choose binding characteristics and selectively modify a 
potential binding agent for targeting a specific type of DNA. 
10.5 Duplex DNA 
Duplex DNA as a therapeutic drug target relies on the recognition of exact sequences 
through either electrostatic interactions, width of the minor/major groove or the twisting 
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conformation arising from the particular sequence.  The binding modes of B-form DNA targeting 
agents rely on three basic principles: minor groove binding, major groove binding and intercalation 
– these binding principles are exemplified in Figure 10-1.  Minor groove binding molecules exhibit 
a curved structure with H-bonding capable sites directed toward the nucleotides with terminal 
cations helping with interactions with the phosphate backbone.  The exact 3-dimensional structure 
of the small molecule must be well suited with planarity and a curved geometry that matches the 
curve of the minor groove of DNA.  This approach is in stark contrast to major groove binding 
agents that tend to dimerize as most small molecules do not have the necessary size to fully fill the 
spatial opening posed by the major groove.  Similar to minor groove binding, intercalating agents 
must be highly planar and bind with an extremely high affinity; thermodynamically speaking, the 
intercalated compound must be more energetically favorable than the formation of B-form DNA 
itself.  
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Figure 10-1 Duplex DNA and binding ligands. Diamidine structures effectively target 
the minor groove while the major groove is effectively bound through dimerization and the 
tetra-cationic cyanine dye can effectively intercalate between the base pairs of dsDNA. 
10.6 i-Motif DNA 
The intercalated motif (i-motif) is a helical hemi-protonated strucutre marked by cytosine-
rich segments that were first reported in 1993 by Gehring et al.  Fortunately, this DNA morphology 
has been extensive employed in nanotechnology, especially employing the sensitivity to pH for 
intracellular monitoring of pH changes.  Despite advances in exploiting this folding pattern, there 
are limited explanations that explain in vivo functions or biological significance of the i-motif, 
nonetheless, binding ligands have been explored to probe exact biological functions though at this 
point, little is known about the potential to employ this route as a target for designing biologically 
relevant therapeutics.       
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10.7 Triplex DNA 
Triple-stranded DNA characterized by three oligionucleotides with one strand binding 
uniquely antiparallel to a common dsDNA structure.  Since the discovery of DNA, it had been 
postulated that triplex DNA could form but several predictions discounted this theory in early 
years.  Throughout the years, it has been increasingly recognized to exist in nature; however, there 
is no concrete evidence that triplex DNA exists selectively in either diseased or native tissues 
which limits the therapeutic relevance of this toward the treatment of disease. Several exciting 
studies do show potential of triplex DNA as a therapeutic but not a therapeutic target which is a 
highly similar situation with holliday junction DNA. 
10.8 Quadruplex DNA 
The scientific community has recently tapped the emerging area of G-quadruplex targeted 
therapeutics.11-17  The quadruplex is defined as a three dimensional folding pattern marked by four 
guanine nucleotides interacting through hydrogen bonds on both the Watson and Crick face and 
Hoogstein face.18  These four guanine nucleotides form a planar surface that then stack on top of 
each other around a central stabilizing cation (either sodium or potassium) as shown in cartoon 
view in Figure 10-2 and 3D view (with cation removed for clarity) in Figure 10-3.   
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Figure 10-2. Cartoon quadruplex structure. The molecular structure of the 
quadruplex stabilized through hydrogen bonding interactions represented by a red-square 
with coordinated metal ion represented as a blue sphere.  These planar tetrads will 
spontaneously stack in vivo much like the cartoon image on the right.  
 
 
Figure 10-3. 3D structure of the quadruplex.  The top view and side view with the 
central quadruplex highlighted in red.  The blue represents the loops of the quadruplex.   
 
This folded G-rich structure has been found greatly interesting and has propelled in recent years 
to one of the most heavily researched areas of nucleic acid-targeted therapeutics for many reasons 
which will be more thoroughly explained in the subsequent sections.  
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10.9 Introduction to the G-Quadruplex Structure and Function 
The quadruplex has very diverse structural arrangements that are directly related to the 
sequence of the linear nucleic acid sequence; the tetraplex can arrange in either parallel or 
antiparallel configuration or either interstranded or intrastranded. Bioinformatics has helped 
deduce which linear sequences display high propensity for the formation of quadruplex stucture.  
The exact biological function of the quadruplex remains highly mysterious and ever elusive.  As 
we start to piece together the complex puzzle, we unravel more questions.   
10.9.1 Rationale for the Quadruplex as a Potent Anti-Cancer Target 
Chemotherapeutic design hinges on the ability to reduce off-target interactions that results 
in debilitating side-effects in the clinic.  Fortunately, the quadruplex represents a potential target 
that offers the required specificity should we be able to capitalize on this strategic route through 
structural manipulation based on well-established medicinal chemistry.   
10.9.2 Early Interest—Wrapped Up in Telomeric DNA 
Initial interest in quadruplex DNA was heavily interested in the human telomere which 
protects chromosomal degradation that could occur through nuclear replication.  The biochemical 
replication pathway results in non-coding nucleic acid segments being cleaved in lieu of the 
biologically necessary segments, these overhanging structures are called telomeres.  Telomeres in 
mammalian cells are usually marked by repeating guanine-rich segments (5’-TTAGGG-3’) units 
that can extend 5-15 kb.  As these well-placed non-coding segments are systematically removed, 
the chromosomal degradation barrier becomes critically short and the cell undergoes apoptotic 
senescence to protect the cells vital information.  A reverse transcriptase ribonucleoprotein 
complex, telomerase, helps to restore the telomere by binding to the linear G-rich telomeric 
sequence and catalyzing the elongation of the telomere by tandem TTAGGG repeats (Figure 10-
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4).  Unfortunately, this enzyme is over expressed in approximately 85% of cancer cells which 
bestows upon them limitless replication processes and the ability to evade normal apoptotic 
protocol; consequently, discovering a route toward inhibiting this enzyme was hypothesized to be 
a potent anti-cancer target.  The most effective strategy came-to-light when the G-rich telomeric 
strand was discovered to spontaneously form folded a quadruplex structure in vivo.  In line with 
this discovery, many laboratories began synthesizing binding agents to the telomeric quadruplex 
that could effectively stabilize the tertiary structure and prevent the enzyme from recognizing the 
linear binding domain.   
 
Figure 10-4.  Telomerase binding to and elongating the terminal TTAGGG segment 
of the telomere and the G-quadruplex DNA blocking telomerase binding.  
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10.9.3 Second Generation Quadruplex Interest—Oncogene Promoter Regions 
First generation telomere-quadruplex binding enticed the drug design community but 
shortly thereafter biological geneticists uncovered that many sequences of DNA throughout the 
genome have high propensity to form quadruplex structures. The quadruplex has been observed to 
form in the genetic code associated with several cancer-related proteins that are highlighted within 
the "hallmarks of cancer." Figure 10-5 shown the formation of quadruplex structure in promoter 
region and when the quadruplex is present, the transcriptional gene expression in effective silenced 
leading to reduced synthesis of the respective protein.  Should a binding ligand interact with a 
quadruplex that forms in a oncogene promoter region, a strong and medicinally tolerable  binding 
ligand would directly correlate to chemotherapeutic proterties by reducing the cellular machinery 
needed for the proliferation of cancer cells. 
 
Figure 10-5. The promoter region leads the expression of particular proteins, 
however, the quadruplex orientation prevents effective translation and can be an effective 
route toward the silencing of oncopromoting genes. 
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10.9.4 How to Bind the Quadruplex with Specificity?  
The quadruplex has three common binding modes that can be exploited in targeting this 
structure; however, this realization is problematic in that duplex DNA, which controls the 
information machinery for all of our natural and much needed proteins, has similar structural 
constraints for binding.  Fortunately, we have found several avenues that may be exploited to 
generate high affinity quadruplex binding compounds with minimal duplex interactions.  
Incorporating several design parameters into the molecular structure alleviates the dsDNA binding 
in favor or strong quadruplex interactions. Since we have covered dsDNA binding in Figure 1, we 
now need to look at the quadruplex-binding ligand interactions that show us through nuclear 
magnetic resonance and x-ray crystallography the mode of interaction shown in Figure 6.  The 
three main interactions that we have observed are intercalation, loop binding and end-stacking.  
Intercalating compounds for the quadruplex display very similar characteristics when comparing 
them to dsDNA intercalators—entirely planar and monocationic.  The second mode of binding is 
through loop interactions.  We see the BRACO-derivitive synthesized by the Neidle lab seemingly 
hugging the blue-colored loop of the quadruplex.  Since dsDNA does not contain loops within the 
helical structure, this avenue could possible be a route for obtaining selectivity.  Lastly, we have 
observed telomestatin among other macrocyclic and non-cyclic ligands that bind quite favorable 
through aromatic  stacking with the top tetrad.  In this case, a telomestatin-based analog sits 
quite well on the top tetrad with two cationic primary amine functionalites interacting quite 
strongly with the phosphate backbone of the quadruplex.  The size of the telomestatin-analog and 
cyclic nature greatly limit dsDNA interactions which is another design strategy for exploiting 
molecular structure for obtaining medically relevant selectivty to the quadruplex over dsDNA.    
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Figure 10-6. G-Quadruplex Binding Modes.  Monocationic difluorinated compound 
effectively intercalates while the BRACO-analog interacts through loop binding and the 
macrocyclic telomestatin analog’s nature and size stacks effectively on the top of the 
tetraplex.   
 
10.9.5 Binding Agents and Efficacy  
Since we have observed some of the binding ligands in the previous sections to demonstrate the 
different binding modes to the plethora of folding patterns of DNA, we will now delve into the 
different routes taken to optimize the biophysical interactions and the medicinal properties for 
clinically utilized therapeutics.  One class of compounds has been heavility researched and are 
based off the the tricyclic anthracene core.     
270 
 
10.9.5.1 Acridine 
Acridine compounds are marked by having a tricyclic nitrogen containing core that is high 
modifiable and the Neidle lab, among others, has pioneered the functionalization and thorough 
evaluation of the acridine core for targeting the quadruplex and inducing a medically relevant 
biological response.  The  compounds they have developed are highlighted in brief in the synthetic 
scheme.19 
 
Figure 10-7. A synthetic pathway toward trisubstituted aridine agents for the 
stabilization of G-quadruplex DNA and generic structure bearing three positions for 
subsitution on the acridine core. 
 
A vast number of strucutral studies, NMR and crystallography, allowed them to fine tune the 
chemical structure to include a central 4-dimethylaminophenyl substituient at the R2 position of 
the general structure. 20-32 These structural manipulations afforded the compound-DNA complex 
shown in Figure 10-8 that depicts strong end-stacking, loop binding and the well placed 
dimethylamine moiety finding an open pocket formed by the loop of the quadruplex top.  These 
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interactions together form a highly potent quadruplex interacting ligand that has and continute to 
serve an a design scaffold for further design considerations.  
 
Figure 10-8. Acridine based compound BRACO-19 complexed to G-quadruplex.  
 
10.9.5.2 Naphthalene Diimide Compounds 
Napthalene is defined as two fused benzene rings that share two aromatic carbon atoms as a part 
of the 10-carbon structure. These characteristics afford a high planar ring system that serves as a 
promising starting scaffold for develoment in quadruplex binding compounds. The 1,4,5,8-
naphthalenetetracarboxylic dianhydride strucutre seen in Figure 9 serves as the starting material 
for diverse modifications.  Bromination and amine modifications afford the general structure with 
various R groups.  Figure 10 depicts a successful binding ligand that targets the quadruplex.  The 
napthalene diimide structure features morpholine groups on the imide nitrogen atoms and 
methylpiprizine substituitens on the napthalene rings.  All of these substitutions maintain a mostly 
planar core thus embodying the design features that are requisite for quadruplex targeting 
compounds.  
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Figure 10-9. Synthetic scheme to the final naphthalene diimide compounds for 
quadruplex binding. 
 
 
Figure 10-10. Naphthalene diimide ligand and crystal structure rendering with 
quadruplex dimer (PDB 3UYH).  
 
The napthalene core features the highly planar pi-pi stacking abilities that are necessary for potent 
quadruplex interacting ligands.  Additionally, the tertiary amines serve as excellent phosphate 
interacting ligands at physiological pH.  The diimides within the core structure are properly located 
to position the morpholine and piprizine moieties at effective positions to bind well to the 
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quadruplex.  Melting termperatures for this model compound are higher than most other 
napthalene diimide compounds studied with nanomolar IC50 inhibition of cancer cell lines. 
10.9.5.3 Carbazole-centered Compounds 
Carbazole, the planar tricyclic heteratomic compound has the potential for diverse modification, 
especially para to the nitrogen atom.  
 
Figure 10-11. Core carbazole structure with positions of variation that have led to 
increased binding efficacy to quaduplex DNA. 
 
A few groups have exploited the planarity and amenability of this heterocycle for tailoring 
quadruplex interacting ligands.  Specifically among them, a dicationic carbazole compound termed 
3,6-bis(1-methyl-4-vinylpyridium)carbazole diiodide (BMVC) was the first to be reported and 
showed excellent fluorescment enhancement upon titration with G4-forming DNA sequences 
(Hum24).39  The facile synthesis of this compounds exploits the robust palladium(II)acetate 
catalyzed heck coupling between 3,6-dibromocarbazole and 4-vinylpyridine followed by usual 
methylation procedures to afford the dicationic BMVC.40  Researchers have been building on this 
work considerably and have designed alternate compounds including BPBC that contains an 
increased number of hydrogen bond donors and accepors and an extended aromatic surface for pi-
pi interactions with the tetrad’s surface.  The medicinal potential is higher as the BPBC compound 
contains ionizable side arms that may form cations in an environment of the proper pH compared 
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to the static and unchanging cations present in BMVC which may hamper the in vivo success due 
to decreased cellular permeability and incerased off-target effects. 
10.9.5.4 Cyanines 
Derived from the work in Greek ‘cyanos’ meaning blue, these are defined as two nitrogen containg 
heterocyclic rings that are connected through an electron deficient polymethine (methine is 
equivalent to -CH=) bridge with a delocalized monocation.  These cyanine compounds are mostly 
known for their red-shifted absorption and fluorescence wavelengths that are a direct function of 
the polymethine bridge and the heterocyclic units with modifications to both moieties allowing for 
structural diversity.  Through structural modifications, cyanines have been modified to serve as 
effective nucleic acid stains for several decades with sequence specificty being attained for the 
minor groove of DNA.  Similarly, several groups have pioneered the avenue of examining this 
exciting class of compounds toward developing novel G4 binding compounds for either probing 
G4 DNA or for developing therapeutics.   
 
Figure 10-12. General structure for carbocyanine compounds with points of 
modification shown by generic groups. 
 
The Henary and Wilson lab have pioneered the development of dimethylindolenine-based cyanines that 
show paramount selectivity toward quadruplex forming sequences versus dsDNA arising from two 
structural modifications – the trimethyl ammonium substituents and the dimethyl groups on the indolenine 
rings. 
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Figure 10-13. The parent structures with non-substituted heterocyclic moieties and 
quaternary substitueints at the N-indolenyl site with representative SPR plots for cMYC in 
blue and human telomere in red. 
 
10.9.6 Limitations of the Quadruplex as a Therapeutic Target   
Despite the recent progresses in the field of quadruplex-targeted compounds, we still have to 
consider the harsh reality.  The first limitation is that the nucleus of the cell maintains the genetic 
code and to reach it, compounds must display a particular size and set of molecular 
physicochemical properties that facilitate its permeation of the nuclear envelope.  Secondly, more 
broadly, the pharmacokinetics and dynamics of the compounds tested to date not been effective at 
offering hope with Quarfloxin potentially offering too many dangerous side effects to be taken 
into the clinic with low top line efficacy.  Lastly and potentially a more minor limitation is the 
ability to synthesize, from the standpoint of an organic chemist standpoint, some of the active 
compounds that require demainingly harsh conditions for their preparation (i.e. porphryns).  The 
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low yields combined with the difficulty in purification limit their overall utility in clinically-
translatable medications.   
10.10 Future Directions for this Field 
Currently, the field of G4-targeted therapeutics has great momentum in various avenues; 
specifically, the determination of various binding modes and more importantly, the molecular 
characteristics, conformations and configurations that allow quadruplex binding and specific 
binding to occur are continuously being unraveled.  Despite always suspecting that RNA would 
form quadruplexes, we now have evidence that they are highly likely to stack in G-tetrads.45-49  
This has great implications in the field of quadruplex-targeted therapeutcs as the nucelus no longer 
must be targeted and some ligands should be tested against these newly discovered RNA-G4 
sequences. 
10.11 Summary and Conclusion  
In conclusion, we have demonstrated that the quadruplex is likely, based on bioinformatics, to be 
heavily involved in oncogene promoter regions and play a pivotal role in the initiation and 
proliferation of carcinogenic tissue.  In line with this finding, quadruplex structures are potent 
targets for the design of new chemotherapeutic agents and several lead compounds have been 
identified as binding the quadruplex with high specificity and affinity.  The medicinal properties 
of these compounds and in vivo efficacy leave much to be desired and further research efforts are 
required to modify and optimize the hit compounds.  
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11 TRIMETHINE CYANINES AS G-QUADRUPLEX STABILIZING COMPOUNDS 
This chapter was adapted from the following publication.  My contributions to the 
manuscript consisted of the synthesis of binding ligands, data analysis, figure and manuscript 
preparation and recurring discussions concerning the project. Drs. Wilson and Germann labs 
wholly contributed to the biophysical and NMR studies. Nanjunda, R., Owens, E. A., Mickelson, 
L., Dost, T. L., Stroeva, E. M., Huynh, H. T., Germann, M. W., Henary, M. M., Wilson W. D., 
Selective G-Quadruplex DNA Recognition by a New Class of Designed Cyanines 2013 Molecules 
18,11, 13588-13607. Invited Article 
11.1 Abstract 
A variety of cyanines provide versatile and sensitive agents as DNA stains and sensors and 
have been structurally modified to bind in the DNA minor groove in a sequence dependent manner.  
Similarly, we are developing a new set of cyanines that have been designed with the goal of 
achieving highly selective binding to DNA G-quadruplexes with much weaker binding to DNA 
duplexes. A systematic set of structurally analogous trimethine cyanines has been synthesized and 
evaluated for quadruplex targeting. The results reveal that elevated quadruplex binding and 
specificity are highly sensitive to the polymethine chain length, heterocyclic structure and intrinsic 
charge of the compound. Biophysical experiments show that the compounds display significant 
selectivity for quadruplex binding with a higher preference for parallel stranded quadruplexes, 
such as cMYC. NMR studies revealed the primary binding through an end-stacking mode and SPR 
studies showed the strongest compounds have primary KD values below 100 nM that are nearly 
100 times higher for duplexes. The high selectivity of these newly designed trimethine cyanines 
for quadruplexes as well their ability to discriminate between different quadruplexes are extremely 
promising features to develop them as novel probes for targeting quadruplexes structures in vivo. 
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11.2 Introduction 
G-quadruplexes are higher order DNA structures formed by either intra or intermolecular 
association of guanine-rich sequences into a stacked array of G-tetrads and stabilized by Hoogsteen 
hydrogen bonds as well as coordinated monovalent cations 1, 2. The formation and stabilization of 
these unique structural motifs are implicated in diverse biological functions such as gene regulation 
and chromosomal stability 3, 4; therefore, these structures have garnered immense interest as a 
viable platform for the development of quadruplex-specific small-molecule drugs for therapeutic 
purposes 5, 6. Furthermore, with the recent exciting evidence showing the formation of G-
quadruplexes during various stages of mammalian cell cycle in vivo as well as convincing evidence 
that small molecules can indeed induce and stabilize quadruplexes in vivo, these unique structures 
are undoubtedly a novel and promising target for the design and development of anticancer 
therapeutic agents using small molecules 7, 8. In fact, a wide range of quadruplex-specific small 
molecules have been reported so far with some compounds showing very promising biological 
activities 9-11.  
Cyanines are a class of small molecules that are being developed as potential G-quadruplex 
targeting agents in addition to their wide-range of applications as cancer imaging agents and 
nucleic acid stains 12, 13. The synthetic ability to structurally tailor cyanines as well as their many 
therapeutically favorable features, such as low toxicity, renders them ideal candidates also for their 
potential development as quadruplex targeting agents. Previously we had reported a new class of 
indolenine scaffold based cyanine molecules with highly favorable quadruplex interactions 14. The 
pentamethine linker between the two indolenine rings provided the needed flexibility for efficient 
stacking at the terminal tetrads of the quadruplex, whereas the dimethyl groups on the indolenine 
rings considerably reduced the intercalation or stacking of the cyanines in the duplex minor groove. 
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The halogen substitutions at different positions on the aromatic core further increased their 
quadruplex affinity. The highly promising results of the pentamethine cyanines as quadruplex 
specific agents encouraged us to further explore the conformational space of cyanine molecules 
for increased quadruplex affinity and selectivity. In the current study, a series of cyanine molecules 
(Figure 1) with reduced methine linker length were synthesized to probe the effects on quadruplex 
binding while maintaining the dimethyl and halogen substitutions. Using a series of powerful 
biophysical techniques, we show that these newly designed trimethine cyanines exhibit more 
favorable quadruplex binding while maintaining a very low duplex affinity. The results are highly 
promising and encouraging towards the development of cyanine-based small molecules as highly 
specific quadruplex targeting agents.  
11.3 Results and Discussion 
The synthesis of trimethine quadruplex binding agents based off of the symmetric cyanine 
model consists of heterocyclic derivation installed through the formation of the dimethyl 
indolenine rings by Fisher indole synthesis from the starting 4-substituted hydrazine compounds.  
After the heterocyclic rings are prepared, facile SN2 quaternization of the heterocyclic enamine 
results in the cationic salts bearing the groups shown in Figure 10-1.  The carbon attached to the 
2-position of the ring contains acidic protons due to the positively charged electron sink of the salt.  
The deprotonation at this position initiates the reaction with triethylorthoformate which produces 
ethoxide thus promoting further reaction.  Two salts condense with a triethyl orthoformate 
molecule which results in the final products 24-32. 
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Figure 11-1. Synthetic scheme and chemical structure of the trimethine cyanine analogs used 
in the current study. The modifications performed on the parent cyanine (26) are highlighted 
in different colors (compounds 24-32). All compounds have one positive charge delocalized 
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on the cyanine system with variance in charge on the heterocyclic rings and the nitrogen 
chain. 
 
11.3.1 UV-Vis Thermal Melting 
UV-Thermal melting is a rapid and robust screening technique to determine selectivity as 
well as to rank the ligand-induced relative stability of quadruplex-ligand complexes 15, 16. 
Preliminary Tm analysis of a synthetic set of symmetric trimethine cyanines containing different 
substituents on the indolenine rings (Figure 1) were conducted with a well-characterized telomeric 
quadruplex sequence (Tel22) and a control hairpin duplex sequence (AATT) that is quite favorable 
for detection of either minor groove or intercalative binding to duplexes. The increase in the 
thermal stability of the complexes upon ligand binding (∆Tm) at different ligand-DNA ratios is 
listed in Table 1. A range of ligand-DNA mole ratios were employed to ensure saturation of 
binding sites on the quadruplex as well as duplex motifs. Drug-DNA ratios beyond 6:1 resulted in 
inconsistent melting curves in some cases due to possible aggregation of cyanines. The trimethine-
linked parent cyanine, compound 26, exhibited a favorable increase in the thermal stability of the 
Tel22 sequence with increasing ratios. This increase in thermal stability of 26 with Tel22 is slightly 
improved compared to the ∆Tm of a similar cyanine with a pentamethine linker reported 
previously (Table 1: compare ∆Tms of 26 and a) 14. Replacing the propyl-(trimethyl ammonium) 
groups on both indolenine rings of 26 with hydrophobic propyl-phenyl groups, 25, slightly reduced 
the thermal stability of the Tel22 complex. A similar replacement with an n-butyl group, 24, 
dramatically reduced the thermal stability of the complex compared to 26. This suggests the 
importance of charge on the substituents to maintain favorable electrostatic interactions with the 
backbone of the anionic quadruplex motif. While retaining the propyl-(trimethyl ammonium) 
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groups, various substitutions were made on the indolenine rings to probe their effect on quadruplex 
binding. Substitutions with  either a sulfonato (–SO3H, 27) or carboxylic acid (–COOH, 28), which 
have negative charges under the experimental conditions, resulted in a minimal increase in the 
thermal stability of Tel22, probably due to unfavorable electrostatic interactions with the 
negatively charged backbone. In accordance with the design principles established in the previous 
studies to enhance quadruplex interactions by halogenation of cyanines, systematic halogen 
substitutions on the indolenine rings in the current trimethine series showed a highly favorable 
increase in the thermal stability of the telomeric quadruplex (compounds 29-32). Furthermore, the 
trimethine chloro (30) and bromo (31) analogs showed a more favorable increase in the thermal 
stability of Tel22 compared to the similar halogen-substituted pentamethine analogs (Table 1, 
compounds b and c). The trimethine-linker scaffold might be a better optimized system than the 
pentamethine-linker cyanines for more favorable interactions with a quadruplex unit. All the 
trimethine halogen derivatives, however, exhibited very similar increases in the thermal stability 
of the quadruplex motif suggesting a minimal effect of the size of the halogens.  
One of the important features observed with these cyanine molecules is their very low 
binding to duplex-DNA sequences (Table 1, ∆Tm of an AATT sequence that is favorable for minor 
groove or intercalation binding mode). The trimethine cyanines exhibited a very small-to-zero 
increase in the thermal stability with duplex-DNA even at relatively high ligand-DNA ratios. The 
dimethyl substituents on the terminal indolenine rings, as predicted, provide the necessary steric 
hindrance and reduce any possible interaction with duplex-DNA. In line with the previous studies 
on pentamethine cyanines, these newly designed trimethine cyanines show an important step in 
further expanding the cyanine scaffolds as a novel quadruplex-targeting class of small molecules 
with reduced duplex-DNA selectivity.  
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Table 10-1. Thermal melting studies of trimethine cyanine analogs with telomeric 
quadruplex (Tel22) and a control duplex (AATT) 
The thermal melting values reported are an average of two independent trials and are reproducible 
within ±0.5 °C. ND = Not Determined. 
 
11.3.2 Biosensor-Surface Plasmon Resonance studies (SPR) 
Biosensor-SPR is an effective technique to determine the equilibrium binding affinity and 
kinetics, as well as the stoichiometry and cooperativity of biomolecular interactions in real-time 
17, 18. To determine the relative binding strength of the trimethine cyanine analogs, SPR 
experiments were performed with biotinylated quadruplex and duplex sequences. In addition to 
the Tel22 quadruplex, a well-characterized oncogenic promoter quadruplex sequence from c-myc, 
cMYC19, was also employed to determine if the compounds can exhibit any selectivity for 
different quadruplex architectures. Figure 2 shows representative SPR sensorgrams and the 
corresponding steady-state affinity plots for the parent cyanine (26) and the brominated analog 
(31) with both quadruplex-forming sequences. The sensorgrams show very fast association and 
dissociation of the compounds and were characteristic of all the analogs, except for compound 24 
Compound/ 
Drug:DNA 
Ratio 
Tel22 AATT duplex 
1:1 2:1 4:1 6:1 1:1 2:1 4:1 6:1 
24 1 1 1 0 ND 
25 1 2 4 11 0 2 2 2 
26 2 4 9 14 0 1 1 2 
27 2 1 1 1 ND 
28 1 1 3 7 1 1 2 3 
29 3 8 12 16 0 1 1 2 
30 3 7 15 19 0 0 1 1 
31 1 5 14 24 0 0 0 0 
32 3 7 17 21 1 1 3 3 
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which did not exhibit any binding with either quadruplex sequences. The equilibrium binding 
affinities for all the analogs were determined using a two-site binding model and are listed in Table 
2. All the compounds exhibit reasonable binding to both quadruplex sequences with a primary 
strong binding (K1) followed by a weaker binding (K2) with an affinity, ca. 10X lower. The 
halogenated analogs (29-32) showed impressive 5-15 times stronger binding affinities with the 
telomeric quadruplex compared to the parent compound (26, K1 = 3.9 x 10
5 M-1) and are in 
agreement with the Tm studies. With the parallel cMYC19 quadruplex, compound 26 showed a 
more favorable 10 times increase in binding affinity compared to the telomeric quadruplex, 
however, the brominated analogs exhibited only a 2-5 fold increase in the binding affinity. The 
anionic substitution analogs (27 and 28) showed a 2-fold increase in the binding affinity with Tel22 
compared to the parent cyanine (26), a trend that was not observed in Tm studies. In general, all 
the strong binding ligands showed a higher preference for the parallel c-myc quadruplex over the 
hybrid telomeric quadruplex. The binding affinities with the duplex sequence were either too low 
(KA < 10
5 M-1) or could not be reasonably determined due to very low steady-state response values 
for the same concentration range (data not shown). SPR results, thus, conclusively show the 
selectivity of the trimethine analogs for quadruplex structures with different folding topologies as 
well as the selectivity over duplex sequences and in agreement with thermal melting studies. The 
two-site fitting model predicted two predominantly bound ligands per quadruplex unit probably 
stacked at the terminal tetrads (discussed below in NMR section), a common mode and 
stoichiometry of binding exhibited by a majority of quadruplex targeting ligands 9, 19-24.  
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Figure 11-2. SPR sensorgrams and the steady-state binding plots for the parent cyanine (26, 
panel a) and the brominated analog (31, panel b) with Tel22 and cMYC19 quadruplex 
sequences. The injected concentration range for 26 is 10 nM - 10 µM and for 31 is 10 nM - 1 
µM. The binding plots were obtained by fitting the steady-state response values (RU) as a 
function of free ligand concentration (Cfree) and fit to a two-site binding model. The 
estimated equilibrium binding affinities (K1 and K2) are reported in Table 10-2. 
 
2.4. Nuclear Magnetic Resonance studies (NMR) 
NMR studies were carried out to locate the binding site(s) on the quadruplex structure and 
the imino proton spectra of a modified c-myc variant, MYC22, with the parent and brominated 
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analogs are shown in Figure 4. The imino protons of MYC22 were previously assigned 25 and 
serve as a convenient monitor to determine the mode of interaction and stoichiometry. Based on 
the imino proton shifts on titration, the primary binding site for compound 26 is the 3’-end tetrad 
of MYC22 (G9, G13, G18, and G22; Figure 4A and 5B).  A secondary binding site at the 5’-end 
tetrad (G7, G11, G16, and G20) is evident after the top face approaches saturation.  Remarkably, 
no precipitation was observed even at a 10-fold excess of either compound.  With the exception of 
G8 imino proton, the middle tetrad is less affected by the binding on either terminal tetrad.  
However, it is noted that the shift of G8 imino proton parallels that of G16 imino proton which 
monitors binding to the 5’-end tetrad. This suggests that the binding to the 5’-end tetrad causes the 
chemical shift change of G8 imino proton.  A similar binding sequence (first 3’-end and then 5’-
end) is also observed for compound 31 (Figure 4B and 5C). Interestingly, the presence of the 
bulkier bromine substituent results in a much smaller effect on the central tetrad, as shown for G8 
imino proton. This is in marked contrast to the result obtained for compound 26 and indicates that 
there are differences in the binding orientation of 26 and 31 (on the 5’-end tetrad). The NMR 
results, which demonstrate binding to the terminal tetrads of MYC22, are consistent with the CD 
results for 26 and 31 which indicate end-stacking interactions as well as small structural 
perturbations in the quadruplex upon complex formation. 
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Figure 11-3. Imino proton spectra of MYC22 quadruplex titrated with the parent 
cyanine 26 (a) and the brominated analogue 31 (b).  Ligands were added to the quadruplex 
at the ratio indicated on the plot. Selected imino protons of 3’-end (9, red) middle (8, blue) 
and 5’-end (16, green) tetrads are marked.  
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Figure 11-4. (a) Schematic structure of the c-myc quadruplex MYC22 (Ambrus et al, 
2005, [26]). For clarity the imino protons of the guanine tetrads are color coded. Red: 3’-end 
tetrad, blue: center tetrad, and green: 5’-end tetrad.  Imino proton titration curves of 3’-end, 
middle and 5’-end tetrad for the parent cyanine (26, b) and the brominated analog (31, c). 
 
11.3.3 Fluorescence studies 
Development of fluorescence probes that are highly selective for quadruplex structures is 
an additional promising area given the involvement of quadruplex motifs in several important 
biochemical processes. The trimethine cyanines were tested for their fluorescence properties with 
both Tel22 and cMYC19 quadruplex structures and the fluorescence spectra of the parent cyanine 
(26) and the brominated analog (31) are shown in Figure 6. From the spectra, it can be readily seen 
that the compounds exhibit enhancement in fluorescence intensities with both quadruplex 
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structures with increasing concentrations of DNA. However, it is strikingly apparent that the 
compounds exhibit very different fluorescence enhancements with both sequences. The 
enhancement in fluorescence intensity is significantly higher with the c-myc quadruplex compared 
to telomeric quadruplex. The preferential signal enhancement with c-myc quadruplex was 
observed with all the trimethine cyanine analogs. It is very clear that the ligands have a much 
stronger preference for the parallel over hybrid quadruplex.  
 
Figure 11-5 Fluorescence emission spectra of the parent cyanine (26, panel a) and the 
brominated analog (31, panel b) with Tel22 and cMYC19 quadruplex sequences. The arrow 
indicates increasing concentrations of DNA titrated into the ligand solution (1 µM) until no 
further change in the fluorescence emission signal was detected. 
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11.4 Discussion 
G-quadruplex structures are associated in many important biological processes such as 
gene regulation and protection against chromosome degradation 3, 26, 27. The recent and very 
exciting evidence showing the formation of G-quadruplex structures in vivo as well as the small-
molecule mediated stabilization of these unique structures in vivo has further driven the need to 
develop potent quadruplex-targeting agents 7. Various classes of small molecules have been 
developed using a G-quadruplex platform as a strategy for improved therapeutic potential as well 
as for enhancing the fundamental understanding of quadruplex-ligand interactions. Cyanines are 
one class of small molecules that have the potential as quadruplex-specific agents 28-30. Previously, 
we have described the binding specificity and affinity of various pentamethine cyanine dyes with 
the telomeric and the c-myc oncogenic quadruplex forming sequences 14. The pentamethine 
analogs exhibited a 2:1 binding stoichiometry with an end-stacking binding mode with a 
preferential binding for parallel c-myc over hybrid telomeric G-quadruplexes. The dimethyl 
substitutions on both indolenine rings considerably reduce their affinity for duplex systems. The 
2:1 complex formation was shown to be entropically-driven, as is observed for many end-stacking 
quadruplex binders. With the success in developing rationally designed pentamethine cyanine 
scaffolds for quadruplex targeting, we have extended the study with the development of a new 
series of cyanine molecules with reduced linker length between the aromatic cores of the cyanine 
scaffold. Herein, we probe the sensitivity and selectivity of binding to the polymethine chain length 
by shortening the distance between the heterocyclic nitrogen atoms by two carbon units.  
Preliminary screening studies of the new trimethine cyanines showed considerable 
improvements in the thermal stability of the Tel22 quadruplex compared to the pentamethine 
analogs. The compounds also showed significant selectivity over duplex sequences in accord with 
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the design principles established by the introduction of dimethyl scaffolds to reduce duplex 
interactions. Effectively targeting the relatively lower abundance quadruplex motifs in an 
essentially duplex-rich genome is a challenging task, and therefore, appropriate scaffolds with 
reduced duplex-DNA interactions can provide alternate platforms to develop further selective 
quadruplex-specific agents. This is especially true if any weak duplex interactions, such as non-
specific electrostatic bindings, do not generate significant biological effects. Biosensor-SPR 
studies showed compound binding to different quadruplex motifs with a 2:1 binding stoichiometry 
and a higher preference for parallel-type quadruplex folds over hybrid quadruplexes. The more 
exposed terminal tetrad surface of the c-myc quadruplex might be more conducive for favorable 
stacking interactions. NMR imino proton chemical shifts provide specific evidence for cyanine 
stacking on both ends of the cMYC quadruplex structure. In addition, the NMR results shows that 
the two ends are saturated with cyanines at different ratios in agreement with the two binding 
affinity values (K1 and K2) observed in SPR studies. The NMR spectral changes for the parent (26) 
and the brominated derivative (31) suggest different stacking geometries by the two molecules. 
This is a very interesting result that will be very helpful in compound design as more structural 
details are obtained in more detailed NMR analyses.  
One of the attractive features of cyanine molecules is their highly favorable fluorescence 
properties and their extensive application as dyes in the detection of biomolecules 31-33. 
Benzothiazole based cyanines have been generally developed as fluorescent dyes for duplex-DNA, 
however, their strong interactions with duplex-DNA have limited their development as 
quadruplex-specific fluorescence probes. Furthermore, given the different types of quadruplex 
structures formed by guanine-rich sequences from various genomic regions, it is highly desirable 
to develop fluorescent probes that are not only selective for quadruplex structures over duplex-
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DNA but also discriminate between different quadruplex topologies. Very interestingly, the 
trimethine cyanines in the current study exhibit differential fluorescence behavior with quadruplex 
sequences. The significantly favorable fluorescence emission property of trimethine cyanine dyes 
with c-myc quadruplex is highly promising for their development as potential biomarkers for 
oncogenic-quadruplex-mediated cellular processes. The propensity of different guanine-rich 
sequences throughout the genome to fold into diverse quadruplex conformations will require the 
design of improved ligands that can discriminate among quadruplex topologies and show 
preferential binding with high selectivity 34-36. 
11.5 Experimental 
11.5.1 Synthesis of Cyanines 
The chemical reagents used in the synthesis of cyanine dyes were obtained from Acros 
Organics, Alfa Aesar and Matrix Scientific. The reactions were followed using silica gel 60 F254 
thin layer chromatography plates (Merck EMD Millipore, Darmstadt, Germany) with 5% methanol 
in DCM as the mobile phase. Open column chromatography was utilized for the purification of all 
final compounds using 60-200u, 60A classic column silica gel (Dynamic Adsorbents, Norcross, 
GA). The 1H NMR and 13C NMR spectra were obtained using high quality Kontes NMR tubes 
(Kimble Chase, Vineland, NJ) rated to 500 MHz and were recorded on a Bruker Avance (400 
MHz) spectrometer using D2O containing tetramethylsilane (TMS) as an internal calibration 
standard. 19F NMR spectra were recorded using hexafluorobenzene as an internal standard.  UV-
Vis/NIR absorption spectra were recorded on a Varian Cary 50 spectrophotometer. High-
resolution accurate mass spectra (HRMS) were obtained either at the Georgia State University 
Mass Spectrometry Facility using a Waters Q-TOF micro (ESI-Q-TOF) mass spectrometer or 
utilizing a Waters Micromass LCT TOF ES+ Premier Mass Spectrometer.  Liquid chromatography 
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utilized a Waters 2487 single wavelength absorption detector with wavelengths set between 640 
and 700 nm depending on the dye’s photophysical properties.  The column used in LC was a 
Waters Delta-Pak 5 uM 100A 3.9 x 150 mm reversed phase C18 column. Evaporative light 
scattering detection analyzes trace impurities that cannot be observed by alternate methods; a 
SEDEX 75 ELSD was utilized in tandem with liquid chromatography to confirm purity.  
The preparation of the heterocyclic precursors 8-14 has been described by our laboratory 
and the compounds were used in the synthesis of the charged salts 15-23.  
General Synthesis for the alkylated indolenine salts 15-23: 
Individual 2,3,3-indolenine heterocyclic precursor 8-14 was dissolved in anhydrous 
acetonitrile (50 mL) and was heated to 40 oC followed by the addition of the appropriate alkylating 
agent in 3 molar excess and was then heated to reflux for 72h.  The reaction progress was followed 
by TLC eluting with DCM/methanol/acetic acid (40/58/2). The reaction mixture was allowed to 
cool and the solvent was partially removed in vacuo.  The final compounds were obtained by 
precipitation from methanol by diluting with acetone, ethyl acetate and diethyl ether.  The 
hygroscopic compounds were allowed to dry for several hours on high vacuum.   
 
General Synthesis for the trimethine cyanine binding agents 24-32:  
Individual alkylated indolenine salts 15-23 were dissolved in acetic anhydride (50 mL) 
followed by the addition of triethylorthoformate in a 2:1 molar ratio. The reaction was heated at 
110 oC for 30 minutes and followed using UV-Vis spectroscopy diluted in methanol. The mixture 
was allowed to cool and was crystallized using hexanes/ethyl acetate/diethyl ether. A colored 
precipitate was filtered, washed and collected. Compounds 24-32 were dried for several hours 
under high vacuum.  
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Compounds 24 and 25 have been previously reported by our lab and were used directly in 
the quadruplex binding interaction studies without any additional modifications.  
The product 26 was obtained in 89% yield. MP 105-107 °C; 1HNMR (400 MHz, D2O), δ: 
1.62 (s, 12H), 2.27 (t, J = 7.6 Hz, 4H), 3.08 (s, 18H), 3.49-3.57 (m, 4H), 4.13 (t, J = 7.2 Hz, 4H), 
6.52 (d, J = 13.2 Hz, 2H), 7.18-7.28 (m, 4H), 7.36 (d, J = 7.6 Hz, 2H), 7.47 (d, J = 7.2 Hz, 2H), 
8.47 (t, J = 13.2 Hz, 1H). 13CNMR (100 MHz, D2O), δ: 21.0, 27.3, 40.5, 49.2, 53.1, 63.2, 102.7, 
110.9, 122.5, 125.7, 128.8, 140.8, 141.3, 151.8, 175.1. 
The product 27 was obtained in 92% yield. MP 295-297 °C; 1HNMR (400 MHz, D2O), δ: 
1.66 (s, 12H), 2.26 (t, J = 6.0 Hz, 4H), 3.09 (s, 18H), 3.44-3.54 (m, 4H), 4.14 (t, J = 7.2 Hz, 4H), 
6.44 (d, J = 13.2 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 8.4 Hz, 2H), 7.83 (s, 2H), 8.50 (t, 
J = 13.2 Hz, 1H). 13CNMR (100 MHz, D2O), δ: 20.9, 21.2, 30.2, 40.8, 49.5, 53.2, 63.1, 103.7, 
111.1, 120.0, 126.7, 139.9, 141.5, 143.6, 153.0, 176.4. Combustion C, H N analysis calculated for 
C35H51BrN4O6S2 (4H2O): C, 50.05; H, 7.08; N, 6.67. Found: C, 50.30; H, 6.83; N, 6.56. 
The product 28 was obtained in 55% yield. MP more than 350 °C; 1HNMR (400 MHz, 
D2O), δ: 1.64 (s, 12H), 2.22 (t, J = 6.0 Hz, 4H), 3.11 (s, 18H), 3.43- 3.53 (m, 4H), 4.16 (t, J = 7.2 
Hz, 4H), 6.46 (d, J = 13.2 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 8.4 Hz, 2H), 7.93 (s, 2H), 
8.55 (t, J = 13.2 Hz, 1H). 13CNMR (100 MHz, D2O), δ: 20.4, 21.3, 30.4, 41.8, 47.5, 54.6, 64.1, 
106.7, 111.6, 122.1, 127.3, 134.9, 141.6, 147.2, 154.5, 177.4, 179.9. 
The product 29 was obtained in 33% yield MP >260 °C. ; 1HNMR (400 MHz, D2O), δ: 
1.70 (s, 12H), 2.29 (t, J = 7.8 Hz, 4H), 3.08 (s, 18H), 3.48 (tt, J = 7.8 Hz, J = 7.8 Hz, 4H), 4.15 (t, 
J = 7.8 Hz, 4H), 6.34 (d, J = 13.6 Hz, 2H), 7.14 (t, J = 9.2 Hz, 2H), 7.242-7.12 (m, 2H), 7.30 (d, 
6.0 Hz, 2H), 8.49 (t, J = 13.6 Hz, 1H) . 19FNMR (135 MHz, D2O, C6F6 standard), δ: -118.8. HR-
MS calculated for [C35H51N4F2Br]
+ 644.3265, found 644.3278. 
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The product 30 was obtained in 77% yield. MP 255-257 °C; 1HNMR (400 MHz, D2O), δ: 
1.81 (s, 12H), 2.36 (t, J = 7.8 Hz, 4H), 3.29 (s, 18H), 3.95 (tt, J = 7.8 Hz, J = 7.8 Hz, 4H), 4.29 (t, 
J = 7.8 Hz, 4H), 7.21 (d, J = 13.4 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 8.0 Hz, 2H), 7.66 
(s, 2H), 8.60 (t, J = 13.4 Hz, 1H) . 13CNMR (100 MHz, D2O), δ: 22.4, 28.4, 42.4, 50.9, 54.2, 64.2, 
105.7, 114.0, 124.4, 130.2, 132.6, 141.9, 144.2, 153.3, 176.1. Combustion C, H N analysis 
calculated for C35H51Br3Cl2N4 (2H2O): C, 48.07; H, 6.34; N, 6.41. Found: C, 48.13; H, 6.31; N, 
6.43. 
The product 31 was obtained in 87% yield. MP 245-247 °C; 1HNMR (400 MHz, D2O), δ: 
1.71 (s, 12H), 2.16 (t, J = 7.4 Hz, 4H), 3.16 (s, 18H), 3.83-3.93 (m, 4H), 4.13 (t, J = 7.6 Hz, 4H), 
7.30 (d, J = 13.2 Hz, 2H), 7.57 (dd, J = 6.4 Hz, J = 4.0 Hz, 2H), 7.69 (d, J = 6.4 Hz, 2H), 7.99 (d, 
J = 4.0 Hz, 2H), 8.38 (t, J = 13.2 Hz, 1H). 13CNMR (100 MHz, D2O), δ: 21.2, 31.1, 41.6, 49.5, 
53.1, 62.5, 104.5, 113.9, 118.2, 126.3, 131.8, 141.4, 151.2, 172.4, 174.2. Combustion C, H N 
analysis calculated for C35H51Br5N4 (3H2O): C, 42.84; H, 5.85; N, 5.71. Found: C, 43.09; H, 5.65; 
N, 5.61. 
The product 32 was obtained in 92% yield. MP 260-262 °C; 1HNMR (400 MHz, D2O), δ: 
1.69 (s, 12H), 2.15 (t, J = 7.8 Hz, 4H), 3.15 (s, 18H), 3.88 (tt, J = 7.8 Hz, J = 8.0 Hz, 4H), 4.11 (t, 
J = 8.0 Hz, 4H), 7.28 (d, J = 13.4 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 7.82 (d, J = 8.0 Hz, 2H), 8.08 
(s, 2H), 8.37 (t, J = 13.4 Hz, 1H);. 13CNMR (100 MHz, D2O), δ: 20.7, 27.2, 41.0, 48.8, 52.6, 62.0, 
89.8, 103.9, 113.7, 131.2, 137.1, 141.4, 143.0, 150.6, 173.2.  Combustion C, H N analysis 
calculated for C35H51Br3I2N4 (2H2O): C, 39.76; H, 5.24; N, 5.30. Found: C, 39.83; H, 5.18; N, 
5.38. 
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11.5.2 Nucleic Acids 
The DNA oligonucleotides: Tel22 d[AGGG(TTAGGG)3], cMYC19 
d[(AGGGTGGGG)2A], and AATT hairpin duplex control d[CGAATTCGTTTTCGAATTCG] 
with and without 5’-biotin labels were purchased from Integrated DNA Technologies (Coralville, 
IA) with HPLC purification and mass spectrometry characterization. For NMR studies, a modified 
c-myc sequence, MYC22, d[TG(AGGGTGGGG)2AA] was used. The concentration of all the 
oligonucleotides was calculated using the absorbance at 260 nm and the manufacturer provided 
extinction coefficients determined by the nearest-neighbor method 37. Stock solutions of the 
oligonucleotides and the dyes were prepared in deionized water and diluted using appropriate 
experimental buffer prior to use. Experiments were conducted in 10 mM TRIS, or 10 mM HEPES 
for SPR, containing 50 mM KCl and 3 mM EDTA adjusted to pH 7.3.  
11.5.3 UV-Thermal Melting 
Thermal stability studies of the ligand-DNA complexes were performed with a Cary 300 
BIO UV-visible spectrophotometer in 1 cm pathlength quartz cuvettes. Samples of ligand-DNA 
complexes were prepared in Tris buffer at different ratios (0:1 up to 6:1) and were mounted in a 
6x6 Series II thermal block. The change in the absorbance of the complexes was monitored (at 295 
nm for quadruplex samples and 260 nm for duplex samples) as a function of temperature with 
computer-controlled heating and cooling rates of 0.5 °C/min. A total of four scans for each sample 
were collected with automatic buffer correction. The buffer corrected scans were normalized and 
the Tm values were determined by using a combination of the derivative function and graphical 
estimation. The reported ∆Tm values are averaged over two independent experiments and are 
reproducible within ±1 °C.  
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11.5.4 Biosensor-Surface Plasmon Resonance 
Biosensor-SPR studies were performed with a four-channel Biacore 2000 optical biosensor 
system (GE Healthcare, Sweden) using streptavidin-derivatized sensor chips (SA). The 
biotinylated oligonucleotides were prepared in HEPES buffer and were immobilized using the 
previously described procedure 17. A series of ligand solutions (10 nM – 10 µM) prepared in 
HEPES buffer were injected over the DNA immobilized sensor chip at a flow rate of 25 µL/min 
for an association and dissociation period of 5 minutes each. After the dissociation phase, the 
sensor-chip surface was regenerated with 10 mM glycine solution (pH 2.5) for a short period and 
was followed by a series of buffer injections to obtain a stable baseline for the next series of ligand 
injections.  The equilibrium steady-state response values (RUobs) at each injected ligand 
concentration (Cfree) were obtained and the values were fitted to a two-site binding model by non-
linear least squares method using the following equation:  
RUobs = RUmax/ligand(K1Cfree+2K1K2Cfree
2)/(1+K1Cfree+K1K2Cfree
2)   ………….…………(1) 
where RUmax/ligand is the predicted response for a single ligand binding. K1 and K2 are 
binding affinities for two different binding sites.  
11.5.5 Fluorescence titrations 
A UV-Vis absorbance scan was obtained  by scanning the ligand solutions (5 μM ) in Tris 
buffer over 800 nm to 200 nm at a rate of 60 nm/min with a 1 nm slit width to determine their 
maximum excitation wavelength (λmax). Fluorescence experiments were performed with a Cary 
Eclipse Fluorescence Spectrometer (Walnut Creek, CA) at 25 °C using an excitation and emission 
slit widths of 5 nm and the λmax of each ligand. Preannealed quadruplex DNA solutions in Tris 
buffer were incrementally titrated (0.05 µM) into the cuvettes containing 1 μM compound and the 
fluorescence emission was monitored over 500 – 800 nm wavelength range. Scans of the 
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quadruplex-ligand samples were collected until no further change in the fluorescence intensity was 
observed upon further DNA titration. The spectra were processed and plotted with Kaleidagraph 
4.0 software.  
11.5.6 Nuclear Magnetic Resonance 
Samples for NMR (100 µM) were prepared in 90% H2O/10% D2O and 20 mM potassium 
phosphate, pH 6.02. 4,4-dimethyl-4silapentane-1-sulphonic acid (DSS) was added as an internal 
reference. NMR experiments were performed on a Avance 600 spectrometer, equipped with a 
5mm QXI 1H{31P,13C,15N} probe (Bruker). Imino proton spectra (1024 scans) were collected at 
308 K using a WATERGATE w5 pulse sequence and a sweep width of 24 ppm. 
11.6 Conclusions  
Herein we are reporting the design, synthesis and characterization of novel series of trimethine 
cyanine molecules with different substituents on the indolenine rings to probe the effects on 
quadruplex binding. Analogous to our previous studies with penthamethine-linked cyanines, 
current molecules exhibit elevated quadruplex binding with considerably reduced duplex affinity. 
The halogen substitutions significantly increase the thermal stability and binding affinity with the 
quadruplex sequences with favorable preference for the parallel quadruplex motif. NMR and SPR 
studies show a 2:1 binding stoichiometry of the ligands while NMR and CD results support a 
stacking complex at the terminal tetrads of the quadruplex. The significant fluorescence 
enhancement observed for the parallel quadruplex over the hybrid type is a highly attractive feature 
of these ligands in discriminating different quadruplex folds. In summary, the current study 
significantly advances our knowledge in developing novel cyanine scaffolds for targeting 
quadruplex structures and their possible development as novel probes for G-quadruplex detection 
in vivo.  
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12 PENTAMETHINE CYANINES WITH HIGH FIDELITY TO QUADRUPLEX DNA 
This chapter is adapted from my publication in Bioorganic and Medicinal Chemistry in 
collaboration with Dr. David Wilson’s lab at Georgia State University.  My contributions as co-
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first author included the synthesis of the binding ligands, interpretation of data, experimental 
design and manuscript preparation. 
Nanjunda, R.*, Owens, E.A.*, Alyaybev, S., Mickelson, L., Wilson, W. D., Henary, M., Synthesis 
and Biophysical Analyses of the Interactions of Diverse Pentamethine Cyanine Dyes with G-
Quadruplex DNA 2012 Bioorg. & Med. Chem. 20, 24, 7002-11. *Co-First Authors 
12.1 Abstract 
Design and optimization of quadruplex-specific small molecules is developing into an 
attractive strategy for anti-cancer therapeutics with some promising candidates in clinical trials. A 
number of therapeutically favorable features of cyanine molecules can be effectively exploited to 
develop them as promising quadruplex-targeting agents. Herein, the design, synthesis and 
evaluation of a series of dimethylindoliene cyanine dyes with varying halogen substitutions are 
reported. Their interactions with telomeric and c-myc quadruplexes as well as a reference duplex 
sequence have been evaluated using thermal melting analysis, biosensor-surface plasmon 
resonance, circular dichroism spectroscopy, isothermal titration calorimetry and mass 
spectrometry. Thermal melting analysis indicates that these ligands exhibit significant quadruplex 
stabilization and a very low duplex binding, with the dimethyl incorporation being of utmost 
importance for decreased duplex affinity. Circular dichroism studies showed that the interaction 
of cyanines with quadruplex structures are primarily through stacking at one or both ends of the 
terminal tetrads with the two (trimethylammonium)propyl groups interacting in the accessible 
quadruplex grooves. Surface plasmon resonance and mass spectral studies shows the formation of 
an initial strong 1:1 complex followed by a significantly weaker secondary binding. Isothermal 
calorimetry studies show that the interaction of cyanines is predominantly entropy driven. In line 
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with the design principles, this work provides new insights for further developing potent, highly 
selective cyanines as promising quadruplex-specific agents.  
12.2 Introduction 
It has now been convincingly demonstrated that small molecules that target quadruplexes 
can have cellular anticancer activity and this area is promising for new drug development.[1-4] 
One compound has entered clinical trials with encouraging initial results against neuroendocrine 
cancer.[5] In spite of this success, additional quadruplex targeting compounds that display 
appealing pharmacodynamics with selective quadruplex binding remain highly desirable. A 
review of quadruplex-targeting structures illustrates a dominance of planar aromatic substituents 
and an overall cationic nature.[6-9] The charged groups are frequently located on a flexible chain 
that is linked to the aromatic system. A common binding mode for compounds displaying this 
motif is stacking of the aromatic moiety on the terminal tetrads of the quadruplex and the flexible 
cationic group(s) in one or more of the quadruplex grooves. With this model in mind a systematic 
set of new cationic carbocyanines (Figure 1) were designed and synthesized as potentially selective 
ligands for DNA quadruplexes. 
Cyanine dyes have extensive applications including cancer imaging, nucleic acid detection, 
photographic processes, and nonlinear optical materials that utilize their outstanding photophysical 
properties.[10, 11] Synthetic cyanines have characteristics, such as low toxicity and stability 
towards chemical decomposition, that make their cellular use extremely appealing. Additionally, 
this class of compounds displays excellent biocompatibility while being amenable to diverse 
chemical modifications.[10] With multiple synthetically active sites, there exist a multitude of 
carbocyanine dyes that can be designed and tested. Various cyanine supramolecular assemblies 
have been shown to probe the presence of the G-quadruplex structure in human telomere 
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sequences.[12] Cyanine dyes have been explored as fluorescent tags to observe the three-
dimensional folding properties of G-quadruplex DNA structures and dyes based on the 
benzothiazole heterocyclic moiety have been shown to inhibit telomerase via a suggested G-
quadruplex stabilization mechanism.[13] The benzothiazole cyanines , however, generally have 
very strong DNA duplex minor groove interactions; therefore, a systematic set of 
dimethylindolenine-based pentamethine cyanine dyes were synthesized to induce steric hindrance 
toward insertion of the compound into the duplex minor groove. Ammonium cations were 
introduced to the heterocyclic nitrogen to enhance solubility and increase quadruplex affinity by 
electrostatic interactions. Further structural diversity was achieved by halogenation at the 5-
position and the meso-carbon of the polymethine-bridge. The interactions of these cyanine analogs 
with quadruplex and duplex DNA were evaluated using a variety of powerful biophysical 
techniques, including: DNA thermal melting screening, biosensor-surface plasmon resonance, 
circular dichroism, isothermal calorimetry and mass spectrometry. These methods reveal 
encouraging results as these cyanine structures bind strongly to quadruplexes with excellent 
selectivity over duplex DNA. 
12.3 Results 
12.3.1 Chemistry 
In order to optimize the binding specificity and strength, we utilized the general 2,3,3-
trimethylindoleline heterocyclic scaffold with heterocyclic halogenation and a 3-(trimethyl 
ammonium)propyl bromide substituent on the indolenine nitrogen. The synthetic pathway for 
obtaining the final pentamethine structures begins with Fisher-indole synthesis utilizing hydrazine 
derivatives 1-3 with 3-methyl-2-butanone to form modified Fischer-bases 4-6 (Figure 1). These 
obtained indolenine derivatives 4-6 were alkylated with (3-bromopropyl) trimethylammonium 
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bromide in anhydrous acetonitrile yielding dicationic salts 7-9. Reagent 10 was commercially 
obtained and compounds 11 and 12 were prepared by decarboxylation of either mucochloric or 
mucobromic acid by aniline. Salts 7-9 were individually reacted with 10-12 in absolute ethanol 
under basic conditions to yield the nine corresponding tricationic pentamethine carboycyanine 
dyes 13-21 with varied halogen substituents. 
 
Figure 12-1. The synthesis of the cyanine structures used in developing G-quadruplex binding 
agents. 
12.3.2 Thermal Melting (Tm) 
An initial comparison of the interaction of all cyanines with Tel22 quadruplex and duplex 
DNA was done using UV thermal melting studies as a screening assay. Thermal melting studies 
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were done only with the telomeric G-quadruplex because the melting temperature of c-myc 
quadruplex is too high under the currently studied salt conditions (50 mM KCl) and the changes 
in Tm for most of the compounds go beyond the measurable limit. The ∆Tm results at ratios of 
cyanine to DNA ranging from 2:1 to 6:1 are shown in Table 1. The parent cyanine, compound 13, 
shows a relatively low ∆Tm for Tel22. Adding chlorine (14) or bromine (15) atom to the central 
carbon of the pentamethine chain resulted in a large increase in ∆Tm with no significant difference 
between the Cl or Br compounds. Pentamethine cyanines with heterocyclic halogenation were then 
tested. Di-halogenated compounds (with terminal Cl and Br, compounds 16 and 17 respectively) 
do not show any increase in ∆Tm over the mono-substituted derivatives. The tricationic 
pentamethine structure was then synthesized with the incorporation of three halogen substituents 
(18-21) and these showed a substantial increase in the ∆Tm with no significant difference between 
the Cl and Br derivatives. In summary, pentamethine cyanines with multiple halogen substituents 
bind to the telomeric quadruplex much more strongly than the unsubstituted parent and with very 
high selectivity over duplex DNA. The selectivity of these compounds is clearly very promising.  
 
Table 12-1. Thermal melting studies of the cyanine analogs with telomeric quadruplex 
(Tel22) and a control duplex (AATT). The thermal melting values reported are reproducible 
within ±1 °C.  $ could not be accurately determined due to complex aggregation.   
 
Compound Tel22 
(2:1, 4:1, 6:1 ratios) 
Duplex 
(6:1 ratio) 
13 2.1, 4.6, 8.7 0 
14 4.6, 12.2, 13.2 2.8 
15 4.6, 11.6, 15.6 0.1 
16 3.1, 8.9, 13.2 0.5 
17 2.5, 15.6, ---$ 1.1 
18 
19 
8.0, 17.0, 20.0 
9.0, 16.0, 21.0 
1.8 
2.5 
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20 7.0, 15.0, 19.0 2.3 
21 8.0, 16.2, 20.3 1.2 
 
12.3.3 Surface Plasmon Resonance (SPR) 
Biosensor-SPR studies were conducted with biotinylated, sensor-surface captured 
quadruplex and duplex sequences to quantitatively evaluate the binding affinity, selectivity and 
stoichiometry of the cyanine analogs. Figure 2 shows the SPR sensorgrams and the steady-state 
affinity plots for the parent compound (13), with the two quadruplex and reference duplex DNA 
sequences, and the binding affinities of all cyanine derivatives are summarized in Table 2. All the 
compounds exhibited an initial strong binding followed by a weaker (ca. 5 – 50 fold) secondary 
binding for both quadruplex sequences, while binding to the duplex sequence was quite low to 
negligible for all the compounds. The binding kinetics were rapid under the experimental 
conditions with both association and dissociation reactions occurring near the instrument injection 
mixing limit. Among the mono-substituted analogs, the bromo substitution (15) resulted in a slight 
increase in the binding affinity (K1 = 1.7 x 10
6 M-1) relative to the parent compound (K1 = 1.3 x 
106 M-1), whereas, the chloro substitution (14) resulted in a decrease in the affinity with the Tel22 
quadruplex. Among the symmetric, tri-substituted and mixed halogen derivatives, no improvement 
in the binding was observed relative to the parent compound (Table 2). 
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Figure 12-2. (A) SPR sensorgram of compound 13 with the two quadruplex as well as a 
reference duplex sequence. (B) Steady-state equilibrium binding plots of analogs 13 and 15. The solid 
colored lines are the fits obtained using a two-site model. In all cases, the steady-state response with 
duplex sequence was too low to fit reasonably.  
 
 
Table 12-2. Equilibrium binding constants of the cyanine analogs with quadruplex and 
duplex sequences obtained from SPR studies. The steady-state response obtained as a function of free 
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ligand concentration was fitted to a two-site model to obtain K1 and K2. In all the cases, no duplex 
binding was observed suggesting a high selectivity of the ligands. 
Compound 
Tel22  
(K1, K2) x 10
6 
M-1 
c-myc  
(K1, K2) x 10
6 M-
1 
Duplex 
13 1.3, 0.17 11.9, 0.07 < 105 
14 0.56, 0.08 9.7, 0.60 < 105 
15 1.7, 0.74 13.0, 0.07 < 105 
16 No binding No binding No binding 
17 0.79, 0.59 5.5, 3.6 No binding 
18 
19 
20 
1.0, 0.13 
0.35, 0.05 
0.59, 0.08 
7.2, 0.25 
4.8, 0.20 
8.0, 0.23 
< 105 
< 105 
< 105 
21 0.39, 0.06 9.7, 2.0 < 105 
 
Interestingly, all the compounds exhibited a similar trend in the relative binding affinities 
with the c-myc quadruplex but with a significantly stronger binding (ca. 10 – 25 fold higher than 
the telomere) and a similar weak secondary binding. The duplex binding in all the cases was too 
low to detect in the concentration range that was tested.  These results show a high selectivity for 
quadruplex sequences and confirm the selectivity observed in thermal melting studies. The lack of 
an increase in affinity for the halogens, relative to the parent, as expected from the Tm results, may 
be due to some absorption of the halogen derivatives to the sensor surface and resulting decrease 
in the compound concentration. 
12.3.4 Mass Spectrometry (MS) 
To quantitatively and directly evaluate complex stoichiometry, mass spectrometry was 
done on the complexes at several compound:DNA ratios to obtain an independent determination 
of binding stoichiometry. Experiments were conducted with all three bromo compounds and 
results for compounds 13 and 15 are shown in Figure 3. For free DNA, the -4 and -5 charge species 
dominate and are of similar magnitude. On addition of the compound, a 1:1 complex peak can be 
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seen. As the ratio is increased, the 1:1 peak grows in intensity and a smaller 2:1 peak can be seen 
at higher ratios. It is clear from the mass spectrometry results that the binding is a two site non-
cooperative interaction in agreement with the SPR analysis. 
 
Figure 12-3. Mass spectra of c-myc quadruplex with 0:1, 1:1, 2:1, 4:1 ratios (top to bottom) 
of parent dye 13 (A) and mono-brominated compound 15 (B).  
12.4 Discussion 
The discovery of G-quadruplex structures and their potential involvement in important 
biological pathways as well as cancer development has significantly extended our understanding 
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of the importance of non-B-form DNA structures in cell function. In addition, such non-B 
structures can provide an alternate platform for developing structure-specific small molecules as 
part of a new therapeutic approach. To use the DNA quadruplex structure as a platform for 
anticancer drug development, it is essential to design and discover new agents that can discriminate 
between quadruplex and duplex structures with very high selectivity. Furthermore, the diversity of 
quadruplex conformations found in the genome also makes the development of ligands that can 
discriminate between different quadruplex folds quite attractive.[2, 14, 15] The 
dimethylindolenine cyanine scaffold was selected based on the concepts that it could not fit into 
the minor groove, as with planar cyanines, but could stack on the terminal tetrads of quadruplex 
structure with cationic chains in the quadruplex grooves. A survey of all the approved drugs that 
are currently being used as well as the drug candidates that are in clinical development shows that 
a majority of the drugs have halogen atoms incorporated to increase the pharmacological properties 
of the drug molecule.[16-18] While fluorine and chlorine are the most prevalent halogens used, 
brominated drugs can also increase the desired pharmacological features.[19] With this in mind 
for an initial test series, coupled with a number of features of cyanine molecules that are considered 
to be therapeutically favorable, a series of pentamethine-bridged cyanine analogs with various 
combinations of chlorine and bromine substitutions on the core aromatic system as well as on the 
meso-carbon of the pentamethine chain were synthesized. Their quadruplex binding potential and 
selectivity over duplex binding were evaluated using a complementary series of biophysical 
techniques. 
The initial screening with thermal melting showed a very high selectivity by all the cyanine 
analogs for the quadruplex over duplex structures. This very promising finding is consistent with 
the design principles aimed at the development of strong quadruplex and weaker duplex binding. 
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The thermal stability of the quadruplex sequence further increased with the addition of halogens 
and with the tri-halogenated analogs inducing the highest stability. The introduction of either 
chlorine or bromine clearly increased the stabilization potential as compared to the parent 
molecule, however, no significant difference in the thermal melting values were found between 
the Cl or Br analogs as they both bound strongly to quadruplexes. The presence of polar atoms 
such as chlorine and bromine clearly has a positive and an additive effect on the binding to the 
quadruplex sequence. The lack of significant selectivity between Cl and Br suggests that the 
unfavorable steric contributions are minimal for these substitutions. Furthermore, the presence of 
two bulky methyl groups on both aromatic rings provides a steric hindrance to minimize binding 
to the duplex sequence.  
Circular dichroism analysis indicates an end-stacking binding mode for all the ligands with 
quadruplex structures, based on the presence of characteristic weak ICD signals in the compound 
absorbance region upon complex formation (data not shown). This weak ICD is a commonly 
observed pattern for ligands that either intercalate with duplex sequences or stack on the terminal 
tetrads of quadruplex motifs.[9, 20-22] The two 3-(trimethylammonium)propyl substituents on 
these cyanine systems (Figure 1) can favorably interact with the accessible grooves of the 
quadruplex. These results are further supported by the presence of an initial strong binding site 
detected by SPR studies. The two-site model predicted an initial strong binding that can be 
attributed to end-stacking and a significantly weaker secondary binding. This stoichiometry 
analysis was strongly supported by the mass spectral results where the formation of a predominant 
1:1 complex species and a weaker 2:1 complex was observed.  
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12.5 Conclusions 
In conclusion, a series of halogenated cyanine dyes were systematically designed, 
synthesized and tested for their interaction potential with quadruplex sequences using 
complementary lines of biophysical techniques. In conjunction with the design principles, to 
enhance quadruplex specificity with low duplex affinity, several of the cyanine analogs in this 
study showed elevated binding to both telomeric and c-myc quadruplex structures while 
maintaining a very low duplex selectivity. The dimethyl substitutions on both indolenine rings 
provide the necessary steric hindrance for the cyanine moiety to decrease duplex groove 
interactions, while the more polar halogen substitutions enhanced quadruplex binding. Thermal 
melting studies showed a relative increase in quadruplex stability as the number of halogen 
substitutions was increased. The small ICD signal observed upon complex formation indicates that 
the cyanines are interacting with the quadruplex structure primarily through end-stacking mode. 
The formation of a strong 1:1 complex as observed in SPR and mass spectral studies further 
supports the end-stacking binding mode of the ligands. The currently designed ligands provide the 
necessary platform in developing further potent cyanine molecules as promising quadruplex-
specific agents. 
12.6 Experiments 
12.6.1 Pentamethine Dye Synthesis 
Sigma Aldrich or TCI America were the commercial sources for the starting materials 
utilized in the presented synthesis and the reagents were used without purification.  The 1H NMR 
and 13C NMR spectra were recorded on a Bruker Avance (400 MHz) spectrometer using DMSO-
d6 or MeOD-d4 containing tetramethylsilane (TMS) as an internal calibration standard. UV-
Vis/NIR absorption spectra were recorded on a Varian Cary 50 spectrophotometer. High-
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resolution accurate mass spectra (HRMS) were obtained either at the Georgia State University 
Mass Spectrometry Facility using a Waters Q-TOF micro (ESI-Q-TOF) mass spectrometer or 
utilizing a Waters Micromass LCT TOF ES+ Premier Mass Spectrometer.  Liquid chromatography 
(LC) utilized a Waters 2487 single wavelength absorption detector with wavelengths set between 
640 and 700 nm depending on the dye’s photophysical properties.  The column used in LC was a 
Waters Delta-Pak 5 uM 100A 3.9 x 150 mm reversed phase C18 column. Evaporative light 
scattering detection analyzes trace impurities that cannot be observed by alternate methods; a 
SEDEX 75 ELSD was utilized in tandem with liquid chromatography to observe and confirm 
purity.  
5-chloro-2,3,3-trimethyl-3H-indole (5) and 5-bromo-2,3,3-trimethyl-3H-indole (6) were 
prepared using the procedure published by Zimmermann et. al.6 They were obtained as reddish 
brown oils in 71% and 90% yield, respectively.  
General Synthetic Procedure for Preparation of Heterocyclic Salts: 
A mixture of corresponding indole derivative 4-6 (31.4 mmol) and 3-bromopropyl 
trimethylammonium bromide (9.0 g, 34.5 mmol) was refluxed for 72 hrs in anhydrous acetonitrile 
(100 mL) under nitrogen.  The reaction was cooled to room temperature and solid product 
precipitated after 4 hours.  The precipitate was filtered and was washed with acetone and diethyl 
ether.  
2,3,3-trimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (7) was 
synthesized by our group and is previously reported.7  
5-chloro-2,3,3-trimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (8) 
Yield 82%; M.P. 215-217 °C; 1HNMR (400 MHz, DMSO-d6), δ: 1.65 (s, 6H), 2.56 (t, J = 8.0 Hz, 
2H), 3.25 (s, 9H), 3.73 (tt, J = 8.0 Hz, J = 8.0 Hz, 2H), 4.64 (t, J = 8.0 Hz, 2H), 4.80 (s, 3H), 7.69 
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(dd, J = 8.8 Hz, J = 2.0 Hz, 1H), 7.84-7.92 (m, 2H); 13CNMR (100 MHz, DMSO-d6): δ 12.2, 20.0, 
20.7, 43.3, 52.1, 53.2, 61.5, 115.9, 123.3, 128.8, 134.3, 138.2, 142.3, 197.9. Composition in theory: 
C(44.91%), H(5.99%), N(6.16%); Composition found: C(45.01%), H(6.29%), N(6.08%); HRMS 
(ESI) calculated for [C17H27ClN2]
2+ m/z 147.4356, found m/z 146.9909, 148.0421 
5-bromo-2,3,3-trimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (9) 
Yield 81%; M.P. 225-227 °C; 1HNMR (400 MHz, DMSO-d6), δ: 1.57 (s, 6H), 2.27 (s, 9H), 3.02 
(s, 3H), 3.83 (t, J = 8.0 Hz, 2H), 4.57 (t, J = 8.0 Hz, 2H), 7.61 (m, 2H), 7.88 (t, J = 5.6 Hz, 1H). 
13CNMR (100 MHz, DMSO-d6): δ 15.2, 22.0, 25.5, 30.6, 52.3, 54.3, 63.9, 115.6, 123.5, 128.8, 
129.3, 140.9, 141.7, 197.7. Composition in theory: C(40.91%), H(5.45%), N(5.61%); Composition 
found: C(40.84%), H(5.48%), N(5.94%); HRMS (ESI) calculated for [C17H27BrN2]
2+ m/z 
169.6611, found m/z 169.7002. 
 General Synthetic Procedure for the Preparation of Methine Bridge Reagent 
(E)-N-((Z)-2-chloro-3-(phenylamino)allylidene) benzenaminium chloride (11) was 
synthesized using the reported procedure. 88% yield; M.P. 214-216°C. 
(E)-N-((Z)-2-bromo-3-(phenylamino)allylidene) benzenaminium chloride (12): 
Mucobromic acid (5.940 g, 23.04 mmol) was dissolved in ethanol (40 mL) and aniline (4.286 g, 
4.2 mL, 46.1 mmol), diluted with ethanol (20 mL), was added dropwise over a 10-minute period.  
The reaction vessel was under vigorous stirring and was gently heated to 40 oC.  After the addition 
of aniline was finished, CO2 (g) was further produced indicating the reaction was not complete.  
Upon completion of CO2 (g) evolution, the golden brown reaction mixture was cooled in an ice 
bath.  Diethyl ether (50 mL) was added slowly at reduced temperature under heavy stirring until a 
bright yellow solid precipitated.  The resulting solid was filtered, washed with ether, dried and was 
used without purification in subsequent reactions. Yield 75%; M.P. 189-191°C; 1HNMR (400 
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MHz, DMSO-d6): δ 7.330 (t, J = 7.2 Hz, 2H), 7.496 (t, J = 8 Hz, 4H), 7.708 (d, J = 8 Hz, 4H), 
9.559 (s, 2H), 11.513 (s, 2H); 13CNMR (100 MHz, DMSO-d6): δ 89.3, 119.5, 123.9, 126.0, 129.2, 
129.6, 138.5, 157.4. 
General procedure for obtaining tricationic pentacarbocyanines 13-21  
A mixture of individual salts 7-9 (2 equivalents), either malonaldehyde bisphenylimine 
monohydrochloride 10, chlorinated analog 11 or brominated analog 12 (1 equivalent) and sodium 
acetate (3 equivalents) were refluxed for 6 hrs in anhydrous ethanol under nitrogen atmosphere 
and then cooled to room temperature. The reaction mixture was concentrated in vacou. The crude 
product was dissolved in deionized water and the target compounds 9-12 were isolated using silica 
gel 40-63 μm 90Å C18 reversed phase column chromatography using 20% methanol in water as 
eluting solvent. 
2-((1E,3E,5E)-5-(3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-ylidene)penta-
1,3-dien-1-yl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (13) Yield 
71%; M.P. 218-221 °C; 1HNMR (400 MHz, MeOD-d4): δ 1.781 (s, 12H), 2.359-2.380 (m, 4H), 
3.248 (s, 18H), 3.750 (t, J = 8.4 Hz, 4H), 4.254 (t, J = 7.6 Hz, 4H), 6.628 (d, J = 13.6 Hz, 2H), 
7.140 (t, J = 12.4 Hz, 1H), 7.287-7.327 (m, 2H), 7.436-7.486 (m, 4H), 7.540 (d, J = 7.6 Hz, 2H), 
8.345 (t, J = 13.2 Hz, 2H); 13CNMR (400 MHz, MeOD-d4): δ 20.93, 26.56, 40.26, 49.22, 52.49, 
63.08, 103.72, 110.41, 122.20, 125.07, 127.11, 128.50, 141.23, 141.76, 154.80, 173.47.  High-
resolution electrospray ionization (ESI) accurate mass spectra calculated m/z for C37H55N4Br2 
713.2793, found 713.2767.  
2-((1E,3Z,5E)-3-chloro-5-(3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-
ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium 
bromide (14) Yield 46%; M.P. 225-227°C; 1HNMR (400 MHz, DMSO-d6): δ 1.81 (s, 12H), 2.40 
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(t, J = 7.4 Hz, 4H), 3.26 (s, 18H), 3.71-3.79 (m, 4H), 4.38 (t, J = 7.6 Hz, 4H),  6.55 (d, J = 13.4 
Hz, 2H), 7.36 (t, J = 7.2 Hz, 2H), 7.50 (t, J = 7.6 Hz, 2H), 7.58 (d, J = 7.6 Hz, 2H), 7.63 (d, J = 
7.6 Hz, 2H), 8.50 (d, J = 13.4 Hz, 2H); 13CNMR (100 MHz, DMSO-d6), δ: 20.9, 26.0, 40.7, 49.4, 
52.5, 63.0, 100.9, 111.9, 122.2, 123.2, 125.6, 128.6, 141.4, 141.7, 148.2, 175.1. Composition in 
theory: (x3H2O): C (50.27%), H (6.84%), N (6.34%); Composition found: С (50.16%), H (6.78%), 
N (6.26%); HRMS (ESI) calculated for [C37H54ClN4]
3+ m/z 196.7742, found m/z 194.9509, 
197.1837. 
2-((1E,3Z,5E)-3-bromo-5-(3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-
ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium 
bromide (15) Yield 66%; M.P. 174-176°C; 1HNMR (400 MHz, DMSO-d6): δ 1.77 (s, 12H), 2.31 
(t, J = 7.1 Hz, 4H), 3.13 (s, 18H), 3.58-3.68 (m, 4H), 4.34 (t, J = 7.0 Hz, 4H), 6.40 (d, J = 13.2 Hz, 
2H), 7.61 (d, J = 8.6 Hz, 2H), 7.76 (d, J = 8.6 Hz, 2H), 8.11 (s, 2H), 8.61 (d, J = 13.2 Hz); 13CNMR 
(100 MHz, DMSO-d6), δ: 22.4, 27.6, 42.2, 51.8, 54.0, 64.2, 112.3, 118.3, 123.2, 127.1, 130.8, 
143.6, 151.3, 176.1. Composition in theory: C (50.82), H (6.22), N (6.41); Composition found: С 
(50.48), H (6.75), N (6.45). High-resolution electrospray ionization (ESI) accurate mass spectra 
calculated m/z for C37H54N4Br2 712.2715, found 712.2722. 
5-chloro-2-((1E,3E,5E)-5-(5-chloro-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide (16) Yield 88%; 1HNMR (400 MHz, MeOD-
d4): δ 1.78 (s, 12H), 2.32 (s, 4H), 3.25 (s, 18H), 3.75 (t, J = 8.4 Hz, 4H), 4.24 (t, J = 7.6 Hz, 4H), 
6.60 (d, J = 13.2 Hz, 2H), 7.11 (t, J = 12.4 Hz, 1H), 7.50-7.43 (m, 4H), 7.58 (s, 2H), 8.35 (t, J = 
13.2 Hz, 2H). 13CNMR (400 MHz, MeOD-d4): δ 20.89, 26.50, 40.58, 49.35, 52.57, 63.05, 104.20, 
111.92, 122.72, 127.75, 128.49, 130.54, 140.59, 143.15, 155.05, 173.28.  High-resolution 
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electrospray ionization (ESI) accurate mass spectra calculated m/z for [C37H53N4Cl2]
3+ 207.7877 
found 207.7555; calculated m/z for [C37H53N4Cl2]
2+ 311.6818, found 311.1284. 
5-bromo-2-((1E,3E,5E)-5-(5-bromo-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide (17) Yield 62%; M.P. 237-240 °C; 1HNMR 
(400 MHz, MeOD-d4): δ 1.782 (s, 12H), 2.318 (t, J = 7.1 Hz, 4H), 3.241 (s, 18H), 3.707-3.750 (m, 
4H), 4.224 (t, J = 7.2 Hz, 4H), 6.642 (d, J = 13.6 Hz, 2H), 7.176 (t, J = 12.8 Hz, 1H), 7.384 (d, J 
= 8.4 Hz, 2H), 7.611 (d, J = 8.4 Hz, 2H), 7.735 (s, 2H), 8.362 (t, J = 12.8 Hz, 2H); 13CNMR (400 
MHz, MeOD-d4): δ 20.89, 26.06, 26.50, 40.55, 49.32, 52.60, 63.03, 104.27, 112.25, 117.93, 
125.63, 131.45, 141.04, 143.44, 155.07, 173.11 High-resolution electrospray ionization (ESI) 
accurate mass spectra calculated m/z for C37H52N4Br2 710.2559, found 710.2552. 
2-((1E,3Z,5E)-3-bromo-5-(5-chloro-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-5-chloro-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide (18) Yield 88%; M.P. 238-240°C; 1HNMR 
(400 MHz, DMSO-d6): δ 1.77 (s, 12H), 2.19 (t, J = 7.6 Hz, 4H), 3.13 (s, 18H), 3.63 (tt, J = 7.6 Hz, 
J = 7.8 Hz, 4H), 4.25 (t, J = 7.8 Hz, 4H), 6.34 (d, J = 13.4 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H), 7.68 
(d, J = 8.0 Hz, 2H), 7.94 (s, 2H), 8.61 (d, J = 13.4 Hz, 2H); 13CNMR (400 MHz, DMSO-d6), δ: 
18.5, 20.6, 26.4, 41.4, 49.8, 52.3, 62.2, 102.7, 113.3, 117.0, 123.2, 128.3, 130.1, 140.5, 143.4, 
150.3, 174.4. Composition in theory: (x3H2O): C (44.56%), H (5.86%), N (5.62%); Composition 
found: С (44.54%), H (5.78%), N (5.56%); HRMS (ESI) calculated for [C37H52BrCl2N4]
3+ m/z 
234.5546, found m/z 234.0587, 236.0536. 
5-bromo-2-((1E,3Z,5E)-5-(5-bromo-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)-3-chloropenta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-
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(trimethylammonio)propyl)-3H-indol-1-ium bromide (19) Yield 80%; M.P. 227-229°C; 1HNMR 
(400 MHz, DMSO-d6): δ 1.76 (s, 12H), 2.17 (t, J = 7.0 Hz, 4H), 3.12 (s, 18H), 3.58-3.68 (m, 4H), 
4.26 (t, J = 6.8 Hz, 4H), 6.35 (d, J = 13.4 Hz, 2H), 7.61 (d, J = 8.6 Hz, 2H), 7.65 (d, J = 8.6 Hz, 
2H), 8.05 (s, 2H), 8.56 (d, J = 13.4 Hz, 2H); 13CNMR (400 MHz, DMSO-d6), δ: 20.7, 26.4, 41.2, 
49.7, 52.3, 62.2, 100.3, 113.7, 118.1, 123.5, 126.0, 131.3, 140.4, 143.5, 148.7, 174.9. Composition 
in theory: (x3H2O): C (42.65%), H (5.61%), N (5.38%); Composition found: С (42.09%), H 
(5.80%), N (5.26%); HRMS (ESI) calculated for [C37H52Br2ClN4]
3+ m/z 249.3716, found m/z 
248.9238, 251.0310. 
5-chloro-2-((1E,3Z,5E)-3-chloro-5-(5-chloro-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide (20) Yield 77%; M.P. 222-224°C; 1HNMR 
(400 MHz, DMSO-d6): δ 1.76 (s, 12H), 2.17 (t, J = 7.2 Hz, 4H), 3.13 (s, 18 H), 3.65 (tt, J = 7.6 
Hz, J = 7.2 Hz, 4H), 4.27 (t, J = 7.6 Hz, 4H), 6.34 (d, J = 13.6 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 
7.70  (d, J = 8.4 Hz, 2H), 7.93 (s, 2H), 8.73 (d, J = 13.6 Hz, 2H); 13CNMR (100 MHz, DMSO-d6), 
δ: 20.7, 26.4, 41.3, 49.7, 52.3, 62.1, 100.3, 113.3, 123.2, 123.5, 128.3, 130.0, 140.5, 143.4, 148.4, 
174.3. Composition in theory: (x3H2O): C (46.63%), H (6.13%), N (5.88%); Composition found: 
С (46.22%), H (6.12%), N (5.78%); HRMS (ESI) calculated for [C37H52Cl3N4]
3+ m/z 219.7376, 
found m/z 219.1727, 221.4561, 223.3207. 
5-bromo-2-((1E,3Z,5E)-3-bromo-5-(5-bromo-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide (21) Yield 77.6%; M.P. 232-234°C; 1HNMR 
(400 MHz, DMSO-d6): δ 1.76 (s, 12H), 2.18 (t, J = 7.1 Hz, 4H), 3.12 (s, 18H), 3.55-3.65 (m, 4H), 
4.24 (t, J = 7.0 Hz, 4H), 6.34 (d, J = 13.2 Hz, 2H), 7.60 (d, J = 8.6 Hz, 2H), 7.66 (d, J = 8.6 Hz, 
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2H), 8.06 (s, 2H), 8.60 (d, J = 13.2 Hz, 2H); 13CNMR (400 MHz, DMSO-d6), δ: 20.66, 26.46, 
41.37, 49.79, 52.35, 62.25, 102.70, 113.74, 116.99, 118.22, 126.03, 131.24, 140.93, 143.72, 
150.42, 174.34. Composition in theory: (3xH2O): C (40.91) H (5.38), N (5.16); Composition 
found: С (40.56), H (5.37), N (5.07). High-resolution electrospray ionization (ESI) accurate mass 
spectra calculated m/z for C37H52N4Br4 868.0925, found 868.0930. 
12.6.2 DNA preparation 
DNA oligonucleotides: Tel22, d[AGGG(TTAGGG)3]; c-myc, d[(AGGGTGGGG)2A]; 
control duplex, d[CGAATTCGTTTTCGAATTCG] with and without 5’-biotin labels were 
purchased from Integrated DNA Technologies (Coralville, IA) with HPLC. NMR and mass 
spectral analysis performed on these sequences further confirmed the purity. The concentration of 
oligonucleotides was determined from absorbance at 260 nm with extinction coefficients 
calculated by the nearest-neighbor method.[23] Appropriate stock solutions of each compound 
were prepared in double deionized water and diluted with the experimental buffer prior to use. 
Experiments were performed in 10 mM HEPES buffer containing 50 mM KCl and 3 mM EDTA 
adjusted to pH 7.3 using 1N HCl.  
12.6.3 UV-thermal melting studies 
Thermal denaturation studies were conducted on a Cary 300 BIO UV-visible 
spectrophotometer in quartz cuvettes of 1 cm pathlength. DNA solutions were prepared at single-
strand concentrations in the range of 2-3 µM. Samples of compound to DNA ratios ranging from 
0:1 to 6:1 was prepared. The absorbance of the oligonucleotides and the complexes was monitored 
at the recommended wavelength of 295 nm for Tel22 and 260 nm for duplex DNA sequences as a 
function of temperature. Cuvettes were mounted in a thermal block, and the solution temperatures 
were monitored by a thermistor in a reference cuvette with computer-controlled heating and  
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12.6.4 Surface Plasmon Resonance 
Biosensor-SPR experiments were performed with a four-channel Biacore 2000 optical 
biosensor system (GE Healthcare, Sweden). The streptavidin-derivatized gold chip (SA chip from 
BIAcore) was prepared for use by conditioning with a series of 60 second injections of 1 M NaCl 
in 50 mM NaOH followed by extensive washing with buffer. Biotinylated DNA samples (25-50 
nM) in HEPES buffer were immobilized on the flow cell surface by non-covalent capture as 
previously described[24]. Flow cell 1 was left blank as a reference, while flow cells 2-4 were 
immobilized with 5’-biotinylated DNA by manual injection of DNA stock solutions (flow rate of 
1 µL/min) until the desired amount of DNA response units  was obtained (350-400 RU). Typically, 
a series of different ligand concentrations (1 nM to 1 µM) were injected onto the chip (flow rate 
of 25 µL/min, 5 min) until a constant steady-state response was obtained followed by a dissociation 
period (running buffer, 5 min). After every cycle, the chip surface was regenerated with 10 mM 
glycine solution (pH 2.5 for 30 seconds) followed by multiple buffer injections to obtain a stable 
baseline for following cycles. 
The observed response (RUobs) in the steady-state region is proportional to the amount of 
bound drug and was typically determined by linear averaging over 10-20 seconds or longer time 
span. The predicted maximum response per bound compound (RUmax/ligand) was calculated from 
the DNA molecular weight, the compound molecular weight, the amount of DNA immobilized on 
the flow cell, and the refractive index gradient ratio of the compound and DNA, as previously 
described.[24, 25] The RUmax/ligand value is required to convert RUobs to determine the moles of 
drug bound to DNA. The RUobs was plotted as a function of free ligand concentration (Cfree) and 
the equilibrium binding constants were determined using a two-site interaction model, RUmax/ligand 
* (K1Cfree + 2K1K2Cfree
2)/(1 + K1Cfree + K1K2Cfree
2) using nonlinear least-squares optimization to 
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obtain an optimal fit with BIAevaluation (BIAcore Inc.) and Kaleidagraph (Synergy Software) 
softwares. K1 and K2 are equilibrium binding constants for two types of binding sites.  
12.6.5 Mass spectrometry 
The mass spectrometry analysis was performed on a Waters Q-TOF micromass 
spectrometer equipped with electrospray ionization source (ESI) in negative mode (Waters 
Corporate, Milford, MA). The mass range was from 500-3000 Da (displayed range in Figure 3 is 
from 1100 – 2100 m/z). Since mass spectrometry generally requires DNA sequences dissolved in 
a volatile salt solution, all the sequences tested with mass spectrometry were dialyzed several times 
with a 1000 Da cut-off membrane (Spectrum Laboratories Inc., Rancho Dominguez, CA, USA) in 
50 mM ammonium acetate buffer at pH 7.2 in order to remove any low molecular weight 
impurities from DNA. The final concentrations of the dialyzed DNA were determined as above. 
Samples containing 25-30 µM c-myc sequence and appropriate amounts of ligands in the desired 
molar ratios to DNA were prepared in 50 mM ammonium acetate buffer with the final volume of 
100 µL. The samples were introduced into the ion source through direct infusion at 5 µl/min flow 
rate. The instrument parameters were as follows: capillary voltage of 2200 V, sample cone voltage 
of 30 V, extraction cone voltage of 2.5 V, desolvation temperature of 70 °C and source temperature 
of 100 °C. Nitrogen was used as nebulizing and drying gas. Spectra were collected for 10 minutes 
and the last two minutes of the scan were used for data analysis. Data analysis and interpretation 
were performed using MassLynx 4.1 software. 
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13  RIGIDITY IN HEPTAMETHINE CYANINES IMPROVES QUADRUPLEX 
BINDING 
This chapter has been prepared as a publication for submission to MedChemComm in 
collaboration with Dr. Donald Hamelberg, Dr. Germann, and Dr. David Wilson’s lab at Georgia 
State University.  My contributions as co-first author included the synthesis of the binding ligands, 
interpretation of data, experimental design and manuscript preparation. 
13.1 Abstract  
Carbocyanine dyes have been long understood to bind strongly in the minor groove of 
DNA through H-aggregation and through electrostatic interactions with varied degrees of sequence 
specificity.  Through carefully placed structural manipulations, we have prepared heptamethine 
cyanine structures that display strong and selective binding to G-quadruplex DNA.  In 
corroboration with our previous reports, we observe a direct correlation with polymethine length 
and intrinsic charge of the binding agent.   
13.2 Introduction  
Within the past few years, it has been increasingly recognized that the G-quadruplex could 
be a potent target for the design of novel chemotherapeutics.1  The quadruplex structure is 
characterized by four guanine nucleotides bound through both Hoogsteen hydrogen bonds and by 
those recognized by the Watson and Crick face.  Early developments in the biological significance 
of this nucleic acid structure include the inhibition of the enzyme telomerase which is overactive 
in a number of cancer cells2, 3; however, the field has moved toward the more appealing arena 
concerning oncogenetic suppression using the quadruplex as an effective silencing mechanism.4-8 
Oncogenetic promoter regions are employed in the biological prevalence of several cancer-
promoting proteins, including c-myc, RET, c-kit and VEGF, which are able to be targeted by the 
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stabilization of the corresponding quadruplex.  Specifically, the MYC oncogene is responsible for 
Burkitt’s Lymphoma9-11 and it becomes active as the Epstein-Barr virus alters native B-cells into 
MYC-expressive cancerous cells.  In line with this observation, the therapeutic potential of the 
quadruplex has been extensively researched with many hit compounds being reported as binding 
this structure with high affinity as measured by a number of complementary biological and 
biophysical techniques. Unfortunately, the Achilles heel of this approach remains a significant 
structural challenge—achieving discrimination against the minor groove of duplex DNA without 
jeopardizing desirable quadruplex affinity.   
 
 
Figure 13-1. The chemical structures of known binding quadruplex binding ligands. 
Cyanine dyes have been long recognized as effective nucleic acid labels owing to their 
inherent ability to bind to the minor groove and offer strong fluorescence signal.12-15  These 
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compounds have been diversely modified to achieve strong binding affinity to both duplex and 
quadruplex DNA based off of the benzothiazole nucleus.  Initially, we postulated that 
incorporating a steric restraint to duplex binding could lead to quadruplex specific binding affinity 
and reported tri- and pentamethine cyanines with dimethyl indolenine heterocycles replacing the 
benzothiazole moieties.  We found out that this molecular design when paired with terminal propyl 
quaternary ammonium cations and heterocyclic halogenations increased the binding affinity while 
maintaining the highly desirable quadruplex selectivity.  The exact position of these binding 
moieties (cations and halogens) was thought to have a significant impact on the binding affinity to 
the quadruplex.  It seemed logical to elongate the polymethine chain of the cyanine chromophore 
by an additional vinylene unit and compare them directly to the previously studied cyanine binding 
ligands. Heptamethine cyanines are the longest of the most common (of mono, tri, penta and hepta) 
and were needed to discover the optimum length for quadruplex binding. Heptamethines are very 
well known compounds across various disciplines including near-infrared imaging.16-23 
13.3 Synthesis  
In synthetic pursuit of heptamethine cyanine dyes with similar structural characteristics as 
our previously reported tri and pentamethine cyanines, we prepared the heterocyclic salts for 
covalent attachment on both ends of the commercially obtained linking intermediate.   Fischer-
indole conditions starting with the corresponding halogenated hydrazine and 3-methyl-2-butanone 
yield heterocyclic compounds in excellent yield.  Applying usual SN2 chemistry in extra dry 
conditions affords the di-quaternary ammonium cation salts as a highly hygroscopic solid followed 
by condensation in acetic anhydride.   As preparing open-chain heptamethine cyanines with a 
meso-halogen is synthetically difficult, we instead chose to incorporate a cyclohexene ring within 
the polymethine chain bearing a meso-chlorine atom. We began this synthetic route with the 
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formylation of cyclohexanone to afford the intermediate.  After treatment with anilinium chloride, 
we obtain the Vilsmeier-Haack reagent in excellent yield which is then reacted with the dicationic 
salts using similar chemistry as previously described.  The final heptamethine cyanines were 
obtained with a cyclic ring and meso-chlorine atom.   
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Scheme 1: The synthetic pathway for the preparation of diverse halogenated heptamethine 
cyanines bearing an open polymethine chain (9-12) and a ridged cyclohexene core (13-16). 
13.4 Ultra-Violet Thermal Melting  
In order to determine the degree of binding for the newly prepared heptamethine binding 
agents, we first use UV thermal melting to screen the compounds for activity against a human 
telomere sequence to gauge the potential for interaction with quadruplex sequences.  The DNA 
melting curve in analyzed without binding agents and with binding ligand in different 
compound:DNA ratios (1:1, 2:1, 4:1, 6:1).  Similarly, a duplex forming AT rich sequence is used 
to determine the potential for interaction with duplex DNA.  
Table 1: Tm changes of heptamethine cyanine binding agents with telomeric quadruplex 
(Tel22) and a control duplex sequence (AATT).  Previously published pentaa- and trimethineb 
cyanines are listed for direct comparison. ND = Not determined 
Compound 
ID 
Tel22 (Compound:DNA) 
AATT 
(Compound:DNA) 
(1:1) (2:1) (4:1) (6:1) (4:1) 
9 3 5 9 12 1 
9a ND 2 5 9 1 
9b 2 4 9 14 0 
10 ND ND 9 ND 1 
10b 3 8 12 16 1 
11 ND ND 10 ND 2 
11a ND 3 9 13 0 
11b 3 7 15 19 1 
12 ND ND 12 ND 1 
12a ND 3 16 ND 0 
12b 1 5 14 24 0 
13 4 13 23 25 ND 
13a ND 5 12 13 3 
14 ND ND 12 ND 1 
15 ND ND 21 ND 3 
15a ND 7 15 19 2 
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16 3 6 22 ND 0 
16a ND 9 16 21 3 
ND = Not Determined 
 
13.5 Nuclear Magnetic Resonance Spectroscopy 
NMR spectroscopy is an excellent tool for deciphering the orientation and mode of 
chemical complexation with nucleic acids and proteins. Titrating DNA with varied ratios of 
binding ligand allows us to determine the location and degree of binding to the quadruplex. From 
the NMR data we can see strong interactions with the bottom of the quadruplex surface. 
 
Figure 13-2. TEL‐24 quadruplex titration with 15  (left), and 13 (right) followed with 
the imino proton spectra of TEL-24. NMR imino proton spectra (T=298 K) of the TEL-24 
quadruplex are shown on the top of the figure. Compounds 13 and 15 were added to a 
constant amount of TEL-24 indicated in terms of their mole ratios. The DNA is mostly 
present as a hybrid-1 form in solution.  Ligands were added to the quadruplex at the ratio 
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indicated on the plot, where 1:0 ratio corresponds to the imino proton spectrum of TEL‐24 
with no ligand added. Schematic structures of TEL‐24 are color coded according to the 
tetrad guanine imino protons affected in the titrations. Red residues are strongly affected, 
yellow are somewhat affected, and green are not affected.  
13.6 Molecular Modeling  
After determining the qualitative binding mode through NMR titrations, we utilized the 
AMBER suite of computational dynamics software to more precisely visualize the binding to both 
hTel and cMYC DNA 
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Figure 13-3. Molecular dynamics snapshots for the binding of compounds 11 and 15 to cMYC 
DNA (PU22, PDB ID: 1XAV).  (A) Compound 11 with cMYC, and (B) Compound 15 with cMYC. 
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Figure 13-4. Molecular dynamics snapshots for the binding of compounds 11 and 15 to hTel 
DNA (hTel22, PDB ID:).  (A) Compound 11 with cMYC, and (B) Compound 15 with cMYC. 
 
13.7 Discussion 
Our previous attempts to obtain selective and strongly-interacting quadruplex ligands led 
with the pentamethine and trimethine classes, respectively.  The heptamethine class of cyanines 
has been long reserved for in vivo imaging or protein labeling.  After modifying the aforementioned 
compounds through the addition of halogens on the heterocyclic units, we observed an increase in 
the overall interaction as indicated by SPR-Kd and Tm measurements.  We then hypothesized 
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that the overall length between heterocyclic units should be altered to observe the most appealing 
binding length for increasing quadruplex interactions and if this structural perturbation would 
increase, decrease or not affect the overall selectivity.  This rationale led us to synthesize the 
heptamethine compounds shown in Scheme 1.  Having these analogous quadruplex ligands in 
hand, they were subjected to an initial screening measurement using DNA uv thermal melting 
which robustly can determine a general order of magnitude binding strength owing to an increase 
in melting temperature of the quadruplex.  Immediately a trend emerges between the two overall 
sets of compounds—the cyclohexene ring in the middle of compounds 13-16 results in an 
unexpected increase in quadruplex affinity with DTm measurements almost doubling from 12 oC 
to 23 oC.   
13.8 Experimental 
Synthesis. All starting reagents were obtained commercially from Sigma Aldrich or Matrix 
Scientific and were used without purification.  Nuclear magnetic resonance experiments were 
performed on a Bruker Avance 400 MHz spectrometer and processed using Topspin 3.1.  Chemical 
shift values are reported versus tetramethylsilane as an internal standard purchased in the 
commercially obtained deuterated solvents (Cambridge Isotope Laboratory).   The reactions were 
followed using silica gel 60 F254 thin layer chromatography plates (Merck EMD Millipore, 
Darmstadt, Germany). Open column chromatography was utilized for the purification of all final 
compounds using 60-200u, 60A, classic column silica gel (Dynamic Adsorbents, Norcross, GA).. 
UV-Vis/NIR absorption spectra were recorded on a Varian Cary 50 spectrophotometer. High-
resolution accurate mass spectra (HRMS) were obtained either at the Georgia State University 
Mass Spectrometry Facility using a Waters Q-TOF micro (ESI-Q-TOF) mass spectrometer or 
utilizing a Waters Micromass LCT TOF ES+ Premier Mass Spectrometer.  Liquid chromatography 
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utilized a Waters 2487 single wavelength absorption detector with wavelengths set between 640 
and 700 nm depending on the particular photophysical properties.  The column used in LC was a 
Waters Delta-Pak 5 uM 100A 3.9 x 150 mm reversed phase C18 column. Evaporative light 
scattering detection analyzes trace impurities that cannot be observed by alternate methods; a 
SEDEX 75 ELSD was utilized in tandem with liquid chromatography to confirm purity (>95% as 
determined by LC-ELSD-MS). 
Synthetic preparation of open-chain heptamethine binding agents 9-12. Individual 
heterocyclic salt and corresponding starting linker were placed in an oven dry and nitrogen purged 
round bottom flask.  Acetic anhydride (3 mL) was added and the reaction mixture was warmed to 
40 oC for 10 minutes.  Sodium acetate (2 mol. eq.) was added to the reaction mixture.  The reaction 
was followed using both UV-Vis-NIR spectroscopy, monitoring the appearance of a absorbance 
band >700nm and the disappearance of absorbance characteristics below 600nm.  TLC using 
neutral alumina coated glass and 5% methanol in DCM afforded efficient separation of the highly 
charged compounds.  The reactions were followed to completion.  After the disappearance of 
starting materials, the reaction mixture was added to a stirring mixture of acetone and ethyl acetate 
(1:1, 30 mL).  The resulting solid was vacuum filtered and quickly dried under high vacuum.  The 
compounds were purified by substantial washing with acetone or open column chromatography 
using alumina gel and a gradient of DCM to 1-5% methanol in DCM as the eluting solvent. The 
final compounds were obtained in the indicated yields of >95% purity as determined by tandem 
LC-ELSD-MS.  
5-fluoro-2-((1E,3E,5E)-7-((E)-5-fluoro-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide  (10): 1H NMR (400 MHz, D2O) (s, 
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12H), 2.602 (bs, 4H), 3.404 (s, 18H), 3.763 (t, J  = 6.0 Hz, 4H), 4.455 (bs, 4H), 6.529 (d, J = 12.4 
Hz, 2H), 6.868 (t, J = 12.8 Hz, 2H), 7.497-7.473 (m, 4H), 7.616 (d, J = 8.0 Hz, 2H), 7.832 (t, J = 
12.4 Hz, 1H), 8.200 (t, J = 13.2 Hz, 2H). 19F NMR (375 MHz, D2O, ref C6F6)  
5-chloro-2-((1E,3E,5E)-7-((E)-5-chloro-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide  (11): 1H NMR (400 MHz, DMSO-
d6) (s, 12H), 2.111 (bs, 4H), 3.148 (s, 18H), 3.775 (bs, 4H), 4.197 (bs, 4H), 6.726 (d, J = 
12.4 Hz, 4H), 7.436 (d, J = 8.4 Hz, 2H), 7.603 (d, J = 7.6 Hz, 2H), 7.744 (s, 3H), 7.857 (bs, 2H).  
2-((E)-2-((E)-2-chloro-3-(2-((E)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-
indol-1-ium bromide  (12): 1H NMR (400 MHz, DMSO-d6)  (s, 12H), 2.309 (bs, 4H), 3.286 
(s, 18H), 3.975 (t, J = 8.0 Hz, 4H), 4.426 (t, J = 6.8 Hz, 4H), 6.776-6.671 (m, 4H), 7.583-7.472 
(m,5H), 7.624 (s, 2H), 7.807 (t, J = 12.4 Hz, 3H).  
5-bromo-2-((1E,3E,5E)-7-((E)-5-bromo-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide (13): 1H NMR (400 MHz, DMSO- d6) 
1.714 (s. 12H), 1.882 (bs, 2H), 2.195 (bs, 4H), 2.793 (s, 4H), 3.125 (s, 18H), 3.613 (s, 4H), 4.289 
(s, 4H), 6.378 (d, J = 14.0 Hz, 2H), 7.315 (t, J = 7.6 Hz, 2H), 7.458 (t, J = 6.8 Hz, 2H), 7.558 (d, 
J = 7.2 Hz, 2H), 7.659 (d, J = 7.2Hz, 2H), 8.315 (d, J = 13.6 Hz, 2H). 
2-((E)-2-((E)-2-chloro-3-(2-((E)-5-fluoro-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-5-fluoro-3,3-
dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (14):  13C NMR (100MHz, 
DMSO-d6) 20.97, 21.41, 26.82, 27.94, 41.88, 49.84, 53.13, 62.95, 102.61, 110.97, 111.23, 113.42, 
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113.51, 115.49, 115.73, 127.12, 143.82, 148.92, 159.69, 162.10, 172.95. 19F NMR (375 MHz, 
D2O, ref C6F6)  
5-chloro-2-((E)-2-((E)-2-chloro-3-(2-((E)-5-chloro-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-
1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (15): 1H NMR (400 MHz, DMSO-d6) 
1.708 (s. 12H), 1.839 (bs, 2H), 2.159 (bs, 4H), 2.806 (s, 4H), 3.139 (s, 18H), 3.698 (s, 4H), 4.309 
(s, 4H), 6.424 (d, J = 14.0 Hz, 2H), 7.498 (d, J = 8.4 Hz, 2H), 7.674 (d, J = 7.6 Hz, 2H), 7.845 (s, 
2H), 8.274 (d, J = 14.0 Hz, 2H).  
5-bromo-2-((E)-2-((E)-3-(2-((E)-5-bromo-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)ethylidene)-2-chlorocyclohex-1-en-1-yl)vinyl)-3,3-
dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (16): 1H NMR (400 MHz, 
MeOD-d4) 1.792 (s. 12H), 1.993 (bs, 2H), 2.347 (bs, 4H), 2.865 (s, 4H), 3.236 (s, 18H), 3.732 
(d, J = 7.6 Hz, 4H), 4.329 (d, J = 6.8 Hz, 4H), 6.438 (d, J = 14.0 Hz, 2H), 7.670 (d, J = 8.4 Hz, 
2H), 7.625 (d, J = 8.4 Hz, 2H), 7.765 (s, 2H), 8.487 (d, J = 14.0 Hz, 2H). 
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14 SECOND GENERATION TRIMETHINE CYANINES 
 This chapter has been prepared for submission to Chemistry—A European Journal and has 
been the work of several labs collaborating across the Georgia State Campus. My contributions as 
first author of this manuscript have included the synthesis/characterization of binding ligands, 
molecular modeling, manuscript/figure preparation, data interpretation, project implementation, 
and overall project management.  
14.1 Abstract 
Second generation trimethine cyanines have been synthesized and evaluated for their 
quadruplex binding properties.  Incorporating a benz[c,d]indolenine heterocyclic unit increased 
overall quadruplex binding and elongating the alkyl length increases the quadruplex-to-duplex 
binding specificity.  Additionally the modification of the alkyl length increased the binding affinity 
to MYC DNA and lowered the targeting of Tel22 resulting in a highly MYC-specific binding 
ligand which is highly important in the recognition of particular quadruplex topologies.  
14.2 Introduction 
Effective drug targets are paramount in the rational design of new therapeutics for 
improving human health. Over the years, DNA has remained an appealing target due to its 
ubiquitous involvement that permeates biological processes—both native and diseased.  
Selectively inhibiting the translation and/or transcription of nucleic acids would give rise to 
personalized medications that would act by silencing the very creation of proteins that eventually 
lead to diseased states.  Unfortunately, we are very far from making this a reality.  Throughout 
recent years, alternate folding patterns of DNA (i.e. holliday junction, triplex, quadruplex, etc) 
have been extensively and excitingly explored as offering a favorable route toward effectively 
targeting the nucleic acid machinery of diseased cells.  In line with this current trend, we have been 
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exploring ligands that bind and stabilize the G-quadruplex structure.  The quadruplex is defined as 
a stacked tetrad of self-associated guanine nucleotides that assemble around a stabilizing cation.1-
7  Bioinformatics suggests that quadruplex-forming sequences prevail in oncogene promoter 
regions and within the telomere domain; both quadruplex associations lend themselves to be 
relevant in the design of new chemotherapeutics targeting either the translation of oncogene 
associated proteins or the enzymatic inhibition of telomerase, which is overexpressed in cancer 
cells and is responsible for limitless replication processes through telomere elongation.   
Developing a compound that strongly and selectively binds and stabilizes relevant 
quadruplex sequences could lead to non-toxic and potent chemotherapeutic.8-12  Towards 
achieving this goal, we have previously reported the synthesis and biophysical evaluation of 
several symmetric cyanines that feature tricationic character with steric restraints toward duplex 
interactions and selectively bind the quadruplex.13, 14  Our binding mode, however, suggests that 
an asymmetric compound would be better suited for increasing quadruplex interactions. 
Asymmetric cyanines are widely employed as nucleic acid labels and noncovalent probes after 
systematically manipulating their core structure to suit individualized needs.15-20  Their remarkable 
amenability to these diverse modifications furthers their applicability in nucleic acid targeting.  It 
has been extensively reported that benzothiazole-based compounds bind with a high degree of 
affinity within the minor groove of DNA and, through systematic modifications, some degree of 
sequence specificity may be obtained.  Through a reverse engineering of these compounds, we 
have removed the duplex binding affinity through well-placed steric restraints and incorporated a 
planar heterocyclic moiety for effective end-stacking with the quadruplex.  
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14.3 Synthesis  
Our effective route toward second generation trimethine cyanine quadruplex binding 
agents begins with the commercially available benz[c,d]indol-2(1H)-one.  Treatment of this 
reagent with phosphorous pentasulfide effectively yields the corresponding thione which is 
activated through simple alkylation using iodomethane.  Meldrum’s acid in a highly basic 
environment will replace the methanethiol affording the enamine intermediate.   At this point, the 
heterocyclic nitrogen is activated to perform SN2 chemistry in basic media.  Alkylation was 
performed using either iodomethane or iodobutane to afford the tertiary amine.  The reactive and 
acidic methyl group was obtained through thermal and acidic decomposition of the protecting 
Meldrum’s acid group leaving the terminal methyl moiety for further modification.  Subjecting the 
reactive methyl group to the Vilsmeier formylation reaction followed by alkaline cleavage affords 
the intermediate for half of the final binding ligand.  The alternate half is formed through the well-
established Fischer-indole reaction with halogenated phenyl hydrazine salts and 3-methyl-2-
butanone which, in the presence of refluxing acetic acid, effectively affords the bicyclic products 
through a hydrazone intermediate followed by a pericyclic rearrangement.  Alkylation of this 
heterocyclic precursor in dry acetonitrile with the corresponding bromopropyl 
trimethylammonium bromide affords the highly hygroscopic dicationic salts for the second half of 
the target binding agents.  Combining each of the heterocyclic precursors in acetic anhydride yields 
the final bright blue colored asymmetric cyanine binding ligands. 
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Scheme 1. Formation of the aldehyde intermediate of the benz[c,d]indolenine heterocyclic 
unit for reaction to form the final quadruplex binding ligands. 
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Scheme 2. Preparation of dicationic salts 14-17, 19, 20. 
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Scheme 3. Final synthetic step for compounds 21-32. 
 
 
Scheme 4. Preparation of the monomethine cyanine compound for quadruplex binding. 
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Scheme 5. Synthetic route for the brominated benz[c,d]indole ring and formation of the 
trimethine cyanine structure. 
Routes to two synthetic precursors were employed to generate potential quadruplex binding 
agents based on our results in previous publications.  We have seen that the length between 
heterocycles can influence the binding interactions; additionally, heterocyclic halogenations were 
observed to increase the binding strength to the quadruplex.  We were interested in whether 
shortening the polymethine bridge by one vinylene (-CH=CH-) unit would make a substantial 
change in the thermal melting data.  The benzo[c,d]indole-intermediate was alkylated and in basic 
conditions, the dicationic salt 14 is nucleophilic enough to displace the thiomethane group to afford 
the monomethine cyanine.  Surprisingly, the binding efficacy was completely removed when 
shortening the compound by a subtle 2.96 angstroms (as determined by measurements of the 
lowest energy structures minimized using DFT calculations with the B3LYP basis set) and we 
therefore we discontinued the pursuit of monomethine cyanines as strong quadruplex interacting 
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agents.  This 2.96 angstrom difference requires the three-dimensional form of the monomethine 
compound to twist out of plane in comparison to the highly planar trimethine cyanine compounds. 
In order to strengthen the quadruplex interactions, we thought that incorporating heterocyclic 
halogenations on the trimethine benz[c,d]indolenine heterocyclic portion should yield an increase 
in binding interaction as we previously found.   
 
Figure 14-1. Molecular depictions of the most energetically favorable state for monomethine 
compound compared to trimethine analog showing drastically different twisting associated with the 
reduction of the polymethine-bridge and corresponding DTm measurements at 4:1 compound:Tel22 
ratio. 
The synthesis of these brominated compounds (monobromo 34 and dibromo 35) involves 
a varied synthetic route starting with the alkylation of the thioester compound affording the butyl 
derivative—as it showed improved G4 binding compared to the methyl counterpart.  The 
heterocyclic portion, para to the tertiary amide nitrogen, was found to be sufficiently activated for 
effective bromination.  This intermediate was prepared and reacted in similar fashion as previously 
described to afford the methylene intermediate.  Correspondingly, the reaction of dicationic salts 
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(14 and 17) with diphenylformamidine in a 1:1 molar ratio in boiling acetic anhydride with careful 
reaction monitoring affords the half-reacted compound which undergoes loss of acetanilide by 
nucleophilic displacement by the brominated benzo[c,d]-containing analog.     
Biophysical Evaluation.  In order to screen for initial efficacy in quadruplex DNA binding 
affinity and corresponding selectivity against duplex DNA, we utilized UV-thermal melting. 
Thermal melting provide a quick scan for a quick selection of compounds for further analysis. 
Next, surface plasmon resonance was done to dyes with high change in thermal melting with 
quadruplex DNA while little to no binding with duplex DNA. Surface plasmon resonance is 
beneficial in quantitatively analyzing the affinity as well as the binding kinetics with two types of 
quadruplex motifs (parallel or mixed) 
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Table 1: General molecular structures and Tm changes of new unsymmetrical trimethine 
cyanine binding agents with telomeric quadruplex (TEL22) and a control duplex sequence 
(AATT). 
 
ID 
Heterocyclic 
Modifications 
Tel22 
(Compound:DNA) 
AATT 
(Compound:DNA) 
Benz[c,d] Other (1:1) (2:1) (4:1) (6:1) (4:1) 
21 Methyl, -H -H 4.4 9.9 17.4 22.5 3.6 
22 Methyl, -H -F 4.3 9.9 18.0 22.0 3.4 
23 Methyl, -H -Cl 0.0 7.4 16.5 22.1 3.5 
24 Methyl, -H -Br 2.7 9.0 16.4 21.8 3.3 
25 Butyl, -H -H 2.1 7.8 20.6 26.3 2.3 
26 Butyl, -H -F 1.1 2.9 19.8 25.3 1.1 
27 Butyl, -H -Cl 4.2 9.2 22.8 23.3 2.2 
28 Butyl, -H -Br 2.5 11.2 20.9 23.3 2.2 
29 Methyl, -H -O-CH2-O- 2.2 5.7 6.3 ND ND 
30 Butyl, -H -O-CH2-O- 1.1 4.1 ND 24.8 2.0 
31 Methyl, -H -S- 2.5 6.1 ND ND 5.6 
32 Butyl, -H -S- 2.5 9.5 ND ND ND 
35 Butyl, -H -H 1.0 0.5 0.9 1.4 0.3 
42 Butyl, -Br -H 1.0 2.0 8.7 ND 2.3 
43 Butyl, -Br -Br 1.1 4.3 ND ND 0.6 
ND = Not Determined 
 
Thermal melting screening data was followed by more sophisticated techniques to 
determine binding constants for these compounds to quadruplex DNA (Tel22 and MYC19). 
Surface plasmon resonance spectroscopy help to determine the exact binding association constants 
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of ligands to the quadruplex.  When the methylated compound was examined, the SPR response 
indicated a strong binding affinity to both MYC19 and Tel22; however, the butylated counterpart 
revealed higher affinity for the MYC19 quadruplex forming sequence compared to the methyl 
analog.  Additionally, the butyl-substituted ligand displayed remarkable selectivity with the 
binding affinity to MYC19 being orders of magnitude higher when analyzed through the steady-
state binding plot. These results fully agree with the Tm measurements and offer more concrete 
and quantitative insight into the binding strength of these asymmetric trimethine compounds to the 
two different quadruplex forming sequences. 
 
 
Figure 14-2. Surface Plasmon Resonance Sensograms. The G4 binding agents 24 (methyl) 
and 28 (butyl) were examined with TEL22 and MYC19 DNA.   
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14.4 Nuclear Magnetic Resonance Spectroscopy 
In order to accurately determine the binding localization on the quadruplex and to guide 
molecular modeling studies, NMR titrations were performed with Tel24 (Figure 3) and MYC (data 
not shown).  Tel24 was selected for NMR studies because there is only a single form in solution 
versus Tel22 which has an unknown major fold.  Several folding patterns associated with Tel22 
complicates the imino proton spectrum and makes deciphering the binding more difficult.  We are 
confident that the two quadruplex sequences are similar enough to be comparable as thermal 
melting data (Supporting Information) shows similar results between Tel22 and Tel24 indicating 
similar binding affinity which suggests similar binding modes. The imino proton NMR spectra in 
Figure 3 shows two binding ligands, compound 22 on the left and 26 on the right, and the guanine 
nucleotides that show pertebations in the spectra when the ratio of compound:DNA is increased 
from 1:0 to 1:1.  The disappearance of the NMR peaks indicates an interaction between the 
compound and the DNA at the location corresponding to the affected imino proton. For example, 
imino protons corresponding to 3, 9 and 17 shift the most as indicated by the red arrows and 
corresponding red coloring on the cartoon schematic.    
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Figure 14-3 TEL24 quadruplex titration with 22 (left) and 26 (right) followed with the imino 
proton spectra of TEL24. Ligands were added to the quadruplex at the ratio indicated on the plot, 
where 1:0 ratio corresponds to the imino proton spectrum of TEL24 with no ligand added. Schematic 
structures of TEL24 are color coded according to the imino protons affected in the titrations. Red 
residues are strongly affected, yellow are somewhat affected, and green are not affected. 
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Molecular Modeling.  
Using the NMR data as a template, we proceeded with molecular dynamics simulations in order 
to examine the binding mode and exact points of contact with the quadruplex.  We see that the 
planar benz[cd] heterocyclic portion inserts under the quadruplex loop which is logical based on 
the steric restraints between the tetraplex surface and the dynamic look.  The alternate heterocyle 
bearing the ammonium arm aligns itself well with the edge of the quadruplex and the quaternary 
ammonium group inserts itself in the available groove of the quadruplex.  This binding paradigm 
is conserved in both the methylated and butylated compounds.  
 
364 
 
 
Figure 14-4. Molecular dynamics and corresponding snapshots for the binding of compounds 
24 and 28 to MYC DNA.  (A) compound 24 with MYC, (B) compound 28 with MYC 
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Figure 14-5. Molecular dynamics and corresponding snapshots for the binding of compounds 
24 and 28 to TEL22 DNA.  (A) Compound 24 with TEL22, (B) Compound 28 with TEL22. 
14.5 Discussion 
The benz[c,d]indole displays a highly planar surface that could interact by both stacking 
with the quadruplex end and intercalating between the base-pairs of AT-rich DNA sequences, 
especially when the heterocyclic nitrogen atom bears a single methyl group.  We have observed 
that by elongating this alkyl chain, we help to discriminate against AT duplex binding probably 
due to the steric repulsion provided by the butyl chain which repels the heterocyclic unit from 
intercalation with the duplex DNA nucleotides and interacts favorably with the quadruplex groove. 
Dyes that have butyl chain are also showed to bind with parallel and discriminating against mixed 
quadruplex DNA using binding affinity data from SPR. In addition the kinetic of the SPR also 
showed that butyl chain have longer dissociation time with parallel quadruplex, this mean that the 
dyes: DNA interaction are tighter.  
14.6 Conclusions 
Through an optimized synthetic route, we have prepared second generation trimethine 
cyanines that display higher binding affinity to quadruplex DNA with high selectivity over the 
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AATT rich sequences.  NMR guided molecular modeling results have given an interesting end 
stacking binding mode with groove interactions being achieved by the quaternary ammonium arm.  
These structures suggest that developing asymmetric binding ligands may help take advantage of 
the asymmetry involved in many quadruplex forming sequences. SPR experimental results of dyes 
binding to quadruplex showed that there are more than one sites interaction where the primary 
sites is stronger while other binding sites weaker than 10-fold. Selectivity using SPR data also 
showed that these set of dyes have more binding and stability with parallel (MYC19) over 
antiparallel quadruplex structure (Tel22). 
14.7 Materials and Methods  
All starting reagents were obtained commercially from Sigma Aldrich or Matrix Scientific 
and were used without purification.  Nuclear magnetic resonance experiments were performed on 
a Bruker Avance 400 MHz spectrometer and processed using Topspin 3.1.  Chemical shift values 
are reported versus tetramethylsilane as an internal standard purchased in the commercially 
obtained deuterated solvents (Cambridge Isotope Laboratory).   The reactions were followed using 
silica gel 60 F254 thin layer chromatography plates (Merck EMD Millipore, Darmstadt, Germany). 
Open column chromatography was utilized for the purification of all final compounds using 60-
200u, 60A, classic column silica gel (Dynamic Adsorbents, Norcross, GA). UV-Vis/NIR 
absorption spectra were recorded on a Varian Cary 50 spectrophotometer. High-resolution 
accurate mass spectra (HRMS) were obtained either at the Georgia State University Mass 
Spectrometry Facility using a Waters Q-TOF micro (ESI-Q-TOF) mass spectrometer or utilizing 
a Waters Micromass LCT TOF ES+ Premier Mass Spectrometer.  Liquid chromatography utilized 
a Waters 2487 single wavelength absorption detector with wavelengths set between 640 and 700 
nm depending on the particular photophysical properties.  The column used in LC was a Waters 
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Delta-Pak 5 uM 100A 3.9 x 150 mm reversed phase C18 column. Evaporative light scattering 
detection analyzes trace impurities that cannot be observed by alternate methods; a SEDEX 75 
ELSD was utilized in tandem with liquid chromatography to confirm purity (>95% as determined 
by LC-ELSD-MS).   
14.7.1 Synthesis.  
 
Benzo[cd]indole-2(1H)-thione (1): Freshly distilled pyridine (200 ml) was added to 
commercially obtained benzo[c,d]indol-2(1H)-one (53.9 g, 0.24 mol) and phosphorus pentasulfide 
(80 g, 0.36 mol).  This mixture was heated at 110° C for 2h and then cooled to room temperature. 
DI water (650 ml) was added to the reaction mixture and the resulting suspension was allowed to 
stand for 1h. An oily residue was obtained which was extracted with diethyl ether (3 x 350 ml) and 
the organic layer was washed with 1M HCl solution followed by brine.  The organic layer was 
collected and dried over MgSO4. The solvent was evaporated to afford the product as orange oil 
(53.1 g) which was used in the next step without additional purification.  
 
2-(methylthio)benzo[c,d]indole (2): A solution of 2 (53.1 g, 0.22 mol) was added to a 
solution of iodomethane (70 ml).  The resulting solution was stirred at room temperature for 24 h. 
The precipitate was filtered off, washed with diethyl ether (3 x 50 ml) and acetone (2 x 50 ml). 
Yield 91%. 
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Compound 3 was synthesized as previously reported. 
 
 
A mixture of compound 3 (10.2 mmol), alkyl iodide (30.6 mmol) and K2CO3 (30.6 mmol) 
were heated in DMF (40 mL) at 90 °C for 18 h under a nitrogen atmosphere. The mixture was 
cooled to room temperature and then filtered. The filtrate was concentrated under reduced pressure. 
The residue was purified on silica gel (flash column chromatography, using EtOAc–hexanes, 1:2 
as an eluent). 
(5): Yield 74%, 1H NMR (400 MHz, DMSO-d6) δ 0.86 (t, J = 7.6 Hz, 3H), 1.27 (q,  J = 7.6, 
2H), 1.75 (s, 6H), 1.82 (p,  J = 7.2 Hz, 2H), 3.39 (t, J = 7.6 Hz, 2H), 7.79 (t, J = 7.6 Hz, 1H), 7.94 
(t, J = 8.0 Hz, 1H), 8.02 (d, J = 7.2 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 8.45 (d, J = 8.0 Hz, 1H), 
8.91 (d, J = 7.2 Hz, 1H). 
 
Ester 4-5 (2.9 mmol) was dissolved in acetic acid (4 mL) and the mixture was refluxed for 
20 min. Concentrated HCl (4 mL) was added dropwise to the refluxing mixture until the color 
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changed from red to green. The mixture was cooled to room temperature, and saturated KI solution 
was added until the product started to precipitate. The product was filtered off, washed with ether, 
and dried in vacuo affording quaternary ammonium salts 6-7 in good yield. 
(7): Yield 82%, 1H NMR (400 MHz, DMSO-d6) δ 0.86 (t, J = 7.2 Hz 3H), 1.27 (m, 2H), 
1.75 (s, 6H), 1.82 (p, J = 6.8 Hz, 2H), 4.39 (t, J = 7.6 Hz, 2H), 7.79 (t, J = 8.0 Hz, 1H), 7.94 (t, 
J = 7.6 Hz, 1H), 8.02 (d, J = 7.2 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.91 
(d, J = 7.2 Hz, 1H). 
Synthesis of Benz[cd]indole aldehydes 8-9 
Individual alkylated compound was subjected to Vilsmeier formylation. DMF (5 mL) was 
added to an oven dried and nitrogen cooled round bottom flask and allowed to stir at 0 oC.  
Phosphorous oxychloride (1.5 mol. eq.) was added dropwise to the cold solution under high 
stirring.  The reaction mixture was allowed to warm to room temperature while stirring for 20 
minutes.  After 20-30 minutes at room temperature, the reaction mixture is cooled to 0 oC again.  
The individual alkylated benz[cd]indole compound was added to the cooled reaction mixture 
dropwise via syringe.  The reaction was then allowed to warm to room temperature and heated to 
80 oC for 8h.  After the starting material was consumed by monitoring with TLC eluting in 5% 
methanol in dichloromethane, the reaction mixture was allowed to cool.  The resulting mixture 
was added to a cold 40% sodium perchlorate solution in water.  The solution was left in the freezer 
for 6h.  The precipitate was then filtered and added to a 50% KOH solution in water and the 
reaction mixture was heated to reflux to hydrolyzed the dimethyl amine moiety and synthesize the 
aldehyde moiety. After 12h., the reaction mixture was allowed to cool and the product was 
extracted in DCM and the solvent was removed under reduced pressure to afford the dark 
green/brown solid in the indicated yield. 
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(E)-2-(1-methylbenzo[cd]indol-2(1H)-ylidene)acetaldehyde (8): Yield 20%; mp 149-
151oC; 1H NMR (400 MHz, DMSO-d6):  3.48 (s, 3H), 5.79 (d, J = 7.6 Hz, 1H), 7.15 (m, 1H), 
7.51-7.70 (m, 2H), 7.71 (t, J = 8.9 Hz, 1H), 8.05 (d, J = 8.0 Hz, 1H), 8.58 (d, J = 7.2 Hz, 1H), 
10.30 (d, J = 7.6 Hz, 1H). 13C NMR (100 MHz, DMSO-d6): 30.08, 102.92, 105.17, 119.29, 
125.74, 126.52, 129.54, 129.57, 130.11, 130.26, 143.16, 156.32, 186.25. 
 
(E)-2-(1-butylbenzo[cd]indol-2(1H)-ylidene)acetaldehyde (9): Yield 41%; mp 178-180 
oC; 1H NMR (400 MHz, DMSO-d6):  0.19 (t, J = 7.6 Hz, 3H), 1.41-1.36 (m, 2H), 1.64 (p, J = 7.2 
Hz, 2H), 3.98 (t, J = 7.6 Hz, 2H), 5.83 (d, J = 7.6 Hz, 1H), 7.13 (t, J = 7.2 Hz, 1H), 7.50 (s, 2H), 
7.72 (t, J = 7.6 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 8.59 (d, J = 7.2 Hz, 1H), 10.32 (d, J = 7.6 Hz, 
1H). 13C NMR (100 MHz, DMSO-d6):  14.22, 20.07, 29.82, 42.60, 102.96, 105.34, 119.27, 
126.70, 129.59, 130.17, 130.38, 142.82, 155.37, 186.36. 
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2,3,3-Trimethyl-1-(3-(trimethylammonio)propyl)-3 H-indol-1-ium bromide (14):  (2.52 g, 
61%); MP 197-199˚C. 1H NMR (400 MHz, DMSO-d6): δ 1.58 (s, 6H), 2.41 (m, 2H), 2.99 (s, 3H), 
3.17 (s, 9H), 3.98 (t, J = 7.6 Hz, 2H), 4.57 (t, J = 7.6 Hz, 2H), 7.45 (m, 2H), 7.86 (d, J = 5.2 Hz, 
1H), 8.19 (d, J = 5.2 Hz, 1H). 13C NMR (100 MHz, DMSO-d6): δ 21.3, 22.0, 25.4, 44.6, 52.5, 
61.9, 64.9, 115.6, 123.5, 129.0, 129.4, 140.9, 141.8, 197.8. HRMS (ESI) calculated for [C17H27N2]
+ 
m/z 259.2174, found m/z 259.2177.   
 
5-Fluoro-2,3,3-trimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (15): 
Yield 90%; mp 237-240 oC; 1H NMR (400 MHz, D2O): δ 1.56 (s, 6H), 2.47 (t, J = 8.8 Hz, 2H), 
3.17 (s, 9H), 3.65 (tt, J = 8.4 Hz, J = 8.4 Hz, 2H), 4.53 (t, J = 8.0 Hz, 2H), 7.34 (t, J = 9.2 Hz, 1H), 
7.82 (dd, J = 8.8 Hz, J = 4.0 Hz, 2H). 13C NMR (100 MHz, DMSO-d6): d 12.2, 20.0, 20.7, 43.3, 
52.1, 53.2, 61.5, 115.9, 123.3, 128.8, 134.3, 138.2, 142.3, 197.9. 
 
5-Chloro-2,3,3-trimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (16): 
Yield 82%; mp 215–217 C; 1H NMR (400 MHz, DMSO-d6): δ 1.65 (s, 6H), 2.56 (t, J = 8.0 Hz, 
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2H), 3.25 (s, 9H), 3.73 (tt, J = 8.0 Hz, J = 8.0 Hz, 2H), 4.64 (t, J = 8.0 Hz, 2H), 4.80 (s, 3H), 7.69 
(dd, J = 8.8 Hz, J = 2.0 Hz, 1H), 7.84–7.92 (m, 2H); 13C NMR (100 MHz, DMSO-d6): δ 12.2, 
20.0, 20.7, 43.3, 52.1, 53.2, 61.5, 115.9, 123.3, 128.8, 134.3, 138.2, 142.3, 197.9. Composition in 
theory: C(44.91%), H(5.99%), N(6.16%); Composition found: C(45.01%), H(6.29%), N(6.08%); 
HRMS (ESI) calculated for [C17H27ClN2]
2+ m/z 147.4356, found m/z 146.9909, 148.0421 
 
5-Bromo-2,3,3-trimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (17): 
Yield 81%; MP 225–227 C; 1H NMR (400 MHz, DMSO-d6): δ 1.57 (s, 6H), 2.27 (s, 9H), 3.02 (s, 
3H), 3.83 (t, J = 8.0 Hz, 2H), 4.57 (t, J = 8.0 Hz, 2H), 7.61 (m, 2H), 7.88 (t, J = 5.6 Hz, 1H). 13C 
NMR (100 MHz, DMSO-d6): δ 15.2, 22.0, 25.5, 30.6, 52.3, 54.3, 63.9, 115.6, 123.5, 128.8, 129.3, 
140.9, 141.7, 197.7. Composition in theory: C(40.91%), H(5.45%), N(5.61%); Composition 
found: C(40.84%), H(5.48%), N(5.94%); HRMS (ESI) calculated for [C17H27BrN2]
2+ m/z 
169.6611, found m/z 169.7002. 
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6,7,7-trimethyl-5-(3-(trimethylammonio)propyl)-7H-[1,3]dioxolo[4,5-f]indol-5-ium 
bromide (19): Yield 70%; Mp 255-257 oC; 1H NMR (400 MHz, D2O), : 1.48 (s, 6H), 2.45-2.40 
(m, 2H), 3.14 (s, 9H), 3.59 (t, J = 8.8 Hz, 2H), 4.44 (t, J = 8.0 Hz, 2H), 6.07 (s, 2H), 7.16 (s, 1H), 
7.31 (s, 1H).  13C NMR (100 MHz, D2O), :  21.50, 21.85, 44.45, 53.26, 54.48, 62.56, 62.59, 96.56, 
103.02, 103.84, 134.31, 137.03, 148.49, 149.67, 195.93.  
 
2-methyl-3-(3-(trimethylammonio)propyl)benzo[d]thiazol-3-ium bromide (20): Yield 
93%; Mp >260 oC; 1H NMR (400 MHz, DMSO-d6), : 2.35 (bs, 2H), 3.07 (s, 9H), 3.19 (s, 3H), 
3.62 (t, J = 8.4 Hz, 2H), 4.73 (t, J = 8.0 Hz, 2H), 7.76 (t, J = 7.6 Hz, 1H), 7.86 (t, J = 7.6 Hz, 1H), 
8.31 (t, J = 7.6 Hz, 1H).  13C NMR (100 MHz, DMSO-d6), :  17.54, 22.04, 46.12, 53.23, 62.26, 
116.95, 124.69, 128.80, 129.18, 130.23, 140.94, 177.87. 
 
3,3-Dimethyl-2-((1E,3E)-3-(1-methylbenzo[cd]indol-2(1H)-ylidene)prop-1-en-1-yl)-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide (21): Yield 33%; Mp >245-247 oC;  1H NMR 
(400 MHz, DMSO-d6): 1.79 (s, 6H), 2.23 (t, J = 7.2 Hz, 2H), 3.17 (s, 9H), 3.80  (t, J = 7.2 Hz, 
2H), 3.87 (s, 3H), 4.29 (t, J = 7.2 Hz, 2H) , 4.64 (t, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 1H), 7.27 
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(d, J = 12.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 
7.63 (d, J = 12.0 Hz, 1H), 7.84-7.79 (m, 2H), 7.97 (d, J = 12.0 Hz, 1H),8.08 (d, J = 8.0 Hz, 1H), 
8.15 (d, J = 8.0 Hz, 1H), 8.25 (d, J = 8.0 Hz, 1H), 8.79 (t, J = 12.0 Hz, 1H). 13C NMR (100 MHz, 
MeOD-d4): 21.22, 23.22, 27.77, 40.91, 49.67, 52.42, 62.96, 105.74, 108.48, 109.82, 111.37, 
122.34, 122.40, 122.93, 123.10, 125.88, 126.76, 127.75, 128.83, 129.29, 129.54, 129.96, 131.47, 
141.38, 141.55, 149.66, 149.68, 149.70, 174.83. 
 
5-Fluoro-3,3-dimethyl-2-((1E,3E)-3-(1-methylbenzo[cd]indol-2(1H)-ylidene)prop-1-en-
1-yl)-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (22): Yield 49%; Mp >260 oC; 1H 
NMR (400 MHz, MeOD-d4), : 1.88 (s, 6H), 2.41 (bs, 2H), 3.21 (bs, 2H), 3.29 (s, 9H), 3.83 (s, 
3H), 4.36 (t, J = 7.6 Hz, 2H), 7.10 (t, J = 14.4 Hz, 2H), 7.28 (t, J = 8.8 Hz, 1H), 7.43 (d, J = 7.2 
Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.66-7.60 (m, 2H), 7.73 (d, J = 8.9 Hz, 1H), 7.86 (t, J = 7.6 Hz, 
1H), 8.16 (d, J = 8.0 Hz, 1H), 8.21 (d, J = 7.2 Hz, 1H), 8.79 (t, J = 13.6 Hz, 1H).  19F NMR (375 
MHz, DMSO-d6), : 114.09. 
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5-Chloro-3,3-dimethyl-2-((1E,3E)-3-(1-methylbenzo[cd]indol-2(1H)-ylidene)prop-1-en-
1-yl)-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (23): Yield 76%; Mp >260 oC; 1H 
NMR (400 MHz, DMSO-d6), : 1.30 (s, 6H), 1.91 (bs, 2H), 3.16 (s, 9H), 3.75 (t, J = 8.0 Hz, 2H), 
3.89 (s, 3H), 4.25 (t, J = 7.6 Hz, 2H), 7.16 (d, J = 14.4 Hz, 1H), 7.29 (d, J = 13.2 Hz, 1H), 7.57 (d, 
J = 7.6 Hz, 1H), 7.74-7.66 (m, 3H), 7.86 (d, J = 7.6 Hz, 1H), 7.90 (s, 1H), 8.02 (t, J = 8.9 Hz, 1H), 
7.86 (t, J = 7.6 Hz, 1H), 8.33 (d, J = 8.0 Hz, 1H), 8.40 (d, J = 7.2 Hz, 1H), 8.71 (t, J = 13.6 Hz, 
1H). 13C NMR (100 MHz, DMSO-d6): 21.46, 28.44, 49.91, 53.09, 62.08, 62.64, 106.83, 111.23, 
113.82, 123.62, 123.77, 124.75, 129.05, 129.88, 130.12, 130.47, 130.70, 132.28, 141.04, 141.78, 
143.73, 149.56, 156.44, 174.23. 
 
 
 
5-Bromo-3,3-dimethyl-2-((1E,3E)-3-(1-methylbenzo[cd]indol-2(1H)-ylidene)prop-1-en-
1-yl)-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (24): Yield 24%; Mp >260 oC; 1H 
NMR (400 MHz, DMSO-d6), : 1.80 (s, 6H), 2.19 (bs, 2H), 3.12 (s, 9H), 3.65 (t, J = 7.2 Hz, 2H), 
3.89 (s, 3H), 4.23 (bs, 2H), 7.04 (d, J = 13.2Hz, 1H), 7.11 (d, J = 13.2 Hz, 1H), 7.60 (d, J = 8.8 
Hz, 1H), 7.76-7.72 (m, 3H), 7.88 (d, J = 6.8 Hz, 1H), 7.90 (s, 1H), 8.06 (m, 2H), 7.35 (d, J = 8.0 
Hz, 1H), 8.42 (d, J = 7.2 Hz, 1H), 8.72 (t, J = 13.2 Hz, 1H). 13C NMR (100 MHz, DMSO-d6): 
22.57, 29.21, 32.12, 42.42, 51.01, 54.11, 64.41, 106.95, 110.22, 114.29, 119.98, 125.23, 126.25, 
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127.30, 128.85, 130.73, 130.89, 131.19, 131.49, 133.22, 133.47, 142.35, 142.84, 144.86, 151.32, 
158.77, 175.22. 
 
 
2-((1E,3E)-3-(1-butylbenzo[cd]indol-2(1H)-ylidene)prop-1-en-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium bromide (25): Yield 54%; Mp 164-165 oC;  1H NMR 
(400 MHz, CDCl3): 0.98 (t, J = 8.0 Hz, 3H),1.60 (q, J = 8.0 Hz, 2H), 1.79 (s, 6H),1.93 (t, J = 8.0 
Hz, 2H), 2.43 (t, J = 8.0 Hz, 2H), 3.41 (s, 9H), 4.36 (t, J = 8.0 Hz, 2H),  4.46 (t, J = 8.0 Hz, 2H), 
4.64 (t, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 1H), 7.27 (d, J = 12.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 
1H), 7.51 (t, J = 8.0 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 7.63 (d, J = 12.0 Hz, 1H), 7.84-7.79 (m, 
2H), 7.97 (d, J = 12.0 Hz, 1H), 8.08 (d, J = 8.0 Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H), 8.25 (d, J = 8.0 
Hz, 1H), 8.79 (t, J = 12.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): 13.61, 19.94, 21.46, 28.69, 30.90, 
40.99, 44.28, 48.92, 53.85, 61.90, 107.24, 108.77, 110.09, 113.14, 121.34, 122.28, 125.10, 125.60, 
125.81, 129.02, 129.07, 129.39, 129.75, 130.71, 140.05, 141.02, 141.11, 149.16, 155.06, 173.29 
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5-Bromo-2-((1E,3E)-3-(1-butylbenzo[cd]indol-2(1H)-ylidene)prop-1-en-1-yl)-3,3-
dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide (28): Yield 50%; Mp >260 oC;  
1H NMR (400 MHz, DMSO-d6): 0.93 (t, J = 8.0 Hz, 3H), 1.50 (t, J = 8.0 Hz, 2H), 1.80 (s, 8H), 
2.22 (s, 2H), 3.16 (s, 9H), 3.80 (bs, 2H), 4.25 (bs, 2H),  4.39 (bs, 2H), 7.31 (d, J = 12.0 Hz, 1H), 
7.46 (d, J = 8.0 Hz, 1H), 7.72-7.69 (m, 3H), 7.87 (bs, 1H), 8.01 (t, J = 8.0 Hz, 1H), 8.34 (d, J = 
8.0 Hz, 1H), 8.41 (d, J = 8.0 Hz, 1H), 8.75 (d, J = 12.0 Hz, 1H). 13C NMR (100 MHz, DMSO-d6): 
14.30, 20.08, 21.46, 28.50, 31.30, 41.80, 44.33, 49.88, 53.09, 62.71, 107.01, 109.35, 111.36, 
114.21, 118.52, 123.77, 124.78, 126.35, 128.36, 129.60, 129.99, 130.18, 130.76, 131.88, 132.33, 
141.28, 141.47, 144.05, 149.73, 155.70, 174.03. 
 
 
6-((1E,3E)-3-(1-butylbenzo[cd]indol-2(1H)-ylidene)prop-1-en-1-yl)-7,7-dimethyl-5-(3-
(trimethylammonio)propyl)-7H-[1,3]dioxolo[4,5-f]indol-5-ium bromide (30): Yield 63%; Mp 
>260 oC; 1H NMR (400 MHz, DMSO-d6), : 0.94 (t, J = 7.2 Hz, 3H), 1.50-1.46 (m, 2H), 1.79-
1.75 (m, 8H), 2.21 (bs, 2H), 3.15 (s, 9H), 3.74 (d, J = 7.6 Hz, 2H), 4.28 (t, J = 8.8 Hz, 2H), 6.15  
(s, 2H),  7.28-7.18 (m, 2H), 7.47 (d, J = 8.8 Hz, 2H), 7.69 (t, J = 8.0 Hz, 1H), 7.75 (d, J = 7.6 Hz, 
1H), 7.98 (t, J = 7.6 Hz, 1H), 8.31-8.25 (m, 2H), 8.64 (t, J = 12.0 Hz, 1H). 13C NMR (100 MHz, 
MeOD-d4): 12.94, 19.90, 21.31, 27.81, 30.83, 41.35, 43.71, 49.77, 52.62, 62.86, 94.11, 102.36, 
103.14, 106.48, 107.82, 109.15, 122.35, 125.01, 126.33, 129.28, 129.46, 129.61, 130.20, 130.93, 
135.52, 135.56, 141.22, 147.16, 148.30, 148.78, 154.79, 174.94. 
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2-((1E,3E)-3-(1-methylbenzo[cd]indol-2(1H)-ylidene)prop-1-en-1-yl)-3-(3-
(trimethylammonio)propyl)benzo[d]thiazol-3-ium bromide (31): Yield 37%; Mp 230-232 oC; 1H 
NMR (400 MHz, DMSO-d6), : 2.28 (bs, 2H), 3.05 (s, 2H), 3.16 (s, 9H), 3.72 (s, 2H), 4.62 (t, J = 
7.2 Hz, 2H), 6.81 (d. J = 13.2 Hz, 1H), 7.41 (d, J = 6.8 Hz, 1H), 7.59 (d, J = 13.2 Hz, 1H), 7.59 
(d, J = 13.2 Hz, 1H). 7.75-7.71(m, 4H), 7.87 (t, J = 8.0 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 8.20 (t, 
J = 8.8 Hz, 2H), 8.45 (d, J = 6.8 Hz, 1H), 8.59 (t, J = 13.2 Hz, 1H). 13C NMR (100 MHz, MeOD-
d4): 21.71, 29.52, 43.59, 52.59, 62.56, 105.28, 107.66, 113.78, 121.34, 122.80, 124.89, 126.05, 
127.92, 128.58, 128.94, 129.31, 129.55, 129.60, 129.82, 130.18, 140.68, 141.39, 146.38, 154.03, 
167.34. HRMS (ESI) calculated for [C17H27BrN2] 2+ m/z 169.6611, found m/z 169.7002. 
 
2-((1E,3E)-3-(1-butylbenzo[cd]indol-2(1H)-ylidene)prop-1-en-1-yl)-3-(3-
(trimethylammonio)propyl)benzo[d]thiazol-3-ium bromide (32): Yield 56%; Mp 247-249oC; 1H 
NMR (400 MHz, DMSO-d6), : 0.94 (t, J = 7.2 Hz, 3H), 1.51-1.42 (m, 2H), 1.76 (p, J = 7.2, 2H), 
2.30 (bs, 2H), 3.12 (s, 9H), 3.80 (s, 2H), 4.21 (t, J = 7.2 Hz, 2H), 4.61 (t, J = 7.6 Hz, 2H),  7.03 (d. 
J = 11.2 Hz, 1H), 7.41 (d, J = 7.2 Hz, 1H), 7.68-7.58 (m, 4H), 7.73 (t, J = 7.6 Hz, 1H), 7.89 (t, J = 
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8.0 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 8.17 (t, J = 8.8 Hz, 2H), 8.44 (d, J = 6.8 Hz, 1H), 8.64 (t, J 
= 12.4 Hz, 1H). 13C NMR (100 MHz, DMSO-d6), : 14.32, 20.14, 22.29, 30.83, 43.57, 44.57, 
53.11, 62.43, 105.94, 107.77, 108.32, 115.38, 121.40, 124.05, 125.35, 126.87, 127.08, 129.16, 
130.01, 130.09, 130.24, 130.61, 141.50,141.96, 147.06, 152.69, 168.33, 168.37.  HRMS (ESI) 
calculated for [C17H27BrN2] 2+ m/z 169.6611, found m/z 169.7002. 
 
(E)-2-((1-butylbenzo[cd]indol-2(1H)-ylidene)methyl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium perchlorate (35):  A suspension of  34 (0.57g, 2.5 
mmol) and corresponding indolium salt 14 (2.5 mmol) in acetonitrile (15 ml) was added to 
triethylamine (1 ml) and then refluxed for 1h. The reaction mixture was cooled to room 
temperature and diethyl ether (75 ml) was added and then allowed to stand for 1h. Precipitated dye 
was filtered off, washed with diethyl ether (2x50ml) and crude product was purified by anion-
exchange reaction with saturated ethanolic solution of sodium perchlorate.  Yield 31%; MP > 250° 
C. 1H NMR (DMSO-d6): δ 8.38 (d, J = 8.0 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.93-7.88 (m, 2H), 
7.78-7.71 (m, 4H), 7.58 (t, J = 8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 6.27 (s, 1H), 4.48 (t, J = 8.0 
Hz, 2H), 4.23 (t, J = 8.0 Hz, 2H), 3.14-3.05 (m, 2H), 2.90 (s, 9H), 2.06 (t, J = 8.0 Hz, 2H), 1.86 (t, 
J = 8.0 Hz, 2H), 1.67 (s, 6H), 1.47 (q, J = 8.0 Hz, 2H), 0.96 (t, J = 8.0 Hz, 3H). 13C NMR (DMSO-
d6): 180.35, 156.35, 141.52, 140.63,140.54, 132, 96, 130.16, 130.08, 129.60, 129.25, 128.59, 
128.56, 126.41, 123.91, 123.71, 123.25, 113.99, 111.53, 83.60, 61.90, 52.24, 51.71, 46.86, 43.74, 
30.00, 25.77, 21.27, 19.49, 13.76. 
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General Procedure for the Synthesis of Trimethine Cyanines 42 and 43. A suspension 
of indolium salt 14 or 17 (1.2 mmol) and diphenyl formamidine (1.2 mmol) in acetic anhydride (5 
ml) was heated at 120° C for 0.5h and then cooled to room temperature. This deep red reaction 
mixture was allowed to cool and a suspension of 31 (0.45g, 1.2mmol) in pyridine (8 ml) was added.  
This mixture was stirred at rt for 2h and was monitored using UV-Vis spectrophotometry and 
alumina TLC plates eluting with 5% methanol in DCM. Diethyl ether (50 ml) was added to a blue-
colored reaction mixture and the solution was allowed to stand for 30 min. The ether layer was 
decanted and this precipitation procedure was repeated twice. Dyes were purified by open column 
chromatography using neutral alumina gel, eluent MeOH/DCM from 1/25 to 1/10. 
 
3-(6-bromo-1-butylbenzo[cd]indol-2(1H)-ylidene)prop-1-enyl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indolium dibromide (42): Yield 31%; MP >250° C. 1H NMR (400 
MHz, DMSO-d6): δ 8.73 (t, J = 12.0 Hz, 1H), 8.33 (d, J = 8.0 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1H), 
8.07 (t, J = 8.0 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.76 (t, J = 8.0 Hz, 2H), 7.55 (t, J = 8.0 Hz, 
1H),7.44-7.35 (m, 4H), 4.32 (t, J = 8.0 Hz, 4H), 3.84 (t, J = 8.0 Hz, 2H), 3.17 (s, 9H),  2.44 (t, J = 
8.0 Hz, 2H), 1.81 (s, 6H), 1.75 (t, J = 8.0 Hz, 2H),1.48 (q, J = 8.0 Hz, 2H), 0.91 (t, J = 8.0 Hz, 
3H). 13C NMR (100 MHz, DMSO-d6): δ 175.90, 153.75, 149.29, 142.19, 141.71, 141.29, 132.91, 
131.79, 129.73, 129.30, 129.20, 128.20, 126.84, 126.09, 123.16, 115.30, 112.99, 110.68, 108.65, 
108.31, 62.56, 53.12, 50.20, 43.96, 41.87, 30.91, 28.43, 21.59, 19.99, 14.23. 
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5-Bromo-3-(6-bromo-1-butylbenzo[cd]indol-2(1H)-ylidene)prop-1-enyl)-3,3-dimethyl-1-
(3-(trimethylammonio)propyl)-3H-indolium dibromide (43): Yield 18%; MP  241-242° C. 1H 
NMR (400 MHz, DMSO-d6): δ 8.70 (m, 1H), 8.37 (m, 1H), 8.16 (m, 1H), 8.12-8.05 (m, 2H), 7.93 
(m, 1H), 7.71 (m, 2H), 7.49 (m, 3H), 4.32 (m, 4H), 3.85 (m, 2H), 3.17 (s, 9H),  2.23 (m, 2H), 1.80 
(m, 8H), 1.47 (q, J = 8.0 Hz, 2H), 0.93 (t, J = 8.0 Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ 
174.44, 153.63, 149.00, 143.69, 140.62, 132.34, 131.29, 129.39, 128.66, 127.94, 125.75, 125.41, 
118.47, 115.15, 114.04, 110.63, 109.09, 107.87, 61.88, 52.41, 49.56, 43.52, 41.42, 30.42, 27.84, 
27.64, 20.93, 19.33, 13.63. 
14.7.2 Nucleic Acids 
The DNA oligonucleotides: Tel22 d[AGGG(TTAGGG)3], MYC19 
d[(AGGGTGGGG)2A], and AATT hairpin duplex control d[CGAATTCGTTTTCGAATTCG] 
with and without 5’-biotin labels were purchased from Integrated DNA Technologies (Coralville, 
IA, USA) with HPLC purification and mass spectrometry characterization. For NMR studies, a 
modified c-myc sequence, MYC22, d[TG(AGGGTGGGG)2AA] was used. The concentration of 
all the oligonucleotides was calculated using the absorbance at 260 nm and the manufacturer 
provided extinction coefficients determined by the nearest-neighbor method [ref]. Stock solutions 
of the oligonucleotides and the dyes were prepared in deionized water and diluted using 
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appropriate experimental buffer prior to use. Experiments were conducted in 10 mM TRIS, or 10 
mM HEPES for SPR, containing 50 mM KCl and 1 mM EDTA adjusted to pH 7.3.  
14.7.3 Thermal Melting 
DNA in TRIS K+ buffer and a specific ratios of cyanine dyes:DNA (0:1 to 6:1) in a 1 cm 
path length quartz cells. The experiment were conducted on a Cary Varian 300 BIO UV-Vis 
thermal melting spectrophotometer (Santa Clara, CA) with monitored heating and cooling rates of 
0.5 °C/min. The controlled wavelength of were set at 295 and 260 nm for quadruplex and duplex, 
respectively. The corrected data were normalized and the Tm were determined using combination 
of derivative function and graphical estimation. The reported ΔTm are reproducible within ± 1  °C. 
14.7.4 Surface Plasmon Resonance 
Biosensor SPR experiments were performed with two-channel BIAcore X100 optical 
biosensor system (BIAcore, Inc.) and streptavidin-coated sensor chips. The chips preparation were 
done by an extensive wash of HBS-EP+ buffer (GE Healthcare, Inc.) followed by activation buffer 
(1 M NaCl and 50 mM NaOH) and again extensive washing of HBS-EP+ buffer. Injection of single 
stranded biotinylated DNA until the change in RUmax reach 330 - 350. Compound serial dilutions 
were prepared in HEPES experimental buffer (10 mM HEPES, 50 mM KCl, 1 mM EDTA, 0.005% 
(v/v) P20 (GE Healthcare, Inc.), pH 7.4). The experiment were set so that the contact time are 
180s, the dissociation time are 900s and the regeneration contact time of 60s with stabilization 
period of 180s, and the constant temperature of 25 °C. Two-site fitting model (equation below) 
was used to fit the sensorgrams curve in Kaleidagraph 4.0 software to obtain the dissociation 
constant. K1 and K2 are equilibrium constants for first and second binding sites respectively and 
Cfree are compound concentrations in equilibrium. 
 r = (K1Cfree + 2 K1K2Cfree
2)/ (1+ K1Cfree) + K1K2Cfree
2) 
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APPENDICES 
The following appendices contain the supplemental information including NMR, MS and 
biological data.  
 
 
MeOD-d4
Appendix A
Experimental Data for Chapter 3 -- CORRELATING TISSUE LOCALIZATION OF HYDROPHOBIC CYANINES
387
MeOD-d4
388
389
MeOD-d4
390
MeOD-d4
391
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
417.2107          417.2098       0.9      2.2      13.5     9.6        C27  H30  N2  Cl
392
393
394
diluted in 80%MeOH 15:28:12  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_32_HENARY-ACCU_02-01-2013_ESI-POS 59 (1.177) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Cm (56:60)
8.82e3463.1554
368.1591
318.1705
556.2771
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
461.1585   461.1592       -0.7     -1.5     13.5     4.5        C27  H30  N2  Br 
395
DMSO-d6
396
DMSO-d6
397
in 75%ACN 15:01:17  25-Apr-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_LO-4_HENARY-ACCU_04252013_ESI-POS01 96 (1.785) AM (Cen,4, 80.00, Ar,6000.0,556.28,0.70); Sm (SG, 3x3.00); Cm (96:107)
1.22e4411.2820
262.0974 453.2940
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
411.2820   411.2800       2.0      4.9      13.5     100.6      C29  H35  N2
398
DMSO-d6
399
DMSO-d6
400
DMSO-d6
401
DMSO-d6
402
403
MeOD-d4
404
405
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
467.3412   467.3426       -1.4     -3.0     13.5     42.8       C33  H43  N2
406
DMSO-d6
407
DMSO-d6
408
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
501.3059   501.3037       2.2      4.4      13.5     1.0        C33  H42  N2  Cl
409
DMSO-d6
410
DMSO-d6
411
in 75%ACN 15:25:04  25-Apr-2013
m/z
440 460 480 500 520 540 560 580 600 620
%
0
100
ERIC_E-50_HENARY-ACCU_04252013_ESI-POS01 94 (1.751) AM (Cen,4, 80.00, Ar,6000.0,556.28,0.70); Sm (SG, 3x3.00); Cm (81:94)
1.28e4545.2532
437.1963 578.2670
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
545.2532   545.2531       0.1      0.2      13.5     154.1      C33  H42  N2  Br 
412
DMSO-d6
413
DMSO-d6
414
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
591.3741   591.3739       0.2      0.3      21.5     84.6       C43  H47  N2 
415
DMSO-d6
416
DMSO-d6
417
in 75%ACN 14:00:10  25-Apr-2013
m/z
540 560 580 600 620 640 660 680 700
%
0
100
ERIC_E-44_HENARY-ACCU_04252013_ESI-POS01 154 (2.862) AM (Cen,4, 80.00, Ar,6000.0,556.28,0.70); Sm (SG, 3x3.00); Cm (153:197)
1.13e4625.3369
610.3130
578.2528
556.2771
Elemental Composition Report
Mass            Calc. Mass     mDa PPM      DBE      i-FIT      Formula
625.3369     625.3350       1.9      3.0      21.5     89.1       C43  H46  N2  Cl 
418
DMSO-d6
419
DMSO-d6
420
in 75%ACN 15:31:43  25-Apr-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_ES-17_HENARY-ACCU_04252013_ESI-POS01 37 (0.689) AM (Cen,4, 80.00, Ar,6000.0,556.28,0.70); Sm (SG, 3x3.00); Cm (36:58)
3.77e4671.2850
556.2771
262.0934 415.2134
in 75%ACN 15:31:43  25-Apr-2013
m/z
666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682
%
0
100
ERIC_ES-17_HENARY-ACCU_04252013_ESI-POS01 37 (0.689) AM (Cen,4, 80.00, Ar,6000.0,556.28,0.70); Sm (SG, 3x3.00); Cm (36:58)
3.77e4671.2850669.2845
670.2936
672.2925
673.2867
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
669.2845   669.2844       0.1      0.1      21.5     870.8      C43  H46  N2  Br 
421
DMSO-d6
422
DMSO-d6
423
424
DMSO-d6 at 50 
oC
425
DMSO-d6 at 50 
oC
426
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
517.2401   517.2411       -1.0     -1.9     19.5     39.9       C35  H34  N2  Cl 
427
DMSO-d6
428
DMSO-d6
429
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
561.1914   561.1905       0.9      1.6      19.5     7.3        C35  H34  N2  Br 
430
DMSO-d6
431
DMSO-d6
432
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
511.3098        511.3113       -1.5     -2.9     19.5     25.7       C37  H39  N2
433
DMSO-d6
434
DMSO-d6
435
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
545.2717   545.2724       -0.7     -1.3     19.5     6.3        C37  H38  N2  Cl 
436
DMSO-d6
437
DMSO-d6
438
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
589.2204           589.2218       -1.4     -2.4     19.5     4.4        C37  H38  N2  Br 
439
DMSO-d6
440
DMSO-d6
441
Eric_E-17_Henary-ACCU_11202013_ESI-POS-01 #101-228 RT: 1.37-3.11 AV: 128 SB: 89 0.58-1.41 , 2.73-3.10 NL: 2.73E7
T: FTMS + p ESI Full ms [100.00-1000.00]
100 200 300 400 500 600 700 800 900 1000
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
567.3718
z=1
291.1792
z=2
920.1746
z=1
728.1408
z=1
468.5737
z=2
195.1012
z=1
348.1950
z=1
583.3656
z=1
136.0753
z=?
417.1023
z=1
553.3573
z=1
676.3667
z=1
809.1992
z=2
879.2629
z=?
986.3150
z=?
m/z Theo. Mass Delta (ppm) RDB equiv. Composition
567.3718 567.3734 -2.81 19.5 C41 H47 N2
442
DMSO-d6
443
DMSO-d6
444
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
601.3350   601.3350       0.0      0.0      19.5     36.1       C41  H46  N2  Cl 
445
DMSO-d6
446
DMSO-d6
447
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
645.2866   645.2844       2.2      3.4      19.5     20.4       C41  H46  N2  Br 
448
DMSO-d6
449
DMSO-d6
450
in 75%ACN 15:39:05  25-Apr-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_E-16_HENARY-ACCU_04252013_ESI-POS02 93 (1.732) AM (Cen,4, 80.00, Ar,6000.0,556.28,0.70); Cm (93:108)
7.57e3499.2690
457.2522322.1617
691.4028
556.2771
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
691.4028   691.4052       -2.4     -3.5     27.5     142.0      C51  H51  N2 
451
DMSO-d6
452
DMSO-d6
453
Elemental Composition Report
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
725.3663   725.3663       0.0      0.0      27.5     69.7       C51  H50  N2  Cl 
454
DMSO-d6
455
DMSO-d6
456
Appendix B
Experimental Data for Chapter 4 -- ELECTRONIC FACTORS INFLUENCE BIODISTRIBUTION OF CYANINES
457
MeOD-d4
458
MeOD-d4 459
460
MeOD-d4 461
MeOD-d4 462
463
DMSO-d6
464
DMSO-d6
465
diluted in 80%MeOH 15:28:12  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_32_HENARY-ACCU_02-01-2013_ESI-POS 59 (1.177) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Cm (56:60)
8.82e3463.1554
368.1591
318.1705
556.2771
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
461.1585   461.1592       -0.7     -1.5     13.5     4.5        C27  H30  N2  Br 
466
DMSO-d6 467
DMSO-d6 468
DMSO-d6 with Hexafluorobenzene
19F Standard
Referenced at -164.9 
469
diluted in 80%MeOH 17:23:31  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_22_HENARY-ACCU_02-01-2013_ESI-POS01 23 (0.458) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Cm (21:25)
1.33e4419.2296
368.1620
173.9916 299.0565
556.2771
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
419.2296      419.2299       -0.3     -0.7     13.5     9.4        C27  H29  N2  F2 
MM19-H
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00
%
0
100
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00
A
U
0.0
2.0e-1
4.0e-1
6.0e-1
T_14 3: Diode Array 
Range: 7.979e-19.95
T_14 1: TOF MS ES+ 
TIC
501
6.60
6.195.965.26
5.02
4.90
4.86
4.53
7.4
8.24
8.44
8.67 10.00
8.92
10.28
470
logD at pH 7.4 : (3.84)
BioD result of Compound 17
Endocrine 
Gland
Salivary Adrenal Thyroid Pituitary Mammary
++ - ++ +++ -
Lymph 
node
Neck Axillary Groin Lumbar Kidney
+ + + + -
Organ & 
Tissue
He Lu Li Pa/Sp Ki Du In Mu
Brain 
(CP)
Brown 
fat
- + - + / - +++ + + - +++ -
Ki       Du      In      Mu
He     Lu         Li     Pa/Sp 
471
DMSO-d6 472
DMSO-d6 with Hexafluorobenzene
19F Standard
Referenced at -164.9 
473
MM19-H
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
A
U
0.0
2.5e-1
5.0e-1
7.5e-1
1.0
1.25
T_20 3: Diode Array 
Range: 1.52210.02
MM19-H
m/z
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400
%
0
100
T_20 508 (10.033) Cm (502:515) 1: TOF MS ES+ 
76452.6628
452.6360
141.9527
142.9355
454.6494
454.6673
454.7300
474
Ki      Du     In        Mu
He     Lu      Li     Pa/Sp 
BioD result of Compound 18
Endocrine 
Gland
Salivary Adrenal Thyroid Pituitary Mammary
++ + ++ ++ -
Lymph 
node
Neck Axillary Groin Lumbar Kidney
- - + ++ -
Organ & 
Tissue
He Lu Li Pa/Sp Ki Du In Mu
Brain 
(CP)
Brown 
fat
- + ++ ++ / - +++ + + - + -
475
476
DMSO-d6 with Hexafluorobenzene
19F Standard
Referenced at -164.9 
477
diluted in 80%MeOH 15:58:33  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_34_HENARY-ACCU_02-01-2013_ESI-POS 45 (0.897) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Sm (SG, 3x3.00); Cm (45:50)
9.20e3499.1402
318.1717
283.0795
231.1836
368.1607 556.2771
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
497.1394 497.1404       -1.0     -2.0     13.5     0.8        C27  H28  N2  F2  Br 
478
BioD result of Compound 19
Endocrine 
Gland
Salivary Adrenal Thyroid Pituitary Mammary
+ - + + -
Lymph 
node
Neck Axillary Groin Lumbar Kidney
- - - - -
Organ & 
Tissue
He Lu Li Pa/Sp Ki Du In Mu
Brain 
(CP)
Brown 
fat
- + + - / - ++ + + - - -
Ki      Du        In      Mu
He     Lu        Li      Pa/Sp 
479
DMSO-d6 480
DMSO-d6 481
diluted in 80%MeOH 17:14:54  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_23_HENARY-ACCU_02-01-2013_ESI-POS01 72 (1.429) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Cm (72:78)
9.98e3451.1733
368.1611
158.0193
556.2771
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
451.1722   451.1708       1.4      3.1      13.5     17.7       C27  H29  N2  Cl2
482
200 ms
1000 ms
1000 ms 250 ms
500 ms
500 ms
750 ms
1000 ms
250 ms
1000 ms
1000 ms
2000 ms
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Injection solution: 30% FBS in saline
Animal: CD-1 mouse
Injection route: Penial vein
Dose: 25 nmol (250 µM x 100 µL)
Ki    Du    In     Mu
He   Lu     Li    Pa/Sp 
Compound 20
(4h post-injection)
483
DMSO-d6
484
DMSO-d6
485
diluted in 80%MeOH 16:44:36  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_29_HENARY-ACCU_02-01-2013_ESI-POS 120 (2.394) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Cm (117:123)
1.35e4485.1317
368.1613
299.0558
158.0198
226.0040
437.1984
556.2771
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
485.1317   485.1318       -0.1     -0.2     13.5     2.3        C27  H28  N2  Cl3 
MM19-H
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00
%
0
100
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00
A
U
0.0
2.5e-1
5.0e-1
7.5e-1
1.0
1.25
T_24 3: Diode Array 
Range: 1.35910.60
T_24 1: TOF MS ES+ 
TIC
5.99e4
10.65
1.63
486
BioD result of Compound 21
Endocrine 
Gland
Salivary Adrenal Thyroid Pituitary Mammary
+ + + + -
Lymph 
node
Neck Axillary Groin Lumbar Kidney
- - - + -
Organ & 
Tissue
He Lu Li Pa/Sp Ki Du In Mu
Brain 
(CP)
Brown 
fat
- - +++ - / - ++ + - - + -
Ki      Du       In        Mu
He     Lu      Li     Pa/Sp 
487
DMSO-d6
488
DMSO-d6
489
diluted in 80%MeOH 15:36:17  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_35_HENARY-ACCU_02-01-2013_ESI-POS 113 (2.254) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Sm (SG, 3x3.00); Cm (110:117)
1.29e4531.0789
368.1623
158.0202226.0048
426.2224
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
529.0810      529.0813       -0.3     -0.6     13.5     1.4        C27  H28  N2  Cl2  Br 
MM19-H
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00
%
0
100
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00
A
U
0.0
2.0e-1
4.0e-1
6.0e-1
8.0e-1
T_25 3: Diode Array 
Range: 1.04210.78
T_25 1: TOF MS ES+ 
TIC
5.26e4
10.81
490
BioD result of Compound 22
Endocrine 
Gland
Salivary Adrenal Thyroid Pituitary Mammary
+ + + + -
Lymph 
node
Neck Axillary Groin Lumbar Kidney
- - - + -
Organ & 
Tissue
He Lu Li Pa/Sp Ki Du In Mu
Brain 
(CP)
Brown 
fat
- + +++ + / - ++ + + - - -
Ki        Du      In        Mu
He     Lu         Li     Pa/Sp 
491
DMSO-d6 492
DMSO-d6 493
diluted in 80%MeOH 17:10:50  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_24_HENARY-ACCU_02-01-2013_ESI-POS01 22 (0.437) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Sm (SG, 3x3.00); Cm (21:32)
1.96e4541.0671
437.1979368.1608
158.0184
231.0713
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
539.0695   539.0697       -0.2     -0.4     13.5     2.8        C27  H29  N2  Br2 
494
200 ms
1000 ms
1000 ms 500 ms
500 ms
500 ms
750 ms
1000 ms
500 ms
1000 ms
1000 ms
2000 ms
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Injection solution: 30% FBS in saline
Animal: CD-1 mouse
Injection route: Penial vein
Dose: 25 nmol (250 µM x 100 µL)
Ki     Du     In     Mu
He     Lu     Li    Pa/Sp 
BioD of Compound 23
(4h post-injection)
495
DMSO-d6
496
DMSO-d6
497
diluted in 80%MeOH 16:40:08  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_30_HENARY-ACCU_02-01-2013_ESI-POS 39 (0.779) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Sm (SG, 3x3.00); Cm (32:42)
1.49e4575.0286
368.1617
415.2133
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
573.0316   573.0308       0.8      1.4      13.5     2.2        C27  H28  N2  Cl Br2 
MM19-H
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00
%
31
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00
A
U
0.0
5.0e-1
1.0
1.5
T_18 3: Diode Array 
Range: 1.67310.89
T_18 1: TOF MS ES+ 
TIC
2.37e3
10.93
6.576.43
6.35
6.777.35
7.79
10.87
498
BioD result of Compound 24
Endocrine 
Gland
Salivary Adrenal Thyroid Pituitary Mammary
++ + ++ ++ -
Lymph 
node
Neck Axillary Groin Lumbar Kidney
- + + - -
Organ & 
Tissue
He Lu Li Pa/Sp Ki Du In Mu
Brain 
(CP)
Brown 
fat
- + +++ + / - +++ + + - + -
Ki   Du         In     Mu
He     Lu        Li     Pa/Sp 
499
DMSO-d6
500
DMSO-d6
501
diluted in 80%MeOH 15:51:38  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_36_HENARY-ACCU_02-01-2013_ESI-POS 64 (1.277) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Sm (SG, 3x3.00); Cm (62:69)
8.09e3620.9786
283.0791
203.1524
142.0433
556.2771
415.2122
368.1633
760.3023
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
616.9814   616.9803       1.1      1.8      13.5     9.0        C27  H28  N2  Br3 
502
200 ms
1000 ms
500 ms 500 ms
750 ms
750 ms
750 ms
1000 ms
750 ms
1000 ms
1000 ms
1000 ms
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Injection solution: 30% FBS in saline
Animal: CD-1 mouse
Injection route: Penial vein
Dose: 25 nmol (250 µM x 100 µL)
Ki      Du   In     Mu
He   Lu     Li    Pa/Sp 
BioD result of Compound 25
(4h post-injection)
503
504
T_81_19F_DMSO.002.esp
0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
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d
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M01(s)
M02(s)
-1
6
5
.0
1
-6
2
.0
0
505
m/z
100 125 150 175 200 225 250 275 300 325 350 375 400 425 450 475 500 525 550 575 600 625 650 675 700 725 750 775 800 825 850 875 900 925 950 975 1000
%
0
100
ERIC_T_81_HENARY_092115_3 448 (4.460) Cm (442:448) TOF MS ES+ 
9.84e3519.2393
381.3347
130.1965
520.2548
521.2836
m/z
488 490 492 494 496 498 500 502 504 506 508 510 512 514 516 518 520 522 524 526 528 530 532 534 536 538 540 542 544 546 548 550 552 554 556
%
0
100
ERIC_T_81_HENARY_092115_3 448 (4.460) Cm (442:448) TOF MS ES+ 
9.84e3519.2393
520.2548
521.2836
506
FLARE Parameters Study Info. Measurement 
Model K-FLARE™ Zoom Channel 700 nm Chemical 26 Formulation C-D5W FOV 5 / 3.3 / 2 cm
Fluence rate 0.54 mW at 660 nm Filter
660-20/673lpxr/Dual BP
(710-50 and 781lp)
Animal CD-1 Inj. route R.O. ROI 13
Working Dt. 9 in Bit depth 16 Gender Female Anesthesia K+X Acquisition time 1 h post inj.
Gain 12 dB Matrix size 512x512 Dose 100 nmol Body Weight 25-30 g Exp. Time (msec) L, M, H
SBR (Bg: Mu)
Neck&Axillary Chest Abdomen
Adrenal GLOvary
Sciatic Nv Brown Fat Organ PA GL
Intestine
Mammary GL
Br Top Br Down Br Section I Br Section II
100 ms
Thyroid
350 ms 250 ms 250 ms
250 ms 250 ms 250 ms 550 ms
350 ms 350 ms 250 ms 350 ms
350 ms
2000 ms 2000 ms 2000 ms 2000 ms
0
1
2
3
4
5
6
7
8
He Lu Li Pa Sp Ki Du In
Exact Mass 519.22
LogD at 7.4 5.31
TPSA 6.25
HBD 0.00
HBA 1.00
Total Charge 1.00
Refractivity 151.00
Rotatable Bond 5.00
SB pKa 1.39
SA pKa 0.00
507
508
T_82_19F_DMSO.002.esp
0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
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a
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d
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-1
6
4
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5
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2
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509
m/z
100 125 150 175 200 225 250 275 300 325 350 375 400 425 450 475 500 525 550 575 600 625 650 675 700 725 750 775 800 825 850 875 900 925 950 975 1000
%
0
100
ERIC_T_82_HENARY_092115_2 686 (6.825) Cm (679:691) TOF MS ES+ 
1.81e4553.1996
130.1904
381.3347
226.9664
158.9820
519.2638
555.2211
556.2332
m/z
549 550 551 552 553 554 555 556 557 558 559 560 561
%
0
100
ERIC_T_82_HENARY_092115_2 686 (6.825) Cm (679:691) TOF MS ES+ 
1.81e4553.1996
555.2211
554.2351
556.2332
510
FLARE Parameters Study Info. Measurement 
Model K-FLARE™ Zoom Channel 700 nm Chemical 27 Formulation C-D5W FOV 5 / 3.3 / 2 cm
Fluence rate 0.54 mW at 660 nm Filter
660-20/673lpxr/Dual BP
(710-50 and 781lp)
Animal CD-1 Inj. route R.O. ROI 13
Working Dt. 9 in Bit depth 16 Gender Female Anesthesia K+X Acquisition time 1 h post inj.
Gain 12 dB Matrix size 512x512 Dose 100 nmol Body Weight 25-30 g Exp. Time (msec) L, M, H
SBR (Bg: Mu)
Neck&Axillary Chest Abdomen
Adrenal GLOvary Thyroid
Sciatic Nv Brown Fat Organ PA GL
Intestine
Mammary GL
150 ms 150 ms 150 ms
150 ms 150 ms 150 ms 150 ms
150 ms 150 ms 150 ms 150 ms
150 ms
Br Top Br Down Br Section I Br Section II
2000 ms 2000 ms 2000 ms 2000 ms
100 ms 0
2
4
6
8
10
12
14
16
18
He Lu Li Pa Sp Ki Du In
Exact Mass 553.18
LogD at 7.4 5.55
TPSA 6.25
HBD 0.00
HBA 1.00
Total Charge 1.00
Refractivity 156.00
Rotatable Bond 5.00
SB pKa 1.31
SA pKa 0.00
511
512
T_83_19F_DMSO.002.esp
0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
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m/z
100 125 150 175 200 225 250 275 300 325 350 375 400 425 450 475 500 525 550 575 600 625 650 675 700 725 750 775 800 825 850 875 900 925 950 975 1000
%
0
100
ERIC_T_83_HENARY_092115 700 (6.962) Cm (698:707) TOF MS ES+ 
9.14e3597.1597
553.2248
130.1965
599.1549
600.1932
601.2061
m/z
579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623
%
0
100
ERIC_T_83_HENARY_092115 700 (6.962) Cm (698:707) TOF MS ES+ 
9.14e3597.1597
599.1549
598.1832
600.1932
601.2061
514
FLARE Parameters Study Info. Measurement 
Model K-FLARE™ Zoom Channel 700 nm Chemical 28 Formulation C-D5W FOV 5 / 3.3 / 2 cm
Fluence rate 0.54 mW at 660 nm Filter
660-20/673lpxr/Dual BP
(710-50 and 781lp)
Animal CD-1 Inj. route R.O. ROI 13
Working Dt. 9 in Bit depth 16 Gender Female Anesthesia K+X Acquisition time 1 h post inj.
Gain 12 dB Matrix size 512x512 Dose 100 nmol Body Weight 25-30 g Exp. Time (msec) L, M, H
SBR (Bg: Mu)Exact Mass 597.13
LogD at 7.4 5.71
TPSA 6.25
HBD 0.00
HBA 1.00
Total Charge 1.00
Refractivity 158.00
Rotatable Bond 5.00
SB pKa 1.33
SA pKa 0.00
Neck&Axillary Chest Abdomen
Adrenal GLOvary Thyroid
Sciatic Nv Brown Fat Organ PA GL
Intestine
Mammary GL
850 ms 500 ms 500 ms
500 ms 500 ms 500 ms 500 ms
850 ms 850 ms 500 ms 850 ms
850 ms
Br Top Br Down Br Section I Br Section II
2000 ms 2000 ms 2000 ms 2000 ms
100 ms 0
0.5
1
1.5
2
2.5
3
He Lu Li Pa Sp Ki Du In
515
DMSO-d6
516
DMSO-d6 517
DMSO-d6 518
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
443.2696   443.2699       -0.3     -0.7     13.5     14.0       C29  H35  N2  O2 
diluted in 80%MeOH 17:00:53  01-Feb-2013
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ERIC_25_HENARY-ACCU_02-01-2013_ESI-POS01 61 (1.215) AM (Cen,2, 80.00, Ar,5000.0,556.28,0.70); Cm (61:80)
2.42e4443.2696
368.1608
519
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BioD of Compound 31
(4h post-injection)
520
521
522
523
500 ms 500 ms
500 ms
200 ms 200 ms 1000 ms 1000 ms 1000 ms 1000 ms 1000 ms
1000 ms 1000 ms
200 ms 200 ms 200 ms
200 ms200 ms 200 ms 200 ms 200 ms 200 ms
BioD of Compound 32
(4h post-injection)
524
DMSO-d6
525
DMSO-d6
526
527
Injection solution: 30% FBS in saline
Animal: CD-1 mouse (n=1)
Injection route: Penial vein
250 µM x 100 µL (25 nmol)
BioD result for Compound 33
Endocrine
Targeting
Adrenal GL +++
Pituitary GL +++
Lymph node
Axillary +++
Groin +++
Lumbar +++
Brain Choroid plexus ++
Organ
Lung ++
Liver +++
Pa/Sp ++
Duodenum +++
Kidney +++
Tissue Brown fat +++
Ki        Du         In     Mu
He        Lu       Li    Pa/Sp 
Groin
LN
Lumbar
LN
528
JGT SALT 14 uM Paper.001.001.1r.esp
16 14 12 10 8 6 4 2 0 -2 -4
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
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5.852.903.011.971.000.97
TMS
DMSO
Water
1
.4
5
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.4
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.6
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7
.6
3
529
DMSO-d6
530
DMSO-d6
531
20-Aug-201315:59:23
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
BRUSHI_NRB-06_HENARY-ACCU_8202013_ESI-POS 6 (0.112) TOF MS ES+ 
761471.1
472.1
Brushi_NRB-06_Henary-ACCU_8202013_ESI-POS #184-189 RT: 2.51-2.58 AV: 6 SB: 8 2.65-2.74 NL:
T: FTMS + p ESI Full ms [100.00-1000.00]
464 466 468 470 472 474 476 478 480 482 484
m/z
0
10
20
30
40
50
60
70
80
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Neck&Axillary
Chest
Abdomen
Adrenal GL
Lumbar LN
Groin LN
Thyroid
Organs
300 ms
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200 ms
300 ms
300 ms
300 ms
Pituitary GL
Brain Top
Brain Inside
Brain Bottom
300 ms
500 ms
200 ms
3000 ms
3000 ms
2000 ms
Exact Mass 471.23
LogD at 7.4 2.8
TPSA 43.17
HBD/A 0/5
Total Charge 1
Refractivity 151.05
Rotatable Bond 3
SB pKa 1.43
SA pKa N/A
FLARE Parameters Study Info. Measurement 
Model F-FLARE™ Channel 700 nm Chemical 36 Formulation 30% FBS FOV 7 / 3.5 / 2 cm
Fluence rate 2.8 mW at 660 nm Filter 660-20/710-50 Animal CD-1 Inj. route Penile ROI 10
Working Dt. 13 in Bit depth 16 Gender Male Anesthesia K+X Acquisition time 4 h post inj.
Gain 24 dB Matrix size 512x512 Dose 25 nmol Exp. Time (msec) L, M, H
0
5
10
15
He Lu Li Pa Sp Ki Du In
SBR Cal.
(ImageJ, BG: Mu)
533
DMSO-d6
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DMSO-d6
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EAO_172_ESIPOS_HENARY_090415 852 (8.438) AM (Cen,2, 80.00, Ht,5000.0,566.89,1.00); Cm (852:862) TOF MS ES+ 
1.51e3505.1871
362.9317
320.2655278.2397
352.2571
430.9133
385.0910 401.0682
498.9037
437.1969
507.1906
549.1466
508.1667
*
566.8891
782.3055702.8864634.8925567.0048 604.1992
650.4476 770.8782719.2261
838.8322
793.3361
906.7891872.7950 974.7834940.8002
985.3887
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
505.1871  505.1894       -2.3     -4.6     15.5     245.1      C29  H30  N2  O4  Cl 
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FLARE Parameters Study Info. Measurement 
Model K-FLARE™ Zoom Channel 700 nm Chemical 37 Formulation C-D5W FOV 5 / 3.3 / 2 cm
Fluence rate 0.54 mW at 660 nm Filter
660-20/673lpxr/Dual BP
(710-50 and 781lp)
Animal CD-1 Inj. route R.O. ROI 13
Working Dt. 9 in Bit depth 16 Gender Female Anesthesia K+X Acquisition time 1 h post inj.
Gain 12 dB Matrix size 512x512 Dose 100 nmol Body Weight 25-30 g Exp. Time (msec) L, M, H
SBR (Bg: Mu)
Neck&Axillary Chest Abdomen
Adrenal GLOvary Thyroid
Sciatic Nv Brown Fat Organ PA GL
Intestine
Mammary GL
Br Top Br Down Br Section I Br Section II
500 ms 250 ms 250 ms
250 ms 250 ms 250 ms 500 ms
500 ms 500 ms 250 ms 500 ms
500 ms
2000 ms 2000 ms 2000 ms 2000 ms
500 ms 0
1
2
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5
6
7
8
He Lu Li Pa Sp Ki Du In
Exact Mass 505.19
LogD at 7.4 3.04
TPSA 43.17
HBD 0.00
HBA 5.00
Total Charge 1.00
Refractivity 155.00
Rotatable Bond 3.00
SB pKa 1.35
SA pKa
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EAO_173_ESIPOS_HENARY_090415 1043 (10.292) TOF MS ES+ 
186551.1253
549.1364
362.9264
430.8964
437.1793 552.1338
566.8987
Mass       Calc. Mass     mDa PPM      DBE      i-FIT      Formula
549.1368 549.1389       -2.1     -3.8     15.5     30.5       C29  H30  N2 O4 Br 
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FLARE Parameters Study Info. Measurement 
Model K-FLARE™ Zoom Channel 700 nm Chemical 38 Formulation C-D5W FOV 5 / 3.3 / 2 cm
Fluence rate 0.54 mW at 660 nm Filter
660-20/673lpxr/Dual BP
(710-50 and 781lp)
Animal CD-1 Inj. route R.O. ROI 13
Working Dt. 9 in Bit depth 16 Gender Female Anesthesia K+X Acquisition time 1 h post inj.
Gain 12 dB Matrix size 512x512 Dose 100 nmol Body Weight 25-30 g Exp. Time (msec) L, M, H
SBR (Bg: Mu)
Br Top
Neck&Axillary Chest Abdomen
Adrenal GLOvary Thyroid
Sciatic Nv Brown Fat Organ PA GL
Intestine
Mammary GL
350 ms 250 ms 250 ms
250 ms 250 ms 250 ms 550 ms
350 ms 350 ms 250 ms 350 ms
350 ms
Br Down Br Section I Br Section II
2000 ms 2000 ms 2000 ms 2000 ms
500 ms 0
2
4
6
8
10
He Lu Li Pa Sp Ki Du In
Exact Mass 549.14
LogD at 7.4 3.21
TPSA 43.17
HBD 0.00
HBA 5.00
Total Charge 1.00
Refractivity 158.00
Rotatable Bond 3.00
SB pKa 1.37
SA pKa 0.00
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Appendix C
Experimental Data for Chapter 6 -- ENVIRONMENTALLY BENIGN SYNTHETIC APPROACHES—APPLIED TO FLUORESCENT DYES AND THEIR PRECURSORS 
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20-Aug-201312:20:24
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BRUSHI_NRB-01_HENARY-ACCU_8202013_ESI-POS 10 (0.185) TOF MS ES+ 
1.86e3439.2
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440.2
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m/z
435 436 437 438 439 440 441 442 443 444 445 446
%
0
100
BRUSHI_NRB-01_HENARY-ACCU_8202013_ESI-POS 10 (0.185) TOF MS ES+ 
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Brushi_NRB-01_Henary-ACCU_8202013_ESI-POS #184-189 RT: 2.51-2.58 AV: 6 SB: 8 2.65-2.74 NL:
T: FTMS + p ESI Full ms [100.00-1000.00]
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m/z Theo. Mass Delta (mmu)          RDB equiv. Composition
439.3093 439.3108 -1.46 13.5 C31 H39 N2 
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20-Aug-201316:05:49
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BRUSHI_NRB-03_HENARY-ACCU_8202013_ESI-POS 11 (0.204) Cm (8:12) TOF MS ES+ 
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Brushi_NRB-03_Henary-ACCU_8202013_ESI-POS #184-189 RT: 2.51-2.58 AV: 6 SB: 8 2.65-2.74 NL:
T: FTMS + p ESI Full ms [100.00-1000.00]
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m/z Theo. Mass Delta (mmu) RDB equiv. Composition
507.2315     507.2328 -1.34 13.5 C31 H37 N2 Cl2 
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NRB_6.001.esp
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NRB_br_pr_DYe.001.001.1r.esp
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20-Aug-201316:10:29
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
BRUSHI_NRB-02_HENARY-ACCU_8202013_ESI-POS 9 (0.168) Cm (8:9) TOF MS ES+ 
4.33e3597.0
595.0
599.0
600.0
20-Aug-201316:10:29
m/z
570 575 580 585 590 595 600 605 610 615 620 625 630
%
0
100
BRUSHI_NRB-02_HENARY-ACCU_8202013_ESI-POS 9 (0.168) Cm (8:9) TOF MS ES+ 
4.33e3597.0
595.0
599.0
600.0
NRB-2
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
%
5
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
A
U
2.0e-2
4.0e-2
6.0e-2
8.0e-2
1.0e-1
1.2e-1
1.4e-1
1.6e-1
1.8e-1
2.0e-1
NRB-2 Sm (Mn, 2x3) 2: Diode Array 
Range: 2.034e-1
Area
5.24
59174
NRB-2 Sm (Mn, 2x3) 1: TOF MS ES+ 
TIC
3.85e4
Area
5.59
23563
7.61
36883
12.36
944
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Brushi_NRB-02_Henary-ACCU_8202013_ESI-POS #184-189 RT: 2.51-2.58 AV: 6 SB: 8 2.65-2.74 NL:
T: FTMS + p ESI Full ms [100.00-1000.00]
570 580 590 600 610 620 630
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597.1282
599.1260
595.1311
601.1312
571.0954 623.1428617.1140582.1031 631.3140590.6513 604.3305
m/z Theo. Mass Delta (ppm) RDB equiv Composition
595.1311 595.1318 -1.19 13.5 C31 H37 N2 Br2
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20-Aug-201315:59:23
m/z
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%
0
100
BRUSHI_NRB-06_HENARY-ACCU_8202013_ESI-POS 6 (0.112) TOF MS ES+ 
761471.1
472.1
20-Aug-201315:59:23
m/z
460 462 464 466 468 470 472 474 476 478 480 482 484 486 488 490
%
0
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BRUSHI_NRB-06_HENARY-ACCU_8202013_ESI-POS 7 (0.130) Cm (6:7) TOF MS ES+ 
1.51e3471.1
472.2
NRB-6
Time
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6.0e-1
8.0e-1
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1.2
NRB-6 Sm (Mn, 2x3) 2: Diode Array 
Range: 1.46
Area
6.17
585042
7.42
358512
NRB-6 Sm (Mn, 2x3) 1: TOF MS ES+ 
TIC
3.47e4
Area
6.99
19579
8.36
13742
570
Brushi_NRB-06_Henary-ACCU_8202013_ESI-POS #184-189 RT: 2.51-2.58 AV: 6 SB: 8 2.65-2.74 NL:
T: FTMS + p ESI Full ms [100.00-1000.00]
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471.2268
472.2296
473.2324
474.2356 482.2522463.3037 479.2685470.6218467.3712 477.3170
m/z Theo. Mass Delta (mmu) RDB equiv. Composition
471.2268       471.2278 -1.01 15.5 C29 H31 O4 N2 
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nrb-diox-p-et-dmso.001.esp
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
6.1112.273.143.861.681.051.821.762.03
DMSO
Water
8
.2
3
8
.2
0
8
.1
7
7
.3
2
7
.1
8
7
.1
6
6
.5
1
6
.4
8
6
.2
2
6
.1
8
6
.0
7
4
.0
8
4
.0
7
3
.5
4
1
.9
9
1
.6
3
1
.2
5
1
.2
4
1
.2
2
0
.0
0
572
NRB_d_et_DYe.001.001.1r.esp
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20-Aug-201316:01:53
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
BRUSHI_NRB-05_HENARY-ACCU_8202013_ESI-POS 3 (0.056) Cm (2:3) TOF MS ES+ 
2.79e3499.2
232.1
500.2
20-Aug-201316:01:53
m/z
495 496 497 498 499 500 501 502 503 504 505 506 507 508
%
0
100
BRUSHI_NRB-05_HENARY-ACCU_8202013_ESI-POS 3 (0.056) Cm (2:3) TOF MS ES+ 
2.79e3499.2
500.2
NRB-5
Time
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4.0e-1
6.0e-1
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NRB-5 Sm (Mn, 2x3) 2: Diode Array 
Range: 1.546
Area
6.22
488361
7.57
255456
NRB-5 Sm (Mn, 2x3) 1: TOF MS ES+ 
TIC
3.41e4
Area
7.02
18421
8.44
8871
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Brushi_NRB-05_Henary-ACCU_8202013_ESI-POS #184-189 RT: 2.51-2.58 AV: 6 SB: 8 2.65-2.74 NL:
T: FTMS + p ESI Full ms [100.00-1000.00]
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501.2632
485.2428 515.4108507.3264 519.9200 531.4059475.2215 491.1853
496.5312
m/z Theo. Mass Delta (mmu) RDB equiv. Composition
499.2577 499.2591 -1.46 15.5 C31 H35 O4 N2 
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NRB_7.001.esp
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NRB_d_pr_DYe.001.001.1r.esp
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20-Aug-201316:14:15
m/z
514 516 518 520 522 524 526 528 530 532 534 536 538 540 542 544 546
%
0
100
BRUSHI_NRB-04_HENARY-ACCU_8202013_ESI-POS 4 (0.075) Cm (2:4) TOF MS ES+ 
1.63e3527.2
528.2
NRB-4
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
%
5
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
A
U
2.5e-2
5.0e-2
7.5e-2
1.0e-1
1.25e-1
1.5e-1
1.75e-1
2.0e-1
2.25e-1
NRB-4 Sm (Mn, 2x3) 2: Diode Array 
Range: 2.727e-1
Area
4.87
72775
NRB-4 Sm (Mn, 2x3) 1: TOF MS ES+ 
TIC
4.62e4
Area
5.58
29550
7.32
29472
10.44
1877
11.46
43
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Brushi_NRB-04_Henary-ACCU_8202013_ESI-POS #184-189 RT: 2.51-2.58 AV: 6 SB: 8 2.65-2.74 NL:
T: FTMS + p ESI Full ms [100.00-1000.00]
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e
527.2883
528.2912
529.2941
530.2971 537.3923533.2875521.9186 539.2514526.5720
m/z Theo. Mass Delta (mmu) RDB equiv. Composition
527.2883 527.2904 -2.14 15.5 C33 H39 O4 N2
579
Appendix D
Experimental Data for Chapter 7 -- CARTILAGE AND BONE TARGETING FLUOROPHORES
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595
Appendix E
Experimental Data for Chapter 9 –
STRUCTURALLY STABLE AND ULTRA-BRIGHT SQUARAINE DYES: THE ROLE OF QUATERNARY AMMONIUM CATIONS IN OXOCYCLOBUTANAL STABILIZATION
596
597
QtofMicroin 50%MeOH+0.1%HCOOH 12-Mar-201410:56:12
m/z
200 300 400 500 600 700 800 900
%
0
100
YOGESH_YY_11_83_ESI_POS_HENARY_03112014 38 (0.707) TOF MS ES+ 
1.01e3298.3
298.8
299.3
YY-II-83
Time
10.00 20.00 30.00 40.00
%
5
10.00 20.00 30.00 40.00
A
U
5.0e-2
1.0e-1
1.5e-1
YY- II-83 2: Diode Array 
Range: 1.776e-14.37
YY- II-83 1: TOF MS ES+ 
TIC
5.64e4
5.30
5.17 5.56
14.11
598
599
600
601
QtofMicroin 50%MeOH+0.1%HCOOH 12-Mar-201410:23:38
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
YOGESH_YY_11_84_ESI_POS_HENARY_03112014 5 (0.093) TOF MS ES+ 
2.97e3316.2
316.7
YY-II-84
Time
5.00 10.00 15.00 20.00 25.00
%
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5.00 10.00 15.00 20.00 25.00
A
U
5.0e-2
1.0e-1
YY- II-  84 2: Diode Array 
Range: 1.091e-113.57
YY- II-  84 1: TOF MS ES+ 
TIC
1.52e4
14.34
12.56
11.17
0.02
5.17 7.43
14.60
14.71
18.65
602
603
604
605
YY-II-117
Time
5.00 10.00 15.00 20.00 25.00
%
5
5.00 10.00 15.00 20.00 25.00
A
U
2.0e-1
4.0e-1
YY-  II- 117 2: Diode Array 
Range: 4.959e-115.67
YY-  II- 117 1: TOF MS ES+ 
TIC
3.81e4
16.36
14.38 19.52
606
607
608
609
QtofMicroin 50%MeOH+0.1%HCOOH 12-Mar-201411:16:12
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
YOGESH_YY_11_85_ESI_POS_HENARY_03112014 98 (1.821) TOF MS ES+ 
1.08e3377.2
376.2
337.2
378.2
378.7
YY-II-85
Time
5.00 10.00 15.00 20.00 25.00
%
5
5.00 10.00 15.00 20.00 25.00
A
U
2.0e-1
4.0e-1
YY-II-85 2: Diode Array 
Range: 4.681e-115.35
14.15
YY-II-85 1: TOF MS ES+ 
TIC
1.92e4
16.03
15.96
15.85
14.80
14.2212.01
4.99 6.82
16.47
18.55
610
611
612
613
YY-II-95
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
YY-II-95 769 (14.106) Cm (762:802) 1: TOF MS ES+ 
1.97e3450.0006
291.3374
263.4206
248.4377
394.1068 508.9077
509.9126
510.8995
614
615
616
617
618
YY-II-107
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
YY-II-107 531 (9.740) Cm (515:567) 1: TOF MS ES+ 
5.54e3309.4845
281.5490
266.5521
255.5855
227.6153
468.2608
412.3150
527.2051
528.2086
619
620
621
622
YY-II-118
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
YY-II-118 661 (12.125) Cm (642:714) 1: TOF MS ES+ 
789543.1108484.1816
325.4084
297.4777
282.4871
243.5431
231.6059
428.2531
545.1194
546.1201
623
624
625
626
YY-II-106
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
YY-II-106 894 (16.399) Cm (871:920) 1: TOF MS ES+ 
2.90e3287.2368
262.4262
237.3622
529.7156
369.0526
471.8214
588.6233
589.6223
627
628
E-46
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
A
U
0.0
2.0e-3
4.0e-3
6.0e-3
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
%
0
100
E-46 ELSD
An1
5.93e5
6.44
8.82
E-46 2: Diode Array 
Range: 1.559e-26.64
0.25
2.10
E-46
Time
5.80 6.00 6.20 6.40 6.60 6.80 7.00 7.20 7.40 7.60 7.80 8.00
%
0
100
E-46MS 1: TOF MS ES+ 
TIC
1.49e5
6.26
E-46
m/z
100 200 300 400 500 600 700 800 900 1000 1100
%
0
100
E-46MS 626 (6.262) Cm (622:635) 1: TOF MS ES+ 
1.12e4185.1070
169.7654
277.1687
185.4501
198.7951
247.6440
277.6795
599.3000278.1908
278.6885 600.3290
M/(+3Z)
M/(+2Z)
Appendix F
Experimental Data for Chapter 12 – PENTAMETHINE CYANINES WITH HIGH FIDELITY TO QUADRUPLEX DNA
629
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Appendix G
Experimental Data for Chapter 13 – RIGIDITY IN HEPTAMETHINE CYANINES IMPROVES QUADRUPLEX BINDING
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644
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EAO_107_1H_DMSO.002.esp
10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
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EAO_91_1H_MeOD.002.esp
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EAO_Hepta_G4 with H and Cl.001.esp
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Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
12.011.674.033.7717.833.713.541.921.901.831.891.962.00
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EAO_92_1H_MeOD.002.esp
10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
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11.752.173.923.9717.564.023.931.891.932.201.932.00
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Appendix H
Experimental Data for Chapter 14 – SECOND GENERATION TRIMETHINE CYANINES
655
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EAO_88_19F_DMSO.003.esp
20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220
Chemical Shift (ppm)
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672
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zk-14
m/z
100 200 300 400 500 600 700 800 900 1000 1100
%
0
100
zk-14-MS 790 (7.904) Cm (779:800) 1: TOF MS ES+ 
3.83e4246.6005
217.1115
247.1219
247.7299
538.2427
248.3254
492.2595267.1676
539.2666
zk-14
Time
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
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100
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
A
U
0.0
2.5e-1
5.0e-1
7.5e-1
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
%
0
100
zk-14(3) ELSD
An1
5.91e5
8.27
zk-14(3) 2: Diode Array 
Range: 7.871e-18.42
zk-14-MS 1: TOF MS ES+ 
TIC
9.99e4
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